

TABLE	PAGE
<b>Data Table 1 A, B and C</b>	<b>2</b>
<b>Data Table 2</b> <div> <div> <u>DT2A</u> <ul style="list-style-type: none"> <li>• 2A All</li> <li>• 2A Multi-PI</li> <li>• 2A Training</li> <li>• 2A BIDD</li> <li>• 2A CC</li> <li>• 2A SPT</li> </ul> </div> <div> <u>DT2B</u> <ul style="list-style-type: none"> <li>• 2B All</li> <li>• 2B Multi-PI</li> <li>• 2B Training</li> <li>• 2B BIDD</li> <li>• 2B CC</li> <li>• 2B SPT</li> </ul> </div> </div>	<b>4</b>
<b>Data Table 3</b>	<b>64</b>
<b>Data Table 4</b> <ul style="list-style-type: none"> <li>• DT4 All</li> <li>• DT4 BIDD</li> <li>• DT4 CC</li> <li>• DT4 SPT</li> </ul>	<b>65</b>

**Data Table 1A – Senior Leadership**
**5P30 CA062203-25**
**Chao Family Comprehensive Cancer Center**
*Reporting Date: 02/14/25*

Name of Senior Leader	Title of Leader	Degree(s)	Is New Leader?
Van Etten, Richard	Principal Investigator, Director	MD, PhD	N
Villalona, Miguel	Deputy Director	MD	Y
Chow, Warren	Associate Director for Clinical Science	MD	N
Dayyani, Farshid	Associate Director for Translational Science	MD, PhD	Y
Fruman, David	Associate Director for Basic Science	PhD	N
Edwards, Karen	Associate Director for Population Science and Cancer Control	PhD	N
Tanjasiri, Sora Park	Associate Director for Cancer Health Disparities & Community Engagement	DrPh, MPH	N
Nelson, Edward	Associate Director for Cancer Research Training and Education	MD	N
Funes, Melanie	Associate Director for Administration & Finance/Chief Administrative Officer	PhD	N
Waterman, Marian	Associate Director for Shared Resources	PhD	N
Worsham, Ursula	Associate Director for Equity, Diversity and Inclusion & the Plan to Enhance Diversity	EdD	Y

**Data Table 1B - Research Programs**
**5P30 CA062203-25**
**Chao Family Comprehensive Cancer Center**
*Reporting Date: 02/14/25*

Program Code	Program Name	Program Leaders	Degree(s)	Is New Leader?	Is New Research Program?	Total # Members (including leader)
BIDD	Biotechnology, Imaging & Drug Development	Ganesan, Anand Paegel, Brian	MD, PhD PhD	N Y	N	93
SPT	Systems, Pathways & Targets	Fleischman, Angela Lowengrub, John	MD, PhD PhD	N N	N	100
CC	Cancer Control	Lee, Sunmin Milam, Joel	ScD, MPH PhD	N N	N	55
ZY	Non-aligned Members					0
Total Members						248

**Data Table 1C - Shared Resources****5P30 CA062203-25****Chao Family Comprehensive Cancer Center***Reporting Date: 02/14/25*

<b>Name of Shared Resource</b>	<b>Resource Director(s)</b>	<b>Degree(s)</b>	<b>Is New Leader?</b>	<b>Is New Resource?</b>	<b>Is Developing Resource?</b>	<b>Category</b>
Transgenic Mouse Facility	MacGregor, Grant	PhD	N	N	N	1.03
Optical Biology Core	Warrior, Rahul	PhD	N	N	N	1.18; 1.33
Genomics Research and Technology Hub	Sandmeyer, Suzanne	PhD	N	N	N	1.35; 1.21; 7.02
In Vivo Functional Onco-Imaging	Gulsen, Gultekin Zhang, Zhuoli	PhD MD, PhD	N N	N	N	1.26; 1.27; 1.37
Experimental Tissue Resource	Edwards, Robert Cozen, Wendy	MD, PhD DO, MPH	N N	N	N	4.06
Biostatistics Shared Resource	Zhang, Min	MD, PhD <sup>2</sup>	N	N	N	6.01
Biobehavioral Shared Resource	Hoyt, Michael	PhD	Y	N	N	3.04; 4.03
Mass Spectrometry Core	Pronin, Sergey Huang, Lan Jang, Cholsoon	PhD PhD PhD	Y Y Y		Y Y Y	1.36; 1.27 (mass); 1.13

## UC Irvine Chao Family Comprehensive Cancer Center

Reporting Date: 02/28/2025

Data Table 2A – Active Funded Projects

## Peer-Reviewed Research

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Acharya M	NIH-NCI	5R01CA262213-02	3/13/2023	2/29/2028	Stem cell-derived exosomes to ameliorate chemobrain	\$217,313	\$217,313	BIDD	100	\$217,313
Acharya M	NIH-NCI	3R01CA251110-04S1	4/1/2024	8/31/2025	Glial immune signaling in radiation-induced brain injury (Diversity Supplement)	\$61,756	\$61,756	ZY	100	\$61,756
Acharya M Loo B (Stanford)	NIH-NCI	5R01CA251110-04	9/1/2021	8/31/2026	Glial immune signaling in radiation-induced brain injury	\$254,980	\$254,980	BIDD	100	\$254,980
Acharya M Mahan K (University of Texas Hlth Sci Ctr Houston)	NIH-NCI University of Texas Hlth Sci Ctr Houston	1R21CA292148-01	7/11/2024	6/30/2026	Circadian regulation of astrocytic adenosine kinase in the irradiated and cancer brain	\$112,250	\$112,250	BIDD	100	\$112,250
Albrecht L	NIH-NIGMS	1R35GM157370-01	9/20/2024	8/31/2029	Deciphering Novel Principles of Rapid Proteostatic Control and Innovating Spatiotemporal Lysosomal Tools	\$250,000	\$125,000	SPT	100	\$125,000
Andersen B	NIH-NIAMS	5R01AR056439-12	9/1/2010	5/31/2026	Circadian Clock Regulation in Skin	\$272,388	\$136,194	SPT	100	\$136,194
Andersen B	NIH-NIAMS	5R34AR081502-03	9/1/2022	6/30/2025	The Initiation of Vesicant Skin Injury at a Single Cell Level	\$179,000	\$89,500	SPT	100	\$89,500
Anton-Culver H	NIH-OD	1OT2OD036428-01	5/1/2024	4/30/2025	All of Us Southern California Consortium (AoUSCC): Engagement, Enrollment, and Retention of Diverse Populations (Assist app# 1476115)	\$2,561,112	\$2,561,112	CC	100	\$2,561,112
Anton-Culver H	NIH-OD	3OT2OD036428-01S1	5/1/2024	4/30/2025	All of Us Southern California Consortium (AoUSCC): CLAD Data COUNTS Project Supplement	\$191,177	\$191,177	ZY	100	\$191,177
Anton-Culver H Thomas N (University of North Carolina, Chapel Hill)	NIH-NCI University of North Carolina, Chapel Hill	5R01CA233524-05	4/1/2020	3/31/2025	Identification of Lethal Melanomas at the Time of Diagnosis	\$8,925	\$8,925	CC	100	\$8,925
Atwood S	NIH-NCI	5R01CA237563-05 (NCE)	4/11/2019	3/31/2025	Phosphorylation-dependent regulation of GLI transcription factors	\$14,645	\$14,645	SPT	100	\$14,645
Atwood S	NSF	CBET-2134916-04	1/1/2022	12/31/2025	RECODE: Functional characterization of human skin organoids	\$242,702	\$121,351	SPT	100	\$121,351
Baker N	NIH-NCI	9R01CA284362-10A1	8/15/2024	7/31/2029	Cell Competition in Development and Homeostasis	\$260,454	\$260,454	SPT	100	\$260,454
Baker N	NIH-NIGMS	7R01GM120451-07	9/16/2016	8/31/2027	Ribosomes and Growth Regulation	\$200,000	\$200,000	SPT	100	\$200,000
Balu M Ganesan A	NIH-NIBIB	5R01EB026705-06	7/1/2018	3/31/2027	Development of a fast scanning, extended field-of-view multiphoton microscope for clinical skin imaging	\$371,894	\$278,921	BIDD	100	\$278,921
Balu M Ganesan A	NIH-NIAMS	5R21AR082648-02 (NCE)	3/1/2023	12/31/2025	In vivo label free optical imaging of immune cells in human skin	\$94,007	\$94,007	BIDD	100	\$94,007
Balu M Kelly K	NIH-NCI	5R01CA259019-03	9/1/2022	8/31/2027	Fast, large area, multiphoton exoscope (FLAME) for improving early detection of melanoma	\$422,551	\$422,551	BIDD	100	\$422,551
Benavente C	NIH-NCI	5R01CA229696-05 (NCE)	6/1/2019	5/31/2025	Role of UHRF1 in osteosarcoma and its relationship to RB	\$160,374	\$160,374	SPT	100	\$160,374
Benmohamed L	NIH-NEI	5R01EY019896-12	9/1/2010	3/31/2026	Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits	\$261,146	\$130,573	CC	100	\$130,573
Blumberg B Shioda T (Mass General Hospital)	NIH-NIEHS	5R01ES031139-05	9/16/2020	6/30/2026	Interactions between prenatal obesogen exposure and Total Western diet lead to a transgenerational thrifty phenotype: functional and epigenomic analysis of effects in fat and liver	\$174,390	\$130,793	SPT	100	\$130,793
Bota D	NIH-NCI	3R01CA263806-04S2	5/1/2024	6/30/2025	Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system (Diversity Supplement)	\$60,808	\$60,808	ZY	100	\$60,808
Bota D	NIH-NCI	3R01CA263806-04S1	3/1/2024	6/30/2025	Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system (Diversity Supplement)	\$59,384	\$59,384	ZY	100	\$59,384
Bota D	NIH-NINDS	3R01NS109423-05S1	6/1/2024	5/31/2025	Targeting of Mitochondrial LON Protease as a Novel Therapy for Glioblastoma (Diversity Supplement)	\$6,400	\$6,400	ZY	100	\$6,400

Bota D	NIH-NCI	3R01CA263806-04S1	7/1/2024	6/30/2025	Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system (Diversity Supplement)	\$59,384	\$59,384	ZY	100	\$59,384
Bota D Das B (LIU: Brooklyn)	NIH-NINDS	5R01NS109423-05	9/1/2020	5/31/2025	Targeting of Mitochondrial LON Protease as a Novel Therapy for Glioblastoma	\$158,054	\$158,054	BIDD	100	\$158,054
Bota D Gupta K	NIH-NCI	5R01CA263806-04	7/1/2021	6/30/2026	Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system	\$366,131	\$366,131	BIDD	100	\$366,131
Botvinick E	NSF	DMS-1953410-03 (NCE)	7/1/2020	6/30/2025	Collaborative Research: Multiscale and Multiphasic Modeling of Single and Collective Migration in Fibrous Extracellular Matrices	\$25,664	\$19,248	BIDD	100	\$19,248
Buisson R	ACS	RSG-24-1249960-01-DMC-01	7/1/2024	6/30/2028	Deciphering DNA Damage Response-Mediated Translation Regulation to Prevent Cancer Initiation	\$199,375	\$199,375	SPT	100	\$199,375
Buisson R	NIH-NCI	3R37CA252081-04S1	7/1/2024	6/30/2025	Molecular Mechanisms of APOBEC-Induced Mutagenesis in Cancer (Diversity Supplement)	\$65,009	\$65,009	ZY	100	\$65,009
Buisson R	NIH-NCI	3R37CA252081-04S2	7/1/2024	6/30/2025	Molecular Mechanisms of APOBEC-Induced Mutagenesis in Cancer (Diversity Supplement)	\$57,052	\$57,052	ZY	100	\$57,052
Buisson R	NIH-NIAID	1R21AI185033-01	1/1/2025	12/31/2026	Role of APOBEC3B in the Innate Immune Response	\$145,500	\$72,750	SPT	100	\$72,750
Buisson R Lawrence M (Mass General)	NIH-NCI	5R37CA252081-04	7/1/2021	6/30/2026	Molecular Mechanisms of APOBEC-Induced Mutagenesis in Cancer	\$193,287	\$193,287	SPT	100	\$193,287
Buisson R Lawrence M (Massachusetts General Hospital)	NIH-NCI Massachusetts General Hospital	1R01CA262874-01A1	4/9/2024	3/31/2029	Mechanisms of APOBEC3A-induced cancer evolution and cancer vulnerability	\$14,377	\$14,377	SPT	100	\$14,377
Burke P	NSF	CBET-2153425-03	7/1/2022	6/30/2025	Artificial nose using electrophysiology coupled to nanowires:Towards single molecule sensitivity with single atom resolution on chemical species	\$102,907	\$51,454	BIDD	100	\$51,454
Chan A Acharya M	NIH-NCI	5R01CA276212-02	9/6/2023	8/31/2028	Neurotrophic strategy to mitigate chemotherapy-related brain injury	\$303,803	\$303,803	CC	50	\$151,902
								BIDD	50	\$151,902
Chan J	NIH-NIEHS	5R01ES029481-05 (NCE)	8/1/2019	4/30/2025	Nrf1-dependent regulation of cellular stress response	\$138,183	\$103,637	SPT	100	\$103,637
Chen Z	NIH-NIBIB	5R01EB030558-03 (NCE)	9/15/2021	9/14/2025	Continuous Monitoring and Management of Vaginal Health via Multifunctional OCT/OCTA Endoscopy	\$695,370	\$347,685	BIDD	100	\$347,685
Chen Z Wong B	NIH-NIBIB	5R01EB030024-05	7/1/2020	3/31/2025	In vivo Imaging and Quantification of Cilia Beating Dynamics Using Phase Resolved Optical Imaging Technology	\$372,627	\$186,314	BIDD	100	\$186,314
Cho K	NIH-NIGMS	5R35GM139617-04	3/1/2021	2/28/2026	Maternal transcription factors shaping early embryonic chromatin landscape	\$265,000	\$132,500	SPT	100	\$132,500
Cho K	NIH-NICHD	5R21HD109696-02 (NCE)	8/19/2022	7/31/2025	Spatiotemporal mapping of enhancer activity in developing frog embryos	\$86,473	\$43,237	SPT	100	\$43,237
Copp S	NIH-NIBIB	1DP2EB037187-01	9/1/2024	8/31/2029	Deep-tissue targeted molecular imaging with a palette of NIR-II emissive DNA-stabilized nanoclusters	\$300,000	\$300,000	BIDD	100	\$300,000
Cozen W Bertrand K (Boston University) Cai Q (Vanderbilt) Espeldegui M (UCLA) Haiman C (USC) Pinkal D (Cornell) Reiner A (Fred Hutchinson)	NIH-NCI	5R01CA260615-04	9/20/2021	8/31/2026	Determinants of the racial/ethnic disparity in MGUS risk: An epidemiologic study in 4 cohorts	\$125,024	\$125,024	CC	100	\$125,024
Dai X	NIH-NIGMS	5R35GM145307-03	6/1/2022	3/31/2027	Intrinsic and extrinsic control of epithelial tissue stem cell activity	\$304,552	\$228,414	SPT	100	\$228,414
Dai X	NIH-NIGMS	3R35GM145307-03S1	4/1/2024	3/31/2025	Intrinsic and extrinsic control of epithelial tissue stem cell activity (Equipment Purchase)	\$57,578	\$43,184	ZY	100	\$43,184
Dayyani F Carvajal-Carmona L (UC Davis)	NIH-NCI UC Davis	5U54CA283766-02	8/1/2024	7/31/2028	University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities	\$27,862	\$27,862	SPT	100	\$27,862
Demetriou M	CIRM	DISC2-13507-02 (NCE)	9/1/2022	2/28/2025	GlyTR CAR T cells for the treatment of Glioblastoma	\$48,134	\$48,134	BIDD	100	\$48,134

Demetriou M Zhou R (Gltlyr Therapeutics)	NIH-NCI Gltlyr Therapeutics	5R42CA285234-02	9/21/2023	8/31/2026	Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy	\$490,561	\$490,561	BIDD	100	\$490,561
Ding F	NIH-NIAMS	DP2GM149554-03	9/1/2022	8/31/2025	Universally-applicable RNA mapping at subcellular and single-base resolution	\$300,000	\$150,000	BIDD	100	\$150,000
Dong V	NIH-NIGMS	5R35GM127071-07	5/1/2018	7/31/2028	Innovative Tools for Chemical Synthesis: Metal-Hydride Catalysis, Medicinal Motifs, and Molecular Probes	\$325,000	\$162,500	BIDD	100	\$162,500
Dong V	NSF	CHE-2247923-02	9/1/2023	8/31/2026	Sustainable Technologies for Building Molecules: Ethers, Phosphines, and Amino Acids	\$155,286	\$77,643	BIDD	100	\$77,643
Dong V	NIH-NIGMS	3R35GM127071-07S1	8/1/2024	7/31/2025	Innovative Tools for Chemical Synthesis: Metal-Hydride Catalysis, Medicinal Motifs, and Molecular Probes (Diversity Supplement)	\$61,008	\$30,504	ZY	100	\$30,504
Dong V	NIH-NIGMS	3R35GM127071-07S2	8/1/2024	7/31/2025	Innovative Tools for Chemical Synthesis: Metal-Hydride Catalysis, Medicinal Motifs, and Molecular Probes (Equipment Purchase)	\$157,216	\$78,608	ZY	100	\$78,608
Douglas J	TRDRP	T34CR8419H-01	7/1/2024	7/30/2026	A community-engaged examination of Black and Latine youth tobacco product use around activity spaces	\$209,382	\$209,382	CC	100	\$209,382
Downing T Spakowitz A (Stanford)	NSF	EF-2022182-05	7/15/2020	6/30/2025	URoL: Epigenetics 2: Connecting cell fate and epigenome drift through physical models of chromatin structure and dynamics	\$240,192	\$180,144	BIDD	100	\$180,144
Edinger A	NIH-NCI	5R01CA247556-05	4/1/2020	3/31/2026	Defining the role of macropinocytosis in solid tumor growth and therapeutic resistance	\$297,860	\$297,860	BIDD	100	\$297,860
Edinger A	NIH-NCI	5R01CA254360-04	3/1/2021	2/28/2026	A novel strategy to overcome drug resistance in cancer	\$287,945	\$287,945	BIDD	100	\$287,945
Edwards R Adetona O (The Ohio State University)	CDC-NIOSH The Ohio State University	SPC-1000007190 / GR129304-03	9/1/2022	8/31/2025	Chronic Respiratory Effect and Control of Occupational Exposure of Wildland Firefighters to Smoke	\$16,459	\$8,230	CC	100	\$8,230
Felgner P	NIH-NIAID	75N93022C00054-03	9/1/2022	8/31/2027	Adjuvant characterization and comparison in three different infection animal models	\$1,767,557	\$883,778	BIDD	100	\$883,778
Flanagan L	NSF	IOS-2019400-05	6/15/2020	5/31/2025	Cell surface glycosylation regulation of stem cell fate decisions	\$195,349	\$97,675	BIDD	100	\$97,675
Flanagan L	NIH-NINDS	5R01NS119829-04	9/1/2021	8/31/2026	Human neural stem cell and endothelial cell reciprocal interactions govern cell function	\$242,500	\$121,250	BIDD	100	\$121,250
Fleischman A	NIH-NCI	5R37CA271172-03	5/30/2022	3/31/2027	Effect of inflammation on JAK2 mutant evolution in the hematopoietic system: mathematical models and experiments	\$352,028	\$352,028	SPT	100	\$352,028
Fleischman A	TRDRP	T32IR5150-03	7/1/2022	6/30/2025	Impact of Electronic Nicotine Delivery Devices on clonal hematopoiesis and hematologic malignancies	\$300,000	\$300,000	SPT	100	\$300,000
Fleischman A	NIH-NIDDK	5R01DK136069-03	9/25/2022	6/30/2025	Role of IL-10R signaling in inflammation induced exhaustion of HSC and emergence of JAK2V617F clonal hematopoiesis	\$144,000	\$144,000	SPT	100	\$144,000
Fleischman A	NIH-NCI	3R37CA271172-03S1	4/1/2024	3/31/2025	Effect of inflammation on JAK2 mutant evolution in the hematopoietic system: mathematical models and experiments (Diversity Supplement)	\$60,484	\$60,484	ZY	100	\$60,484
Fleischman A	NSF	DMS-2424855-01	10/1/2024	9/30/2027	eMB: Collaborative Research: Using mathematics to bridge between evolutionary dynamics in the hematopoietic systems of mice and humans: from in vivo to epidemiological scales	\$73,952	\$73,952	SPT	100	\$73,952
Fleischman A	NIH-NIDDK	3R01DK136069-03S1	7/1/2024	6/30/2025	Role of IL-10R signaling in inflammation induced exhaustion of HSC and emergence of JAK2V617F clonal hematopoiesis (Diversity Supplement)	\$63,630	\$63,630	ZY	100	\$63,630
Fleischman A	NSF	DMS-2424855-01	9/1/2024	8/31/2027	Collaborative Research: Using mathematics to bridge between evolutionary dynamics in the hematopoietic systems of mice and humans: from in vivo to epidemiological scales	\$73,952	\$73,952	SPT	100	\$73,952
Fowler C	NIH-NIDA	5R01DA051831-05	6/15/2020	4/30/2025	Impact of THC on Extracellular Vesicle Signaling	\$237,500	\$118,750	CC	100	\$118,750
Fowler C	TRDRP	T32IR4866-03	7/1/2022	6/30/2025	Cannabidiol as a therapeutic approach for tobacco and nicotine cessation	\$299,477	\$224,608	CC	100	\$224,608
Fowler C Ganesh T (Northeastern)	NIH-NIDA Northeastern	1R01DA059985-01	8/1/2024	5/31/2029	Selective Positive Allosteric Modulators of a4b2 Nicotinic Receptors	\$35,617	\$17,809	CC	100	\$17,809
Fowler C Gay E (RTI International)	NIH-NIDA RTI International	5R01DA058493-02	9/30/2023	7/31/2028	Discovery and development of GPR3 agonists for nicotine cessation	\$68,237	\$51,178	CC	100	\$51,178
Frank S	NSF	DEB-2325755-01	4/1/2024	3/31/2026	OPUS: Robustness and complexity: how evolution builds precise traits from sloppy components	\$78,587	\$58,940	SPT	100	\$58,940
Fruman D	ALSF	22-25509-02 (NCE)	11/1/2022	1/15/2026	Enhancing TKI therapy in Ph-like leukemia	\$35,008	\$35,008	SPT	100	\$35,008

Fruman D	ACS	DBG-24-1319247-01-IBCD-01	1/1/2025	12/31/2026	Control of leukemia cell survival by the mevalonate pathway	\$135,000	\$135,000	SPT	100	\$135,000
Ganesan A	NIH-NCI	5R01CA244571-05 (NCE)	12/4/2019	11/30/2025	Identifying Therapeutic Targets for Stage III Melanoma	\$20,344	\$20,344	BIDD	100	\$20,344
Goodman-Gruen D Esserman L (UCSF)	NIH-NCI UCSF	1P01CA281826-01A1	9/11/2024	8/31/2029	WISDOM:A platform to optimize subtype-specific screening and prevention	\$53,119	\$53,119	CC	100	\$53,119
Guan Z	NSF	DMR-2004555-03 (NCE)	7/15/2020	6/30/2025	Structure-property study for dendronized polymer vectors for CRISPR delivery	\$175,358	\$87,679	BIDD	100	\$87,679
Gupta K Hui S (City of Hope)	NIH-NHLBI City of Hope	5R01HL164895-02	7/1/2023	6/30/2026	Novel Targeted Marrow Irradiation Based Bone Marrow Transplantation for Sickle Cell Disorders	\$45,000	\$22,500	SPT	100	\$22,500
Halbrook C	NIH-NCI	1R37CA283575-01A1	5/1/2024	4/30/2029	Targeting Metabolic Crosstalk in Pancreatic Cancer	\$283,085	\$283,085	SPT	100	\$283,085
Halbrook C	ACS	RSG-24-1320209-01-MM-01	1/1/2025	12/31/2028	Deconvoluting the Metastatic Pancreatic Cancer Tumor Microenvironment	\$197,083	\$197,083	SPT	100	\$197,083
Hertel K	NIH-NIGMS	5R35GM145254-03	8/9/2022	6/30/2027	Regulation and impact of alternative splicing in biology and disease	\$250,000	\$187,500	SPT	100	\$187,500
Hertel K	NIH-NIGMS	3R35GM145254-03S1	7/1/2024	6/30/2025	Regulation and impact of alternative splicing in biology and disease (Diversity Supplement)	\$65,008	\$48,756	ZY	100	\$48,756
Hicks M	NIH-NIAMS	1R01AR084027-01	8/16/2024	7/31/2029	Modulating the Stem Cell Niche Set Point to Improve Skeletal Muscle Regeneration	\$324,018	\$162,009	SPT	100	\$162,009
Hoyt M	DOD/CDMRP	W81XWH-20-1-0308-03 (NCE)	5/1/2020	5/14/2025	Inflammatory Processes, Emotion Regulation, and Depression in Prostate Cancer Survivors	\$58,041	\$58,041	CC	100	\$58,041
Hoyt M Applebaum A (Sloan Kettering)	NIH-NCI Sloan Kettering	5R01CA244185-05	9/1/2020	5/31/2025	A Randomized Controlled Trial of Emotion Regulation Therapy for Cancer Caregivers: A Mechanism-Targeted Approach to Addressing Caregiver Distress	\$87,063	\$87,063	CC	100	\$87,063
Hoyt M Nelson C (Memorial Sloan Kettering)	NIH-NCI	5R01CA276143-02	7/8/2023	6/30/2028	A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors	\$332,237	\$332,237	CC	100	\$332,237
Huang L	NIH-NIGMS	5R35GM145249-03	8/1/2022	7/31/2027	Advancing Proteomics Technologies to Decipher the Ubiquitin-Proteasome System	\$375,000	\$281,250	BIDD	100	\$281,250
Huang L	NIH-NIGMS	3R35GM145249-03S1	8/1/2024	7/31/2025	Advancing Proteomics Technologies to Decipher the Ubiquitin-Proteasome System (Equipment Purchase)	\$35,811	\$26,858	ZY	100	\$26,858
Huang L Wiita A (UCSF)	NIH-NCI UCSF	1R01CA290875-01	8/1/2024	7/31/2029	Structural surfaceomics to probe conformation-selective immunotherapy targets	\$99,772	\$99,772	BIDD	100	\$99,772
Huang L Zhang H (Johns Hopkins University)	NIH-NCI Johns Hopkins University	5U24CA271079-03	6/1/2022	5/31/2025	Proteogenomic Characterization of Tumor Tissues and Preclinical Models with High Precision	\$93,000	\$93,000	BIDD	100	\$93,000
Hughes C	NIH-NCI	5R21CA280567-02	5/1/2023	4/30/2025	In search of synergistic drug interactions in cancer	\$111,031	\$111,031	BIDD	100	\$111,031
Hughes C Senthil M	NIH-NCI	1R01CA290115-01	6/1/2024	5/31/2029	A vascularized microphysiological system (MPS) platform for modeling peritoneal carcinomatosis	\$332,000	\$332,000	BIDD	100	\$332,000
Hughes C Thompson L	NIH-NHLBI	5R61HL154307-05	9/3/2020	8/31/2025	A Vascularized Micro-Organ platform for the study of Brain-BBB-Blood interaction	\$397,303	\$198,652	BIDD	100	\$198,652
Jang C	NIH-NIAAA	5R01AA029124-04	8/1/2021	5/31/2026	Elucidating dietary fructose and alcohol interactions during liver cancer development	\$225,000	\$225,000	SPT	100	\$225,000
Jang C	NIH-NIAAA	3R01AA029124-04S1	6/1/2024	5/31/2025	Elucidating dietary fructose and alcohol interactions during liver cancer development (Diversity Supplement)	\$60,484	\$60,484	ZY	100	\$60,484
Jang C Guertin D (Univ of Mass)	NIH-NIDDK Univ of Mass	5R01DK127175-04	8/4/2021	5/31/2026	Quantitative and functional analysis of brown fat nutrient fluxes in vivo and its role in organ metabolite exchange	\$93,937	\$70,453	SPT	100	\$70,453
Jang C Seldin M	NIH-NIAAA	5R21AA030358-02	9/12/2023	8/31/2025	Elucidating alcohol-induced metabolic remodeling of critical organs	\$262,500	\$196,875	SPT	100	\$196,875
Jarvo E	NSF	CHE1900340-06	8/1/2019	7/31/2025	Mechanism-based development of new nickel-catalyzed stereospecific cross-electrophile coupling reactions of sulfonamides	\$121,699	\$60,850	BIDD	100	\$60,850
Jarvo E	NIH-NIGMS	5R01GM135603-04	9/1/2021	5/31/2025	Stereoselective Nickel-Catalyzed Coupling and Cascade Reactions	\$205,000	\$102,500	BIDD	100	\$102,500
Jin R Shoemaker C (Tufts University)	NIH-NIAID Tufts University	5R01AI173059-02	8/4/2023	7/31/2027	A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents	\$98,881	\$49,441	BIDD	100	\$49,441

Kaiser P	NIH-NIGMS	5R35GM148350-02	3/1/2023	2/29/2028	Ubiquitin and Metabolite Signaling	\$385,918	\$289,439	SPT	100	\$289,439
Kaiser P	NIH-NIGMS	3R35GM148350-02S1	3/1/2024	2/28/2025	Ubiquitin and Metabolite Signaling (Diversity Supplement)	\$54,174	\$40,631	ZY	100	\$40,631
Kaiser P	NIH-NIGMS	3R35GM148350-02S2	3/1/2024	2/28/2025	Ubiquitin and Metabolite Signaling (Equipment Purchase)	\$217,747	\$163,310	SPT	100	\$163,310
Kaiser P Rychnovsky S	NIH-NCI	5R01CA283462-02	7/10/2023	6/30/2028	Mechanisms of mutant p53 reactivation	\$348,047	\$348,047	SPT	50	\$174,024
								BIDD	50	\$174,024
Kelly K Huang Y (Western University of Health Sciences)	NIH-NCI Western University of Health Sciences	5R01CA269653-03	7/1/2022	6/30/2027	Preventing UV-induced immunosuppression and skin carcinogenesis with R-carvedilol	\$6,370	\$6,370	BIDD	100	\$6,370
Kessenbrock K	NIH-NCI	2R01CA234496-06	2/1/2019	7/31/2029	Microenvironmental Regulation of Breast Tumorigenesis	\$311,835	\$311,835	SPT	100	\$311,835
Kessenbrock K Chan K (Method Hospital Research Institute)	NIH-NCI Method Hospital Research Institute	3U54CA274375-03S1	9/1/2024	8/31/2025	A single-cell spatial map characterizing the stromal TME in bladder and breast early-lesions	\$50,000	\$50,000	SPT	100	\$50,000
Kim J	NIH-NCI	5R00CA246058-04	7/1/2020	6/30/2025	Supportive Care Needs in Asian Americans with Metastatic Cancer	\$158,599	\$158,599	CC	100	\$158,599
Kim J	NIH-NCI	3R00CA246058-05S1	4/1/2024	8/31/2025	Supportive Care Needs in Asian Americans with Metastatic Cancer (Diversity Supplement)	\$43,651	\$43,651	ZY	100	\$43,651
Komarova N Wodarz D	NSF	DMS-2152155-03	7/1/2022	6/30/2026	Mutant evolution in spatially structured, hierarchical populations	\$85,282	\$63,962	SPT	100	\$63,962
Komarova N Wodarz D	NSF	MCB-2141651-03	5/1/2022	4/30/2025	Collaborative Research: MODULUS: Copy Number Alterations and Xenobiotic adaptation	\$95,773	\$71,830	SPT	100	\$71,830
Kong M	NIH-NCI	5R01CA244360-04	7/1/2021	6/30/2026	Using dietary glutamine supplementation for melanoma prevention and targeted therapy	\$257,161	\$257,161	SPT	100	\$257,161
Kong M	ACS	DBG-23-1037710-01-TBE-02	7/1/2023	6/30/2025	Role of metabolic microenvironment in cancer metastasis	\$120,000	\$120,000	SPT	100	\$120,000
Kong M	NIH-NIGMS	1R35GM153227-01	9/10/2024	8/31/2029	Role of PP2A family protein phosphatases in nutrient sensing pathways	\$250,000	\$250,000	SPT	100	\$250,000
Kvon E	NIH-NIGMS	5DP2GM149555-03	9/9/2022	8/31/2025	Deciphering the mechanism of long-range gene regulation in vivo	\$300,000	\$150,000	SPT	100	\$150,000
Kvon E	NIH-NICHD	1R01HD115268-01	7/1/2024	4/30/2029	Decoding the Mechanism of Pathogenic Enhancer Mutations In Congenital Limb Disorders	\$255,012	\$127,506	SPT	100	\$127,506
Lara-Gonzalez P	NIH-NIGMS	5R35GM150786-02	7/1/2023	6/30/2028	Developmental regulation of the cell cycle machinery	\$250,000	\$250,000	SPT	100	\$250,000
Lawson D	NIH-NCI	1R01CA237376-05	3/1/2020	2/28/2026	Inflammatory Microenvironment in Brain Metastasis	\$217,313	\$217,313	SPT	100	\$217,313
Lee A	NIH-NIGMS	5R01GM145987-03	6/1/2022	5/31/2026	Acoustic microvortices instrumentation for dosage controlled, high efficiency cell engineering	\$200,000	\$200,000	BIDD	100	\$200,000
Lee A Agrawal A	NIH-NCI	5R33CA267258-03	9/2/2022	8/31/2025	Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy	\$134,058	\$134,058	BIDD	100	\$134,058
Lee F Blanke C (Oregon Health & Science University)	NIH-NCI Oregon Health & Science University	UG1CA189974	8/1/2019	7/31/2025	SWOG NCORP Research Base	\$11,905	\$11,905	ZY	100	\$11,905
Lee F Blanke C (Oregon Health & Science University)	NIH-NCI Oregon Health & Science University	U10CA180888	3/1/2019	2/28/2025	SWOG Network Group Operations Center of the NCTN	\$116,062	\$116,062	ZY	100	\$116,062
Lee S	NIH-NIMHD	5R01MD012778-06 (NCE)	9/26/2017	12/31/2025	Culturally Adapted Multilevel Decision Support Navigation Trial To Reduce Colorectal Cancer Disparity Among At-Risk Asian American Primary Care Patients	\$103,394	\$103,394	CC	100	\$103,394
Lee S Gomez S (UC San Francisco)	NIH-NCI UC San Francisco	1U01CA290831-01	7/8/2024	6/30/2029	A national Asian American cohort for assessing multi-level determinants in cancer etiology: the ASPIRE Cohort	\$116,430	\$116,430	CC	100	\$116,430



Lee S Kawachi I (Harvard University) Redline S (Brigham & Women's Hospital)	NIH-NIMHD	5R01MD015186-05	4/8/2021	1/31/2026	Sleep and health disparities among Asian Americans: role of stressors and protective factors	\$291,427	\$145,714	CC	100	\$145,714
Li W	NIH-NCI	5R01CA193466-09	12/1/2015	2/28/2026	Computational and Experimental Modeling of Alternative Polyadenylation	\$256,528	\$256,528	SPT	100	\$256,528
Li W	NIH-NCI	5R01CA228140-04 (NCE)	2/1/2010	1/31/2026	DNA Methylation Canyons in Human Cancers: Methods, Target Genes and Functional Consequences	\$50,435	\$50,435	SPT	100	\$50,435
Li W Chua K (Palo Alto's Veteran Institute for Research)	NIH-NCI Palo Alto's Veteran Institute for Research	5R01CA268925-04	7/9/2021	6/30/2026	Histone Deacetylation Signaling in Aging and Cancer Pathways	\$5,996	\$5,996	SPT	100	\$5,996
Li W Wang Q (Duke)	NIH-NCI Duke	1R01CA290720-01	5/1/2024	4/30/2029	Elucidating alternative polyadenylation regulation during prostate cancer progression to castration-resistance	\$110,344	\$110,344	SPT	100	\$110,344
Limoli C	NIH-NCI	5R01CA254892-04	7/1/2021	6/30/2026	Improving pediatric brain tumor treatments using FLASH radiotherapy	\$130,516	\$130,516	SPT	100	\$130,516
Limoli C Various V (Consortium)	NIH-NCI	P01CA244091-05	6/1/2020	5/31/2025	Increasing the therapeutic index of brain tumor treatment through innovative FLASH radiotherapy	\$450,140				
Limoli C	NIH-NCI	P01CA244091-AC-05	6/1/2020	5/31/2025	Administrative Core		\$164,829	ZY	100	
Limoli C Loo B (Stanford University) Maxim P (Indiana University) Vozenin M (Centre Hospitalier Universitaire Vaudois)	NIH-NCI	P01CA244091-DPMC-05	6/1/2020	5/31/2025	Dosimetry, Physics & Modeling Core		\$0	ZY	100	
Limoli C	NIH-NCI	P01CA244091-NBC-05	6/1/2020	5/31/2025	Neurobiology Core		\$84,711	ZY	100	
Limoli C Loo B (Stanford University) Maxim P (Indiana University)	NIH-NCI	P01CA244091-P1-05	6/1/2020	5/31/2025	Project 1: Optimizing Treatment Of GBM By Flash		\$82,933	SPT	100	\$82,933
Limoli C Loo B (Stanford University) Max P (Indiana University)	NIH-NCI	P01CA244091-P2-05	6/1/2020	5/31/2025	Project 2: Sparing in Tumor Free Animals		\$68,240	SPT	100	\$68,240
Limoli C Loo B (Stanford University) Maxim P (Indiana University) Spitz D (University of Iowa) Vozenin M (Centre Hospitalier Universitaire Vaudois)	NIH-NCI	P01CA244091-P4-05	6/1/2020	5/31/2025	Project 4: Mechanistic Basics of Flash Effect: Role of O2		\$39,666	SPT	100	\$39,666
Liu C	NIH-NIGMS	5R35GM136297-05	6/1/2020	5/31/2025	Synthetic genetic systems for rapid biomolecular evolution in vivo	\$290,372	\$145,186	BIDD	100	\$145,186
Liu C Kruse/Marks A (Harvard Medical School)	NIH-NCI	5R01CA260415-05	9/10/2020	8/31/2025	Making antibody generation rapid, scalable, and democratic through machine learning and continuous evolution	\$371,407	\$371,407	BIDD	100	\$371,407
Lotfipour S	TRDRP	T34IR8049-01	7/1/2024	6/30/2027	Genetic Mechanisms of Adolescent and Adult Nicotine Use	\$300,000	\$150,000	CC	100	\$150,000
Lotfipour S	TRDRP	T33IP6417-02	12/1/2023	11/30/2025	Mechanisms of a human 3' UTR alpha6 nicotinic receptor polymorphism in adolescent nicotine use	\$250,000	\$125,000	CC	100	\$125,000
Luderer U Shioda T (Mass General)	NIH-NIEHS Mass General	1R01ES035401-01	4/4/2024	2/28/2029	Environmental chemicals impair epigenetic suppression of the endogenous retrovirus HML-2 in human primordial germ cells, predisposing the next generation to malignancies through HML-2 reactivation	\$64,593	\$64,593	CC	100	\$64,593

Luo R	NIH-NIGMS	2R35GM130367-06	9/1/2019	1/31/2030	Multi-scaled Modeling of Electrostatic and Polarization Effects in Biomolecules	\$275,000	\$137,500	BIDD	100	\$137,500
Marangoni F	MRA	929155-03	6/1/2022	5/31/2025	Mechanisms and relevance of Treg expansion after PD-1 blockade in melanoma	\$85,000	\$85,000	SPT	100	\$85,000
Marangoni F	DOD/CDMRP	HT94252311024-02	9/15/2023	8/14/2026	Intravital imaging of melanoma tumors for mechanism discovery and patient surveillance after checkpoint blockade immunotherapy	\$146,571	\$146,571	SPT	100	\$146,571
Marsden M zhen A (UCLA)	NIH-NIAID UCLA	5R01AI172727-03	6/25/2022	5/31/2027	Induction of autophagy to enhance CAR T cells in HIV cure approaches	\$191,368	\$95,684	SPT	100	\$95,684
Masri S	NIH-NCI	5R01CA244519-05	3/1/2020	2/28/2026	Circadian Clock Disruption and Colorectal Cancer	\$205,875	\$205,875	SPT	100	\$205,875
Masri S	NIH-NCI	5R01CA244519-05S1	3/1/2024	2/28/2025	Circadian Clock Disruption and Colorectal Cancer (Equipment Purchase)	\$41,438	\$41,438	ZY	100	\$41,438
Masri S Waterman M	NIH-NCI	5R01CA259370-04	1/1/2022	12/31/2026	Circadian Clock and Myc-dependent Regulation of Cellular Transformation	\$332,730	\$332,730	SPT	100	\$332,730
Milam J	NIH-NCI	5R01CA237230-05 (NCE)	1/1/2021	12/31/2025	Project Milestones: Young Adult Cancer Survivorship	\$196,996	\$196,996	CC	100	\$196,996
Milam J Miller K (USC)	NIH-NCI USC	5R01CA261888-04	9/6/2021	8/31/2026	Individual, cultural, and area-based factors associated with survivorship care among Asian/Asian-American childhood cancer survivors.	\$173,363	\$173,363	CC	100	\$173,363
Milam J Miller K (University of Southern California)	NIH-NCI University of Southern California	5R37CA256867-04	3/1/2021	2/28/2026	Social Health, Activity Behaviors, and Quality of Life among Young Adult Cancer Survivors: A Longitudinal Study	\$8,371	\$8,371	CC	100	\$8,371
Milner T Feldman M (UTHSC SA)	NIH-NHLBI	5R01HL163582-03	5/1/2022	4/30/2026	Transvenous Optoacoustic-Ultrasound Guided Cold Laser Wire for Crossing Coronary Chronic Total Occlusion	\$183,516	\$91,758	BIDD	100	\$91,758
Mobley D	NIH-NIGMS	5R35GM148236-02	3/1/2023	2/29/2028	Accelerating drug discovery via ML-guided iterative design and optimization	\$380,000	\$190,000	BIDD	100	\$190,000
Morey B Kroenke C (Kaiser Research Foundation)	NIH-NCI Kaiser Research Foundation	5R01CA230440-05	7/1/2019	3/31/2025	Social Networks and Disparities in Health Behaviors and Breast Cancer Outcomes in Immigrant Women	\$15,873	\$15,873	CC	100	\$15,873
Nelson E	ACS	DICR INTR-24-1297195-01-DICR INTR-01	1/1/2025	12/31/2027	Cultivating Undergraduate Research Excellence in Cancer (CURE-Cancer)	\$44,000	\$44,000	ZY	100	\$44,000
Ng S Tsukamoto H (USC)	NIH-NIAAA USC	2P50AA011999-26	5/10/2024	4/30/2025	2024 Pilot Project: Multi-omic profiling of the IL-17/NF-kB pathway to track and target steatohepatitis and hepatocellular carcinoma clones	\$35,000	\$35,000	SPT	100	\$35,000
Nie Q	NIH-NIGMS	1R01GM152494-01	9/20/2024	6/30/2028	Development of new tools for analyzing cell-cell communication using spatial transcriptomic data	\$260,000	\$195,000	SPT	100	\$195,000
Nie Q Dai X Lander A Lowengrub J	NSF	DMS1763272-05 (NCE)	7/1/2018	6/30/2025	NSF-Simons Center for Multiscale Cell Fate Research	\$1,333,885	\$1,000,414	SPT	100	\$1,000,414
Nyamathi A	NIH-NCI	5R01CA285063-02	8/1/2023	7/31/2028	Secondary Cervical Cancer Prevention of Vulnerable Women with HPV and HIV Co-infection in India	\$476,005	\$476,005	CC	100	\$476,005
Paegel B	NIH-NIGMS	5R35GM140890-05	4/1/2021	1/31/2026	Activity-Based DNA-Encoded Library Technology	\$225,000	\$168,750	BIDD	100	\$168,750
Pandey P	NIH-NCI	1R50CA283816-01	9/3/2024	8/31/2029	Quantitative in vivo dosimetry for radiotherapy using model-based X-ray-induced acoustic computed tomography	\$51,101	\$51,101	BIDD	100	\$51,101
Pannunzio N	NIH-NCI	5R01CA276470-02	2/15/2024	1/31/2029	Aberrant V(D)J recombination in B cells initiates lymphoid malignancy	\$211,495	\$211,495	SPT	100	\$211,495
Pannunzio N Frock R (Stanford University)	NIH-NCI	5R37CA266042-04	2/14/2022	1/31/2027	Defining the Mechanism of Genome Rearrangements in Ph-Like ALL to Determine Predictive Markers in High-Risk Hispanic Populations	\$247,494	\$247,494	SPT	100	\$247,494
Payan D	TRDRP	T32KT4713-03	7/1/2022	6/30/2027	Policy surveillance and implementation of local flavored tobacco product sales bans in California	\$205,550	\$154,163	CC	100	\$154,163
Penner R	NSF	CBET-2149631-04	9/1/2021	8/31/2025	The Aptamer BioResistor: A Broadly Applicable Protein Biosensor with Dip-and-Read Simplicity for Point-of-Care Diagnostics	\$85,337	\$64,003	BIDD	100	\$64,003
Penner R	NSF	CHE-2201042-03	8/1/2022	7/31/2025	Chemical Sensors Based Upon Metal Nanowires and Nanogaps in Metal Nanowires Transduced Using Impedance	\$104,676	\$52,338	BIDD	100	\$52,338
Plikus M Nie Q	NIH-NIAMS	5R01AR079150-04	2/1/2022	11/30/2026	Tissue size and precision control in growing hair follicles	\$322,612	\$161,306	SPT	100	\$161,306

Plikus M Scumpia P (UCLA)	NIH-NIAMS UCLA	5R01AR079470-04	9/1/2021	8/31/2025	Leveraging immune-fibroblast interactions for biomaterial induced skin regeneration	\$140,530	\$70,265	SPT	100	\$70,265
Potma E	NIH-NIBIB	5R21EB034084-02	7/1/2023	6/30/2025	Broadband Focusing For Extreme Multimodal Microscopy	\$100,000	\$50,000	BIDD	100	\$50,000
Poulos T	NIH-NIGMS	5R35GM131920-05 (NCE)	6/1/2019	5/31/2025	Metalloenzyme structure, function, and as targets for neurodegeneration and bacterial pathogenesis	\$192,194	\$96,097	BIDD	100	\$96,097
Prescher J Shaner N (UC San Diego)	NIH-NCI UC San Diego	5R01CA279813-02	1/1/2024	12/31/2028	New tools for quantitative non-invasive recording of biochemical signals	\$104,180	\$104,180	BIDD	100	\$104,180
Pronin S	NIH-NIGMS	5R35GM153231-02	3/5/2024	1/31/2029	Development of new methods and strategies for the synthesis of complex molecules	\$225,000	\$112,500	BIDD	100	\$112,500
Qiao F	NIH-NIGMS	5R35GM149572-02	4/13/2023	3/31/2028	Molecular Mechanisms of Telomere Length Homeostasis	\$250,000	\$250,000	SPT	100	\$250,000
Qiao F	NIH-NIGMS	3R35GM149572-02S1	4/1/2024	3/31/2025	Molecular Mechanisms of Telomere Length Homeostasis (Equipment Purchase)	\$246,978	\$246,978	ZY	100	\$246,978
Qu P	NIH-NCI	1R01CA297869-01	7/1/2024	6/30/2028	SCH: Individualized learning and prediction for heterogeneous multimodal data from wearable devices	\$198,693	\$198,693	CC	100	\$198,693
Rahmatpanah F	NIH-NCI	5R01CA226570-05 (NCE)	4/3/2019	3/31/2025	Aggressive prostate cancer of African Americans is correlated with regulation of Immunoregulatory Genes in stroma	\$179,785	\$179,785	CC	100	\$179,785
Razorenova O	NIH-NCI	5R21CA280564-02	1/1/2024	12/31/2025	Therapeutic targeting of VHL-deficient clear cell renal cell carcinoma	\$126,225	\$126,225	SPT	100	\$126,225
Richardson D	NIH-NCI	5R01CA242852-05 (NCE)	9/1/2021	8/31/2025	Low-Dose Exposure to Ionizing Radiation in Adulthood and Subsequent Cancer	\$354,465	\$354,465	CC	100	\$354,465
Richardson D	CDC-NIOSH	1R01OH012527-01 (NCE)	9/1/2021	7/31/2025	Occupational Exposure to Ionizing Radiation: Models for Policy Making	\$49,791	\$49,791	CC	100	\$49,791
Sadigh G	NIH-NCI	5R01CA262312-03	8/10/2022	7/31/2027	Improving medication adherence using a CONnected CUsomized Treatment Platform (CONCURxP)	\$283,372	\$283,372	CC	100	\$283,372
Sadigh G TB D (Emory University)	NIH-NCI	5R01CA272680-03	1/4/2023	12/31/2027	Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer patients	\$202,230	\$202,230	CC	100	\$202,230
Schilling T	NSF	MCB-2028424-05	9/1/2020	8/31/2025	MODULUS:RoL: Uncovering Roles of Cell Fate Decisions in Migrating Neural Crest Cells	\$168,867	\$84,433	SPT	100	\$84,433
Schilling T Nie Q	NIH-NIDCR	5R01DE030565-04	4/1/2021	3/31/2026	Dissecting single cell dynamics that coordinate neural crest migration and diversification	\$344,831	\$172,416	SPT	100	\$172,416
Seldin M	NIH-NIDDK	5DP1DK130640-04	9/17/2021	7/31/2026	Integrative approaches to dissection of endocrine communication	\$377,885	\$188,943	SPT	100	\$188,943
Seldin M	NIH-NIDDK	3DP1DK130640-04S1	4/26/2024	7/31/2026	Integrative approaches to dissection of endocrine communication (Diversity Supplement)	\$59,714	\$29,857	ZY	100	\$29,857
Sevrioukova I	NIH-NIEHS	5R01ES025767-09	6/1/2016	1/31/2026	Toxicological importance of CYP3A4 catalysis and inhibition	\$357,704	\$268,278	BIDD	100	\$268,278
Shah P	NIH-NCI	1R21CA294195-01	9/1/2024	8/31/2026	Virtual Digital Histopathology with Explainable Deep Learning for Prostate Cancer Diagnosis	\$144,389	\$144,389	BIDD	100	\$144,389
Shi X	NIH-NIGMS	5DP2GM150017-03	9/1/2022	8/31/2025	Gel-based Optical-isolation Single-Cell 3D Spatial Multiomics	\$300,000	\$225,000	BIDD	100	\$225,000
Shi X	NSF	CBET-2341058-01	7/1/2024	6/30/2029	Optogel Proteomics: unbiased subcellular proteomics powered by photoreactions in hydrogel	\$112,787	\$112,787	BIDD	100	\$112,787
Shi Y	NIH-NIGMS	5R35GM149294-02	5/1/2023	2/29/2028	Mechanisms and regulation of mRNA 3' processing	\$305,672	\$229,254	SPT	100	\$229,254
Shi Y	NIH-NIAID	3R01AI170840-03S1	8/15/2023	4/30/2025	mRNA alternative polyadenylation in B cell development (Diversity Supplement)	\$60,484	\$30,242	ZY	100	\$30,242
Shi Y Sciammas R (UC Davis)	NIH-NIAID	5R01AI170840-03	5/26/2022	4/30/2027	mRNA alternative polyadenylation in B cell development	\$398,992	\$199,496	SPT	100	\$199,496
Shi Y Seelig G (Univ Washington)	NIH-NCI	1R01CA297834-01	2/1/2025	1/31/2030	Decode polyadenylation in health and disease	\$207,336	\$207,336	SPT	100	\$207,336
Suetterlin C Tan M	NIH-NIAID	5R01AI153410-05	7/17/2020	6/30/2025	Primary cilia loss and cell cycle re-entry in Chlamydia-infected cells	\$338,207	\$169,104	SPT	100	\$169,104
Sun S	NIH-NIGMS	5R01GM141424-04	9/9/2021	7/31/2026	Elucidating the molecular basis of lncRNA evolution for mammalian dosage compensation	\$210,000	\$105,000	SPT	100	\$105,000

Tanjasiri S Brown A (UCLA)	NIH-NIMHD UCLA	5P50MD017366-04	9/24/2021	6/30/2026	UCLA-UCI Center for Eliminating Cardio-Metabolic Disparities in Multi-Ethnic Populations (UC END-DISPARITIES) - Community Engagement Core	\$135,989	\$67,995	ZY	100	\$67,995
Tanjasiri S Tomalsky M (California State University Fullerton)	NIH-NCI	5P20CA253254-04	9/23/2021	8/31/2025	2/2 CSUF/UCI-CFCCC Cancer Health Equity Research Partnership (CHERP)	\$143,595				
Tanjasiri S Bristow R	NIH-NCI	5P20CA253254-PP2-04	9/23/2021	8/31/2025	Examining the disparities in ovarian cancer survival among Asian Americans		\$45,750	CC	100	\$45,750
Tanjasiri S Razorenova O	NIH-NCI	5P20CA253254-PP1-04	9/23/2021	8/31/2025	Racial disparity in triple-negative breast cancer lipid metabolism		\$45,750	SPT	100	\$45,750
Tanjasiri S Tomalsky M (California State University Fullerton)	NIH-NCI	5P20CA253254-AC-04	9/23/2021	8/31/2025	Administrative Core		\$38,991	ZY	100	
Tewari K Wolmark N (NRG)	NIH-NCI NRG	U10CA180868	3/1/2019	2/28/2025	NRG Oncology	\$44,325	\$44,325	ZY	100	\$44,325
Thiel de Bocanegra H	NIH-NLM	5G08LM014109-03	9/1/2022	7/31/2025	Reproductive Health Equity in Afghan and Syrian newcomers through digital health literacy	\$133,175	\$66,588	CC	100	\$66,588
Tian L Kaur B (Augusta University)	NIH-NINDS Augusta University	1R61NS128191-01A1	9/9/2024	6/30/2026	Development of murine glioblastoma model for oncolytic HSV therapy	\$14,441	\$14,441	SPT	100	\$14,441
Tobias D Ladokhin A (Univ Kansas MC)	NIH-NIGMS Univ Kansas MC	5R01GM145991-02	9/1/2023	7/31/2027	Elucidating the Molecular Mechanisms of Conformational Switching during Protein Insertion into Membranes	\$51,436	\$51,436	BIDD	100	\$51,436
Tombola F	NIH-NIGMS	5R01GM098973-12	7/1/2011	5/31/2026	Mechanisms Of Permeation And Gating Of Voltage-Sensing Domains	\$323,196	\$242,397	BIDD	100	\$242,397
Van Etten R	NIH-NCI	1R01CA280606-01A1	5/1/2024	4/30/2029	Mechanisms of treatment-free remission in a mouse model of chronic myeloid leukemia	\$228,750	\$228,750	SPT	100	\$228,750
Vanderwal C	NIH-NIGMS	5R35GM145252-03	9/1/2022	6/30/2027	Chemical Synthesis of Bioactive Diterpenoids	\$300,000	\$150,000	BIDD	100	\$150,000
Venugopalan V	NIH-NIMH	5R01GM129426-04 (NCE)	6/1/2019	3/31/2025	A Biophotonics Platform for Mechanotransduction and Metabolic Microscopy	\$206,246	\$206,246	BIDD	100	\$206,246
Vieira V Metayer C (UC Berkeley)	NIH-NIEHS UC Berkeley	5R01ES032196-03 (NCE)	9/3/2021	8/31/2025	Exposure to per- and polyfluoroalkyl substances (PFAS) and risk of cancer in children	\$65,564	\$65,564	CC	100	\$65,564
Villalona Calero M Yu J	NIH-NCI	5R01CA266457-04	8/16/2022	11/30/2027	Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors	\$337,061	\$337,061	SPT	100	\$337,061
Wagar L Zhong Q (CHOC)	NIH-NIAID	5R01AI173023-02	6/1/2023	5/31/2028	Investigating protective adaptive immune responses to influenza antigens using human tonsil organoids	\$362,171	\$181,086	SPT	100	\$181,086
Walsh C	CIRM	1NFR6.2-15368-01	7/1/2024	6/30/2029	UCI CIRM SRL	\$615,206	\$307,603	SPT	100	\$307,603
Wang W	NIH-NIGMS	5R01GM126048-08	2/1/2018	1/31/2027	Lipid signaling in Hippo pathway regulation	\$206,000	\$206,000	SPT	100	\$206,000
Wang W	NIH-NIGMS	5R01GM143233-03	8/4/2022	7/31/2026	Interplay of heavy metal homeostasis and cell growth-related signaling networks	\$200,000	\$150,000	SPT	100	\$150,000
Wilder-Smith P Rongguang L (University of Arizona)	NIH-NIDCR University of Arizona	5R01DE030682-04	8/10/2021	7/31/2026	Multimodal Intraoral Imaging System for Oral Cancer Detection and Diagnosis in Low Resource Setting	\$30,315	\$30,315	BIDD	100	\$30,315
Xiang L	NIH-NCI	5R37CA240806-06	9/20/2019	8/31/2026	Academic-Industry Partnership for the Translation of a 4D in vivo Dosimetry Approach for Radiation Therapy	\$299,926	\$299,926	BIDD	100	\$299,926
Xiang L Chen Y (Univ of OK) Ren L (Univ of MD)	NIH-NCI	1U01CA288351-01	8/12/2024	7/31/2029	3D In vivo dosimetry for FLASH proton therapy	\$171,039	\$171,039	BIDD	100	\$171,039
Yaghmai V Li D (Cedars Sinai Medical Center)	NIH-NCI Cedars Sinai Medical Center	5R01CA260955-04	9/1/2021	8/31/2026	Predicting Pancreatic Ductal Adenocarcinoma (PDAC) through Artificial Intelligence Analysis of Pre-diagnostic CT Images	\$67,965	\$67,965	BIDD	100	\$67,965
Yu J	CIRM	TRAN1-14003-B-01	8/26/2024	5/31/2026	Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1a	\$1,516,988	\$1,516,988	SPT	100	\$1,516,988

Yu J Finley S (USC)	NIH-NCI USC	5U01CA275808-03	12/1/2024	8/31/2027	Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy	\$72,702	\$72,702	SPT	100	\$72,702
Zell J	NIH-NCI	1R50CA285412-01	9/24/2024	8/31/2029	Advancing novel cancer preventive and therapeutic strategies across the modern NCI clinical trial networks	\$125,011	\$125,011	CC	100	\$125,011
Zhang Z Yaghmai V	NIH-NCI	5R01CA241532-05	3/15/2020	2/28/2026	Image-Guided Interventional Combination Liver Cancer Immunotherapy	\$230,459	\$230,459	BIDD	100	\$230,459
Zhang Z Yaghmai V	NIH-NCI	5R01CA209886-08	1/4/2021	7/31/2028	MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer	\$237,500	\$237,500	BIDD	100	\$237,500
Zhao W Gratton E	NIH-NIGMS	5R01GM147741-03	9/22/2022	8/31/2026	Spatial proteomics using highly parallel fluorescence hyperspectral and lifetime imaging	\$438,300	\$219,150	BIDD	100	\$219,150
Zheng K Hanauer D (University of Michigan)	NIH-NCI University of Michigan	5U24CA269315-02	9/15/2023	8/31/2025	Extending the Capabilities and Reach of EMERSE in Support of Cancer Research	\$7,800	\$7,800	BIDD	100	\$7,800
Zi X	NIH-NCI	1UG3CA290368-01	6/1/2024	4/30/2027	Natural products for targeting Skp2 in cancer interception	\$212,500	\$212,500	CC	100	\$212,500
Zi X	DOD/CDMRP	HT9425-24-1-0656-01	6/1/2024	5/31/2027	An epigenetic approach for alleviating enzalutamide resistance in prostate cancer	\$100,000	\$100,000	CC	100	\$100,000
Zi X Agrawal A Lilly M (Medical University of South Carolina)	NIH-NCI	5R01CA260351-04	12/9/2021	11/30/2026	Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer	\$182,063	\$182,063	CC	100	\$182,063
Peer-Reviewed Research Subtotals						\$47,230,477	\$37,671,730			\$37,383,201

Non-Peer-Reviewed Research

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Abi-Jaoudeh N	OM1, INC.	2019-ONC-02	6/30/2022	6/29/2025	REGISTRY TO EVALUATE EFFECTIVENESS AND SAFETY OF THE NANOKNIFE SYSTEM FOR THE ABLATION OF STAGE 3 PANCREATIC ADENOCARCINOMA	\$0	\$0	BIDD	100	\$0
Abi-Jaoudeh N	Sirtex	STX2001	3/16/2023	3/15/2027	A prospective, multicenter, open-label single arm study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres Y-90 resin microspheres on duration of response (DoR) and objective response rate (ORR) in unresectable hepatocellular carcinoma (HCC) patients	\$37,907	\$37,907	BIDD	100	\$37,907
Abi-Jaoudeh N	Teclison USA Ltd	TL-228071-01	6/12/2024	6/12/2025	A novel locoregional therapy for Hepatocellular Carcinoma in different animal models	\$114,460	\$114,460	BIDD	100	\$114,460
Abi-Jaoudeh N	ABK BIOMEDICAL USA INC.	ABK-CA-PROT-85	3/14/2024	3/13/2028	Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)	\$110,912	\$110,912	BIDD	100	\$110,912
Abi-Jaoudeh N	IMPACT BIOTECH LTD	CLIN2301 PNCM101	6/10/2024	6/5/2028	A Phase 1 trial to evaluate safety and preliminary efficacy of endovascularly applied Padeliporfin vascular targeted photodynamic therapy for patients with locally advanced unresectable pancreatic ductal adenocarcinoma	\$28,041	\$28,041	BIDD	100	\$28,041
Anton-Culver H	Smith Fdn	LVSF-5653648-01 (NCE)	5/1/2022	4/30/2025	Collaboration with the Breast Cancer Consortium (BCAC) in the Confluence Project to Study the Genetic Architecture of Breast Cancer	\$16,286	\$16,286	CC	100	\$16,286
Anton-Culver H	Smith Fdn	LVSF-5682439-01 (NCE)	5/1/2023	4/30/2025	Follow up, Genetic Associations, and Survival of Breast Cancer in the UCI Confluence Breast Cancer Cohort	\$11,924	\$11,924	CC	100	\$11,924
Anton-Culver H	Smith Fdn	LVSF-5715573-01	5/1/2024	4/30/2025	Characterization of breast and ovarian cancer in the national NIH All of Us Research Program compared to the population-based SEER and California Cancer Registry	\$25,000	\$25,000	CC	100	\$25,000
Banker R	AstraZeneca PLC	D798EC00001	6/20/2024	6/17/2028	A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)	\$24,415	\$24,415	CC	100	\$24,415
Banker R	PRA Inc	TAK-676-1002	10/28/2024	10/28/2028	An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors	\$30,421	\$30,421	CC	100	\$30,421
Banker R	Merck Sharp & Dohme	V940-007-1154	12/4/2024	10/31/2031	A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK- 3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC) (INTerpath-007)	\$44,647	\$44,647	CC	100	\$44,647
Banker R	FLAMINGO THERAPEUTICS	FLM-6774-201	12/19/2023	12/10/2027	An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	\$88,643	\$88,643	CC	100	\$88,643
Benavente C	American Lung Association	LCD-1034555-02	7/1/2023	6/30/2025	Harnessing the ubiquitin system as a therapeutic approach in SCLC	\$50,000	\$50,000	SPT	100	\$50,000
Bota D	Agios	AG881-C-004	1/7/2020	12/31/2025	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of AG-881 in Subjects with Residual/Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation.	\$21,441	\$21,441	SPT	100	\$21,441
Bota D	Tocagen	TG511-15-01	10/23/2015	12/31/2025	A Phase II/III Randomized, Open Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma	\$23,650	\$23,650	CC	100	\$23,650
Bota D	Janssen R&D LLC	42756493BLC2001	3/4/2022	3/31/2025	A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations	\$18,259	\$18,259	BIDD	100	\$18,259
Bota D	VBI VACCINES INC.	VBI-1901-01	12/1/2022	12/31/2025	A Three-part Phase I/II Dose-Escalation Study to Define the Safety Tolerability and Optimal Dose of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM subjects	\$48,709	\$48,709	BIDD	100	\$48,709

Bota D	Boehringer Ingelheim Pharmaceuticals Inc	1438-0003	12/11/2023	12/5/2027	A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3	\$107,957	\$107,957	BIDD	100	\$107,957
Bota D	NERVIANO MEDICAL SCIENCES SRL	PARPA-293-002	11/25/2024	11/22/2028	A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma	\$30,421	\$30,421	BIDD	100	\$30,421
Brem E	GENMAB US, INC.	GCT3013-05	3/3/2022	3/2/2025	A Randomized Open-Label Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma	\$12,336	\$12,336	SPT	100	\$12,336
Brem E	SORRENTO THERAPEUTICS, INC.	38DART-RRMM-101	8/17/2022	9/30/2025	A Phase 1b Open-Label Study of the Safety and Efficacy of Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor (DAR)-T Cells in Patients with Relapsed or Refractory Multiple Myeloma	\$29,367	\$29,367	SPT	100	\$29,367
Brem E	ICONClinRes	KT-US-473-0133 (ZUMA-22)	2/4/2023	12/31/2027	A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucef Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma	\$83,311	\$83,311	SPT	100	\$83,311
Brem E	Morphosys Ag	MOR208C414	1/22/2024	1/22/2028	REAL-MIND Prospective Multicenter Observational Study of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Starting Second- or Third-Line Therapy and Not Receiving Autologous Stem Cell Transplants	\$21,552	\$21,552	SPT	100	\$21,552
Brem E	Regeneron	R1979-ONC-2105	2/15/2024	2/15/2028	A Phase III, Open label, Randomized Study Comparing the Safety and Efficacy of Odonextamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with CHOP (O-CHOP) versus Rituximab in Combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)	\$42,495	\$42,495	SPT	100	\$42,495
Brem E	Regeneron	R1979-HM-2298	3/15/2024	3/15/2028	A Phase III, Open-Label, Randomized Study to Compare the Safety and Efficacy of Odonextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Investigator's Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)	\$30,286	\$30,286	SPT	100	\$30,286
Brem E	AbbVie	M23-362	8/15/2024	8/15/2029	A Phase II, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) When Administered in the Outpatient Setting	\$42,945	\$42,945	SPT	100	\$42,945
Burke T	UCOP	C25CR8552-01	10/1/2024	9/30/2025	Determining mechanisms of anti-tumor synergy elicited by innate immune agonist cancer therapies	\$85,000	\$85,000	BIDD	100	\$85,000
Chow W	IGM BIOSCIENCES, INC.	IGM-8444-001	10/18/2022	11/30/2025	AN OPEN-LABEL MULTICENTER PHASE I STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLY DIAGNOSED CANCERS	\$88,993	\$88,993	SPT	100	\$88,993
Chow W	Novotech Clinical Research USA LLC	SGN-P01-001	2/3/2023	2/2/2027	Phase I, Open-label study to evaluate safety, tolerability and preliminary efficacy of modified Salmonella typhimurium SGN1 in Patients with Advanced Solid Tumor	\$72,004	\$72,004	SPT	100	\$72,004
Chow W	Brst Myrs Sq	CA224127	3/31/2023	3/30/2027	A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma	\$468,831	\$468,831	SPT	100	\$468,831
Chow W	Topalliance Biosciences Inc	TAB004	4/6/2023	4/5/2027	A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma	\$72,597	\$72,597	SPT	100	\$72,597
Chow W	SANDOZ INC.	CGME751A12101	11/24/2024	11/20/2028	A randomized, double-blind, parallel-group study to compare pharmacokinetics of GME751 (proposed pembrolizumab biosimilar) and US-licensed and EU authorized Keytruda in participants with stage II and III melanoma requiring adjuvant treatment with pembrolizumab	\$8,905	\$8,905	SPT	100	\$8,905
Ciurea S	CELULARITY INC.	CYNK-001-AML-001	10/1/2022	9/30/2025	A PHASE I MULTI-DOSE STUDY OF HUMAN PLACENTAL HEMATOPOIETIC STEM CELL DERIVED NATURAL KILLER CELLS (CYNK-001) WITH OR WITHOUT RECOMBINANT HUMAN INTERLEUKIN-2 (RHIL-2) IN ADULTS WITH PRIMARY OR SECONDARY ACUTE MYELOID LEUKEMIA (AML) IN MORPHOLOGIC COMPLETE REMISSION WITH MINIMAL RESIDUAL DISEASE (MRD) OR RELAPSED/REFRACTORY AML	\$14,010	\$14,010	SPT	100	\$14,010
Ciurea S	Adicet Therapeutics Inc	ADI-20200101	4/26/2023	4/26/2027	A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta T Cells in Adults with B Cell Malignancies	\$80,895	\$80,895	SPT	100	\$80,895

Ciurea S	Celgene	CA089-1043	5/22/2024	5/22/2028	A Randomized, Open-Label, Phase III Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)	\$92,288	\$92,288	SPT	100	\$92,288
Ciurea S	CARTESIAN THERAPEUTICS, INC.	DC15-MM-1	8/12/2024	8/12/2028	Descartes-15 for Patients with Relapsed/Refractory Multiple Myeloma	\$28,041	\$28,041	SPT	100	\$28,041
Ciurea S	IMPACT BIO USA INC.	MPCT-012L	4/25/2024	4/25/2028	Phase I/II Multi-Center Study Evaluating the Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma	\$30,723	\$30,723	SPT	100	\$30,723
Ciurea S	CYTOAGENTS, INC.	CTA-2101	7/24/2024	6/30/2028	Phase IB/IIA Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients With Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy	\$27,824	\$27,824	SPT	100	\$27,824
Coombs C	Beigene	BGB-11417-301	3/28/2024	3/21/2028	A Phase III, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia	\$136,971	\$136,971	BIDD	100	\$136,971
Coombs C	CARNA BIOSCIENCES, INC.	C1763102	11/1/2023	11/1/2027	A Phase IB Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma	\$160,709	\$160,709	BIDD	100	\$160,709
Coombs C	ANALYSIS GROUP, INC	228334	10/2/2024	8/31/2028	Chronic Lymphocytic Leukemia (CLL) Collaborative Study Of Real-World Evidence (CORE)	\$3,955	\$3,955	BIDD	100	\$3,955
Copp S	Chan-Zuck	2024-337801-01	3/1/2024	2/29/2028	Molecular deep-tissue imaging in the NIR-II transparency window	\$112,968	\$84,726	BIDD	100	\$84,726
Cozen W Desai P (Cornell)	DOD Misc Cornell	226659-2-02	9/30/2023	9/29/2026	Mutational and Aging Risk Factors for Myelodysplastic Syndrome	\$6,968	\$6,968	CC	100	\$6,968
Dayyani F	Exelixis	UCI-18-124	2/4/2020	2/4/2026	Phase II Study of Cabozantinib Combined with Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma	\$69,206	\$69,206	SPT	100	\$69,206
Dayyani F	Genentech	GO42216	10/1/2020	9/30/2026	A PHASE I/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORPHEUS-LIVER)	\$66,442	\$66,442	BIDD	100	\$66,442
Dayyani F	Exelixis	XL184-IST119	4/1/2021	4/30/2026	A Phase 1 Study of the Combination of Cabozantinib with Trifluridine/Tipiracil (TAS-102) in patients with metastatic colorectal adenocarcinoma (mCRC)	\$82,912	\$82,912	SPT	100	\$82,912
Dayyani F	ERASCA, INC.	ERAS-007-03	3/8/2022	3/7/2025	A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)	\$134,412	\$134,412	SPT	100	\$134,412
Dayyani F	Hoffman LaRoche	GO42661	6/1/2022	5/31/2025	A PHASE II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED ADVANCED BILIARY TRACT CANCER.	\$0	\$0	SPT	100	\$0
Dayyani F	Amgen	20210098.00	7/1/2022	6/30/2025	A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)	\$80,868	\$80,868	SPT	100	\$80,868
Dayyani F	WORLDWIDE CLINICAL TRIALS, INC.	MRG004A-001	4/5/2022	3/31/2025	An Open-Label Multi-center Phase I/II Dose Escalation and Expansion Study to Assess the Safety Tolerability Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors	\$105,445	\$105,445	SPT	100	\$105,445
Dayyani F	TRANSTHERA SCIENCES (NANJING), INC.	TT420X1103	7/1/2022	6/30/2025	A Phase Ib/II Multicenter Open-Label Study of TT-00420 Tablet as Monotherapy or in Combination Regimens in Patients with Advanced Solid Tumors	\$256,954	\$256,954	SPT	100	\$256,954
Dayyani F	COSMO TECHNOLOGIES LIMITED	CB-03-10/01	11/1/2022	10/31/2025	Open-Label Multicenter Phase I Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 with Dose Expansion Phase in Subjects with Advanced Solid Tumors	\$121,330	\$121,330	SPT	100	\$121,330
Dayyani F	AstraZeneca PLC	D8151C00001	11/7/2022	11/6/2025	A Phase II Study to Evaluate the Safety Pharmacokinetics and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours	\$107,584	\$107,584	SPT	100	\$107,584
Dayyani F	Amgen	200420755	2/27/2023	2/26/2027	A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301)	\$71,618	\$71,618	SPT	100	\$71,618



Dayyani F	Arcus Biosciences, Inc	STAR-221	4/7/2023	4/6/2027	A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma	\$94,632	\$94,632	SPT	100	\$94,632
Dayyani F	Xiamen Lp Pharmaceutical Co Ltd	LP-CT-PALO-202101	5/25/2023	5/24/2027	A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy	\$25,540	\$25,540	SPT	100	\$25,540
Dayyani F	Tvardi Therapeutics Inc	TVD-101-001H	6/21/2023	6/21/2027	A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma	\$254,343	\$254,343	SPT	100	\$254,343
Dayyani F	Eisai Inc	E7386-G000-201	6/1/2023	5/31/2027	An Open-Label, Multicenter, Phase Ib/II Study of E7386 in Combination with Pembrolizumab in Previously Treated Subjects with Selected Solid Tumors	\$47,022	\$47,022	SPT	100	\$47,022
Dayyani F	Boehringer Ingelheim Pharmaceuticals Inc	1454-001	7/31/2023	7/31/2027	A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial Of Bi 765049 And Bi 765049 + Ezabenlimab Administered By Repeated Intravenous Infusions In Patients With Malignant Solid Tumors Expressing B7 H6	\$190,753	\$190,753	SPT	100	\$190,753
Dayyani F	PRA Inc	TACH101-CS-0001	7/25/2023	7/25/2027	A Phase I/IIb Open-Label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Patients with Advanced or Metastatic Solid Tumors	\$195,621	\$195,621	SPT	100	\$195,621
Dayyani F	Brst Myrs Sq	CA115-001	8/31/2023	8/31/2027	A Phase Ib/II Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer	\$39,393	\$39,393	SPT	100	\$39,393
Dayyani F	Astra Z	D7987C00001	10/4/2023	10/4/2027	Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)	\$178,892	\$178,892	SPT	100	\$178,892
Dayyani F	Covance	MPSA-153-001	10/4/2023	10/4/2027	Phase I/II study on safety and efficacy of NMS-01940153E in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy	\$44,462	\$44,462	SPT	100	\$44,462
Dayyani F	AstraZeneca PLC	D4191C00140	10/13/2023	10/12/2027	A Phase IIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers	\$92,307	\$92,307	SPT	100	\$92,307
Dayyani F	AbbVie	M24-147	10/1/2023	9/30/2027	A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC	\$45,805	\$45,805	SPT	100	\$45,805
Dayyani F	Brst Myrs Sq	CA043-001	11/20/2023	11/17/2027	A Phase I/II First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors	\$36,502	\$36,502	SPT	100	\$36,502
Dayyani F	SloanKettter	21-324	3/13/2024	2/26/2028	Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer	\$6,800	\$6,800	SPT	100	\$6,800
Dayyani F	AbbVie	M24-052	3/19/2024	3/12/2028	A Phase II/III, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment	\$79,872	\$79,872	SPT	100	\$79,872
Dayyani F	Genentech	ML44719	3/26/2024	3/20/2028	A Phase II, Open-label, Multi-Cohort, Multicenter Study in Patients With Hepatocellular Carcinoma and Child-Pugh B Cirrhosis	\$33,673	\$33,673	SPT	100	\$33,673
Dayyani F	SeaGen	SGNDV-004	4/5/2024	3/20/2028	A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors	\$33,152	\$33,152	SPT	100	\$33,152
Dayyani F	AstraZeneca PLC	D9800C00001	7/23/2024	7/17/2028	A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2.	\$32,644	\$32,644	SPT	100	\$32,644
Dayyani F	Astrazeneca AB	D7025C00001	9/15/2024	9/9/2028	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment after Resection of Biliary Tract Cancer with Curative Intent	\$28,342	\$28,342	SPT	100	\$28,342

Dayyani F	IQVIA RDS INC.	BI1479-0012	10/21/2024	10/9/2028	Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) in combination with intravenous trastuzumab deruxtecan (T-DXd) or in combination with intravenous trastuzumab emtansine (T-DM1) for treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)	\$28,041	\$28,041	SPT	100	\$28,041
Dayyani F	ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.	2138-CL-0101	3/4/2024	3/4/2028	A Phase I/Ib Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression	\$461,259	\$461,259	SPT	100	\$461,259
Dayyani F	FRONTIER MEDICINES CORPORATION	FMC-376-CL101	10/31/2024	10/27/2028	AN OPEN-LABEL, PHASE 1/2 DOSE ESCALATION, DOSE EXPANSION AND COHORT EXPANSION STUDY EVALUATING THE SAFETY, PK AND CLINICAL ACTIVITY OF FMC-376 IN PARTICIPANTS WITH KRAS G12C MUTATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS	\$34,161	\$34,161	SPT	100	\$34,161
Fleischman A	PRA HEALTH SCIENCES, INC.	ISIS 702843-CS4	6/20/2022	7/31/2025	A Phase 2a Randomized Open-Label Study to Evaluate the Efficacy Safety Tolerability Pharmacokinetics and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)	\$107,948	\$107,948	SPT	100	\$107,948
Fortier M	Cambia Health Fdn	CHF-5658623-02 (NCE)	12/1/2022	12/1/2025	A Community Engaged Approach to Develop a Culturally Appropriate Palliative Care Model for Spanish-speaking Families Impacted by Childhood Cancer	\$33,978	\$33,978	CC	100	\$33,978
Ganesan A	US Army Medical Research Acquisition Activity	HT94252311027-01	9/15/2023	9/14/2026	The Intravital Imaging of Melanoma Tumors for Mechanism Discovery and Patient Surveillance after Checkpoint Blockade Immunotherapy	\$111,088	\$111,088	BIDD	100	\$111,088
Ganesan A	AbbVie	252645-02	9/28/2023	9/27/2025	Observational Study on Identifying Cytologic and Molecular Biomarkers of Vitiligo Therapeutic Response	\$370,279	\$185,140	BIDD	100	\$185,140
Griffin M	V FDN	VF-5689360-02	9/1/2023	9/1/2026	Developing precision probiotics to overcome melanoma resistance to anti-PD-1 therapy	\$200,000	\$200,000	BIDD	100	\$200,000
Griffin M	UCOP	C25CR8608-01	10/1/2024	9/30/2025	Controlling tumor metastasis via the gut microbiota	\$85,000	\$85,000	BIDD	100	\$85,000
Halbrook C	American Pancreatic Association	APAF-5687381-01 (NCE)	7/1/2023	7/31/2025	Targeting Metabolic Heterogeneity in Pancreatic Cancer	\$0	\$0	SPT	100	\$0
Imagawa D	Dana Farber Partners	DF-5579935	11/26/2019	11/26/2025	PACER (Pancreatic AdenoCarcinoma with Electron Intraoperative Radiation Therapy): A Phase II Study of Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients with Pancreatic Cancer with Vascular Involvement	\$6,782	\$6,782	BIDD	100	\$6,782
Jeyakumar D	Janssen R&D LLC	75276617ALE1001	3/11/2022	11/30/2025	A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia	\$10,555	\$10,555	SPT	100	\$10,555
Jeyakumar D	Syneos Health Inc	2020-306-GLOB1	8/2/2022	8/31/2025	A Phase 1 Open-Label Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations	\$33,045	\$33,045	SPT	100	\$33,045
Jeyakumar D	Amgen	20190360.00	8/8/2022	8/31/2025	Phase 3 Randomized Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in	\$72,678	\$72,678	SPT	100	\$72,678
Jeyakumar D	Biomea Fusion Inc	COVALENT-101	2/22/2023	1/31/2027	A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral, covalent, menin inhibitor, in adult patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)	\$58,851	\$58,851	SPT	100	\$58,851
Jeyakumar D	Puretech Health LLC	LYT-200-2022-02	2/28/2023	2/28/2027	A Phase I, Open-Label, Multi-Center Study of the Safety, Pharmacokinetics (PK), and Anti-Tumor Activity of LYT-200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High/Very High Risk Myelodysplastic Syndrome (MDS)	\$215,380	\$215,380	SPT	100	\$215,380
Jeyakumar D	PRA Inc	GS-US-590-6154	3/10/2023	3/10/2027	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy	\$72,871	\$72,871	SPT	100	\$72,871
Jeyakumar D	Parexel International LLC	2215-CL-0203	6/12/2023	6/11/2027	A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy	\$162,683	\$162,683	SPT	100	\$162,683

Jeyakumar D	Servier Bio-Innovation LLC	CL2-95015-001	8/17/2023	8/16/2027	A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To > 65 Years with Newly-diagnosed Philadelphia-negative ALL	\$89,589	\$89,589	SPT	100	\$89,589
Jeyakumar D	Covance	HM-FLTI-101	8/29/2023	8/29/2027	A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)	\$65,658	\$65,658	SPT	100	\$65,658
Jeyakumar D	SELLAS LIFE SCIENCES GROUP AG	SLSG18-301	11/7/2023	11/7/2027	A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy	\$34,477	\$34,477	SPT	100	\$34,477
Jeyakumar D	GLUBIO THERAPEUTICS INC.	GLB-001-01	12/21/2023	12/20/2027	A First-in-human (FIH), Phase I, Multicenter, Open- label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes	\$51,105	\$51,105	SPT	100	\$51,105
Jeyakumar D	KURA ONCOLOGY, INC.	KO-MEN-007	3/4/2024	3/1/2028	Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia	\$231,050	\$231,050	SPT	100	\$231,050
Keshava H	Merck Sharp & Dohme	V940-002-0030	7/17/2024	6/30/2028	A Phase III, Randomized, Double-blind, Placebo- and Active-Comparator Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA,IIIB (N2) Non-small Cell Lung Cancer	\$19,737	\$19,737	CC	100	\$19,737
Kessenbrock K	The Mark Fdn for Cancer Research	24-036-ELA-01	1/1/2025	12/31/2027	Cancer Immunoprevention in BRCA1 mutation carriers	\$227,272	\$227,272	SPT	100	\$227,272
Kong X	CHIMERIX, INC.	ONC019	6/3/2022	5/31/2025	A Retrospective Observational Study for H3 K27M-mutant Glioma	\$5,848	\$5,848	CC	100	\$5,848
Kong X	CHIMERIX, INC.	ONC201-108	6/23/2023	6/23/2027	ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study	\$36,290	\$36,290	CC	100	\$36,290
Kong X	NUVOX PHARMA, LLC.	RESTORE P2	4/19/2024	4/17/2028	A Phase II Double-blind, Randomized, Prospective, Placebo Controlled Study of Nano2 TM Combined with Radiation and Temozolomide in Patients with Newly-diagnosed Glioblastoma Multiforme RESTORE	\$22,025	\$22,025	CC	100	\$22,025
Kongtim P	Rigel Pharmaceuticals Inc	C-906289-002	1/25/2023	12/31/2027	An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS) Who are Refractory/Resistant to Prior Therapies	\$95,007	\$95,007	CC	100	\$95,007
Kongtim P	EUROFINS VIRACOR, INC.	22-188 PROVE	6/11/2024	6/10/2026	Assessment of CMV-specific T Cell Immunity in Patients Receiving Letermovir Prophylaxis after Allogeneic Hematopoietic Cell Transplantation (PROVE)	\$24,350	\$24,350	CC	100	\$24,350
Kwon Y	PharmRes	PRP-05577432-05	10/22/2019	6/30/2026	Preliminary pre-clinical studies on DNA/drug complexes for cancer chemotherapy with optimized formulations	\$66,215	\$66,215	BIDD	100	\$66,215
Lee F	ICONClinRes	BXQ-350.AG	12/1/2022	12/1/2025	A Phase1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma	\$129,975	\$129,975	BIDD	100	\$129,975
Lee F	PRA Inc	CRDF-003	7/7/2023	7/7/2027	A Phase II, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation	\$47,119	\$47,119	BIDD	100	\$47,119
Lee F	Exelixis	XL092-303	9/16/2023	9/16/2027	A Randomized Open-Label Phase III Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer	\$256,006	\$256,006	BIDD	100	\$256,006
Lee L	Pfizer	PF-06863135	11/18/2022	11/30/2025	ELCANATAMAB (PF-06863135) MONOTHERAPY EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPY	\$114,478	\$114,478	SPT	100	\$114,478
Lee L	PRA Inc	TAK-573-1501	12/12/2022	12/31/2025	A Phase I/II Open-label Study to Investigate the Safety and Tolerability Efficacy Pharmacokinetics and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma	\$28,101	\$28,101	SPT	100	\$28,101

Lee L	Janssen R&D LLC	64007957MMY3006	7/8/2023	7/8/2027	A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PvD) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide	\$285,032	\$285,032	SPT	100	\$285,032
Lee L	Pfizer	C1071015	1/18/2024	1/17/2028	ELRANATAMAB POST TRIAL ACCESS AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES	\$30,412	\$30,412	SPT	100	\$30,412
Lee L	Regeneron	R5458-ONC-2158	3/25/2024	3/24/2028	Phase I/II Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma	\$105,475	\$105,475	SPT	100	\$105,475
Liu C	Keck	WMK-5649589-03	7/1/2022	6/30/2025	Accessing a new dimension of GPCR biology through biased GPCR modulators	\$333,334	\$166,667	BIDD	100	\$166,667
Liu C	Amgen	9720193-02	8/22/2023	8/21/2025	Evolution of minibinders using OrthoRep	\$44,866	\$22,433	BIDD	100	\$22,433
Luderer U	NASA-SSC	80NSSC19K1620-06	8/20/2019	8/19/2025	Ovarian Cancer and Space Radiation	\$32,003	\$32,003	CC	100	\$32,003
Luptak A	Keck	KF-05617242-03 (NCE)	7/1/2021	6/30/2025	Tracing the synaptic transcriptome in live animals with luminescent RNAs	\$34,910	\$17,455	BIDD	100	\$17,455
Luptak A Burke-Aguero D (University of Missouri)	NASA University of Missouri	C00077406-3-04	8/1/2021	7/31/2026	Bringing RNA to Life - Emergence of Biological Catalysis	\$98,268	\$49,134	BIDD	100	\$49,134
Mar N	SeaGen	RC48-G001	10/1/2022	9/30/2025	A Phase II Multi-Cohort Open-Label Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Subjects with HER2-Expressing Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma	\$67,977	\$67,977	SPT	100	\$67,977
Mar N	AVEO PHARMACEUTICALS , INC.	AV-951-20-304	11/1/2022	10/31/2025	A Phase III, Randomized, Controlled, Multicenter, Open-Label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor	\$17,688	\$17,688	SPT	100	\$17,688
Mar N	Biotheryx Inc	BTX-1188-001	2/10/2023	2/9/2027	An Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects with Advanced Malignancies	\$20,391	\$20,391	SPT	100	\$20,391
Mar N	Syneos Health Inc	BO43936	6/12/2023	4/30/2026	A RANDOMIZED OPEN LABEL PHASE II STUDY OF IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC RENAL CELL CARCINOMA	\$392,255	\$392,255	SPT	100	\$392,255
Mar N	WORLDWIDE CLINICAL TRIALS, INC.	ACR-368-201	9/13/2023	9/13/2027	PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM -RESISTANT OVARIAN CARCINOMA, ENDOMETRIAL ADENOCARCINOMA, AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS	\$34,768	\$34,768	SPT	100	\$34,768
Mar N	Oxon Epidemiology SI	SGNDV-003	10/17/2023	9/30/2025	A retrospective chart review of real-world treatment outcomes in patients with locally advanced unresectable or metastatic urothelial cancer based on HER2 expression	\$10,490	\$10,490	SPT	100	\$10,490
Mar N	Gilead	UCI 23-59/CO-US-979-6824	10/31/2024	10/17/2028	Adjuvant Sacituzumab Govitecan Plus Nivolumab in Patients with Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence	\$12,716	\$12,716	SPT	100	\$12,716
Masri S	Johnson & Johnson	JJ-222466-03	4/1/2022	4/30/2026	Eradicating Young-Onset Cancers by Targeting the Circadian Clock	\$50,000	\$50,000	SPT	100	\$50,000
Masri S	Catalym GMBH	227195-01	6/15/2023	6/30/2025	Targeting Factors that Regulate Cachexia and Immunity	\$95,866	\$95,866	SPT	100	\$95,866
Mehta R	IQVIA RDS INC.	DB-1303-O-3002	7/31/2024	7/31/2028	A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2) low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)	\$25,759	\$25,759	BIDD	100	\$25,759
Mehta R	POSEIDA THERAPEUTICS, INC.	P-MUC1C-ALLO1-001	3/20/2024	3/5/2028	COHORT A PHASE 1 DOSE ESCALATION AND EXPANDED STUDY OF P-MUC1C-ALLO1 IN ADULT SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS	\$43,514	\$43,514	BIDD	100	\$43,514
Milner T	Clayton Foundation	CF-5615468-05	1/1/2022	12/31/2028	The Use of Light for Cardiological, Surgical and Related Purposes	\$443,495	\$221,748	BIDD	100	\$221,748
Milner T	National Philanthropic Trust	2005975266-02	3/1/2023	2/28/2026	Optical Detection of Nascent cNF and Development of a Laser Treatment Strategy	\$115,116	\$115,116	BIDD	100	\$115,116
Milner T	AFOSR	FA9550-23-1-0685-02	9/30/2023	9/29/2026	Advanced Optical Technologies for Defense Trauma and Critical Care	\$528,052	\$264,026	BIDD	100	\$264,026

Mobley D	JANSSEN PHARMACEUTICALS INC.	ICD 2078330-01	6/14/2024	6/13/2026	Improving potency prediction via binding mode preparation and sampling enhancements	\$72,209	\$36,105	BIDD	100	\$36,105
Nagasaka M	Beigene	BGB-900-102	6/29/2022	7/31/2025	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors	\$81,031	\$81,031	SPT	100	\$81,031
Nagasaka M	Amgen	20210102.00	7/20/2022	8/31/2025	A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Bemarizumab Monotherapy and Combination with Docetaxel in Subjects with Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201)	\$34,560	\$34,560	SPT	100	\$34,560
Nagasaka M	Janssen R&D LLC	61186372NSC3002	11/1/2022	12/31/2025	A Phase III, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure	\$78,410	\$78,410	SPT	100	\$78,410
Nagasaka M	Covance	BA3021-001	11/3/2022	11/30/2025	A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3021 ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS	\$36,587	\$36,587	SPT	100	\$36,587
Nagasaka M	Astra Z	D516FC00001	11/16/2022	11/30/2025	A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2)	\$30,913	\$30,913	SPT	100	\$30,913
Nagasaka M	Covance	BA3011-002	11/28/2022	11/30/2025	A PHASE 2 STUDY OF BA3011 ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHO HAD PRIOR DISEASE PROGRESSION ON A PD-1/L1 EGFR OR ALK INHIBITOR	\$100,923	\$100,923	SPT	100	\$100,923
Nagasaka M	IQVIA RDS INC.	AB-106-G208	5/24/2022	5/31/2025	A Single-Arm Open-Label Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors	\$77,467	\$77,467	SPT	100	\$77,467
Nagasaka M	AstraZeneca PLC	D967SC00001	10/13/2022	10/31/2025	An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)	\$23,256	\$23,256	SPT	100	\$23,256
Nagasaka M	J Ints Bio Co Ltd	JIN202206-A02-01	2/2/2023	1/31/2026	A Phase I/II, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer	\$39,764	\$39,764	SPT	100	\$39,764
Nagasaka M	Brst Myrs Sq	BMS CA116-003 8478823	6/28/2023	6/28/2027	A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies	\$97,999	\$97,999	SPT	100	\$97,999
Nagasaka M	Janssen R&D LLC	61186372NSC2002	9/29/2023	9/29/2027	A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer	\$225,156	\$225,156	SPT	100	\$225,156
Nagasaka M	Summit Therapeutics Inc	AK112-301	10/30/2023	10/30/2027	A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced orMetastatic Non-squamous NSCLCWho Have Failed to EGFR-TKI Treatment (HARMONI)	\$391,573	\$391,573	SPT	100	\$391,573
Nagasaka M	Covance	D3S-001-100	11/9/2023	11/9/2027	A Phase I, Open-Label, Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation	\$30,270	\$30,270	SPT	100	\$30,270
Nagasaka M	AstraZeneca PLC	D926NC00001	12/5/2023	12/1/2027	A Phase III, Randomised, Open-Label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)	\$37,171	\$37,171	SPT	100	\$37,171
Nagasaka M	Boehringer Ingelheim Pharmaceuticals Inc	1479-0001	2/23/2024	2/23/2028	An Open Label, Phase I Dose Escalation Trial, with Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients with Advanced or Metastatic Solid Tumors with HER2 Aberrations	\$94,103	\$94,103	SPT	100	\$94,103
Nagasaka M	IQVIA RDS INC.	CJB-101-01	7/25/2024	6/30/2028	Phase I/II Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination with Pembrolizumab in Subjects with Selected Types of Advanced or Metastatic Cancer	\$51,154	\$51,154	SPT	100	\$51,154

Nagasaka M	Janssen R&D LLC	61186372PANSC2003	9/16/2024	9/16/2028	A Phase I/II Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer (SwallowTail)	\$30,019	\$30,019	SPT	100	\$30,019
Naqvi K	Delta-Fly	D19-11186	8/1/2024	8/1/2028	Phase I/II Study of DFP-10917 in Combination with Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia	\$96,977	\$96,977	SPT	100	\$96,977
Naqvi K	KURA ONCOLOGY, INC.	KO-MEN-008	5/1/2024	3/31/2028	Phase I Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia	\$46,666	\$46,666	SPT	100	\$46,666
Nelson E	PDS BIOTECHNOLOGY CORPORATION	VERSATILE-002	6/1/2022	5/31/2025	A Phase 2, Open-Label, Multi-Center Study of PDS0101 (R-DOTAP [Versamune] + HPV/mix) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection	\$31,807	\$31,807	BIDD	100	\$31,807
O'Brien S	Regeneron	R1979-HM-1333	10/12/2015	10/11/2025	An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy	\$111,310	\$111,310	SPT	100	\$111,310
O'Brien S	CARIBOU BIOSCIENCES, INC.	CB-LTSS	7/1/2022	6/30/2025	A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients with Hematologic Malignancies	\$27,958	\$27,958	SPT	100	\$27,958
O'Brien S	MUSTANG BIO, INC.	MB106-CD20-001	5/1/2022	4/30/2025	A Phase 1/2 Open Label Multicenter Study to Assess the Safety Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia	\$53,335	\$53,335	SPT	100	\$53,335
O'Brien S	IQVIA RDS INC.	LOXO-BTK-20022	8/1/2022	7/31/2025	A Phase 3 Open-Label Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)	\$170,584	\$170,584	SPT	100	\$170,584
O'Brien S	MUSTANG BIO, INC.	MB100-OBS-001	5/4/2023	5/4/2027	A Long-term Follow-up Study in Patients Previously Treated with Mustang Bio, Inc. CAR-T Cell Investigational Products	\$19,875	\$19,875	SPT	100	\$19,875
Ou S	Janssen R&D LLC	61186372EDI1001	7/30/2019	5/31/2026	A Phase I, First-In-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMET Antibody, in Subjects with Non-Small Cell Lung Cancer	\$29,385	\$29,385	BIDD	100	\$29,385
Ou S	Syneos Health Inc	LVGN6051-101	1/19/2022	8/31/2025	An Open Label, First in Human (FIH), Phase I Trial of LVGN6051 as Single Agent and in Combination with Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy	\$30,035	\$30,035	SPT	100	\$30,035
Ou S	NUVALENT, INC.	NVL-655-01	10/4/2022	10/31/2025	A Phase I/II Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Patients with Advanced NSCLC and Other Solid Tumors	\$199,992	\$199,992	SPT	100	\$199,992
Ou S	Regeneron	R5093-M114-ONC-1864	7/18/2022	8/31/2025	A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER	\$23,073	\$23,073	SPT	100	\$23,073
Ou S	ICON CLINICAL RESEARCH LIMITED	GS-US-576-6220	10/13/2022	11/30/2025	An Open-label Multicenter Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations	\$150,653	\$150,653	SPT	100	\$150,653
Ou S	Revolution	RMC-6291-001	12/19/2022	12/31/2025	Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors	\$79,495	\$79,495	SPT	100	\$79,495
Ou S	Syneos Health Inc	PF-06463922	1/24/2023	1/23/2027	[EXEMPT] LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES	\$60,533	\$60,533	SPT	100	\$60,533
Ou S	Revolution	RMC-6236-001	8/14/2023	8/13/2027	Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in KRAS	\$986,414	\$986,414	SPT	100	\$986,414
Ou S	Revolution	RMC-6291-101	10/28/2024	10/28/2028	Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C-Mutated Solid Tumors	\$30,421	\$30,421	SPT	100	\$30,421
Ou S	SYSTIMMUNE INC.	BL-B01D1-LUNG-101	4/3/2024	4/1/2028	A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer	\$108,781	\$108,781	SPT	100	\$108,781
Paegel B	Initial Therapeutics	ITI- 5606105-05 (NCE)	10/1/2020	11/15/2025	DNA-Encoded Library Design and Screening Technology Development to Discover Selective Terminators of Protein Synthesis	\$0	\$0	BIDD	100	\$0
Parajuli R	AbbVie	M16-573	4/29/2020	4/30/2026	A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors	\$34,222	\$34,222	BIDD	100	\$34,222

Parajuli R	Lilly	13Y-US-X013	6/22/2020	6/21/2025	A Phase II Clinical Trial of Neo-adjuvant Abemaciclib with Fulvestrant in patients who develop localized recurrence while on adjuvant endocrine therapy with molecular evidence of endocrine resistance	\$40,641	\$40,641	SPT	100	\$40,641
Parajuli R	ORINOVE INC	ORIN1001-001	5/16/2022	6/30/2025	A Phase 1/2 Open Label Dose-Escalation Study of Oral ORIN1001 with and without Chemotherapy in the Treatment of Subjects with Solid Tumors	\$42,730	\$42,730	SPT	100	\$42,730
Parajuli R	Gilead	GS-US-592-6173 (ASCENT-04)	12/22/2022	12/31/2027	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	\$21,310	\$21,310	SPT	100	\$21,310
Parajuli R	Astra Z	D967RC00001	2/10/2023	2/9/2027	A Phase III Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)	\$301,139	\$301,139	SPT	100	\$301,139
Parajuli R	PSI Pharma Support America Inc	CELC-G-301	4/26/2023	4/26/2027	A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)	\$74,920	\$74,920	SPT	100	\$74,920
Parajuli R	Syneos Health Inc	ML43171	5/5/2023	8/31/2026	A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2- NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER	\$101,747	\$101,747	SPT	100	\$101,747
Parajuli R	AstraZeneca PLC	D926XC00001	5/30/2023	5/30/2027	A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)	\$62,653	\$62,653	SPT	100	\$62,653
Parajuli R	Genentech	WO43919	8/8/2023	8/8/2027	A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS FULVESTRANT VERSUS ALPELISIB PLUS FULVESTRANT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE, PIK3CA MUTATED, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO PROGRESSED DURING OR AFTER CDK4/6 INHIBITOR AND ENDOCRINE COMBINATION THERAPY	\$27,161	\$27,161	SPT	100	\$27,161
Parajuli R	AstraZeneca PLC	D926QC00001	7/25/2024	6/30/2028	A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2- negative Breast Cancer (D926QC00001; TROPION-Breast04)	\$26,190	\$26,190	SPT	100	\$26,190
Parajuli R	LILLY USA, LLC	J2J-MC-JZLH	12/18/2023	12/7/2027	EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence	\$62,232	\$62,232	SPT	100	\$62,232
Parajuli R	TURNSTONE BIOLOGICS INC	TBio-4101-001	12/19/2023	12/17/2027	A Phase Ib Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients with Advanced Solid Tumor Malignancies (STARLING)	\$25,572	\$25,572	SPT	100	\$25,572
Park H Badal K (UCSF)	UCOP UCSF	15197sc-01	3/1/2024	2/28/2027	Investigating the relationship between chemical exposures, DNA methylation, and breast cancer risk	\$82,175	\$82,175	CC	100	\$82,175
Pinter-Brown L	Verastem	VS-0145-225	12/14/2018	10/31/2025	A Multi-Center, Phase II, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)	\$18,949	\$18,949	SPT	100	\$18,949
Pinter-Brown L	Medpace	IPH4102-201	10/12/2022	10/31/2025	TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma	\$74,168	\$74,168	SPT	100	\$74,168
Pinter-Brown L	Parexel	KT333-TL-101	11/3/2022	11/30/2025	A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors	\$57,500	\$57,500	SPT	100	\$57,500

Pinter-Brown L	ARTIVA BIOTHERAPEUTICS, INC.	AB-101-01	4/20/2021	4/30/2025	A Multi-Center Open-Label Phase I/II Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non Hodgkin Lymphoma of B-Cell Origin	\$158,121	\$158,121	SPT	100	\$158,121
Pinter-Brown L	CATALYST PHARMACEUTICAL RESEARCH, LLC	IPH4102-102	7/28/2022	8/31/2025	A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2	\$51,755	\$51,755	SPT	100	\$51,755
Pinter-Brown L	Syneos Health Inc	GO43693	1/27/2023	12/31/2027	A PHASE IB, OPEN-LABEL, MULTICENTER, SINGLE ARM STUDY EVALUATING THE PRELIMINARY EFFICACY, SAFETY, AND PHARMACOKINETICS OF GLOFITAMAB IN COMBINATION WITH RITUXIMAB PLUS IFOSFAMIDE, CARBOPLATIN ETOPOSIDE PHOSPHATE IN PATIENTS WITH RELAPSED/REFRACTORY TRANSPLANT ELIGIBLE DIFFUSE B-CELL LYMPHOMA	\$774,486	\$774,486	SPT	100	\$774,486
Pinter-Brown L	AFFIMED N.V.	AFM13-203	2/1/2024	2/1/2028	A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma (LuminICE-203	\$30,343	\$30,343	SPT	100	\$30,343
Prescher J	PAF	PAF-5604128-03 (NCE)	12/1/2020	8/1/2025	Bioluminescent tools for noninvasive, real-time imaging of immunometabolism	\$287,401	\$215,551	BIDD	100	\$215,551
Prescher J	Chan-Zuck	2021-234603-03 (NCE)	8/1/2021	12/31/2025	Chemically triggered probes for high-resolution, multiplexed imaging of protein interactomes	\$75,566	\$37,783	BIDD	100	\$37,783
Razorenova O	Regeninix Inc	226939-02 (NCE)	3/20/2023	12/31/2025	Investigation into the Impact of CDK9 Inhibition on VHL-deficient Clear Cell Renal Cell Carcinoma	\$6,858	\$6,858	SPT	100	\$6,858
Rezazadeh Kalebasti A	POINT BIOPHARMA INC.	PBP-301	1/14/2022	6/30/2025	SPLASH: Study Evaluating Metastatic Castrate Resistant Prostrate Cancer Treatment Using Lu-PNT2002 PSMA Therapy After Second-Line Hormonal Treatment	\$327,687	\$327,687	BIDD	100	\$327,687
Rezazadeh Kalebasti A	Novartis	CAAA617C12301	7/13/2022	8/31/2025	PSMAAddition: An International Prospective Open-Label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination with Standard of Care, Versus Standard of Care Alone, in Adult Male Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)	\$335,512	\$335,512	BIDD	100	\$335,512
Rezazadeh Kalebasti A	Merck Sharp & Dohme	022-00	10/20/2022	11/30/2025	A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)	\$86,177	\$86,177	BIDD	100	\$86,177
Rezazadeh Kalebasti A	NAVIRE PHARMA, INC.	NAV-1001	1/26/2022	6/30/2025	A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in Patients with Advanced Solid Tumors	\$65,188	\$65,188	BIDD	100	\$65,188
Rezazadeh Kalebasti A	4D PHARMA PLC	MRx0518-004 (AVENU)	6/7/2022	6/30/2025	Phase 2 Switch Maintenance Study of MRx0518 and Avelumab in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma Who Did Not Progress on First-Line Platinum-Containing Chemotherapy	\$21,624	\$21,624	BIDD	100	\$21,624
Rezazadeh Kalebasti A	Merck Sharp & Dohme	04A-02	1/19/2023	12/31/2026	A Phase I/II Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A	\$21,904	\$21,904	BIDD	100	\$21,904
Rezazadeh Kalebasti A	Merck Sharp & Dohme	MK-3475-04B-3045	9/1/2023	9/1/2027	A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B	\$49,761	\$49,761	BIDD	100	\$49,761
Rezazadeh Kalebasti A	Merck Sharp & Dohme	004-00	6/13/2024	6/12/2028	A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA)	\$150,195	\$150,195	BIDD	100	\$150,195
Rezazadeh Kalebasti A	Merck Sharp & Dohme	003-00	6/13/2024	6/12/2028	A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	\$32,379	\$32,379	BIDD	100	\$32,379
Rezazadeh Kalebasti A	EIKON THERAPEUTICS, INC.	EIK1003-001	4/3/2024	4/1/2028	A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors	\$31,743	\$31,743	BIDD	100	\$31,743
Sadigh G	RSNA	RSNA-5709750-01 (NCE)	1/1/2024	12/31/2025	Empowering Latinx patients Lung Cancer Screening Uptake (Empower Latinx)	\$36,675	\$36,675	CC	100	\$36,675



Sadigh G Torres M (Emory University)	ASCO Emory University	A811277-03	7/1/2022	6/30/2025	Genetic Determinants of Treatment-Related Comorbidities, Poor Treatment Adherence, and Worse Survival Among Black Patients with Early-Stage Breast Cancer	\$2,345	\$2,345	CC	100	\$2,345
Senthil M	On Target	UCI-23-184	6/26/2024	6/26/2028	A Phase I Pilot Study of Pafolacianine Injection for Intraoperative Imaging of Gastrointestinal Cancer Peritoneal Carcinomatosis	\$15,785	\$15,785	BIDD	100	\$15,785
Shi X	Silicon Valley Community Fdn	2023-321237-02	3/1/2023	2/28/2025	Dissemination of chemical-based super-resolution microscopy	\$175,217	\$87,609	BIDD	100	\$87,609
Smith J	HOTH THERAPEUTICS, INC.	CLEER-001	6/12/2024	5/31/2028	A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors	\$25,620	\$25,620	CC	100	\$25,620
Srinivas S	TELIX PHARMACEUTICALS LIMITED	177Lu-TLX591-203	11/25/2024	11/25/2028	A Multinational, Multicenter, Prospective, Open-Label, Dosimetry and Safety Study of Lutetium (177Lu) Rosopatamab tetraxetan in Combination with Standard of Care in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer after Androgen Receptor Pathway Inhibitor Treatment	\$31,370	\$31,370	BIDD	100	\$31,370
Tewari K	Merck Sharp & Dohme	005-03	4/18/2022	4/30/2025	A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors	\$12,460	\$12,460	CC	100	\$12,460
Tewari K	Amgen	20210007.00	12/16/2022	12/31/2025	Phase I First-in-Human Study to Explore the Safety Tolerability and Pharmacokinetics of AMG 794 in Subjects with Claudin 6-Positive Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer or Epithelial Ovarian Cancer	\$61,187	\$61,187	CC	100	\$61,187
Tewari K	ELLIPSES PHARMA LTD	EP0057-201	5/27/2022	6/30/2025	A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 - platinum resistant disease and are PARP inhibitor naïve; Cohort 2 - had at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance	\$38,828	\$38,828	CC	100	\$38,828
Tewari K	Advenchen Laboratories LLC	AL3818-US-002	2/6/2023	2/5/2027	A Phase I/IIa/III Evaluation of the Safety and Efficacy of Adding AL3818, (Anlotinib,INN: Catequentinib) a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma	\$24,052	\$24,052	CC	100	\$24,052
Tewari K	KSQ Therapeutics Inc	KSQ-4279-1101	2/7/2023	2/6/2027	A Phase I Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors	\$37,707	\$37,707	CC	100	\$37,707
Tewari K	Ascendis Pharma A/S	TCTLR-101	8/16/2023	8/15/2027	Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies	\$23,642	\$23,642	CC	100	\$23,642
Tewari K	GOG	XPORT-EC-042 / GOG-3083	8/23/2023	8/23/2027	ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA	\$29,153	\$29,153	CC	100	\$29,153
Tewari K	GOG	GoG-3078/IMGN853-0421	9/29/2023	9/28/2027	Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum based chemotherapy plus bevacizumab (GLORIOSA)	\$22,440	\$22,440	CC	100	\$22,440
Tewari K	GOG	Olvi-Vec-022 /GOG-3076	10/26/2023	10/26/2027	A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime/GOG-3076 Study)	\$26,857	\$26,857	CC	100	\$26,857
Tewari K	GOG	ZN-c3-005/GOG-3066	10/26/2023	10/25/2027	A PHASE 2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ZN-c3 IN SUBJECTS WITH HIGH-GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER	\$22,202	\$22,202	CC	100	\$22,202
Tewari K	Blueprint Medicines Corporation	BLU-222-1101	6/12/2024	4/30/2028	A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors	\$24,580	\$24,580	CC	100	\$24,580
Tewari K	Merck Sharp & Dohme	587-05	8/6/2024	7/31/2028	A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab	\$25,483	\$25,483	CC	100	\$25,483
Tinoco R	US Army Medical Research Acquisition Activity	HT94252311020-02	9/15/2023	9/14/2026	Intravital imaging of melanoma tumors for mechanism discovery and patient surveillance after checkpoint blockade immunotherapy	\$108,935	\$108,935	BIDD	100	\$108,935

Tseng J	Winsantor Inc	WST-PZP-005	1/19/2023	12/31/2026	A Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Topical Pirenzepine (WST-057) or Placebo for the Prevention of Dose Limiting Chemotherapy Induced Peripheral Neuropathy in Oncology Patients Administered Carboplatin and Paclitaxel	\$78,872	\$78,872	CC	100	\$78,872
Tseng J	GOG	MER-XMT-1536-3 (GoG-3049)	2/3/2023	2/2/2027	STUDY MER-XMT-1536-3 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF UPIFITAMAB RILSODOTIN (XMT-1536) AS POSTPLATINUM MAINTENANCE THERAPY FOR PARTICIPANTS WITH RECURRENT, PLATINUMSENSITIVE OVARIAN CANCER (UP-NEXT)	\$27,291	\$27,291	CC	100	\$27,291
Uchio E	Pfizer	C3441021	1/10/2020	8/31/2025	C3441021- A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.	\$36,608	\$36,608	SPT	100	\$36,608
Uchio E	PRA Inc	P17-1	1/30/2019	8/2/2026	PROVENT - A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER	\$19,740	\$19,740	CC	100	\$19,740
Uchio E	Merck Sharp & Dohme	MK-3475-676	6/24/2019	6/23/2027	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)	\$101,297	\$101,297	BIDD	100	\$101,297
Uchio E	Arcus Biosciences, Inc	ARC-6	5/11/2020	5/31/2025	A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer	\$19,036	\$19,036	SPT	100	\$19,036
Uchio E	Immunomedics	IMMU-132-13	11/20/2020	11/19/2025	2551537 - IMMU 132-13-Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer	\$13,373	\$13,373	CC	100	\$13,373
Uchio E	Bayer	21516	9/21/2021	9/20/2028	UCI 21-130 Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm (ARASEC)	\$29,126	\$29,126	CC	100	\$29,126
Uchio E	Brst Myrs Sq	CA045-009-0015	1/10/2020	12/31/2026	CA045-009: A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214 Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible	\$2,172	\$2,172	CC	100	\$2,172
Uchio E	Janssen R&D LLC	67652000PCR3002	9/8/2020	9/7/2025	UCI 20-146 - Amplitude - A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone (AA-P) and ADT Versus Abiraterone Acetate and Prednisone and ADT in Subjects With Metastatic Castration Sensitive Prostate Cancer (mCSPC) with DNA-repair gene defects	\$2,911	\$2,911	CC	100	\$2,911
Uchio E	SeaGen	SGN22E-004	8/27/2021	8/26/2028	EV-104: A study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)	\$4,004	\$4,004	CC	100	\$4,004
Uchio E	Exact	THR-CS-001	12/23/2021	12/22/2025	Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing-Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)	\$1,190	\$1,190	CC	100	\$1,190
Uchio E	ColdGen	BOND-003	3/1/2021	2/29/2028	UCI 20-210- BOND 3- A Phase 3 Study of CG0070 in Patients with Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)	\$70,515	\$70,515	CC	100	\$70,515
Uchio E	Iqvia Holdings Inc	MDV3100-13	10/1/2015	6/30/2025	EMBARK: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy	\$105,045	\$105,045	CC	100	\$105,045
Uchio E	ColdGen	CORE-001	6/1/2020	5/31/2025	CORE-001: A Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)	\$30,651	\$30,651	CC	100	\$30,651
Valerin J	Elicio Operating Company Inc	ELI-002-201	7/25/2023	7/25/2027	First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Solid Tumors	\$142,762	\$142,762	SPT	100	\$142,762
Valerin J	IQVIA RDS INC.	DF9001-001	8/23/2023	8/22/2027	A Phase I/II, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a Monotherapy and in Combination with Nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications	\$379,101	\$379,101	SPT	100	\$379,101
Valerin J	Actuate Therapeutics Inc	1801	10/12/2023	10/12/2027	Actuate 1801: Phase I/II Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignances or Solid Tumors	\$32,275	\$32,275	SPT	100	\$32,275

Valerin J	Incyte	INCB 99280-205	3/14/2024	3/13/2028	A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors	\$58,089	\$58,089	SPT	100	\$58,089
Valerin J	Dragonfly Therapeutics	DF6215-001	7/9/2024	7/7/2028	A PHASE 1/1B, FIRST-IN-HUMAN, MULTI-PART, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, BIOLOGICAL AND CLINICAL ACTIVITY OF DF6215 IN PATIENTS WITH ADVANCED (UNRESECTABLE, RECURRENT, OR METASTATIC) SOLID TUMORS	\$94,376	\$94,376	SPT	100	\$94,376
Valerin J	BIOATLA, INC.	BA3182-001	3/4/2024	2/28/2028	An Open-Label, Multicenter, Phase I Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, A Bispecific Epithelial Cell Adhesion Molecule (EPCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma	\$27,836	\$27,836	SPT	100	\$27,836
Valerin J	IKENA ONCOLOGY, INC.	IK595-001	12/10/2024	12/5/2028	A FIRST-IN-HUMAN STUDY OF IK-595, AN ORAL DUAL MEK/RAF INHIBITOR, IN PATIENTS WITH RAS- OR RAF-ALTERED ADVANCED SOLID TUMORS	\$47,211	\$47,211	SPT	100	\$47,211
Van Etten R	TERNS, INC.	TERN701-1012	2/8/2024	2/8/2028	A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Myeloid Leukemia	\$110,872	\$110,872	SPT	100	\$110,872
Villalona Calero M	Amgen	20230167	12/6/2024	11/30/2028	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion	\$5,692	\$5,692	SPT	100	\$5,692
Wagar L	Hoffman LaRoche	ROCHE-221446-04	9/10/2021	9/9/2025	Tonsil organoids for immunogenicity evaluation of biologics	\$150,400	\$112,800	SPT	100	\$112,800
Wagar L	NCRRA	NC3Rs-5704638-01 (NCE)	7/1/2023	2/28/2025	Modeling human adaptive immune responses with tonsil organoids	\$35,321	\$17,661	SPT	100	\$17,661
Wagar L	BMSF	229372-01 (NCE)	12/11/2023	6/30/2025	Uncovering novel functions and MOA of anti-CTLA-4 on T cells using human lymphoid tissue organoid models	\$81,991	\$81,991	SPT	100	\$81,991
Weiss G Yang P (UC Berkeley)	BASF UC Berkeley	11751-01	4/1/2024	3/31/2025	Enzyme characterization using Single Walled Carbon Nanotubes (SWCNT)	\$111,114	\$55,557	BIDD	100	\$55,557
Yamamoto M	Astellas Pha	5354-CL-1201	6/1/2022	5/31/2025	A Phase 2 Open-label Dose-finding Study to Determine the Optimal dose for Lymph Node Visualization using ASP5354 in Participants with Breast Cancer or Melanoma Undergoing Sentinel Lymph Node Biopsy	\$25,606	\$25,606	BIDD	100	\$25,606
Non-Peer-Reviewed Research Subtotals						\$21,513,764	\$20,214,759			\$20,214,759

**UC Irvine Chao Family Comprehensive Cancer Center**  
**Reporting Date: 02/28/2025**  
**Data Table 2A – Active Funded Projects (Multi-PI Grants)**

**Peer-Reviewed Research**

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Acharya M Mahan K (University of Texas Hlth Sci Ctr Houston)	NIH-NCI University of Texas Hlth Sci Ctr Houston	1R21CA292148-01	7/11/2024	6/30/2026	Circadian regulation of astrocytic adenosine kinase in the irradiated and cancer brain	\$112,250	\$112,250	BIDD	100	\$112,250
Anton-Culver H	NIH-OD	1OT2OD036428-01	5/1/2024	4/30/2025	All of Us Southern California Consortium (AoUSCC): Engagement, Enrollment, and Retention of Diverse Populations (Assist app# 1476115)	\$2,561,112	\$2,561,112	CC	100	\$2,561,112
Balu M Kelly K	NIH-NCI	5R01CA259019-03	9/1/2022	8/31/2027	Fast, large area, multiphoton exoscope (FLAME) for improving early detection of melanoma	\$422,551	\$422,551	BIDD	100	\$422,551
Blumberg B Shioda T (Mass General Hospital)	NIH-NIEHS	5R01ES031139-05	9/16/2020	6/30/2026	Interactions between prenatal obesogen exposure and Total Western diet lead to a transgenerational thrifty phenotype: functional and epigenomic analysis of effects in fat and liver	\$174,390	\$130,793	SPT	100	\$130,793
Bota D Das B (LIU: Brooklyn)	NIH-NINDS	5R01NS109423-05	9/1/2020	5/31/2025	Targeting of Mitochondrial LON Protease as a Novel Therapy for Glioblastoma	\$158,054	\$158,054	BIDD	100	\$158,054
Buisson R Lawrence M (Mass General)	NIH-NCI	5R37CA252081-04	7/1/2021	6/30/2026	Molecular Mechanisms of APOBEC-Induced Mutagenesis in Cancer	\$193,287	\$193,287	SPT	100	\$193,287
Chan A Acharya M	NIH-NCI	5R01CA276212-02	9/6/2023	8/31/2028	Neurotrophic strategy to mitigate chemotherapy-related brain injury	\$303,803	\$303,803	CC	50	\$151,902
								BIDD	50	\$151,902
Chen Z Wong B	NIH-NIBIB	5R01EB030024-05	7/1/2020	3/31/2025	In vivo Imaging and Quantification of Cilia Beating Dynamics Using Phase Resolved Optical Imaging Technology	\$372,627	\$186,314	BIDD	100	\$186,314
Cozen W Bertrand K (Boston University) Cai Q (Vanderbilt) Espeldegui M (UCLA) Haiman C (USC) Pinkal D (Cornell) Reiner A (Fred Hutchinson)	NIH-NCI	5R01CA260615-04	9/20/2021	8/31/2026	Determinants of the racial/ethnic disparity in MGUS risk: An epidemiologic study in 4 cohorts	\$125,024	\$125,024	CC	100	\$125,024
Dayyani F Carvajal-Carmona L (UC Davis)	NIH-NCI UC Davis	5U54CA283766-02	8/1/2024	7/31/2028	University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities	\$27,862	\$27,862	SPT	100	\$27,862
Demetriou M Zhou R (Gityr Therapeutics)	NIH-NCI Gityr Therapeutics	5R42CA285234-02	9/21/2023	8/31/2026	Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy	\$490,561	\$490,561	BIDD	100	\$490,561
Downing T Spakowitz A (Stanford)	NSF	EF-2022182-05	7/15/2020	6/30/2025	URoL: Epigenetics 2: Connecting cell fate and epigenome drift through physical models of chromatin structure and dynamics	\$240,192	\$180,144	BIDD	100	\$180,144
Fowler C Ganesh T (Northeastern)	NIH-NIDA Northeastern	1R01DA059985-01	8/1/2024	5/31/2029	Selective Positive Allosteric Modulators of a4b2 Nicotinic Receptors	\$35,617	\$17,809	CC	100	\$17,809
Fowler C Gay E (RTI International)	NIH-NIDA RTI International	5R01DA058493-02	9/30/2023	7/31/2028	Discovery and development of GPR3 agonists for nicotine cessation	\$68,237	\$51,178	CC	100	\$51,178
Goodman-Gruen D Esserman L (UCSF)	NIH-NCI UCSF	1P01CA281826-01A1	9/11/2024	8/31/2029	WISDOM:A platform to optimize subtype-specific screening and prevention	\$53,119	\$53,119	CC	100	\$53,119
Huang L Wiita A (UCSF)	NIH-NCI UCSF	1R01CA290875-01	8/1/2024	7/31/2029	Structural surfaceomics to probe conformation-selective immunotherapy targets	\$99,772	\$99,772	BIDD	100	\$99,772

Huang L Zhang H (Johns Hopkins University)	NIH-NCI Johns Hopkins University	5U24CA271079-03	6/1/2022	5/31/2025	Proteogenomic Characterization of Tumor Tissues and Preclinical Models with High Precision	\$93,000	\$93,000	BIDD	100	\$93,000
Hughes C Senthil M	NIH-NCI	1R01CA290115-01	6/1/2024	5/31/2029	A vascularized microphysiological system (MPS) platform for modeling peritoneal carcinomatosis	\$332,000	\$332,000	BIDD	100	\$332,000
Hughes C Thompson L	NIH-NHLBI	5R61HL154307-05	9/3/2020	8/31/2025	A Vascularized Micro-Organ platform for the study of Brain-BBB-Blood interaction	\$397,303	\$198,652	BIDD	100	\$198,652
Jang C Guertin D (Univ of Mass)	NIH-NIDDK Univ of Mass	5R01DK127175-04	8/4/2021	5/31/2026	Quantitative and functional analysis of brown fat nutrient fluxes in vivo and its role in organ metabolite exchange	\$93,937	\$70,453	SPT	100	\$70,453
Jang C Seldin M	NIH-NIAAA	5R21AA030358-02	9/12/2023	8/31/2025	Elucidating alcohol-induced metabolic remodeling of critical organs	\$262,500	\$196,875	SPT	100	\$196,875
Jin R Shoemaker C (Tufts University)	NIH-NIAID Tufts University	5R01AI173059-02	8/4/2023	7/31/2027	A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents	\$98,881	\$49,441	BIDD	100	\$49,441
Kaiser P Rychnovsky S	NIH-NCI	5R01CA283462-02	7/10/2023	6/30/2028	Mechanisms of mutant p53 reactivation	\$348,047	\$348,047	SPT	50	\$174,024
								BIDD	50	\$174,024
Kessenbrock K Chan K (Method Hospital Research Institute)	NIH-NCI Method Hospital Research Institute	3U54CA274375-03S1	9/1/2024	8/31/2025	A single-cell spatial map characterizing the stromal TME in bladder and breast early-lesions	\$50,000	\$50,000	SPT	100	\$50,000
Komarova N Wodarz D	NSF	MCB-2141651-03	5/1/2022	4/30/2025	Collaborative Research: MODULUS: Copy Number Alterations and Xenobiotic adaptation	\$95,773	\$71,830	SPT	100	\$71,830
Lee A Agrawal A	NIH-NCI	5R33CA267258-03	9/2/2022	8/31/2025	Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy	\$134,058	\$134,058	BIDD	100	\$134,058
Lee S	NIH-NIMHD	5R01MD012778-06 (NCE)	9/26/2017	12/31/2025	Culturally Adapted Multilevel Decision Support Navigation Trial To Reduce Colorectal Cancer Disparity Among At-Risk Asian American Primary Care Patients	\$103,394	\$103,394	CC	100	\$103,394
Lee S Gomez S (UC San Francisco)	NIH-NCI UC San Francisco	1U01CA290831-01	7/8/2024	6/30/2029	A national Asian American cohort for assessing multi-level determinants in cancer etiology: the ASPIRE Cohort	\$116,430	\$116,430	CC	100	\$116,430
Lee S Kawachi I (Harvard University) Redline S (Brigham & Women's Hospital)	NIH-NIMHD	5R01MD015186-05	4/8/2021	1/31/2026	Sleep and health disparities among Asian Americans: role of stressors and protective factors	\$291,427	\$145,714	CC	100	\$145,714
Li W	NIH-NCI	5R01CA228140-04 (NCE)	2/1/2010	1/31/2026	DNA Methylation Canyons in Human Cancers: Methods, Target Genes and Functional Consequences	\$50,435	\$50,435	SPT	100	\$50,435
Li W Wang Q (Duke)	NIH-NCI Duke	1R01CA290720-01	5/1/2024	4/30/2029	Elucidating alternative polyadenylation regulation during prostate cancer progression to castration-resistance	\$110,344	\$110,344	SPT	100	\$110,344
Limoli C	NIH-NCI	5R01CA254892-04	7/1/2021	6/30/2026	Improving pediatric brain tumor treatments using FLASH radiotherapy	\$130,516	\$130,516	SPT	100	\$130,516
Liu C Kruse/Marks A (Harvard Medical School)	NIH-NCI	5R01CA260415-05	9/10/2020	8/31/2025	Making antibody generation rapid, scalable, and democratic through machine learning and continuous evolution	\$371,407	\$371,407	BIDD	100	\$371,407
Marsden M zhen A (UCLA)	NIH-NIAID UCLA	5R01AI172727-03	6/25/2022	5/31/2027	Induction of autophagy to enhance CAR T cells in HIV cure approaches	\$191,368	\$95,684	SPT	100	\$95,684
Masri S Waterman M	NIH-NCI	5R01CA259370-04	1/1/2022	12/31/2026	Circadian Clock and Myc-dependent Regulation of Cellular Transformation	\$332,730	\$332,730	SPT	100	\$332,730
Milam J	NIH-NCI	5R01CA237230-05 (NCE)	1/1/2021	12/31/2025	Project Milestones: Young Adult Cancer Survivorship	\$196,996	\$196,996	CC	100	\$196,996
Milam J Miller K (USC)	NIH-NCI USC	5R01CA261888-04	9/6/2021	8/31/2026	Individual, cultural, and area-based factors associated with survivorship care among Asian/Asian-American childhood cancer survivors.	\$173,363	\$173,363	CC	100	\$173,363
Milner T Feldman M (UTHSC SA)	NIH-NHLBI	5R01HL163582-03	5/1/2022	4/30/2026	Transvenous Optoacoustic-Ultrasound Guided Cold Laser Wire for Crossing Coronary Chronic Total Occlusion	\$183,516	\$91,758	BIDD	100	\$91,758
Nie Q	NIH-NIGMS	1R01GM152494-01	9/20/2024	6/30/2028	Development of new tools for analyzing cell-cell communication using spatial transcriptomic data	\$260,000	\$195,000	SPT	100	\$195,000

Nie Q Dai X Lander A Lowengrub J	NSF	DMS1763272-05 (NCE)	7/1/2018	6/30/2025	NSF-Simons Center for Multiscale Cell Fate Research	\$1,333,885	\$1,000,414	SPT	100	\$1,000,414
Nyamathi A	NIH-NCI	5R01CA285063-02	8/1/2023	7/31/2028	Secondary Cervical Cancer Prevention of Vulnerable Women with HPV and HIV Co-infection in India	\$476,005	\$476,005	CC	100	\$476,005
Pannunzio N Frock R (Stanford University)	NIH-NCI	5R37CA266042-04	2/14/2022	1/31/2027	Defining the Mechanism of Genome Rearrangements in Ph-Like ALL to Determine Predictive Markers in High-Risk Hispanic Populations	\$247,494	\$247,494	SPT	100	\$247,494
Plikus M Scumpia P (UCLA)	NIH-NIAMS UCLA	5R01AR079470-04	9/1/2021	8/31/2025	Leveraging immune-fibroblast interactions for biomaterial induced skin regeneration	\$140,530	\$70,265	SPT	100	\$70,265
Prescher J Shaner N (UC San Diego)	NIH-NCI UC San Diego	5R01CA279813-02	1/1/2024	12/31/2028	New tools for quantitative non-invasive recording of biochemical signals	\$104,180	\$104,180	BIDD	100	\$104,180
Qu P	NIH-NCI	1R01CA297869-01	7/1/2024	6/30/2028	SCH: Individualized learning and prediction for heterogeneous multimodal data from wearable devices	\$198,693	\$198,693	CC	100	\$198,693
Sadigh G	NIH-NCI	5R01CA262312-03	8/10/2022	7/31/2027	Improving medication adherence using a CONnected CUsomized Treatment Platform (CONCURxP)	\$283,372	\$283,372	CC	100	\$283,372
Schilling T Nie Q	NIH-NIDCR	5R01DE030565-04	4/1/2021	3/31/2026	Dissecting single cell dynamics that coordinate neural crest migration and diversification	\$344,831	\$172,416	SPT	100	\$172,416
Shi Y Sciammas R (UC Davis)	NIH-NIAID	5R01AI170840-03	5/26/2022	4/30/2027	mRNA alternative polyadenylation in B cell development	\$398,992	\$199,496	SPT	100	\$199,496
Shi Y Seelig G (Univ Washington)	NIH-NCI	1R01CA297834-01	2/1/2025	1/31/2030	Decode polyadenylation in health and disease	\$207,336	\$207,336	SPT	100	\$207,336
Suetterlin C Tan M	NIH-NIAID	5R01AI153410-05	7/17/2020	6/30/2025	Primary cilia loss and cell cycle re-entry in Chlamydia-infected cells	\$338,207	\$169,104	SPT	100	\$169,104
Tanjasiri S Brown A (UCLA)	NIH-NIMHD UCLA	5P50MD017366-04	9/24/2021	6/30/2026	UCLA-UCI Center for Eliminating Cardio-Metabolic Disparities in Multi-Ethnic Populations (UC END-DISPARITIES) - Community Engagement Core	\$135,989	\$67,995	ZY	100	\$67,995
Tian L Kaur B (Augusta University)	NIH-NINDS Augusta University	1R61NS128191-01A1	9/9/2024	6/30/2026	Development of murine glioblastoma model for oncolytic HSV therapy	\$14,441	\$14,441	SPT	100	\$14,441
Tobias D Ladokhin A (Univ Kansas MC)	NIH-NIGMS Univ Kansas MC	5R01GM145991-02	9/1/2023	7/31/2027	Elucidating the Molecular Mechanisms of Conformational Switching during Protein Insertion into Membranes	\$51,436	\$51,436	BIDD	100	\$51,436
Vieira V Metayer C (UC Berkeley)	NIH-NIEHS UC Berkeley	5R01ES032196-03 (NCE)	9/3/2021	8/31/2025	Exposure to per- and polyfluoroalkyl substances (PFAS) and risk of cancer in children	\$65,564	\$65,564	CC	100	\$65,564
Villalona Calero M Yu J	NIH-NCI	5R01CA266457-04	8/16/2022	11/30/2027	Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors	\$337,061	\$337,061	SPT	100	\$337,061
Xiang L Chen Y (Univ of OK) Ren L (Univ of MD)	NIH-NCI	1U01CA288351-01	8/12/2024	7/31/2029	3D In vivo dosimetry for FLASH proton therapy	\$171,039	\$171,039	BIDD	100	\$171,039
Yu J Finley S (USC)	NIH-NCI USC	5U01CA275808-03	12/1/2024	8/31/2027	Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy	\$72,702	\$72,702	SPT	100	\$72,702
Zhang Z Yaghmai V	NIH-NCI	5R01CA241532-05	3/15/2020	2/28/2026	Image-Guided Interventional Combination Liver Cancer Immunotherapy	\$230,459	\$230,459	BIDD	100	\$230,459
Zhao W Gratton E	NIH-NIGMS	5R01GM147741-03	9/22/2022	8/31/2026	Spatial proteomics using highly parallel fluorescence hyperspectral and lifetime imaging	\$438,300	\$219,150	BIDD	100	\$219,150
Zi X Agrawal A Lilly M (Medical University of South Carolina)	NIH-NCI	5R01CA260351-04	12/9/2021	11/30/2026	Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer	\$182,063	\$182,063	CC	100	\$182,063
Peer-Reviewed Research Subtotals						\$15,628,462	\$13,312,445			\$13,312,447

Non-Peer-Reviewed Research

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Luptak A Burke-Aguero D (University of Missouri)	NASA University of Missouri	C00077406-3-04	8/1/2021	7/31/2026	Bringing RNA to Life - Emergence of Biological Catalysis	\$98,268	\$49,134	BIDD	100	\$49,134
Non-Peer-Reviewed Research Subtotals						\$98,268	\$49,134			\$49,134

## UC Irvine Chao Family Comprehensive Cancer Center

Reporting Date: 02/28/2025

## Data Table 2A – Active Funded Projects (Training)

## Peer-Reviewed Training

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Andersen B Ganesan A	NIH-NIAMS	5T32AR080622-03	5/1/2022	4/30/2027	Interdisciplinary Skin Biology Training Program at UC Irvine	\$205,444	\$162,301	T	100	\$162,301
Edinger A	ACS	PF-22-133-01-IBCD-02	7/1/2023	6/30/2025	Defining the role of macropinocytosis in the tumor-immune microenvironment	\$59,750	\$59,750	T	100	\$59,750
Fruman D	NIH-NCI	5T32CA009054-44	7/1/1980	6/30/2026	A Training Program in Cancer Biology and Therapeutics (CBT)	\$389,935	\$389,935	T	100	\$389,935
Griffin M	NIH-NCI	5K22CA272915-03	1/1/2023	12/31/2025	Augmenting cancer checkpoint immunotherapies via microbially-derived metabolites	\$132,060	\$132,060	T	100	\$132,060
Jang C	NIH-NIDDK	5F31DK134173-02	3/2/2023	3/1/2027	Elucidating the role of nonessential amino acid metabolism in diabetic skin wounds	\$44,445	\$22,223	T	100	\$22,223
Kvon E	NIH-NICHD	5F31HD112201-02	9/30/2023	9/29/2026	Characterizing a mechanism of enhancer-promoter interaction in vivo	\$45,458	\$22,729	T	100	\$22,729
Lander A Nie Q	NIH-NIGMS	5T32GM136624-05	7/1/2020	6/30/2025	Mathematical, Computational and Systems Biology	\$295,602	\$198,053	T	100	\$198,053
Lawson D	NIH-NCI	5F31CA281331-02	5/9/2023	5/8/2025	Intratumor heterogeneity in BRCA1-mutated breast cancer metastasis	\$43,661	\$43,661	T	100	\$43,661
Lee G	NIH-NCI	5K22CA234399-03	9/1/2022	8/31/2025	Elucidating the regulation of RNA methylation by mTOR signaling in cancer	\$168,728	\$168,728	T	100	\$168,728
Luderer U	CDC	20222886-03	7/1/2022	6/30/2025	Southern California Education and Research Center	\$631,465	\$315,733	T	100	\$315,733
Martinez T	NIH-NCI	5K01CA249038-04	9/1/2021	8/31/2026	The Roles of a Novel Microprotein in Wound Healing and Cancer	\$159,233	\$159,233	T	100	\$159,233
Masri S	NIH-NCI	1F31CA287992-01	3/2/2024	3/1/2025	Clock Disruption Accelerates Colorectal Cancer and Promotes Immunosuppression	\$44,850	\$44,850	T	100	\$44,850
Nelson E	ACS	IRG-22-984453-18-IRG-03	1/1/2023	12/31/2025	Institutional Research Grant	\$120,000	\$120,000	T	100	\$120,000
Semler B	NIH-NIAID	2T32AI007319-35	9/30/1988	8/31/2025	Virus-Host Interactions: A Multi-Scale Training Program	\$128,866	\$64,433	T	100	\$64,433
Sworder B	NIH-NCI	5K08CA267307-03	9/1/2023	6/30/2028	Determinants of resistance to engineered T-cell therapies targeting CD19 in lymphoma	\$174,353	\$174,353	T	100	\$174,353
Tanjasiri S Tomalsky M (California State University Fullerton)	NIH-NCI	5P20CA253254-04	9/23/2021	8/31/2025	2/2 CSUF/UCI-CFCCC Cancer Health Equity Research Partnership (CHERP)	\$143,595				
Tanjasiri S	NIH-NCI	5P20CA253254-EP-04	9/23/2021	8/31/2025	CHERP Cancer Research Education Program		\$13,104	T	100	\$13,104
Thompson L Donovan P	NIH-NINDS	5T32NS082174-12	7/1/2013	6/30/2028	Training Program in Stem Cell Translational Medicine for Neurological Disorders	\$248,420	\$119,242	T	100	\$119,242
Venugopalan V	NIH-NIGMS	5R25GM147294-03	9/12/2022	7/31/2027	Computational Biophotonics: A Platform for Interdisciplinary Biomedical Research Training and Career Development	\$392,715	\$196,358	T	100	\$196,358
Yokomori K	NIH-NIAMS	1T32AR083870-01	5/13/2024	4/30/2029	MAXIMUS: MAXimizing Training in MUScle Research	\$97,502	\$27,301	T	100	\$27,301
Zhang M	NIH-NCI	2R25CA233429-06	9/1/2023	8/31/2029	Big Data Training for Cancer Research	\$283,908	\$283,908	T	100	\$283,908
Peer-Reviewed Training Subtotals						\$3,679,499	\$2,717,955			\$2,717,955



Non-Peer-Reviewed Training

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Martinez T	PewCharTrst	36910-02	8/16/2023	7/31/2027	Uncovering the Oncogenic Kras-regulated Microproteome in Pancreatic Ductal Adenocarcinoma	\$32,500	\$32,500	T	100	\$32,500
Samarasena J	Cook Medical	24-0405-3F-02	7/1/2023	6/30/2025	Endoscopic Ultrasonography (EUS) Fellowship	\$100,000	\$75,000	T	100	\$75,000
Non-Peer-Reviewed Training Subtotals						\$132,500	\$107,500			\$107,500

**UC Irvine Chao Family Comprehensive Cancer Center**  
**Reporting Date: 02/28/2025**  
**Program Area: Biotechnology, Imaging & Drug Development**  
**Data Table 2A – Active Funded Projects**

**Peer-Reviewed Research**

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Acharya M	NIH-NCI	5R01CA262213-02	3/13/2023	2/29/2028	Stem cell-derived exosomes to ameliorate chemobrain	\$217,313	\$217,313	BIDD	100	\$217,313
Acharya M Loo B (Stanford)	NIH-NCI	5R01CA251110-04	9/1/2021	8/31/2026	Glial immune signaling in radiation-induced brain injury	\$254,980	\$254,980	BIDD	100	\$254,980
Acharya M Mahan K (University of Texas Hlth Sci Ctr Houston)	NIH-NCI University of Texas Hlth Sci Ctr Houston	1R21CA292148-01	7/11/2024	6/30/2026	Circadian regulation of astrocytic adenosine kinase in the irradiated and cancer brain	\$112,250	\$112,250	BIDD	100	\$112,250
Balu M Ganesan A	NIH-NIBIB	5R01EB026705-06	7/1/2018	3/31/2027	Development of a fast scanning, extended field-of-view multiphoton microscope for clinical skin imaging	\$371,894	\$278,921	BIDD	100	\$278,921
Balu M Ganesan A	NIH-NIAMS	5R21AR082648-02 (NCE)	3/1/2023	12/31/2025	In vivo label free optical imaging of immune cells in human skin	\$94,007	\$94,007	BIDD	100	\$94,007
Balu M Kelly K	NIH-NCI	5R01CA259019-03	9/1/2022	8/31/2027	Fast, large area, multiphoton exoscope (FLAME) for improving early detection of melanoma	\$422,551	\$422,551	BIDD	100	\$422,551
Bota D Das B (LIU: Brooklyn)	NIH-NINDS	5R01NS109423-05	9/1/2020	5/31/2025	Targeting of Mitochondrial LON Protease as a Novel Therapy for Glioblastoma	\$158,054	\$158,054	BIDD	100	\$158,054
Bota D Gupta K	NIH-NCI	5R01CA263806-04	7/1/2021	6/30/2026	Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system	\$366,131	\$366,131	BIDD	100	\$366,131
Botvinick E	NSF	DMS-1953410-03 (NCE)	7/1/2020	6/30/2025	Collaborative Research: Multiscale and Multiphasic Modeling of Single and Collective Migration in Fibrous Extracellular Matrices	\$25,664	\$19,248	BIDD	100	\$19,248
Burke P	NSF	CBET-2153425-03	7/1/2022	6/30/2025	Artificial nose using electrophysiology coupled to nanowires:Towards single molecule sensitivity with single atom resolution on chemical species	\$102,907	\$51,454	BIDD	100	\$51,454
Chan A Acharya M	NIH-NCI	5R01CA276212-02	9/6/2023	8/31/2028	Neurotrophic strategy to mitigate chemotherapy-related brain injury	\$303,803	\$303,803	BIDD	50	\$151,902
Chen Z	NIH-NIBIB	5R01EB030558-03 (NCE)	9/15/2021	9/14/2025	Continuous Monitoring and Management of Vaginal Health via Multifunctional OCT/OCTA Endoscopy	\$695,370	\$347,685	BIDD	100	\$347,685
Chen Z Wong B	NIH-NIBIB	5R01EB030024-05	7/1/2020	3/31/2025	In vivo Imaging and Quantification of Cilia Beating Dynamics Using Phase Resolved Optical Imaging Technology	\$372,627	\$186,314	BIDD	100	\$186,314
Copp S	NIH-NIBIB	1DP2EB037187-01	9/1/2024	8/31/2029	Deep-tissue targeted molecular imaging with a palette of NIR-II emissive DNA-stabilized nanoclusters	\$300,000	\$300,000	BIDD	100	\$300,000
Demetriou M	CIRM	DISC2-13507-02 (NCE)	9/1/2022	2/28/2025	GlyTR CAR T cells for the treatment of Glioblastoma	\$48,134	\$48,134	BIDD	100	\$48,134
Demetriou M Zhou R (Gityr Therapeutics)	NIH-NCI Gityr Therapeutics	5R42CA285234-02	9/21/2023	8/31/2026	Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy	\$490,561	\$490,561	BIDD	100	\$490,561
Ding F	NIH-NIAMS	DP2GM149554-03	9/1/2022	8/31/2025	Universally-applicable RNA mapping at subcellular and single-base resolution	\$300,000	\$150,000	BIDD	100	\$150,000
Dong V	NIH-NIGMS	5R35GM127071-07	5/1/2018	7/31/2028	Innovative Tools for Chemical Synthesis: Metal-Hydride Catalysis, Medicinal Motifs, and Molecular Probes	\$325,000	\$162,500	BIDD	100	\$162,500
Dong V	NSF	CHE-2247923-02	9/1/2023	8/31/2026	Sustainable Technologies for Building Molecules: Ethers, Phosphines, and Amino Acids	\$155,286	\$77,643	BIDD	100	\$77,643
Downing T Spakowitz A (Stanford)	NSF	EF-2022182-05	7/15/2020	6/30/2025	URoL: Epigenetics 2: Connecting cell fate and epigenome drift through physical models of chromatin structure and dynamics	\$240,192	\$180,144	BIDD	100	\$180,144
Edinger A	NIH-NCI	5R01CA247556-05	4/1/2020	3/31/2026	Defining the role of macropinocytosis in solid tumor growth and therapeutic resistance	\$297,860	\$297,860	BIDD	100	\$297,860
Edinger A	NIH-NCI	5R01CA254360-04	3/1/2021	2/28/2026	A novel strategy to overcome drug resistance in cancer	\$287,945	\$287,945	BIDD	100	\$287,945

Felgner P	NIH-NIAID	75N93022C00054-03	9/1/2022	8/31/2027	Adjuvant characterization and comparison in three different infection animal models	\$1,767,557	\$883,778	BIDD	100	\$883,778
Flanagan L	NSF	IOS-2019400-05	6/15/2020	5/31/2025	Cell surface glycosylation regulation of stem cell fate decisions	\$195,349	\$97,675	BIDD	100	\$97,675
Flanagan L	NIH-NINDS	5R01NS119829-04	9/1/2021	8/31/2026	Human neural stem cell and endothelial cell reciprocal interactions govern cell function	\$242,500	\$121,250	BIDD	100	\$121,250
Ganesan A	NIH-NCI	5R01CA244571-05 (NCE)	12/4/2019	11/30/2025	Identifying Therapeutic Targets for Stage III Melanoma	\$20,344	\$20,344	BIDD	100	\$20,344
Guan Z	NSF	DMR-2004555-03 (NCE)	7/15/2020	6/30/2025	Structure-property study for dendronized polymer vectors for CRISPR delivery	\$175,358	\$87,679	BIDD	100	\$87,679
Huang L	NIH-NIGMS	5R35GM145249-03	8/1/2022	7/31/2027	Advancing Proteomics Technologies to Decipher the Ubiquitin-Proteasome System	\$375,000	\$281,250	BIDD	100	\$281,250
Huang L Wiita A (UCSF)	NIH-NCI UCSF	1R01CA290875-01	8/1/2024	7/31/2029	Structural surfaceomics to probe conformation-selective immunotherapy targets	\$99,772	\$99,772	BIDD	100	\$99,772
Huang L Zhang H (Johns Hopkins University)	NIH-NCI Johns Hopkins University	5U24CA271079-03	6/1/2022	5/31/2025	Proteogenomic Characterization of Tumor Tissues and Preclinical Models with High Precision	\$93,000	\$93,000	BIDD	100	\$93,000
Hughes C	NIH-NCI	5R21CA280567-02	5/1/2023	4/30/2025	In search of synergistic drug interactions in cancer	\$111,031	\$111,031	BIDD	100	\$111,031
Hughes C Senthil M	NIH-NCI	1R01CA290115-01	6/1/2024	5/31/2029	A vascularized microphysiological system (MPS) platform for modeling peritoneal carcinomatosis	\$332,000	\$332,000	BIDD	100	\$332,000
Hughes C Thompson L	NIH-NHLBI	5R61HL154307-05	9/3/2020	8/31/2025	A Vascularized Micro-Organ platform for the study of Brain-BBB-Blood interaction	\$397,303	\$198,652	BIDD	100	\$198,652
Jarvo E	NSF	CHE1900340-06	8/1/2019	7/31/2025	Mechanism-based development of new nickel-catalyzed stereospecific cross-electrophile coupling reactions of sulfonamides	\$121,699	\$60,850	BIDD	100	\$60,850
Jarvo E	NIH-NIGMS	5R01GM135603-04	9/1/2021	5/31/2025	Stereoselective Nickel-Catalyzed Coupling and Cascade Reactions	\$205,000	\$102,500	BIDD	100	\$102,500
Jin R Shoemaker C (Tufts University)	NIH-NIAID Tufts University	5R01AI173059-02	8/4/2023	7/31/2027	A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents	\$98,881	\$49,441	BIDD	100	\$49,441
Kaiser P Rychnovsky S	NIH-NCI	5R01CA283462-02	7/10/2023	6/30/2028	Mechanisms of mutant p53 reactivation	\$348,047	\$348,047	BIDD	50	\$174,024
Kelly K Huang Y (Western University of Health Sciences)	NIH-NCI Western University of Health Sciences	5R01CA269653-03	7/1/2022	6/30/2027	Preventing UV-induced immunosuppression and skin carcinogenesis with R-carvedilol	\$6,370	\$6,370	BIDD	100	\$6,370
Lee A	NIH-NIGMS	5R01GM145987-03	6/1/2022	5/31/2026	Acoustic microvortices instrumentation for dosage controlled, high efficiency cell engineering	\$200,000	\$200,000	BIDD	100	\$200,000
Lee A Agrawal A	NIH-NCI	5R33CA267258-03	9/2/2022	8/31/2025	Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy	\$134,058	\$134,058	BIDD	100	\$134,058
Liu C	NIH-NIGMS	5R35GM136297-05	6/1/2020	5/31/2025	Synthetic genetic systems for rapid biomolecular evolution in vivo	\$290,372	\$145,186	BIDD	100	\$145,186
Liu C Kruse/Marks A (Harvard Medical School)	NIH-NCI	5R01CA260415-05	9/10/2020	8/31/2025	Making antibody generation rapid, scalable, and democratic through machine learning and continuous evolution	\$371,407	\$371,407	BIDD	100	\$371,407
Luo R	NIH-NIGMS	2R35GM130367-06	9/1/2019	1/31/2030	Multi-scaled Modeling of Electrostatic and Polarization Effects in Biomolecules	\$275,000	\$137,500	BIDD	100	\$137,500
Milner T Feldman M (UTHSC SA)	NIH-NHLBI	5R01HL163582-03	5/1/2022	4/30/2026	Transvenous Optoacoustic-Ultrasound Guided Cold Laser Wire for Crossing Coronary Chronic Total Occlusion	\$183,516	\$91,758	BIDD	100	\$91,758
Mobley D	NIH-NIGMS	5R35GM148236-02	3/1/2023	2/29/2028	Accelerating drug discovery via ML-guided iterative design and optimization	\$380,000	\$190,000	BIDD	100	\$190,000
Paegel B	NIH-NIGMS	5R35GM140890-05	4/1/2021	1/31/2026	Activity-Based DNA-Encoded Library Technology	\$225,000	\$168,750	BIDD	100	\$168,750
Pandey P	NIH-NCI	1R50CA283816-01	9/3/2024	8/31/2029	Quantitative in vivo dosimetry for radiotherapy using model-based X-ray-induced acoustic computed tomography	\$51,101	\$51,101	BIDD	100	\$51,101
Penner R	NSF	CBET-2149631-04	9/1/2021	8/31/2025	The Aptamer BioResistor: A Broadly Applicable Protein Biosensor with Dip-and-Read Simplicity for Point-of-Care Diagnostics	\$85,337	\$64,003	BIDD	100	\$64,003
Penner R	NSF	CHE-2201042-03	8/1/2022	7/31/2025	Chemical Sensors Based Upon Metal Nanowires and Nanogaps in Metal Nanowires Transduced Using Impedance	\$104,676	\$52,338	BIDD	100	\$52,338

Potma E	NIH-NIBIB	5R21EB034084-02	7/1/2023	6/30/2025	Broadband Focusing For Extreme Multimodal Microscopy	\$100,000	\$50,000	BIDD	100	\$50,000
Poulos T	NIH-NIGMS	5R35GM131920-05 (NCE)	6/1/2019	5/31/2025	Metalloenzyme structure, function, and as targets for neurodegeneration and bacterial pathogenesis	\$192,194	\$96,097	BIDD	100	\$96,097
Prescher J Shaner N (UC San Diego)	NIH-NCI UC San Diego	5R01CA279813-02	1/1/2024	12/31/2028	New tools for quantitative non-invasive recording of biochemical signals	\$104,180	\$104,180	BIDD	100	\$104,180
Pronin S	NIH-NIGMS	5R35GM153231-02	3/5/2024	1/31/2029	Development of new methods and strategies for the synthesis of complex molecules	\$225,000	\$112,500	BIDD	100	\$112,500
Sevrioukova I	NIH-NIEHS	5R01ES025767-09	6/1/2016	1/31/2026	Toxicological importance of CYP3A4 catalysis and inhibition	\$357,704	\$268,278	BIDD	100	\$268,278
Shah P	NIH-NCI	1R21CA294195-01	9/1/2024	8/31/2026	Virtual Digital Histopathology with Explainable Deep Learning for Prostate Cancer Diagnosis	\$144,389	\$144,389	BIDD	100	\$144,389
Shi X	NIH-NIGMS	5DP2GM150017-03	9/1/2022	8/31/2025	Gel-based Optical-isolation Single-Cell 3D Spatial Multiomics	\$300,000	\$225,000	BIDD	100	\$225,000
Shi X	NSF	CBET-2341058-01	7/1/2024	6/30/2029	Optogel Proteomics: unbiased subcellular proteomics powered by photoreactions in hydrogel	\$112,787	\$112,787	BIDD	100	\$112,787
Tobias D Ladokhin A (Univ Kansas MC)	NIH-NIGMS Univ Kansas MC	5R01GM145991-02	9/1/2023	7/31/2027	Elucidating the Molecular Mechanisms of Conformational Switching during Protein Insertion into Membranes	\$51,436	\$51,436	BIDD	100	\$51,436
Tombola F	NIH-NIGMS	5R01GM098973-12	7/1/2011	5/31/2026	Mechanisms Of Permeation And Gating Of Voltage-Sensing Domains	\$323,196	\$242,397	BIDD	100	\$242,397
Vanderwal C	NIH-NIGMS	5R35GM145252-03	9/1/2022	6/30/2027	Chemical Synthesis of Bioactive Diterpenoids	\$300,000	\$150,000	BIDD	100	\$150,000
Venugopalan V	NIH-NIMH	5R01GM129426-04 (NCE)	6/1/2019	3/31/2025	A Biophotonics Platform for Mechanotransduction and Metabolic Microscopy	\$206,246	\$206,246	BIDD	100	\$206,246
Wilder-Smith P Rongguang L (University of Arizona)	NIH-NIDCR University of Arizona	5R01DE030682-04	8/10/2021	7/31/2026	Multimodal Intraoral Imaging System for Oral Cancer Detection and Diagnosis in Low Resource Setting	\$30,315	\$30,315	BIDD	100	\$30,315
Xiang L	NIH-NCI	5R37CA240806-06	9/20/2019	8/31/2026	Academic-Industry Partnership for the Translation of a 4D in vivo Dosimetry Approach for Radiation Therapy	\$299,926	\$299,926	BIDD	100	\$299,926
Xiang L Chen Y (Univ of OK) Ren L (Univ of MD)	NIH-NCI	1U01CA288351-01	8/12/2024	7/31/2029	3D In vivo dosimetry for FLASH proton therapy	\$171,039	\$171,039	BIDD	100	\$171,039
Yaghmai V Li D (Cedars Sinai Medical Center)	NIH-NCI Cedars Sinai Medical Center	5R01CA260955-04	9/1/2021	8/31/2026	Predicting Pancreatic Ductal Adenocarcinoma (PDAC) through Artificial Intelligence Analysis of Pre-diagnostic CT Images	\$67,965	\$67,965	BIDD	100	\$67,965
Zhang Z Yaghmai V	NIH-NCI	5R01CA241532-05	3/15/2020	2/28/2026	Image-Guided Interventional Combination Liver Cancer Immunotherapy	\$230,459	\$230,459	BIDD	100	\$230,459
Zhang Z Yaghmai V	NIH-NCI	5R01CA209886-08	1/4/2021	7/31/2028	MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer	\$237,500	\$237,500	BIDD	100	\$237,500
Zhao W Gratton E	NIH-NIGMS	5R01GM147741-03	9/22/2022	8/31/2026	Spatial proteomics using highly parallel fluorescence hyperspectral and lifetime imaging	\$438,300	\$219,150	BIDD	100	\$219,150
Zheng K Hanauer D (University of Michigan)	NIH-NCI University of Michigan	5U24CA269315-02	9/15/2023	8/31/2025	Extending the Capabilities and Reach of EMERSE in Support of Cancer Research	\$7,800	\$7,800	BIDD	100	\$7,800
Peer-Reviewed Research Subtotals						\$16,732,643	\$12,334,702			\$12,008,778

Non-Peer-Reviewed Research

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Abi-Jaoudeh N	OM1, INC.	2019-ONC-02	6/30/2022	6/29/2025	REGISTRY TO EVALUATE EFFECTIVENESS AND SAFETY OF THE NANOKNIFE SYSTEM FOR THE ABLATION OF STAGE 3 PANCREATIC ADENOCARCINOMA	\$0	\$0	BIDD	100	\$0
Abi-Jaoudeh N	Sirtex	STX2001	3/16/2023	3/15/2027	A prospective, multicenter, open-label single arm study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR Spheres Y-90 resin microspheres on duration of response (DoR) and objective response rate (ORR) in unresectable hepatocellular carcinoma (HCC) patients	\$37,907	\$37,907	BIDD	100	\$37,907
Abi-Jaoudeh N	Teclicon USA Ltd	TL-228071-01	6/12/2024	6/12/2025	A novel locoregional therapy for Hepatocellular Carcinoma in different animal models	\$114,460	\$114,460	BIDD	100	\$114,460
Abi-Jaoudeh N	ABK BIOMEDICAL USA INC.	ABK-CA-PROT-85	3/14/2024	3/13/2028	Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)	\$110,912	\$110,912	BIDD	100	\$110,912
Abi-Jaoudeh N	IMPACT BIOTECH LTD	CLIN2301 PNCM101	6/10/2024	6/5/2028	A Phase 1 trial to evaluate safety and preliminary efficacy of endovascularly applied Padeliporfin vascular targeted photodynamic therapy for patients with locally advanced unresectable pancreatic ductal adenocarcinoma	\$28,041	\$28,041	BIDD	100	\$28,041
Bota D	Janssen R&D LLC	42756493BLC2001	3/4/2022	3/31/2025	A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations	\$18,259	\$18,259	BIDD	100	\$18,259
Bota D	VBI VACCINES INC.	VBI-1901-01	12/1/2022	12/31/2025	A Three-part Phase I/II Dose-Escalation Study to Define the Safety Tolerability and Optimal Dose of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM subjects	\$48,709	\$48,709	BIDD	100	\$48,709
Bota D	Boehringer Ingelheim Pharmaceuticals Inc	1438-0003	12/11/2023	12/5/2027	A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3	\$107,957	\$107,957	BIDD	100	\$107,957
Bota D	NERVIANO MEDICAL SCIENCES SRL	PARPA-293-002	11/25/2024	11/22/2028	A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma	\$30,421	\$30,421	BIDD	100	\$30,421
Burke T	UCOP	C25CR8552-01	10/1/2024	9/30/2025	Determining mechanisms of anti-tumor synergy elicited by innate immune agonist cancer therapies	\$85,000	\$85,000	BIDD	100	\$85,000
Coombs C	Beigene	BGB-11417-301	3/28/2024	3/21/2028	A Phase III, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia	\$136,971	\$136,971	BIDD	100	\$136,971
Coombs C	CARNA BIOSCIENCES, INC.	C1763102	11/1/2023	11/1/2027	A Phase IB Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma	\$160,709	\$160,709	BIDD	100	\$160,709
Coombs C	ANALYSIS GROUP, INC	228334	10/2/2024	8/31/2028	Chronic Lymphocytic Leukemia (CLL) Collaborative Study Of Real-World Evidence (CORE)	\$3,955	\$3,955	BIDD	100	\$3,955
Copp S	Chan-Zuck	2024-337801-01	3/1/2024	2/29/2028	Molecular deep-tissue imaging in the NIR-II transparency window	\$112,968	\$84,726	BIDD	100	\$84,726
Dayyani F	Genentech	GO42216	10/1/2020	9/30/2026	A PHASE Ib/II, OPEN-LABEL, MULTICENTER,RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORPHEUS-LIVER)	\$66,442	\$66,442	BIDD	100	\$66,442
Ganesan A	US Army Medical Research Acquisition Activity	HT94252311027-01	9/15/2023	9/14/2026	The Intravital Imaging of Melanoma Tumors for Mechanism Discovery and Patient Surveillance after Checkpoint Blockade Immunotherapy	\$111,088	\$111,088	BIDD	100	\$111,088
Ganesan A	AbbVie	252645-02	9/28/2023	9/27/2025	Observational Study on Identifying Cytologic and Molecular Biomarkers of Vitiligo Therapeutic Response	\$370,279	\$185,140	BIDD	100	\$185,140
Griffin M	V FDN	VF-5689360-02	9/1/2023	9/1/2026	Developing precision probiotics to overcome melanoma resistance to anti-PD-1 therapy	\$200,000	\$200,000	BIDD	100	\$200,000
Griffin M	UCOP	C25CR8608-01	10/1/2024	9/30/2025	Controlling tumor metastasis via the gut microbiota	\$85,000	\$85,000	BIDD	100	\$85,000
Imagawa D	Dana Farber Partners	DF-5579935	11/26/2019	11/26/2025	PACER (Pancreatic AdenoCarcinoma with Electron Intraoperative Radiation Therapy): A Phase II Study of Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients with Pancreatic Cancer with Vascular Involvement	\$6,782	\$6,782	BIDD	100	\$6,782
Kwon Y	PharmRes	PRP-05577432-05	10/22/2019	6/30/2026	Preliminary pre-clinical studies on DNA/drug complexes for cancer chemotherapy with optimized formulations	\$66,215	\$66,215	BIDD	100	\$66,215

Lee F	ICONClinRes	BXQ-350.AG	12/1/2022	12/1/2025	A Phase1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma	\$129,975	\$129,975	BIDD	100	\$129,975
Lee F	PRA Inc	CRDF-003	7/7/2023	7/7/2027	A Phase II, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation	\$47,119	\$47,119	BIDD	100	\$47,119
Lee F	Exelixis	XL092-303	9/16/2023	9/16/2027	A Randomized Open-Label Phase III Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer	\$256,006	\$256,006	BIDD	100	\$256,006
Liu C	Keck	WMK-5649589-03	7/1/2022	6/30/2025	Accessing a new dimension of GPCR biology through biased GPCR modulators	\$333,334	\$166,667	BIDD	100	\$166,667
Liu C	Amgen	9720193-02	8/22/2023	8/21/2025	Evolution of minibinders using OrthoRep	\$44,866	\$22,433	BIDD	100	\$22,433
Luptak A	Keck	KF-05617242-03 (NCE)	7/1/2021	6/30/2025	Tracing the synaptic transcriptome in live animals with luminescent RNAs	\$34,910	\$17,455	BIDD	100	\$17,455
Luptak A Burke-Aguero D (University of Missouri)	NASA University of Missouri	C00077406-3-04	8/1/2021	7/31/2026	Bringing RNA to Life - Emergence of Biological Catalysis	\$98,268	\$49,134	BIDD	100	\$49,134
Mehta R	IQVIA RDS INC.	DB-1303-O-3002	7/31/2024	7/31/2028	A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2) low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)	\$25,759	\$25,759	BIDD	100	\$25,759
Mehta R	POSEIDA THERAPEUTICS, INC.	P-MUC1C-ALLO1-001	3/20/2024	3/5/2028	COHORT A PHASE 1 DOSE ESCALATION AND EXPANDED STUDY OF P-MUC1C-ALLO1 IN ADULT SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS	\$43,514	\$43,514	BIDD	100	\$43,514
Milner T	Clayton Foundation	CF-5615468-05	1/1/2022	12/31/2028	The Use of Light for Cardiological, Surgical and Related Purposes	\$443,495	\$221,748	BIDD	100	\$221,748
Milner T	National Philanthropic Trust	2005975266-02	3/1/2023	2/28/2026	Optical Detection of Nascent cNF and Development of a Laser Treatment Strategy	\$115,116	\$115,116	BIDD	100	\$115,116
Milner T	AFOSR	FA9550-23-1-0685-02	9/30/2023	9/29/2026	Advanced Optical Technologies for Defense Trauma and Critical Care	\$528,052	\$264,026	BIDD	100	\$264,026
Mobley D	JANSSEN PHARMACEUTICALS INC.	ICD 2078330-01	6/14/2024	6/13/2026	Improving potency prediction via binding mode preparation and sampling enhancements	\$72,209	\$36,105	BIDD	100	\$36,105
Nelson E	PDS BIOTECHNOLOGY CORPORATION	VERSATILE-002	6/1/2022	5/31/2025	A Phase 2, Open-Label, Multi-Center Study of PDS0101 (R-DOTAP [Versamune] + HPVmix) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection	\$31,807	\$31,807	BIDD	100	\$31,807
Ou S	Janssen R&D LLC	61186372EDI1001	7/30/2019	5/31/2026	A Phase I, First-In-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMET Antibody, in Subjects with Non-Small Cell Lung Cancer	\$29,385	\$29,385	BIDD	100	\$29,385
Parajuli R	AbbVie	M16-573	4/29/2020	4/30/2026	A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors	\$34,222	\$34,222	BIDD	100	\$34,222
Prescher J	PAF	PAF-5604128-03 (NCE)	12/1/2020	8/1/2025	Bioluminescent tools for noninvasive, real-time imaging of immunometabolism	\$287,401	\$215,551	BIDD	100	\$215,551
Prescher J	Chan-Zuck	2021-234603-03 (NCE)	8/1/2021	12/31/2025	Chemically triggered probes for high-resolution, multiplexed imaging of protein interactomes	\$75,566	\$37,783	BIDD	100	\$37,783
Rezazadeh Kalebasty A	POINT BIOPHARMA INC.	PBP-301	1/14/2022	6/30/2025	SPLASH: Study Evaluating Metastatic Castrate Resistant Prostrate Cancer Treatment Using Lu-PNT2002 PSMA Therapy After Second-Line Hormonal Treatment	\$327,687	\$327,687	BIDD	100	\$327,687
Rezazadeh Kalebasty A	Novartis	CAA617C12301	7/13/2022	8/31/2025	PSMAAddition: An International Prospective Open-Label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination with Standard of Care, Versus Standard of Care Alone, in Adult Male Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)	\$335,512	\$335,512	BIDD	100	\$335,512
Rezazadeh Kalebasty A	Merck Sharp & Dohme	022-00	10/20/2022	11/30/2025	A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)	\$86,177	\$86,177	BIDD	100	\$86,177
Rezazadeh Kalebasty A	NAVIRE PHARMA, INC.	NAV-1001	1/26/2022	6/30/2025	A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in Patients with Advanced Solid Tumors	\$65,188	\$65,188	BIDD	100	\$65,188
Rezazadeh Kalebasty A	4D PHARMA PLC	MRx0518-004 (AVENU)	6/7/2022	6/30/2025	Phase 2 Switch Maintenance Study of MRx0518 and Avelumab in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma Who Did Not Progress on First-Line Platinum-Containing Chemotherapy	\$21,624	\$21,624	BIDD	100	\$21,624

Rezazadeh Kalebasti A	Merck Sharp & Dohme	04A-02	1/19/2023	12/31/2026	A Phase I/II Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A	\$21,904	\$21,904	BIDD	100	\$21,904
Rezazadeh Kalebasti A	Merck Sharp & Dohme	MK-3475-04B-3045	9/1/2023	9/1/2027	A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B	\$49,761	\$49,761	BIDD	100	\$49,761
Rezazadeh Kalebasti A	Merck Sharp & Dohme	004-00	6/13/2024	6/12/2028	A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA)	\$150,195	\$150,195	BIDD	100	\$150,195
Rezazadeh Kalebasti A	Merck Sharp & Dohme	003-00	6/13/2024	6/12/2028	A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	\$32,379	\$32,379	BIDD	100	\$32,379
Rezazadeh Kalebasti A	EIKON THERAPEUTICS, INC.	EIK1003-001	4/3/2024	4/1/2028	A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors	\$31,743	\$31,743	BIDD	100	\$31,743
Senthil M	On Target	UCI-23-184	6/26/2024	6/26/2028	A Phase I Pilot Study of Pafolacianine Injection for Intraoperative Imaging of Gastrointestinal Cancer Peritoneal Carcinomatosis	\$15,785	\$15,785	BIDD	100	\$15,785
Shi X	Silicon Valley Community Fdn	2023-321237-02	3/1/2023	2/28/2025	Dissemination of chemical-based super-resolution microscopy	\$175,217	\$87,609	BIDD	100	\$87,609
Srinivas S	TELIX PHARMACEUTICALS LIMITED	177Lu-TLX591-203	11/25/2024	11/25/2028	A Multinational, Multicenter, Prospective, Open-Label, Dosimetry and Safety Study of Lutetium (177Lu) Rosopitamab tetraxetan in Combination with Standard of Care in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer after Androgen Receptor Pathway Inhibitor Treatment	\$31,370	\$31,370	BIDD	100	\$31,370
Tinoco R	US Army Medical Research Acquisition Activity	HT94252311020-02	9/15/2023	9/14/2026	Intravital imaging of melanoma tumors for mechanism discovery and patient surveillance after checkpoint blockade immunotherapy	\$108,935	\$108,935	BIDD	100	\$108,935
Uchio E	Merck Sharp & Dohme	MK-3475-676	6/24/2019	6/23/2027	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)	\$101,297	\$101,297	BIDD	100	\$101,297
Weiss G Yang P (UC Berkeley)	BASF UC Berkeley	11751-01	4/1/2024	3/31/2025	Enzyme characterization using Single Walled Carbon Nanotubes (SWCNT)	\$111,114	\$55,557	BIDD	100	\$55,557
Yamamoto M	Astellas Pha	5354-CL-1201	6/1/2022	5/31/2025	A Phase 2 Open-label Dose-finding Study to Determine the Optimal dose for Lymph Node Visualization using ASP5354 in Participants with Breast Cancer or Melanoma Undergoing Sentinel Lymph Node Biopsy	\$25,606	\$25,606	BIDD	100	\$25,606
Non-Peer-Reviewed Research Subtotals						\$6,224,573	\$4,980,828			\$4,980,828

## UC Irvine Chao Family Comprehensive Cancer Center

Reporting Date: 02/28/2025

Program Area: Cancer Control

## Data Table 2A – Active Funded Projects

## Peer-Reviewed Research

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Anton-Culver H	NIH-OD	1OT2OD036428-01	5/1/2024	4/30/2025	All of Us Southern California Consortium (AoUSCC): Engagement, Enrollment, and Retention of Diverse Populations (Assist app# 1476115)	\$2,561,112	\$2,561,112	CC	100	\$2,561,112
Anton-Culver H Thomas N (University of North Carolina, Chapel Hill)	NIH-NCI University of North Carolina, Chapel Hill	5R01CA233524-05	4/1/2020	3/31/2025	Identification of Lethal Melanomas at the Time of Diagnosis	\$8,925	\$8,925	CC	100	\$8,925
Benmohamed L	NIH-NEI	5R01EY019896-12	9/1/2010	3/31/2026	Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits	\$261,146	\$130,573	CC	100	\$130,573
Chan A Acharya M	NIH-NCI	5R01CA276212-02	9/6/2023	8/31/2028	Neurotrophic strategy to mitigate chemotherapy-related brain injury	\$303,803	\$303,803	CC	50	\$151,902
Cozen W Bertrand K (Boston University) Cai Q (Vanderbilt) Espeldegui M (UCLA) Haiman C (USC) Pinkal D (Cornell) Reiner A (Fred Hutchinson)	NIH-NCI	5R01CA260615-04	9/20/2021	8/31/2026	Determinants of the racial/ethnic disparity in MGUS risk: An epidemiologic study in 4 cohorts	\$125,024	\$125,024	CC	100	\$125,024
Douglas J	TRDRP	T34CR8419H-01	7/1/2024	7/30/2026	A community-engaged examination of Black and Latine youth tobacco product use around activity spaces	\$209,382	\$209,382	CC	100	\$209,382
Edwards R Adetona O (The Ohio State University)	CDC-NIOSH The Ohio State University	SPC-1000007190 / GR129304-03	9/1/2022	8/31/2025	Chronic Respiratory Effect and Control of Occupational Exposure of Wildland Firefighters to Smoke	\$16,459	\$8,230	CC	100	\$8,230
Fowler C	NIH-NIDA	5R01DA051831-05	6/15/2020	4/30/2025	Impact of THC on Extracellular Vesicle Signaling	\$237,500	\$118,750	CC	100	\$118,750
Fowler C	TRDRP	T32IR4866-03	7/1/2022	6/30/2025	Cannabidiol as a therapeutic approach for tobacco and nicotine cessation	\$299,477	\$224,608	CC	100	\$224,608
Fowler C Ganesh T (Northeastern)	NIH-NIDA Northeastern	1R01DA059985-01	8/1/2024	5/31/2029	Selective Positive Allosteric Modulators of a4b2 Nicotinic Receptors	\$35,617	\$17,809	CC	100	\$17,809
Fowler C Gay E (RTI International)	NIH-NIDA RTI International	5R01DA058493-02	9/30/2023	7/31/2028	Discovery and development of GPR3 agonists for nicotine cessation	\$68,237	\$51,178	CC	100	\$51,178
Goodman-Gruen D Esserman L (UCSF)	NIH-NCI UCSF	1P01CA281826-01A1	9/11/2024	8/31/2029	WISDOM:A platform to optimize subtype-specific screening and prevention	\$53,119	\$53,119	CC	100	\$53,119
Hoyt M	DOD/CDMRP	W81XWH-20-1-0308-03 (NCE)	5/1/2020	5/14/2025	Inflammatory Processes, Emotion Regulation, and Depression in Prostate Cancer Survivors	\$58,041	\$58,041	CC	100	\$58,041
Hoyt M Applebaum A (Sloan Kettering)	NIH-NCI Sloan Kettering	5R01CA244185-05	9/1/2020	5/31/2025	A Randomized Controlled Trial of Emotion Regulation Therapy for Cancer Caregivers: A Mechanism-Targeted Approach to Addressing Caregiver Distress	\$87,063	\$87,063	CC	100	\$87,063
Hoyt M Nelson C (Memorial Sloan Kettering)	NIH-NCI	5R01CA276143-02	7/8/2023	6/30/2028	A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors	\$332,237	\$332,237	CC	100	\$332,237
Kim J	NIH-NCI	5R00CA246058-04	7/1/2020	6/30/2025	Supportive Care Needs in Asian Americans with Metastatic Cancer	\$158,599	\$158,599	CC	100	\$158,599



Lee S	NIH-NIMHD	5R01MD012778-06 (NCE)	9/26/2017	12/31/2025	Culturally Adapted Multilevel Decision Support Navigation Trial To Reduce Colorectal Cancer Disparity Among At-Risk Asian American Primary Care Patients	\$103,394	\$103,394	CC	100	\$103,394
Lee S Gomez S (UC San Francisco)	NIH-NCI UC San Francisco	1U01CA290831-01	7/8/2024	6/30/2029	A national Asian American cohort for assessing multi-level determinants in cancer etiology: the ASPIRE Cohort	\$116,430	\$116,430	CC	100	\$116,430
Lee S Kawachi I (Harvard University) Redline S (Brigham & Women's Hospital)	NIH-NIMHD	5R01MD015186-05	4/8/2021	1/31/2026	Sleep and health disparities among Asian Americans: role of stressors and protective factors	\$291,427	\$145,714	CC	100	\$145,714
Lotfipour S	TRDRP	T34IR8049-01	7/1/2024	6/30/2027	Genetic Mechanisms of Adolescent and Adult Nicotine Use	\$300,000	\$150,000	CC	100	\$150,000
Lotfipour S	TRDRP	T33IP6417-02	12/1/2023	11/30/2025	Mechanisms of a human 3 UTR alpha6 nicotinic receptor polymorphism in adolescent nicotine use	\$250,000	\$125,000	CC	100	\$125,000
Luderer U Shioda T (Mass General)	NIH-NIEHS Mass General	1R01ES035401-01	4/4/2024	2/28/2029	Environmental chemicals impair epigenetic suppression of the endogenous retrovirus HML-2 in human primordial germ cells, predisposing the next generation to malignancies through HML-2 reactivation	\$64,593	\$64,593	CC	100	\$64,593
Milam J	NIH-NCI	5R01CA237230-05 (NCE)	1/1/2021	12/31/2025	Project Milestones: Young Adult Cancer Survivorship	\$196,996	\$196,996	CC	100	\$196,996
Milam J Miller K (USC)	NIH-NCI USC	5R01CA261888-04	9/6/2021	8/31/2026	Individual, cultural, and area-based factors associated with survivorship care among Asian/Asian-American childhood cancer survivors.	\$173,363	\$173,363	CC	100	\$173,363
Milam J Miller K (University of Southern California)	NIH-NCI University of Southern California	5R37CA256867-04	3/1/2021	2/28/2026	Social Health, Activity Behaviors, and Quality of Life among Young Adult Cancer Survivors: A Longitudinal Study	\$8,371	\$8,371	CC	100	\$8,371
Morey B Kroenke C (Kaiser Research Foundation)	NIH-NCI Kaiser Research Foundation	5R01CA230440-05	7/1/2019	3/31/2025	Social Networks and Disparities in Health Behaviors and Breast Cancer Outcomes in Immigrant Women	\$15,873	\$15,873	CC	100	\$15,873
Nyamathi A	NIH-NCI	5R01CA285063-02	8/1/2023	7/31/2028	Secondary Cervical Cancer Prevention of Vulnerable Women with HPV and HIV Co-infection in India	\$476,005	\$476,005	CC	100	\$476,005
Payan D	TRDRP	T32KT4713-03	7/1/2022	6/30/2027	Policy surveillance and implementation of local flavored tobacco product sales bans in California	\$205,550	\$154,163	CC	100	\$154,163
Qu P	NIH-NCI	1R01CA297869-01	7/1/2024	6/30/2028	SCH: Individualized learning and prediction for heterogeneous multimodal data from wearable devices	\$198,693	\$198,693	CC	100	\$198,693
Rahmatpanah F	NIH-NCI	5R01CA226570-05 (NCE)	4/3/2019	3/31/2025	Aggressive prostate cancer of African Americans is correlated with regulation of Immunoregulatory Genes in stroma	\$179,785	\$179,785	CC	100	\$179,785
Richardson D	NIH-NCI	5R01CA242852-05 (NCE)	9/1/2021	8/31/2025	Low-Dose Exposure to Ionizing Radiation in Adulthood and Subsequent Cancer	\$354,465	\$354,465	CC	100	\$354,465
Richardson D	CDC-NIOSH	1R01OH012527-01 (NCE)	9/1/2021	7/31/2025	Occupational Exposure to Ionizing Radiation: Models for Policy Making	\$49,791	\$49,791	CC	100	\$49,791
Sadigh G	NIH-NCI	5R01CA262312-03	8/10/2022	7/31/2027	Improving medication adherence using a CONnected CUsomized Treatment Platform (CONCURxP)	\$283,372	\$283,372	CC	100	\$283,372
Sadigh G TB D (Emory University)	NIH-NCI	5R01CA272680-03	1/4/2023	12/31/2027	Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer patients	\$202,230	\$202,230	CC	100	\$202,230
Tanjasiri S Tomalsky M (California State University Fullerton)	NIH-NCI	5P20CA253254-04	9/23/2021	8/31/2025	2/2 CSUF/UCI-CFCCC Cancer Health Equity Research Partnership (CHERP)					
Tanjasiri S Bristow R	NIH-NCI	5P20CA253254-PP2-04	9/23/2021	8/31/2025	Examining the disparities in ovarian cancer survival among Asian Americans	\$45,750	\$45,750	CC	100	\$45,750
Thiel de Bocanegra H	NIH-NLM	5G08LM014109-03	9/1/2022	7/31/2025	Reproductive Health Equity in Afghan and Syrian newcomers through digital health literacy	\$133,175	\$66,588	CC	100	\$66,588
Vieira V Metayer C (UC Berkeley)	NIH-NIEHS UC Berkeley	5R01ES032196-03 (NCE)	9/3/2021	8/31/2025	Exposure to per- and polyfluoroalkyl substances (PFAS) and risk of cancer in children	\$65,564	\$65,564	CC	100	\$65,564
Zell J	NIH-NCI	1R50CA285412-01	9/24/2024	8/31/2029	Advancing novel cancer preventive and therapeutic strategies across the modern NCI clinical trial networks	\$125,011	\$125,011	CC	100	\$125,011

Zi X	NIH-NCI	1UG3CA290368-01	6/1/2024	4/30/2027	Natural products for targeting Skp2 in cancer interception	\$212,500	\$212,500	CC	100	\$212,500
Zi X	DOD/CDMRP	HT9425-24-1-0656-01	6/1/2024	5/31/2027	An epigenetic approach for alleviating enzalutamide resistance in prostate cancer	\$100,000	\$100,000	CC	100	\$100,000
Zi X Agrawal A Lilly M (Medical University of South Carolina)	NIH-NCI	5R01CA260351-04	12/9/2021	11/30/2026	Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer	\$182,063	\$182,063	CC	100	\$182,063
Peer-Reviewed Research Subtotals						\$9,150,142	\$8,244,167			\$8,092,266

Non-Peer-Reviewed Research

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Anton-Culver H	Smith Fdn	LVSF-5653648-01 (NCE)	5/1/2022	4/30/2025	Collaboration with the Breast Cancer Consortium (BCAC) in the Confluence Project to Study the Genetic Architecture of Breast Cancer	\$16,286	\$16,286	CC	100	\$16,286
Anton-Culver H	Smith Fdn	LVSF-5682439-01 (NCE)	5/1/2023	4/30/2025	Follow up, Genetic Associations, and Survival of Breast Cancer in the UCI Confluence Breast Cancer Cohort	\$11,924	\$11,924	CC	100	\$11,924
Anton-Culver H	Smith Fdn	LVSF-5715573-01	5/1/2024	4/30/2025	Characterization of breast and ovarian cancer in the national NIH All of Us Research Program compared to the population-based SEER and California Cancer Registry	\$25,000	\$25,000	CC	100	\$25,000
Banker R	AstraZeneca PLC	D798EC00001	6/20/2024	6/17/2028	A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)	\$24,415	\$24,415	CC	100	\$24,415
Banker R	PRA Inc	TAK-676-1002	10/28/2024	10/28/2028	An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors	\$30,421	\$30,421	CC	100	\$30,421
Banker R	Merck Sharp & Dohme	V940-007-1154	12/4/2024	10/31/2031	A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK- 3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC) (INTerpath-007)	\$44,647	\$44,647	CC	100	\$44,647
Banker R	FLAMINGO THERAPEUTICS	FLM-6774-201	12/19/2023	12/10/2027	An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	\$88,643	\$88,643	CC	100	\$88,643
Bota D	Tocagen	TG511-15-01	10/23/2015	12/31/2025	A Phase II/III Randomized, Open Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma	\$23,650	\$23,650	CC	100	\$23,650
Cozen W Desai P (Cornell)	DOD Misc Cornell	226659-2-02	9/30/2023	9/29/2026	Mutational and Aging Risk Factors for Myelodysplastic Syndrome	\$6,968	\$6,968	CC	100	\$6,968
Fortier M	Cambia Health Fdn	CHF-5658623-02 (NCE)	12/1/2022	12/1/2025	A Community Engaged Approach to Develop a Culturally Appropriate Palliative Care Model for Spanish-speaking Families Impacted by Childhood Cancer	\$33,978	\$33,978	CC	100	\$33,978
Keshava H	Merck Sharp & Dohme	V940-002-0030	7/17/2024	6/30/2028	A Phase III, Randomized, Double-blind, Placebo- and Active-Comparator Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA,IIIB (N2) Non-small Cell Lung Cancer	\$19,737	\$19,737	CC	100	\$19,737
Kong X	CHIMERIX, INC.	ONC019	6/3/2022	5/31/2025	A Retrospective Observational Study for H3 K27M-mutant Glioma	\$5,848	\$5,848	CC	100	\$5,848
Kong X	CHIMERIX, INC.	ONC201-108	6/23/2023	6/23/2027	ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study	\$36,290	\$36,290	CC	100	\$36,290
Kong X	NUVOX PHARMA, LLC.	RESTORE P2	4/19/2024	4/17/2028	A Phase II Double-blind, Randomized, Prospective, Placebo Controlled Study of NanO2 TM Combined with Radiation and Temozolomide in Patients with Newly-diagnosed Glioblastoma Multiforme RESTORE	\$22,025	\$22,025	CC	100	\$22,025

Kongtim P	Rigel Pharmaceuticals Inc	C-906289-002	1/25/2023	12/31/2027	An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS) Who are Refractory/Resistant to Prior Therapies	\$95,007	\$95,007	CC	100	\$95,007
Kongtim P	EUROFINS VIRACOR, INC.	22-188 PROVE	6/11/2024	6/10/2026	Assessment of CMV-specific T Cell Immunity in Patients Receiving Letermovir Prophylaxis after Allogeneic Hematopoietic Cell Transplantation (PROVE)	\$24,350	\$24,350	CC	100	\$24,350
Luderer U	NASA-SSC	80NSSC19K1620-06	8/20/2019	8/19/2025	Ovarian Cancer and Space Radiation	\$32,003	\$32,003	CC	100	\$32,003
Park H Badal K (UCSF)	UCOP UCSF	15197sc-01	3/1/2024	2/28/2027	Investigating the relationship between chemical exposures, DNA methylation, and breast cancer risk	\$82,175	\$82,175	CC	100	\$82,175
Sadigh G	RSNA	RSNA-5709750-01 (NCE)	1/1/2024	12/31/2025	Empowering Latinx patients Lung Cancer Screening Uptake (Empower Latinx)	\$36,675	\$36,675	CC	100	\$36,675
Sadigh G Torres M (Emory University)	ASCO Emory University	A811277-03	7/1/2022	6/30/2025	Genetic Determinants of Treatment-Related Comorbidities, Poor Treatment Adherence, and Worse Survival Among Black Patients with Early-Stage Breast Cancer	\$2,345	\$2,345	CC	100	\$2,345
Smith J	HOTH THERAPEUTICS, INC.	CLEER-001	6/12/2024	5/31/2028	A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors	\$25,620	\$25,620	CC	100	\$25,620
Tewari K	Merck Sharp & Dohme	005-03	4/18/2022	4/30/2025	A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors	\$12,460	\$12,460	CC	100	\$12,460
Tewari K	Amgen	20210007.00	12/16/2022	12/31/2025	Phase I First-in-Human Study to Explore the Safety Tolerability and Pharmacokinetics of AMG 794 in Subjects with Claudin 6-Positive Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer or Epithelial Ovarian Cancer	\$61,187	\$61,187	CC	100	\$61,187
Tewari K	ELLIPSES PHARMA LTD	EP0057-201	5/27/2022	6/30/2025	A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 - platinum resistant disease and are PARP inhibitor naive; Cohort 2 - had at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance	\$38,828	\$38,828	CC	100	\$38,828
Tewari K	Advenchen Laboratories LLC	AL3818-US-002	2/6/2023	2/5/2027	A Phase I/IIa/III Evaluation of the Safety and Efficacy of Adding AL3818, (Anlotinib,INN: Catequentinib) a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma	\$24,052	\$24,052	CC	100	\$24,052
Tewari K	KSQ Therapeutics Inc	KSQ-4279-1101	2/7/2023	2/6/2027	A Phase I Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors	\$37,707	\$37,707	CC	100	\$37,707
Tewari K	Ascendis Pharma A/S	TCTLR-101	8/16/2023	8/15/2027	Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies	\$23,642	\$23,642	CC	100	\$23,642
Tewari K	GOG	XPORT-EC-042 / GOG-3083	8/23/2023	8/23/2027	ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA	\$29,153	\$29,153	CC	100	\$29,153
Tewari K	GOG	GoG-3078/IMGN853-0421	9/29/2023	9/28/2027	Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum based chemotherapy plus bevacizumab (GLORIOSA)	\$22,440	\$22,440	CC	100	\$22,440
Tewari K	GOG	Olvi-Vec-022 /GOG-3076	10/26/2023	10/26/2027	A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime/GOG-3076 Study)	\$26,857	\$26,857	CC	100	\$26,857
Tewari K	GOG	ZN-c3-005/GOG-3066	10/26/2023	10/25/2027	A PHASE 2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ZN-c3 IN SUBJECTS WITH HIGH-GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER	\$22,202	\$22,202	CC	100	\$22,202
Tewari K	Blueprint Medicines Corporation	BLU-222-1101	6/12/2024	4/30/2028	A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors	\$24,580	\$24,580	CC	100	\$24,580
Tewari K	Merck Sharp & Dohme	587-05	8/6/2024	7/31/2028	A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab	\$25,483	\$25,483	CC	100	\$25,483

Tseng J	Winsantor Inc	WST-PZP-005	1/19/2023	12/31/2026	A Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Topical Pirenzepine (WST-057) or Placebo for the Prevention of Dose Limiting Chemotherapy Induced Peripheral Neuropathy in Oncology Patients Administered Carboplatin and Paclitaxel	\$78,872	\$78,872	CC	100	\$78,872
Tseng J	GOG	MER-XMT-1536-3 (GoG-3049)	2/3/2023	2/2/2027	STUDY MER-XMT-1536-3 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF UPIFITAMAB RILSODOTIN (XMT-1536) AS POSTPLATINUM MAINTENANCE THERAPY FOR PARTICIPANTS WITH RECURRENT, PLATINUMSENSITIVE OVARIAN CANCER (UP-NEXT)	\$27,291	\$27,291	CC	100	\$27,291
Uchio E	PRA Inc	P17-1	1/30/2019	8/2/2026	PROVENT - A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER	\$19,740	\$19,740	CC	100	\$19,740
Uchio E	Immunomedics	IMMU-132-13	11/20/2020	11/19/2025	2551537 - IMMU 132-13-Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer	\$13,373	\$13,373	CC	100	\$13,373
Uchio E	Bayer	21516	9/21/2021	9/20/2028	UCI 21-130 Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm (ARASEC)	\$29,126	\$29,126	CC	100	\$29,126
Uchio E	Brst Myrs Sq	CA045-009-0015	1/10/2020	12/31/2026	CA045-009: A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214 Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible	\$2,172	\$2,172	CC	100	\$2,172
Uchio E	Janssen R&D LLC	67652000PCR3002	9/8/2020	9/7/2025	UCI 20-146 - Amplitude - A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone (AA-P) and ADT Versus Abiraterone Acetate and Prednisone and ADT in Subjects With Metastatic Castration Sensitive Prostate Cancer (mCSPC) with DNA-repair gene defects	\$2,911	\$2,911	CC	100	\$2,911
Uchio E	SeaGen	SGN22E-004	8/27/2021	8/26/2028	EV-104: A study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)	\$4,004	\$4,004	CC	100	\$4,004
Uchio E	Exact	THR-CS-001	12/23/2021	12/22/2025	Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing-Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)	\$1,190	\$1,190	CC	100	\$1,190
Uchio E	ColdGen	BOND-003	3/1/2021	2/29/2028	UCI 20-210- BOND 3- A Phase 3 Study of CG0070 in Patients with Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)	\$70,515	\$70,515	CC	100	\$70,515
Uchio E	Iqvia Holdings Inc	MDV3100-13	10/1/2015	6/30/2025	EMBARK: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy	\$105,045	\$105,045	CC	100	\$105,045
Uchio E	ColdGen	CORE-001	6/1/2020	5/31/2025	CORE-001: A Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)	\$30,651	\$30,651	CC	100	\$30,651
Non-Peer-Reviewed Research Subtotals						\$1,421,488	\$1,421,488			\$1,421,488

## UC Irvine Chao Family Comprehensive Cancer Center

Reporting Date: 02/28/2025

Program Area: Systems, Pathways &amp; Targets

Data Table 2A – Active Funded Projects

## Peer-Reviewed Research

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Albrecht L	NIH-NIGMS	1R35GM157370-01	9/20/2024	8/31/2029	Deciphering Novel Principles of Rapid Proteostatic Control and Innovating Spatiotemporal Lysosomal Tools	\$250,000	\$125,000	SPT	100	\$125,000
Andersen B	NIH-NIAMS	5R01AR056439-12	9/1/2010	5/31/2026	Circadian Clock Regulation in Skin	\$272,388	\$136,194	SPT	100	\$136,194
Andersen B	NIH-NIAMS	5R34AR081502-03	9/1/2022	6/30/2025	The Initiation of Vesicant Skin Injury at a Single Cell Level	\$179,000	\$89,500	SPT	100	\$89,500
Atwood S	NIH-NCI	5R01CA237563-05 (NCE)	4/11/2019	3/31/2025	Phosphorylation-dependent regulation of GLI transcription factors	\$14,645	\$14,645	SPT	100	\$14,645
Atwood S	NSF	CBET-2134916-04	1/1/2022	12/31/2025	RECODE: Functional characterization of human skin organoids	\$242,702	\$121,351	SPT	100	\$121,351
Baker N	NIH-NCI	9R01CA284362-10A1	8/15/2024	7/31/2029	Cell Competition in Development and Homeostasis	\$260,454	\$260,454	SPT	100	\$260,454
Baker N	NIH-NIGMS	7R01GM120451-07	9/16/2016	8/31/2027	Ribosomes and Growth Regulation	\$200,000	\$200,000	SPT	100	\$200,000
Benavente C	NIH-NCI	5R01CA229696-05 (NCE)	6/1/2019	5/31/2025	Role of UHRF1 in osteosarcoma and its relationship to RB	\$160,374	\$160,374	SPT	100	\$160,374
Blumberg B Shioda T (Mass General Hospital)	NIH-NIEHS	5R01ES031139-05	9/16/2020	6/30/2026	Interactions between prenatal obesogen exposure and Total Western diet lead to a transgenerational thrifty phenotype: functional and epigenomic analysis of effects in fat and liver	\$174,390	\$130,793	SPT	100	\$130,793
Buisson R	ACS	RSG-24-1249960-01-DMC-01	7/1/2024	6/30/2028	Deciphering DNA Damage Response-Mediated Translation Regulation to Prevent Cancer Initiation	\$199,375	\$199,375	SPT	100	\$199,375
Buisson R	NIH-NIAID	1R21AI185033-01	1/1/2025	12/31/2026	Role of APOBEC3B in the Innate Immune Response	\$145,500	\$72,750	SPT	100	\$72,750
Buisson R Lawrence M (Mass General)	NIH-NCI	5R37CA252081-04	7/1/2021	6/30/2026	Molecular Mechanisms of APOBEC-Induced Mutagenesis in Cancer	\$193,287	\$193,287	SPT	100	\$193,287
Buisson R Lawrence M (Massachusetts General Hospital)	NIH-NCI Massachusetts General Hospital	1R01CA262874-01A1	4/9/2024	3/31/2029	Mechanisms of APOBEC3A-induced cancer evolution and cancer vulnerability	\$14,377	\$14,377	SPT	100	\$14,377
Chan J	NIH-NIEHS	5R01ES029481-05 (NCE)	8/1/2019	4/30/2025	Nrf1-dependent regulation of cellular stress response	\$138,183	\$103,637	SPT	100	\$103,637
Cho K	NIH-NIGMS	5R35GM139617-04	3/1/2021	2/28/2026	Maternal transcription factors shaping early embryonic chromatin landscape	\$265,000	\$132,500	SPT	100	\$132,500
Cho K	NIH-NICHD	5R21HD109696-02 (NCE)	8/19/2022	7/31/2025	Spatiotemporal mapping of enhancer activity in developing frog embryos	\$86,473	\$43,237	SPT	100	\$43,237
Dai X	NIH-NIGMS	5R35GM145307-03	6/1/2022	3/31/2027	Intrinsic and extrinsic control of epithelial tissue stem cell activity	\$304,552	\$228,414	SPT	100	\$228,414
Dayyani F Carvajal-Carmona L (UC Davis)	NIH-NCI UC Davis	5U54CA283766-02	8/1/2024	7/31/2028	University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities	\$27,862	\$27,862	SPT	100	\$27,862
Fleischman A	NIH-NCI	5R37CA271172-03	5/30/2022	3/31/2027	Effect of inflammation on JAK2 mutant evolution in the hematopoietic system: mathematical models and experiments	\$352,028	\$352,028	SPT	100	\$352,028
Fleischman A	TRDRP	T32IR5150-03	7/1/2022	6/30/2025	Impact of Electronic Nicotine Delivery Devices on clonal hematopoiesis and hematologic malignancies	\$300,000	\$300,000	SPT	100	\$300,000
Fleischman A	NIH-NIDDK	5R01DK136069-03	9/25/2022	6/30/2025	Role of IL-10R signaling in inflammation induced exhaustion of HSC and emergence of JAK2V617F clonal hematopoiesis	\$144,000	\$144,000	SPT	100	\$144,000
Fleischman A	NSF	DMS-2424855-01	10/1/2024	9/30/2027	eMB: Collaborative Research: Using mathematics to bridge between evolutionary dynamics in the hematopoietic systems of mice and humans: from in vivo to epidemiological scales	\$73,952	\$73,952	SPT	100	\$73,952

Fleischman A	NSF	DMS-2424855-01	9/1/2024	8/31/2027	Collaborative Research: Using mathematics to bridge between evolutionary dynamics in the hematopoietic systems of mice and humans: from in vivo to epidemiological scales	\$73,952	\$73,952	SPT	100	\$73,952
Frank S	NSF	DEB-2325755-01	4/1/2024	3/31/2026	OPUS: Robustness and complexity: how evolution builds precise traits from sloppy components	\$78,587	\$58,940	SPT	100	\$58,940
Fruman D	ALSF	22-25509-02 (NCE)	11/1/2022	1/15/2026	Enhancing TKI therapy in Ph-like leukemia	\$35,008	\$35,008	SPT	100	\$35,008
Fruman D	ACS	DBG-24-1319247-01-IBCD-01	1/1/2025	12/31/2026	Control of leukemia cell survival by the mevalonate pathway	\$135,000	\$135,000	SPT	100	\$135,000
Gupta K Hui S (City of Hope)	NIH-NHLBI City of Hope	5R01HL164895-02	7/1/2023	6/30/2026	Novel Targeted Marrow Irradiation Based Bone Marrow Transplantation for Sickle Cell Disorders	\$45,000	\$22,500	SPT	100	\$22,500
Halbrook C	NIH-NCI	1R37CA283575-01A1	5/1/2024	4/30/2029	Targeting Metabolic Crosstalk in Pancreatic Cancer	\$283,085	\$283,085	SPT	100	\$283,085
Halbrook C	ACS	RSG-24-1320209-01-MM-01	1/1/2025	12/31/2028	Deconvoluting the Metastatic Pancreatic Cancer Tumor Microenvironment	\$197,083	\$197,083	SPT	100	\$197,083
Hertel K	NIH-NIGMS	5R35GM145254-03	8/9/2022	6/30/2027	Regulation and impact of alternative splicing in biology and disease	\$250,000	\$187,500	SPT	100	\$187,500
Hicks M	NIH-NIAMS	1R01AR084027-01	8/16/2024	7/31/2029	Modulating the Stem Cell Niche Set Point to Improve Skeletal Muscle Regeneration	\$324,018	\$162,009	SPT	100	\$162,009
Jang C	NIH-NIAAA	5R01AA029124-04	8/1/2021	5/31/2026	Elucidating dietary fructose and alcohol interactions during liver cancer development	\$225,000	\$225,000	SPT	100	\$225,000
Jang C Guertin D (Univ of Mass)	NIH-NIDDK Univ of Mass	5R01DK127175-04	8/4/2021	5/31/2026	Quantitative and functional analysis of brown fat nutrient fluxes in vivo and its role in organ metabolite exchange	\$93,937	\$70,453	SPT	100	\$70,453
Jang C Seldin M	NIH-NIAAA	5R21AA030358-02	9/12/2023	8/31/2025	Elucidating alcohol-induced metabolic remodeling of critical organs	\$262,500	\$196,875	SPT	100	\$196,875
Kaiser P	NIH-NIGMS	5R35GM148350-02	3/1/2023	2/29/2028	Ubiquitin and Metabolite Signaling	\$385,918	\$289,439	SPT	100	\$289,439
Kaiser P	NIH-NIGMS	3R35GM148350-02S2	3/1/2024	2/28/2025	Ubiquitin and Metabolite Signaling (Equipment Purchase)	\$217,747	\$163,310	SPT	100	\$163,310
Kaiser P Rychnovsky S	NIH-NCI	5R01CA283462-02	7/10/2023	6/30/2028	Mechanisms of mutant p53 reactivation	\$348,047	\$348,047	SPT	50	\$174,024
Kessenbrock K	NIH-NCI	2R01CA234496-06	2/1/2019	7/31/2029	Microenvironmental Regulation of Breast Tumorigenesis	\$311,835	\$311,835	SPT	100	\$311,835
Kessenbrock K Chan K (Method Hospital Research Institute)	NIH-NCI Method Hospital Research Institute	3U54CA274375-03S1	9/1/2024	8/31/2025	A single-cell spatial map characterizing the stromal TME in bladder and breast early-lesions	\$50,000	\$50,000	SPT	100	\$50,000
Komarova N Wodarz D	NSF	DMS-2152155-03	7/1/2022	6/30/2026	Mutant evolution in spatially structured, hierarchical populations	\$85,282	\$63,962	SPT	100	\$63,962
Komarova N Wodarz D	NSF	MCB-2141651-03	5/1/2022	4/30/2025	Collaborative Research: MODULUS: Copy Number Alterations and Xenobiotic adaptation	\$95,773	\$71,830	SPT	100	\$71,830
Kong M	NIH-NCI	5R01CA244360-04	7/1/2021	6/30/2026	Using dietary glutamine supplementation for melanoma prevention and targeted therapy	\$257,161	\$257,161	SPT	100	\$257,161
Kong M	ACS	DBG-23-1037710-01-TBE-02	7/1/2023	6/30/2025	Role of metabolic microenvironment in cancer metastasis	\$120,000	\$120,000	SPT	100	\$120,000
Kong M	NIH-NIGMS	1R35GM153227-01	9/10/2024	8/31/2029	Role of PP2A family protein phosphatases in nutrient sensing pathways	\$250,000	\$250,000	SPT	100	\$250,000
Kvon E	NIH-NIGMS	5DP2GM149555-03	9/9/2022	8/31/2025	Deciphering the mechanism of long-range gene regulation in vivo	\$300,000	\$150,000	SPT	100	\$150,000
Kvon E	NIH-NICHD	1R01HD115268-01	7/1/2024	4/30/2029	Decoding the Mechanism of Pathogenic Enhancer Mutations In Congenital Limb Disorders	\$255,012	\$127,506	SPT	100	\$127,506
Lara-Gonzalez P	NIH-NIGMS	5R35GM150786-02	7/1/2023	6/30/2028	Developmental regulation of the cell cycle machinery	\$250,000	\$250,000	SPT	100	\$250,000
Lawson D	NIH-NCI	1R01CA237376-05	3/1/2020	2/28/2026	Inflammatory Microenvironment in Brain Metastasis	\$217,313	\$217,313	SPT	100	\$217,313
Li W	NIH-NCI	5R01CA193466-09	12/1/2015	2/28/2026	Computational and Experimental Modeling of Alternative Polyadenylation	\$256,528	\$256,528	SPT	100	\$256,528
Li W	NIH-NCI	5R01CA228140-04 (NCE)	2/1/2010	1/31/2026	DNA Methylation Canyons in Human Cancers: Methods, Target Genes and Functional Consequences	\$50,435	\$50,435	SPT	100	\$50,435

Li W Chua K (Palo Alto's Veteran Institute for Research)	NIH-NCI Palo Alto's Veteran Institute for Research	5R01CA268925-04	7/9/2021	6/30/2026	Histone Deacetylation Signaling in Aging and Cancer Pathways	\$5,996	\$5,996	SPT	100	\$5,996
Li W Wang Q (Duke)	NIH-NCI Duke	1R01CA290720-01	5/1/2024	4/30/2029	Elucidating alternative polyadenylation regulation during prostate cancer progression to castration-resistance	\$110,344	\$110,344	SPT	100	\$110,344
Limoli C	NIH-NCI	5R01CA254892-04	7/1/2021	6/30/2026	Improving pediatric brain tumor treatments using FLASH radiotherapy	\$130,516	\$130,516	SPT	100	\$130,516
Limoli C Various V (Consortium)	NIH-NCI	P01CA244091-05	6/1/2020	5/31/2025	Increasing the therapeutic index of brain tumor treatment through innovative FLASH radiotherapy					
Limoli C Loo B (Stanford University) Maxim P (Indiana University)	NIH-NCI	P01CA244091-P1-05	6/1/2020	5/31/2025	Project 1: Optimizing Treatment Of GBM By Flash	\$82,933	\$82,933	SPT	100	\$82,933
Limoli C Loo B (Stanford University) Max P (Indiana University)	NIH-NCI	P01CA244091-P2-05	6/1/2020	5/31/2025	Project 2: Sparing in Tumor Free Animals	\$68,240	\$68,240	SPT	100	\$68,240
Limoli C Loo B (Stanford University) Maxim P (Indiana University) Spitz D (University of Iowa) Vozenin M (Centre Hospitalier Universitaire Vaudois)	NIH-NCI	P01CA244091-P4-05	6/1/2020	5/31/2025	Project 4: Mechanistic Basics of Flash Effect: Role of O2	\$39,666	\$39,666	SPT	100	\$39,666
Marangoni F	MRA	929155-03	6/1/2022	5/31/2025	Mechanisms and relevance of Treg expansion after PD-1 blockade in melanoma	\$85,000	\$85,000	SPT	100	\$85,000
Marangoni F	DOD/CDMRP	HT94252311024-02	9/15/2023	8/14/2026	Intravital imaging of melanoma tumors for mechanism discovery and patient surveillance after checkpoint blockade immunotherapy	\$146,571	\$146,571	SPT	100	\$146,571
Marsden M zhen A (UCLA)	NIH-NIAID UCLA	5R01AI172727-03	6/25/2022	5/31/2027	Induction of autophagy to enhance CAR T cells in HIV cure approaches	\$191,368	\$95,684	SPT	100	\$95,684
Masri S	NIH-NCI	5R01CA244519-05	3/1/2020	2/28/2026	Circadian Clock Disruption and Colorectal Cancer	\$205,875	\$205,875	SPT	100	\$205,875
Masri S Waterman M	NIH-NCI	5R01CA259370-04	1/1/2022	12/31/2026	Circadian Clock and Myc-dependent Regulation of Cellular Transformation	\$332,730	\$332,730	SPT	100	\$332,730
Ng S Tsukamoto H (USC)	NIH-NIAAA USC	2P50AA011999-26	5/10/2024	4/30/2025	2024 Pilot Project: Multi-omic profiling of the IL-17/NF-kB pathway to track and target steatohepatitis and hepatocellular carcinoma clones	\$35,000	\$35,000	SPT	100	\$35,000
Nie Q	NIH-NIGMS	1R01GM152494-01	9/20/2024	6/30/2028	Development of new tools for analyzing cell-cell communication using spatial transcriptomic data	\$260,000	\$195,000	SPT	100	\$195,000
Nie Q Dai X Lander A Lowengrub J	NSF	DMS1763272-05 (NCE)	7/1/2018	6/30/2025	NSF-Simons Center for Multiscale Cell Fate Research	\$1,333,885	\$1,000,414	SPT	100	\$1,000,414
Pannunzio N	NIH-NCI	5R01CA276470-02	2/15/2024	1/31/2029	Aberrant V(D)J recombination in B cells initiates lymphoid malignancy	\$211,495	\$211,495	SPT	100	\$211,495
Pannunzio N Frock R (Stanford University)	NIH-NCI	5R37CA266042-04	2/14/2022	1/31/2027	Defining the Mechanism of Genome Rearrangements in Ph-Like ALL to Determine Predictive Markers in High-Risk Hispanic Populations	\$247,494	\$247,494	SPT	100	\$247,494
Plikus M Nie Q	NIH-NIAMS	5R01AR079150-04	2/1/2022	11/30/2026	Tissue size and precision control in growing hair follicles	\$322,612	\$161,306	SPT	100	\$161,306
Plikus M Scumpia P (UCLA)	NIH-NIAMS UCLA	5R01AR079470-04	9/1/2021	8/31/2025	Leveraging immune-fibroblast interactions for biomaterial induced skin regeneration	\$140,530	\$70,265	SPT	100	\$70,265
Qiao F	NIH-NIGMS	5R35GM149572-02	4/13/2023	3/31/2028	Molecular Mechanisms of Telomere Length Homeostasis	\$250,000	\$250,000	SPT	100	\$250,000
Razorenova O	NIH-NCI	5R21CA280564-02	1/1/2024	12/31/2025	Therapeutic targeting of VHL-deficient clear cell renal cell carcinoma	\$126,225	\$126,225	SPT	100	\$126,225
Schilling T	NSF	MCB-2028424-05	9/1/2020	8/31/2025	MODULUS:RoL: Uncovering Roles of Cell Fate Decisions in Migrating Neural Crest Cells	\$168,867	\$84,433	SPT	100	\$84,433

Schilling T Nie Q	NIH-NIDCR	5R01DE030565-04	4/1/2021	3/31/2026	Dissecting single cell dynamics that coordinate neural crest migration and diversification	\$344,831	\$172,416	SPT	100	\$172,416
Seldin M	NIH-NIDDK	5DP1DK130640-04	9/17/2021	7/31/2026	Integrative approaches to dissection of endocrine communication	\$377,885	\$188,943	SPT	100	\$188,943
Shi Y	NIH-NIGMS	5R35GM149294-02	5/1/2023	2/29/2028	Mechanisms and regulation of mRNA 3' processing	\$305,672	\$229,254	SPT	100	\$229,254
Shi Y Sciammas R (UC Davis)	NIH-NIAID	5R01AI170840-03	5/26/2022	4/30/2027	mRNA alternative polyadenylation in B cell development	\$398,992	\$199,496	SPT	100	\$199,496
Shi Y Seelig G (Univ Washington)	NIH-NCI	1R01CA297834-01	2/1/2025	1/31/2030	Decode polyadenylation in health and disease	\$207,336	\$207,336	SPT	100	\$207,336
Suetterlin C Tan M	NIH-NIAID	5R01AI153410-05	7/17/2020	6/30/2025	Primary cilia loss and cell cycle re-entry in Chlamydia-infected cells	\$338,207	\$169,104	SPT	100	\$169,104
Sun S	NIH-NIGMS	5R01GM141424-04	9/9/2021	7/31/2026	Elucidating the molecular basis of lncRNA evolution for mammalian dosage compensation	\$210,000	\$105,000	SPT	100	\$105,000
Tanjasiri S Tomalsky M (California State University Fullerton)	NIH-NCI	5P20CA253254-04	9/23/2021	8/31/2025	2/2 CSUF/UCI-CFCCC Cancer Health Equity Research Partnership (CHERP)					
Tanjasiri S Razorenova O	NIH-NCI	5P20CA253254-PP1-04	9/23/2021	8/31/2025	Racial disparity in triple-negative breast cancer lipid metabolism	\$45,750	\$45,750	SPT	100	\$45,750
Tian L Kaur B (Augusta University)	NIH-NINDS Augusta University	1R61NS128191-01A1	9/9/2024	6/30/2026	Development of murine glioblastoma model for oncolytic HSV therapy	\$14,441	\$14,441	SPT	100	\$14,441
Van Etten R	NIH-NCI	1R01CA280606-01A1	5/1/2024	4/30/2029	Mechanisms of treatment-free remission in a mouse model of chronic myeloid leukemia	\$228,750	\$228,750	SPT	100	\$228,750
Villalona Calero M Yu J	NIH-NCI	5R01CA266457-04	8/16/2022	11/30/2027	Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors	\$337,061	\$337,061	SPT	100	\$337,061
Wagar L Zhong Q (CHOC)	NIH-NIAID	5R01AI173023-02	6/1/2023	5/31/2028	Investigating protective adaptive immune responses to influenza antigens using human tonsil organoids	\$362,171	\$181,086	SPT	100	\$181,086
Walsh C	CIRM	INFR6.2-15368-01	7/1/2024	6/30/2029	UCI CIRM SRL	\$615,206	\$307,603	SPT	100	\$307,603
Wang W	NIH-NIGMS	5R01GM126048-08	2/1/2018	1/31/2027	Lipid signaling in Hippo pathway regulation	\$206,000	\$206,000	SPT	100	\$206,000
Wang W	NIH-NIGMS	5R01GM143233-03	8/4/2022	7/31/2026	Interplay of heavy metal homeostasis and cell growth-related signaling networks	\$200,000	\$150,000	SPT	100	\$150,000
Yu J	CIRM	TRAN1-14003-B-01	8/26/2024	5/31/2026	Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1a	\$1,516,988	\$1,516,988	SPT	100	\$1,516,988
Yu J Finley S (USC)	NIH-NCI USC	5U01CA275808-03	12/1/2024	8/31/2027	Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy	\$72,702	\$72,702	SPT	100	\$72,702
Peer-Reviewed Research Subtotals						\$19,730,102	\$15,765,618			\$15,591,595

Non-Peer-Reviewed Research

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Benavente C	American Lung Association	LCD-1034555-02	7/1/2023	6/30/2025	Harnessing the ubiquitin system as a therapeutic approach in SCLC	\$50,000	\$50,000	SPT	100	\$50,000
Bota D	Agios	AG881-C-004	1/7/2020	12/31/2025	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of AG-881 in Subjects with Residual/Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation.	\$21,441	\$21,441	SPT	100	\$21,441
Brem E	GENMAB US, INC.	GCT3013-05	3/3/2022	3/2/2025	A Randomized Open-Label Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma	\$12,336	\$12,336	SPT	100	\$12,336
Brem E	SORRENTO THERAPEUTICS, INC.	38DART-RRMM-101	8/17/2022	9/30/2025	A Phase 1b Open-Label Study of the Safety and Efficacy of Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor (DAR)-T Cells in Patients with Relapsed or Refractory Multiple Myeloma	\$29,367	\$29,367	SPT	100	\$29,367
Brem E	ICONClinRes	KT-US-473-0133 (ZUMA-22)	2/4/2023	12/31/2027	A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucl Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma	\$83,311	\$83,311	SPT	100	\$83,311



Brem E	Morphosys Ag	MOR208C414	1/22/2024	1/22/2028	REAL-MIND Prospective Multicenter Observational Study of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Starting Second- or Third-Line Therapy and Not Receiving Autologous Stem Cell Transplants	\$21,552	\$21,552	SPT	100	\$21,552
Brem E	Regeneron	R1979-ONC-2105	2/15/2024	2/15/2028	A Phase III, Open label, Randomized Study Comparing the Safety and Efficacy of Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with CHOP (O-CHOP) versus Rituximab in Combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)	\$42,495	\$42,495	SPT	100	\$42,495
Brem E	Regeneron	R1979-HM-2298	3/15/2024	3/15/2028	A Phase III, Open-Label, Randomized Study to Compare the Safety and Efficacy of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Investigator's Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)	\$30,286	\$30,286	SPT	100	\$30,286
Brem E	AbbVie	M23-362	8/15/2024	8/15/2029	A Phase II, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) When Administered in the Outpatient Setting	\$42,945	\$42,945	SPT	100	\$42,945
Chow W	IGM BIOSCIENCES, INC.	IGM-8444-001	10/18/2022	11/30/2025	AN OPEN-LABEL MULTICENTER PHASE I STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLY DIAGNOSED CANCERS	\$88,993	\$88,993	SPT	100	\$88,993
Chow W	Novotech Clinical Research USA LLC	SGN-P01-001	2/3/2023	2/2/2027	Phase I, Open-label study to evaluate safety, tolerability and preliminary efficacy of modified Salmonella typhimurium SGN1 in Patients with Advanced Solid Tumor	\$72,004	\$72,004	SPT	100	\$72,004
Chow W	Brst Myrs Sq	CA224127	3/31/2023	3/30/2027	A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma	\$468,831	\$468,831	SPT	100	\$468,831
Chow W	Topalliance Biosciences Inc	TAB004	4/6/2023	4/5/2027	A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma	\$72,597	\$72,597	SPT	100	\$72,597
Chow W	SANDOZ INC.	CGME751A12101	11/24/2024	11/20/2028	A randomized, double-blind, parallel-group study to compare pharmacokinetics of GME751 (proposed pembrolizumab biosimilar) and US-licensed and EU authorized Keytruda in participants with stage II and III melanoma requiring adjuvant treatment with pembrolizumab	\$8,905	\$8,905	SPT	100	\$8,905
Ciurea S	CELULARITY INC.	CYNK-001-AML-001	10/1/2022	9/30/2025	A PHASE I MULTI-DOSE STUDY OF HUMAN PLACENTAL HEMATOPOIETIC STEM CELL DERIVED NATURAL KILLER CELLS (CYNK-001) WITH OR WITHOUT RECOMBINANT HUMAN INTERLEUKIN-2 (RHIL-2) IN ADULTS WITH PRIMARY OR SECONDARY ACUTE MYELOID LEUKEMIA (AML) IN MORPHOLOGIC COMPLETE REMISSION WITH MINIMAL RESIDUAL DISEASE (MRD) OR RELAPSED/REFRACTORY AML	\$14,010	\$14,010	SPT	100	\$14,010
Ciurea S	Adicet Therapeutics Inc	ADI-20200101	4/26/2023	4/26/2027	A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta T Cells in Adults with B Cell Malignancies	\$80,895	\$80,895	SPT	100	\$80,895
Ciurea S	Celgene	CA089-1043	5/22/2024	5/22/2028	A Randomized, Open-Label, Phase III Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)	\$92,288	\$92,288	SPT	100	\$92,288
Ciurea S	CARTESIAN THERAPEUTICS, INC.	DC15-MM-1	8/12/2024	8/12/2028	Descartes-15 for Patients with Relapsed/Refractory Multiple Myeloma	\$28,041	\$28,041	SPT	100	\$28,041
Ciurea S	IMPACT BIO USA INC.	MPCT-012L	4/25/2024	4/25/2028	Phase I/II Multi-Center Study Evaluating the Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma	\$30,723	\$30,723	SPT	100	\$30,723
Ciurea S	CYTOAGENTS, INC.	CTA-2101	7/24/2024	6/30/2028	Phase IB/IIA Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients With Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy	\$27,824	\$27,824	SPT	100	\$27,824
Dayyani F	Exelixis	UCI-18-124	2/4/2020	2/4/2026	Phase II Study of Cabozantinib Combined with Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma	\$69,206	\$69,206	SPT	100	\$69,206
Dayyani F	Exelixis	XL184-IST119	4/1/2021	4/30/2026	A Phase 1 Study of the Combination of Cabozantinib with Trifluridine/Tipiracil (TAS-102) in patients with metastatic colorectal adenocarcinoma (mCRC)	\$82,912	\$82,912	SPT	100	\$82,912

Dayyani F	ERASCA, INC.	ERAS-007-03	3/8/2022	3/7/2025	A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)	\$134,412	\$134,412	SPT	100	\$134,412
Dayyani F	Hoffman LaRoche	GO42661	6/1/2022	5/31/2025	A PHASE II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED ADVANCED BILIARY TRACT CANCER.	\$0	\$0	SPT	100	\$0
Dayyani F	Amgen	20210098.00	7/1/2022	6/30/2025	A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)	\$80,868	\$80,868	SPT	100	\$80,868
Dayyani F	WORLDWIDE CLINICAL TRIALS, INC.	MRG004A-001	4/5/2022	3/31/2025	An Open-Label Multi-center Phase I/II Dose Escalation and Expansion Study to Assess the Safety Tolerability Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors	\$105,445	\$105,445	SPT	100	\$105,445
Dayyani F	TRANSTHERA SCIENCES (NANJING), INC.	TT420X1103	7/1/2022	6/30/2025	A Phase Ib/II Multicenter Open-Label Study of TT-00420 Tablet as Monotherapy or in Combination Regimens in Patients with Advanced Solid Tumors	\$256,954	\$256,954	SPT	100	\$256,954
Dayyani F	COSMO TECHNOLOGIES LIMITED	CB-03-10/01	11/1/2022	10/31/2025	Open-Label Multicenter Phase I Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 with Dose Expansion Phase in Subjects with Advanced Solid Tumors	\$121,330	\$121,330	SPT	100	\$121,330
Dayyani F	AstraZeneca PLC	D8151C00001	11/7/2022	11/6/2025	A Phase II Study to Evaluate the Safety Pharmacokinetics and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours	\$107,584	\$107,584	SPT	100	\$107,584
Dayyani F	Amgen	200420755	2/27/2023	2/26/2027	A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301)	\$71,618	\$71,618	SPT	100	\$71,618
Dayyani F	Arcus Biosciences, Inc	STAR-221	4/7/2023	4/6/2027	A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma	\$94,632	\$94,632	SPT	100	\$94,632
Dayyani F	Xiamen Lp Pharmaceutical Co Ltd	LP-CT-PALO-202101	5/25/2023	5/24/2027	A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy	\$25,540	\$25,540	SPT	100	\$25,540
Dayyani F	Tvardi Therapeutics Inc	TVD-101-001H	6/21/2023	6/21/2027	A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma	\$254,343	\$254,343	SPT	100	\$254,343
Dayyani F	Eisai Inc	E7386-G000-201	6/1/2023	5/31/2027	An Open-Label, Multicenter, Phase Ib/II Study of E7386 in Combination with Pembrolizumab in Previously Treated Subjects with Selected Solid Tumors	\$47,022	\$47,022	SPT	100	\$47,022
Dayyani F	Boehringer Ingelheim Pharmaceuticals Inc	1454-001	7/31/2023	7/31/2027	A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial Of Bi 765049 And Bi 765049 + Ezabenlimab Administered By Repeated Intravenous Infusions In Patients With Malignant Solid Tumors Expressing B7 H6	\$190,753	\$190,753	SPT	100	\$190,753
Dayyani F	PRA Inc	TACH101-CS-0001	7/25/2023	7/25/2027	A Phase I/IIb Open-Label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Patients with Advanced or Metastatic Solid Tumors	\$195,621	\$195,621	SPT	100	\$195,621
Dayyani F	Brst Myrs Sq	CA115-001	8/31/2023	8/31/2027	A Phase Ib/II Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer	\$39,393	\$39,393	SPT	100	\$39,393
Dayyani F	Astra Z	D7987C00001	10/4/2023	10/4/2027	Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)	\$178,892	\$178,892	SPT	100	\$178,892
Dayyani F	Covance	MPSA-153-001	10/4/2023	10/4/2027	Phase I/II study on safety and efficacy of NMS-01940153E in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy	\$44,462	\$44,462	SPT	100	\$44,462
Dayyani F	AstraZeneca PLC	D4191C00140	10/13/2023	10/12/2027	A Phase IIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers	\$92,307	\$92,307	SPT	100	\$92,307

Dayyani F	AbbVie	M24-147	10/1/2023	9/30/2027	A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC	\$45,805	\$45,805	SPT	100	\$45,805
Dayyani F	Brst Myrs Sq	CA043-001	11/20/2023	11/17/2027	A Phase I/II First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors	\$36,502	\$36,502	SPT	100	\$36,502
Dayyani F	SloanKetter	21-324	3/13/2024	2/26/2028	Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer	\$6,800	\$6,800	SPT	100	\$6,800
Dayyani F	AbbVie	M24-052	3/19/2024	3/12/2028	A Phase II/III, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment	\$79,872	\$79,872	SPT	100	\$79,872
Dayyani F	Genentech	ML44719	3/26/2024	3/20/2028	A Phase II, Open-label, Multi-Cohort, Multicenter Study in Patients With Hepatocellular Carcinoma and Child-Pugh B Cirrhosis	\$33,673	\$33,673	SPT	100	\$33,673
Dayyani F	SeaGen	SGNDV-004	4/5/2024	3/20/2028	A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors	\$33,152	\$33,152	SPT	100	\$33,152
Dayyani F	AstraZeneca PLC	D9800C00001	7/23/2024	7/17/2028	A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2.	\$32,644	\$32,644	SPT	100	\$32,644
Dayyani F	Astrazeneca AB	D7025C00001	9/15/2024	9/9/2028	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment after Resection of Biliary Tract Cancer with Curative Intent	\$28,342	\$28,342	SPT	100	\$28,342
Dayyani F	IQVIA RDS INC.	BI1479-0012	10/21/2024	10/9/2028	Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) in combination with intravenous trastuzumab deruxtecan (T-DXd) or in combination with intravenous trastuzumab emtansine (T-DM1) for treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)	\$28,041	\$28,041	SPT	100	\$28,041
Dayyani F	ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.	2138-CL-0101	3/4/2024	3/4/2028	A Phase I/Ib Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression	\$461,259	\$461,259	SPT	100	\$461,259
Dayyani F	FRONTIER MEDICINES CORPORATION	FMC-376-CL101	10/31/2024	10/27/2028	AN OPEN-LABEL, PHASE 1/2 DOSE ESCALATION, DOSE EXPANSION AND COHORT EXPANSION STUDY EVALUATING THE SAFETY, PK AND CLINICAL ACTIVITY OF FMC-376 IN PARTICIPANTS WITH KRAS G12C MUTATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS	\$34,161	\$34,161	SPT	100	\$34,161
Fleischman A	PRA HEALTH SCIENCES, INC.	ISIS 702843-CS4	6/20/2022	7/31/2025	A Phase 2a Randomized Open-Label Study to Evaluate the Efficacy Safety Tolerability Pharmacokinetics and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)	\$107,948	\$107,948	SPT	100	\$107,948
Halbrook C	American Pancreatic Association	APAF-5687381-01 (NCE)	7/1/2023	7/31/2025	Targeting Metabolic Heterogeneity in Pancreatic Cancer	\$0	\$0	SPT	100	\$0
Jeyakumar D	Janssen R&D LLC	75276617ALE1001	3/11/2022	11/30/2025	A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia	\$10,555	\$10,555	SPT	100	\$10,555
Jeyakumar D	Syneos Health Inc	2020-306-GLOB1	8/2/2022	8/31/2025	A Phase 1 Open-Label Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations	\$33,045	\$33,045	SPT	100	\$33,045
Jeyakumar D	Amgen	20190360.00	8/8/2022	8/31/2025	Phase 3 Randomized Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in	\$72,678	\$72,678	SPT	100	\$72,678
Jeyakumar D	Biomea Fusion Inc	COVALENT-101	2/22/2023	1/31/2027	A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral, covalent, menin inhibitor, in adult patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)	\$58,851	\$58,851	SPT	100	\$58,851
Jeyakumar D	Puretech Health LLC	LYT-200-2022-02	2/28/2023	2/28/2027	A Phase I, Open-Label, Multi-Center Study of the Safety, Pharmacokinetics (PK), and Anti-Tumor Activity of LYT-200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High/Very High Risk Myelodysplastic Syndrome (MDS)	\$215,380	\$215,380	SPT	100	\$215,380

Jeyakumar D	PRA Inc	GS-US-590-6154	3/10/2023	3/10/2027	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy	\$72,871	\$72,871	SPT	100	\$72,871
Jeyakumar D	Parexel International LLC	2215-CL-0203	6/12/2023	6/11/2027	A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy	\$162,683	\$162,683	SPT	100	\$162,683
Jeyakumar D	Servier Bio-Innovation LLC	CL2-95015-001	8/17/2023	8/16/2027	A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To > 65 Years with Newly-diagnosed Philadelphia-negative ALL	\$89,589	\$89,589	SPT	100	\$89,589
Jeyakumar D	Covance	HM-FLTI-101	8/29/2023	8/29/2027	A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)	\$65,658	\$65,658	SPT	100	\$65,658
Jeyakumar D	SELLAS LIFE SCIENCES GROUP AG	SLSG18-301	11/7/2023	11/7/2027	A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy	\$34,477	\$34,477	SPT	100	\$34,477
Jeyakumar D	GLUBIO THERAPEUTICS INC.	GLB-001-01	12/21/2023	12/20/2027	A First-in-human (FIH), Phase I, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes	\$51,105	\$51,105	SPT	100	\$51,105
Jeyakumar D	KURA ONCOLOGY, INC.	KO-MEN-007	3/4/2024	3/1/2028	Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia	\$231,050	\$231,050	SPT	100	\$231,050
Kessenbrock K	The Mark Fdn for Cancer Research	24-036-ELA-01	1/1/2025	12/31/2027	Cancer Immunoprevention in BRCA1 mutation carriers	\$227,272	\$227,272	SPT	100	\$227,272
Lee L	Pfizer	PF-06863135	11/18/2022	11/30/2025	ELRANATAMAB (PF-06863135) MONOTHERAPY EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPY	\$114,478	\$114,478	SPT	100	\$114,478
Lee L	PRA Inc	TAK-573-1501	12/12/2022	12/31/2025	A Phase I/II Open-label Study to Investigate the Safety and Tolerability Efficacy Pharmacokinetics and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma	\$28,101	\$28,101	SPT	100	\$28,101
Lee L	Janssen R&D LLC	64007957MMY3006	7/8/2023	7/8/2027	A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (Pvd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide	\$285,032	\$285,032	SPT	100	\$285,032
Lee L	Pfizer	C1071015	1/18/2024	1/17/2028	ELRANATAMAB POST TRIAL ACCESS AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES	\$30,412	\$30,412	SPT	100	\$30,412
Lee L	Regeneron	R5458-ONC-2158	3/25/2024	3/24/2028	Phase I/II Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma	\$105,475	\$105,475	SPT	100	\$105,475
Mar N	SeaGen	RC48-G001	10/1/2022	9/30/2025	A Phase II Multi-Cohort Open-Label Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Subjects with HER2-Expressing Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma	\$67,977	\$67,977	SPT	100	\$67,977
Mar N	AVEO PHARMACEUTICALS , INC.	AV-951-20-304	11/1/2022	10/31/2025	A Phase III, Randomized, Controlled, Multicenter, Open-Label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor	\$17,688	\$17,688	SPT	100	\$17,688
Mar N	Biotheryx Inc	BTX-1188-001	2/10/2023	2/9/2027	An Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects with Advanced Malignancies	\$20,391	\$20,391	SPT	100	\$20,391

Mar N	Syneos Health Inc	BO43936	6/12/2023	4/30/2026	A RANDOMIZED OPEN LABEL PHASE II STUDY OF IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC RENAL CELL CARCINOMA	\$392,255	\$392,255	SPT	100	\$392,255
Mar N	WORLDWIDE CLINICAL TRIALS, INC.	ACR-368-201	9/13/2023	9/13/2027	PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM -RESISTANT OVARIAN CARCINOMA, ENDOMETRIAL ADENOCARCINOMA, AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS	\$34,768	\$34,768	SPT	100	\$34,768
Mar N	Oxon Epidemiology SI	SGNDV-003	10/17/2023	9/30/2025	A retrospective chart review of real-world treatment outcomes in patients with locally advanced unresectable or metastatic urothelial cancer based on HER2 expression	\$10,490	\$10,490	SPT	100	\$10,490
Mar N	Gilead	UCI 23-59/CO-US-979-6824	10/31/2024	10/17/2028	Adjuvant Sacituzumab Govitecan Plus Nivolumab in Patients with Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence	\$12,716	\$12,716	SPT	100	\$12,716
Masri S	Johnson & Johnson	JJ-222466-03	4/1/2022	4/30/2026	Eradicating Young-Onset Cancers by Targeting the Circadian Clock	\$50,000	\$50,000	SPT	100	\$50,000
Masri S	Catalym GMBH	227195-01	6/15/2023	6/30/2025	Targeting Factors that Regulate Cachexia and Immunity	\$95,866	\$95,866	SPT	100	\$95,866
Nagasaka M	Beigene	BGB-900-102	6/29/2022	7/31/2025	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors	\$81,031	\$81,031	SPT	100	\$81,031
Nagasaka M	Amgen	20210102.00	7/20/2022	8/31/2025	A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Bemarituzumab Monotherapy and Combination with Docetaxel in Subjects with Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201)	\$34,560	\$34,560	SPT	100	\$34,560
Nagasaka M	Janssen R&D LLC	61186372NSC3002	11/1/2022	12/31/2025	A Phase III, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure	\$78,410	\$78,410	SPT	100	\$78,410
Nagasaka M	Covance	BA3021-001	11/3/2022	11/30/2025	A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3021 ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS	\$36,587	\$36,587	SPT	100	\$36,587
Nagasaka M	Astra Z	D516FC00001	11/16/2022	11/30/2025	A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2)	\$30,913	\$30,913	SPT	100	\$30,913
Nagasaka M	Covance	BA3011-002	11/28/2022	11/30/2025	A PHASE 2 STUDY OF BA3011 ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHO HAD PRIOR DISEASE PROGRESSION ON A PD-1/L1 EGFR OR ALK INHIBITOR	\$100,923	\$100,923	SPT	100	\$100,923
Nagasaka M	IQVIA RDS INC.	AB-106-G208	5/24/2022	5/31/2025	A Single-Arm Open-Label Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors	\$77,467	\$77,467	SPT	100	\$77,467
Nagasaka M	AstraZeneca PLC	D967SC00001	10/13/2022	10/31/2025	An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)	\$23,256	\$23,256	SPT	100	\$23,256
Nagasaka M	J Ints Bio Co Ltd	JIN202206-A02-01	2/2/2023	1/31/2026	A Phase I/II, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer	\$39,764	\$39,764	SPT	100	\$39,764
Nagasaka M	Brst Myrs Sq	BMS CA116-003 8478823	6/28/2023	6/28/2027	A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies	\$97,999	\$97,999	SPT	100	\$97,999
Nagasaka M	Janssen R&D LLC	61186372NSC2002	9/29/2023	9/29/2027	A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer	\$225,156	\$225,156	SPT	100	\$225,156
Nagasaka M	Summit Therapeutics Inc	AK112-301	10/30/2023	10/30/2027	A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced orMetastatic Non-squamous NSCLCWho Have Failed to EGFR-TKI Treatment (HARMONI)	\$391,573	\$391,573	SPT	100	\$391,573

Nagasaka M	Covance	D3S-001-100	11/9/2023	11/9/2027	A Phase I, Open-Label, Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation	\$30,270	\$30,270	SPT	100	\$30,270
Nagasaka M	AstraZeneca PLC	D926NC00001	12/5/2023	12/1/2027	A Phase III, Randomised, Open-Label, Multicentre, Global Study of Datopotamab Deruxtecán (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)	\$37,171	\$37,171	SPT	100	\$37,171
Nagasaka M	Boehringer Ingelheim Pharmaceuticals Inc	1479-0001	2/23/2024	2/23/2028	An Open Label, Phase I Dose Escalation Trial, with Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients with Advanced or Metastatic Solid Tumors with HER2 Aberrations	\$94,103	\$94,103	SPT	100	\$94,103
Nagasaka M	IQVIA RDS INC.	CJB-101-01	7/25/2024	6/30/2028	Phase I/II Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination with Pembrolizumab in Subjects with Selected Types of Advanced or Metastatic Cancer	\$51,154	\$51,154	SPT	100	\$51,154
Nagasaka M	Janssen R&D LLC	61186372PANSC2003	9/16/2024	9/16/2028	A Phase I/II Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer (SwallowTail)	\$30,019	\$30,019	SPT	100	\$30,019
Naqvi K	Delta-Fly	D19-11186	8/1/2024	8/1/2028	Phase I/II Study of DFP-10917 in Combination with Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia	\$96,977	\$96,977	SPT	100	\$96,977
Naqvi K	KURA ONCOLOGY, INC.	KO-MEN-008	5/1/2024	3/31/2028	Phase I Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia	\$46,666	\$46,666	SPT	100	\$46,666
O'Brien S	Regeneron	R1979-HM-1333	10/12/2015	10/11/2025	An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy	\$111,310	\$111,310	SPT	100	\$111,310
O'Brien S	CARIBOU BIOSCIENCES, INC.	CB-LTSS	7/1/2022	6/30/2025	A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients with Hematologic Malignancies	\$27,958	\$27,958	SPT	100	\$27,958
O'Brien S	MUSTANG BIO, INC.	MB106-CD20-001	5/1/2022	4/30/2025	A Phase 1/2 Open Label Multicenter Study to Assess the Safety Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia	\$53,335	\$53,335	SPT	100	\$53,335
O'Brien S	IQVIA RDS INC.	LOXO-BTK-20022	8/1/2022	7/31/2025	A Phase 3 Open-Label Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)	\$170,584	\$170,584	SPT	100	\$170,584
O'Brien S	MUSTANG BIO, INC.	MB100-OBS-001	5/4/2023	5/4/2027	A Long-term Follow-up Study in Patients Previously Treated with Mustang Bio, Inc. CAR-T Cell Investigational Products	\$19,875	\$19,875	SPT	100	\$19,875
Ou S	Syneos Health Inc	LVGN6051-101	1/19/2022	8/31/2025	An Open Label, First in Human (FIH), Phase I Trial of LVGN6051 as Single Agent and in Combination with Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy	\$30,035	\$30,035	SPT	100	\$30,035
Ou S	NUVALENT, INC.	NVL-655-01	10/4/2022	10/31/2025	A Phase I/II Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Patients with Advanced NSCLC and Other Solid Tumors	\$199,992	\$199,992	SPT	100	\$199,992
Ou S	Regeneron	R5093-M114-ONC-1864	7/18/2022	8/31/2025	A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER	\$23,073	\$23,073	SPT	100	\$23,073
Ou S	ICON CLINICAL RESEARCH LIMITED	GS-US-576-6220	10/13/2022	11/30/2025	An Open-label Multicenter Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations	\$150,653	\$150,653	SPT	100	\$150,653
Ou S	Revolution	RMC-6291-001	12/19/2022	12/31/2025	Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors	\$79,495	\$79,495	SPT	100	\$79,495
Ou S	Syneos Health Inc	PF-06463922	1/24/2023	1/23/2027	[EXEMPT] LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES	\$60,533	\$60,533	SPT	100	\$60,533
Ou S	Revolution	RMC-6236-001	8/14/2023	8/13/2027	Phase 1/1b Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in KRAS	\$986,414	\$986,414	SPT	100	\$986,414

Ou S	Revolution	RMC-6291-101	10/28/2024	10/28/2028	Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C-Mutated Solid Tumors	\$30,421	\$30,421	SPT	100	\$30,421
Ou S	SYSTIMMUNE INC.	BL-B01D1-LUNG-101	4/3/2024	4/1/2028	A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer	\$108,781	\$108,781	SPT	100	\$108,781
Parajuli R	Lilly	13Y-US-X013	6/22/2020	6/21/2025	A Phase II Clinical Trial of Neo-adjuvant Abemaciclib with Fulvestrant in patients who develop localized recurrence while on adjuvant endocrine therapy with molecular evidence of endocrine resistance	\$40,641	\$40,641	SPT	100	\$40,641
Parajuli R	ORINOVE INC	ORIN1001-001	5/16/2022	6/30/2025	A Phase 1/2 Open Label Dose-Escalation Study of Oral ORIN1001 with and without Chemotherapy in the Treatment of Subjects with Solid Tumors	\$42,730	\$42,730	SPT	100	\$42,730
Parajuli R	Gilead	GS-US-592-6173 (ASCENT-04)	12/22/2022	12/31/2027	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	\$21,310	\$21,310	SPT	100	\$21,310
Parajuli R	Astra Z	D967RC00001	2/10/2023	2/9/2027	A Phase III Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)	\$301,139	\$301,139	SPT	100	\$301,139
Parajuli R	PSI Pharma Support America Inc	CELC-G-301	4/26/2023	4/26/2027	A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)	\$74,920	\$74,920	SPT	100	\$74,920
Parajuli R	Syneos Health Inc	ML43171	5/5/2023	8/31/2026	A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2- NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER	\$101,747	\$101,747	SPT	100	\$101,747
Parajuli R	AstraZeneca PLC	D926XC00001	5/30/2023	5/30/2027	A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)	\$62,653	\$62,653	SPT	100	\$62,653
Parajuli R	Genentech	WO43919	8/8/2023	8/8/2027	A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS FULVESTRANT VERSUS ALPESISIB PLUS FULVESTRANT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE, PIK3CA MUTATED, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO PROGRESSED DURING OR AFTER CDK4/6 INHIBITOR AND ENDOCRINE COMBINATION THERAPY	\$27,161	\$27,161	SPT	100	\$27,161
Parajuli R	AstraZeneca PLC	D926QC00001	7/25/2024	6/30/2028	A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2- negative Breast Cancer (D926QC00001; TROPION-Breast04)	\$26,190	\$26,190	SPT	100	\$26,190
Parajuli R	LILLY USA, LLC	J2J-MC-JZLH	12/18/2023	12/7/2027	EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence	\$62,232	\$62,232	SPT	100	\$62,232
Parajuli R	TURNSTONE BIOLOGICS INC	TBio-4101-001	12/19/2023	12/17/2027	A Phase Ib Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients with Advanced Solid Tumor Malignancies (STARLING)	\$25,572	\$25,572	SPT	100	\$25,572
Pinter-Brown L	Verastem	VS-0145-225	12/14/2018	10/31/2025	A Multi-Center, Phase II, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)	\$18,949	\$18,949	SPT	100	\$18,949
Pinter-Brown L	Medpace	IPH4102-201	10/12/2022	10/31/2025	TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma	\$74,168	\$74,168	SPT	100	\$74,168

Pinter-Brown L	Parexel	KT333-TL-101	11/3/2022	11/30/2025	A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors	\$57,500	\$57,500	SPT	100	\$57,500
Pinter-Brown L	ARTIVA BIOTHERAPEUTICS, INC.	AB-101-01	4/20/2021	4/30/2025	A Multi-Center Open-Label Phase I/II Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non Hodgkin Lymphoma of B-Cell Origin	\$158,121	\$158,121	SPT	100	\$158,121
Pinter-Brown L	CATALYST PHARMACEUTICAL RESEARCH, LLC	IPH4102-102	7/28/2022	8/31/2025	A multi-center phase Ib trial evaluating the safety and efficacy of Iacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2	\$51,755	\$51,755	SPT	100	\$51,755
Pinter-Brown L	Syneos Health Inc	GO43693	1/27/2023	12/31/2027	A PHASE IB, OPEN-LABEL, MULTICENTER, SINGLE ARM STUDY EVALUATING THE PRELIMINARY EFFICACY, SAFETY, AND PHARMACOKINETICS OF GLOFITAMAB IN COMBINATION WITH RITUXIMAB PLUS IFOSFAMIDE, CARBOPLATIN ETOPOSIDE PHOSPHATE IN PATIENTS WITH RELAPSED/REFRACTORY TRANSPLANT ELIGIBLE DIFFUSE B-CELL LYMPHOMA	\$774,486	\$774,486	SPT	100	\$774,486
Pinter-Brown L	AFFIMED N.V.	AFM13-203	2/1/2024	2/1/2028	A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma (LuminICE-203	\$30,343	\$30,343	SPT	100	\$30,343
Razorenova O	Regenicin Inc	226939-02 (NCE)	3/20/2023	12/31/2025	Investigation into the Impact of CDK9 Inhibition on VHL-deficient Clear Cell Renal Cell Carcinoma	\$6,858	\$6,858	SPT	100	\$6,858
Uchio E	Pfizer	C3441021	1/10/2020	8/31/2025	C3441021- A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.	\$36,608	\$36,608	SPT	100	\$36,608
Uchio E	Arcus Biosciences, Inc	ARC-6	5/11/2020	5/31/2025	A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer	\$19,036	\$19,036	SPT	100	\$19,036
Valerin J	Elicio Operating Company Inc	ELI-002-201	7/25/2023	7/25/2027	First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Solid Tumors	\$142,762	\$142,762	SPT	100	\$142,762
Valerin J	IQVIA RDS INC.	DF9001-001	8/23/2023	8/22/2027	A Phase I/II, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a Monotherapy and in Combination with Nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications	\$379,101	\$379,101	SPT	100	\$379,101
Valerin J	Actuate Therapeutics Inc	1801	10/12/2023	10/12/2027	Actuate 1801: Phase I/II Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignances or Solid Tumors	\$32,275	\$32,275	SPT	100	\$32,275
Valerin J	Incyte	INCB 99280-205	3/14/2024	3/13/2028	A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors	\$58,089	\$58,089	SPT	100	\$58,089
Valerin J	Dragonfly Therapeutics	DF6215-001	7/9/2024	7/7/2028	A PHASE 1/1B, FIRST-IN-HUMAN, MULTI-PART, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, BIOLOGICAL AND CLINICAL ACTIVITY OF DF6215 IN PATIENTS WITH ADVANCED (UNRESECTABLE, RECURRENT, OR METASTATIC) SOLID TUMORS	\$94,376	\$94,376	SPT	100	\$94,376
Valerin J	BIOATLA, INC.	BA3182-001	3/4/2024	2/28/2028	An Open-Label, Multicenter, Phase I Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, A Bispecific Epithelial Cell Adhesion Molecule (EPCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma	\$27,836	\$27,836	SPT	100	\$27,836
Valerin J	IKENA ONCOLOGY, INC.	IK595-001	12/10/2024	12/5/2028	A FIRST-IN-HUMAN STUDY OF IK-595, AN ORAL DUAL MEK/RAF INHIBITOR, IN PATIENTS WITH RAS- OR RAF-ALTERED ADVANCED SOLID TUMORS	\$47,211	\$47,211	SPT	100	\$47,211
Van Etten R	TERNS, INC.	TERN701-1012	2/8/2024	2/8/2028	A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Myeloid Leukemia	\$110,872	\$110,872	SPT	100	\$110,872
Villalona Calero M	Amgen	20230167	12/6/2024	11/30/2028	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion	\$5,692	\$5,692	SPT	100	\$5,692
Wagar L	Hoffman LaRoche	ROCHE-221446-04	9/10/2021	9/9/2025	Tonsil organoids for immunogenicity evaluation of biologics	\$150,400	\$112,800	SPT	100	\$112,800
Wagar L	NCCRRA	NC3Rs-5704638-01 (NCE)	7/1/2023	2/28/2025	Modeling human adaptive immune responses with tonsil organoids	\$35,321	\$17,661	SPT	100	\$17,661



Wagar L	BMSF	229372-01 (NCE)	12/11/2023	6/30/2025	Uncovering novel functions and MOA of anti-CTLA-4 on T cells using human lymphoid tissue organoid models	\$81,991	\$81,991	SPT	100	\$81,991
Non-Peer-Reviewed Research Subtotals						\$13,867,703	\$13,812,443			\$13,812,443

**UC Irvine Chao Family Comprehensive Cancer Center**  
**Reporting Date: 02/28/2025**  
**Data Table 2B - Active Funded Projects**

Specific Funding Source	Project Direct Cost	Total Number of Projects
NCI Peer-Reviewed Projects	\$14,991,942	94
Other NIH Peer-Reviewed Projects	\$16,171,177	96
Other Peer-Reviewed Projects	\$6,508,611	37
<b>Subtotal Of Peer Reviewed Projects</b>	<b>\$37,671,730</b>	<b>227</b>
Industry Non-Peer Reviewed Projects	\$17,510,034	212
Other Non-Peer Reviewed Projects	\$2,704,725	36
<b>Subtotal Of Non-Peer Reviewed Projects</b>	<b>\$20,214,759</b>	<b>248</b>
<b>Grand Total (All Projects)</b>	<b>\$57,886,489</b>	<b>475</b>

**UC Irvine Chao Family Comprehensive Cancer Center**  
**Reporting Date: 02/28/2025**  
**Data Table 2B - Active Funded Projects (Multi-PI Grants)**

Specific Funding Source	Project Direct Cost	Total Number of Projects
NCI Peer-Reviewed Projects	\$6,777,959	33
Other NIH Peer-Reviewed Projects	\$5,282,098	24
Other Peer-Reviewed Projects	\$1,252,388	3
<b>Subtotal Of Peer Reviewed Projects</b>	<b>\$13,312,445</b>	<b>60</b>
Industry Non-Peer Reviewed Projects	\$0	0
Other Non-Peer Reviewed Projects	\$49,134	1
<b>Subtotal Of Non-Peer Reviewed Projects</b>	<b>\$49,134</b>	<b>1</b>
<b>Grand Total (All Projects)</b>	<b>\$13,361,579</b>	<b>61</b>

**UC Irvine Chao Family Comprehensive Cancer Center**  
**Reporting Date: 02/28/2025**  
**Data Table 2B - Active Funded Projects (Training)**

Specific Funding Source	Project Direct Cost	Total Number of Projects
NCI Peer-Reviewed Projects	\$1,409,832	9
Other NIH Peer-Reviewed Projects	\$812,640	8
Other Peer-Reviewed Projects	\$495,483	3
<b>Subtotal Of Peer Reviewed Projects</b>	<b>\$2,717,955</b>	<b>20</b>
Industry Non-Peer Reviewed Projects	\$75,000	1
Other Non-Peer Reviewed Projects	\$32,500	1
<b>Subtotal Of Non-Peer Reviewed Projects</b>	<b>\$107,500</b>	<b>2</b>
<b>Grand Total (All Projects)</b>	<b>\$2,825,455</b>	<b>22</b>

**UC Irvine Chao Family Comprehensive Cancer Center**  
**Reporting Date: 02/28/2025**  
**Program Area: Biotechnology, Imaging & Drug Development**  
**Data Table 2B - Active Funded Projects**

Specific Funding Source	Project Direct Cost	Total Number of Projects
NCI Peer-Reviewed Projects	\$5,257,858	27
Other NIH Peer-Reviewed Projects	\$5,898,965	31
Other Peer-Reviewed Projects	\$851,955	11
<b>Subtotal Of Peer Reviewed Projects</b>	<b>\$12,008,778</b>	<b>69</b>
Industry Non-Peer Reviewed Projects	\$3,130,990	42
Other Non-Peer Reviewed Projects	\$1,849,838	15
<b>Subtotal Of Non-Peer Reviewed Projects</b>	<b>\$4,980,828</b>	<b>57</b>
<b>Grand Total (All Projects)</b>	<b>\$16,989,606</b>	<b>126</b>

**UC Irvine Chao Family Comprehensive Cancer Center**  
**Reporting Date: 02/28/2025**  
**Program Area: Cancer Control**  
**Data Table 2B - Active Funded Projects**

Specific Funding Source	Project Direct Cost	Total Number of Projects
NCI Peer-Reviewed Projects	\$3,687,776	22
Other NIH Peer-Reviewed Projects	\$3,383,296	12
Other Peer-Reviewed Projects	\$1,021,194	7
<b>Subtotal Of Peer Reviewed Projects</b>	<b>\$8,092,266</b>	<b>41</b>
Industry Non-Peer Reviewed Projects	\$1,046,191	31
Other Non-Peer Reviewed Projects	\$375,297	14
<b>Subtotal Of Non-Peer Reviewed Projects</b>	<b>\$1,421,488</b>	<b>45</b>
<b>Grand Total (All Projects)</b>	<b>\$9,513,754</b>	<b>86</b>

**UC Irvine Chao Family Comprehensive Cancer Center**  
**Reporting Date: 02/28/2025**  
**Program Area: Systems, Pathways & Targets**  
**Data Table 2B - Active Funded Projects**

Specific Funding Source	Project Direct Cost	Total Number of Projects
NCI Peer-Reviewed Projects	\$5,076,521	31
Other NIH Peer-Reviewed Projects	\$5,923,612	39
Other Peer-Reviewed Projects	\$4,591,462	18
<b>Subtotal Of Peer Reviewed Projects</b>	<b>\$15,591,595</b>	<b>88</b>
Industry Non-Peer Reviewed Projects	\$13,332,853	139
Other Non-Peer Reviewed Projects	\$479,590	7
<b>Subtotal Of Non-Peer Reviewed Projects</b>	<b>\$13,812,443</b>	<b>146</b>
<b>Grand Total (All Projects)</b>	<b>\$29,404,038</b>	<b>234</b>

**UC Irvine Chao Family Comprehensive Cancer Center**  
**Reporting Period: 01/01/2023 - 12/31/2023**  
**Data Table 3 - Newly Registered Patients by Primary Cancer**

Primary Site	Newly Registered Patients
Lip, Oral Cavity and Pharynx	187
Esophagus	66
Stomach	128
Small Intestine	22
Colon	241
Rectum	105
Anus	29
Liver	87
Pancreas	198
Other Digestive Organ	114
Larynx	28
Lung	211
Other Respiratory and Intrathoracic Organs	22
Bones and Joints	18
Soft Tissue	86
Melanoma, Skin	625
Kaposi's Sarcoma	8
Mycosis Fungoides	26
Other Skin	32
Breast	363
Cervix	56
Corpus Uteri	147
Ovary	66
Other Female Genital	36
Prostate	505
Other Male Genital	29
Urinary Bladder	137
Kidney	203
Other Urinary	11
Eye and Orbit	15
Brain and Nervous System	183
Thyroid	154
Other Endocrine System	58
Non-Hodgkin Lymphoma	194
Hodgkin Lymphoma	20
Multiple Myeloma	68
Lymphoid Leukemia	2
Myeloid and Monocytic Leukemia	54
Leukemia, other	69
Other Hematopoietic	27
Unknown Sites	60
III-Defined Sites	24
<b>TOTAL:</b>	<b>4714</b>



UC Irvine Chao Family Comprehensive Cancer Center

Reporting Period: 01/01/2024 - 12/31/2024

Reporting Prepared: 02/10/2025

Data Table 4 – Clinical Research Protocols

Legend	Rare Cancer Trial
--------	-------------------

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	ANC/COR	E	NCI	Multiple	NCT04410302	UCI-20-04	Y	Dayyani	Farshid	SPT	03/16/2020		N/A	N	Bas	N	University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities	130	130	4	102			102
01/01/2024	12/31/2024	ANC/COR	I	Department of Defense; UCI	Other Hematopoietic		UCI-14-03	N	Fleischman	Angela	CC	02/28/2014		N/A	N	Bas	N	Role of Inflammation in the Pathogenesis of Myeloproliferative Neoplasm	225	225	0	121			121
01/01/2024	12/31/2024	ANC/COR	I	UCI	Other Hematopoietic		INDP-14-9995	N	Fleischman	Angela	CC	02/28/2014		N/A	N	Bas	N	Role of Inflammation in the Pathogenesis of Myeloproliferative Neoplasm	225		12	149			149
01/01/2024	12/31/2024	ANC/COR	I	UCI	Non-Hodgkin's Lymphoma; Lymphoid Leukemia		UCI-21-236	N	Fleischman	Angela	CC	05/27/2022		N/A	N	Bas	N	Addressing the Hispanic Cancer Disparity in B Cell Acute Lymphoblastic Leukemia	25	25	4	9			9
01/01/2024	12/31/2024	ANC/COR	I	UCI	Other Skin		UCI-20-15	N	Gao	Ling	BIDD	01/08/2021	07/11/2024	N/A	N	Bas	N	Mechanisms of Merkel Cell Carcinoma Pathogenesis and Identification of Potential Therapies	50	50	0	0			0
01/01/2024	12/31/2024	ANC/COR	I	UCI	Breast		UCI-17-05	N	Parajuli	Ritesh	BIDD	06/05/2017		N/A	Y	Bas	N	Understanding Intratumoral Heterogeneity Using Single Cell RNA Sequencing	75	75	0	48			48
01/01/2024	12/31/2024	ANC/COR	I	UCI	Breast	NCT99999999	UCI-18-136	N	Parajuli	Ritesh	BIDD	12/01/2021		N/A	N	Bas	N	Blood Collection Protocol for the Analysis of Exosomes in Patients with Breast Cancer	100	100	15	74			74
01/01/2024	12/31/2024	ANC/COR	I	UCI	Multiple		UCI-20-101	N	Senthil	Maheswari	BIDD	04/12/2021	08/15/2024	N/A	N	Bas	N	Prospective Study to Assess the Role of Plasma Exosomal Gene Signature and PD-L1 Expression to Predict Response to Treatment in Solid Organ Malignancies	80	80	0	53			53
01/01/2024	12/31/2024	ANC/COR	I	UCI	Multiple		UCI-23-21	N	Senthil	Maheswari	SPT	11/17/2023	06/13/2024	N/A	Y	Scr	N	Study of Exosomes Gene Expression in Peritoneal Fluid and Plasma in Patients with Gastrointestinal Malignancy	70	70	0	0			0
01/01/2024	12/31/2024	ANC/COR	I	UCI	Multiple		UCI-20-214	N	Tang	Cathy	CC	07/11/2023		N/A	N	Bas	N	The Interplay of the Skin Microbiome, Solar UV Exposure and Skin Pathologies	50	50	0	0			0
01/01/2024	12/31/2024	INT	N	Alliance	Lip, Oral Cavity and Pharynx	NCT05904080	ALLIANCE-A092105	Y	Attarian	Shirin	BIDD	06/06/2024		II	N	Tre	N	Randomized Phase II Study of Nivolumab and Ipilimumab with or without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy		5	0	0			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Lip, Oral Cavity and Pharynx	NCT02734537	ECOG-EA3132	Y	Attarian	Shirin	SPT	11/01/2024		II	N	Tre	N	Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing		5	0	0			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Lip, Oral Cavity and Pharynx	NCT05063552	ECOG-EA3202	Y	Attarian	Shirin	BIDD	07/11/2024		II/III	N	Tre	N	A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers		5	2	2			
01/01/2024	12/31/2024	INT	N	ETCTN	Lip, Oral Cavity and Pharynx	NCT05669664	ETCTN-10553	Y	Attarian	Shirin	SPT	06/26/2024		II	N	Tre	N	A Phase II Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer		5	1	1			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Lip, Oral Cavity and Pharynx	NCT05050162	NRG-HN009	Y	Attarian	Shirin	SPT	07/23/2024		II/III	N	Tre	N	Randomized Phase II/III Trial of Radiation with Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation with Weekly Cisplatin at 40 mg/m2 for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)		5	0	0			
01/01/2024	12/31/2024	INT	N	Alliance	Brain and Nervous System	NCT02523014	ALLIANCE-A071401	Y	Bota	Daniela	SPT	01/27/2016		II	N	Tre	N	Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 /CDK Pathway Mutations		3	1	2			
01/01/2024	12/31/2024	INT	N	CHILDREN'S ONCOLOGY GROUP	Non-Hodgkin's Lymphoma	NCT04759586	COG-ANHL1931	Y	Brem	Elizabeth A	BIDD	02/07/2022		III	N	Tre	N	A Randomized Phase III Trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma			1	2			
01/01/2024	12/31/2024	INT	N	SWOG	Multiple	NCT04799275	SWOG-S1918	Y	Brem	Elizabeth A	SPT	05/25/2021		II/III	N	Tre	N	A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B-Cell Lymphoma, Grade IIB, Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements	10	10	2	5			5
01/01/2024	12/31/2024	INT	N	SWOG	Non-Hodgkin's Lymphoma	NCT05633615	SWOG-S2114	Y	Brem	Elizabeth A	BIDD	08/16/2023		II	N	Tre	N	A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma		6	0	0			
01/01/2024	12/31/2024	INT	N	Alliance	Multiple	NCT03994796	A071701	Y	Choi	Yoon Jae	SPT	10/16/2019	01/18/2024	II	N	Tre	N	Genomically-Guided Treatment Trial in Brain Metastases		5	0	1			
01/01/2024	12/31/2024	INT	N	Alliance	Brain and Nervous System	NCT03224767	ALLIANCE-A071601	Y	Choi	Yoon Jae	SPT	06/04/2018	05/02/2024	II	N	Tre	N	Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas		5	0	3			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Melanoma, Skin	NCT02339571	ECOG-EA6141	Y	Chow	Warren A	BIDD	05/18/2021		II/III	N	Tre	N	Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma		7	0	4			
01/01/2024	12/31/2024	INT	N	ETCTN	Bones and Joints; Soft Tissue	NCT05836571	ETCTN-10556	Y	Chow	Warren A	SPT	12/07/2023		II	N	Tre	N	Randomized Phase II Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma		5	1	1			
01/01/2024	12/31/2024	INT	N	SWOG	Multiple	NCT04269902	SWOG-S1925	Y	Coombs	Catherine	SPT	06/10/2021		III	N	Tre	N	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study		10	1	2			
01/01/2024	12/31/2024	INT	N	Alliance	Stomach; Esophagus	NCT05677490	ALLIANCE-A022102	Y	Dayyani	Farshid	SPT	12/13/2023		III	N	Tre	N	A Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-line Treatment of Metastatic HER2-negative Gastroesophageal Adenocarcinoma		14	8	8			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	N	ETCTN	Liver	NCT04068194	ETCTN-10276	Y	Dayyani	Farshid	BIDD	11/08/2023		I/II	N	Tre	N	A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies		5	2	3			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple	NCT04704661	ETCTN-10358	Y	Dayyani	Farshid	BIDD	05/05/2023		I	N	Tre	N	Phase I/IB Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)		3	2	2			
01/01/2024	12/31/2024	INT	N	ETCTN	Pancreas	NCT04172532	ETCTN-10366	Y	Dayyani	Farshid	BIDD	01/11/2021		I/II	N	Tre	N	A Phase I/II Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma		8	1	5			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple	NCT05372614	ETCTN-10495	Y	Dayyani	Farshid	BIDD	05/24/2023		I	N	Tre	N	Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations		7	1	1			
01/01/2024	12/31/2024	INT	N	ETCTN	Pancreas	NCT05685602	ETCTN-10522	Y	Dayyani	Farshid	BIDD	05/17/2023		I	N	Tre	N	A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma		4	0	3			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple	NCT05724108	ETCTN-10558	Y	Dayyani	Farshid	SPT	10/29/2024		II	N	Tre	N	A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors		7	0	0			
01/01/2024	12/31/2024	INT	N	Alliance	Colon; Rectum	NCT05673148	ALLIANCE-A022101	Y	Eng	Oliver	BIDD	09/21/2023		III	N	Tre	N	A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery [ERASUR]		2	0	0			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Other Skin	NCT03712605	EA6174	Y	Gao	Ling	BIDD	04/30/2019	06/06/2024	III	N	Tre	N	STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial		13	0	8			
01/01/2024	12/31/2024	INT	N	ETCTN	Other Skin	NCT05947500	ETCTN-10592	Y	Gao	Ling	SPT	01/29/2024		II	N	Tre	N	A Phase II Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma		6	2	2			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Lung	NCT04402788	NRG-LU007	Y	Harris	Jeremy	BIDD	05/24/2022		II/III	N	Tre	N	Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial		5	1	2			
01/01/2024	12/31/2024	INT	N	SWOG	Lung	NCT04214262	SWOG-S1914	Y	Harris	Jeremy	BIDD	09/24/2021	09/06/2024	III	N	Tre	N	S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC		5	0	1			
01/01/2024	12/31/2024	INT	N	Canadian Cancer Trials Group (CCTG)	Breast	NCT03488693	CCTG-MA39	Y	Healy	Erin Heather	BIDD	05/19/2022	03/07/2024	III	N	Tre	N	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer		5	0	0			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Breast	NCT05705401	NRG-BR008	Y	Healy	Erin Heather	BIDD	07/24/2023		III	N	Tre	N	A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer* (HERO*)		5	0	0			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Stomach; Esophagus	NCT04248452	ECOG-EA2183	Y	Hong	David	BIDD	02/01/2024		III	N	Tre	N	A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)		7	0	0			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Prostate	NCT04513717	NRG-GU009	Y	Hong	David	SPT	05/11/2022		III	N	Tre	N	Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk And Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (Predict-Rt*)		10	5	8			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Prostate	NCT05050084	NRG-GU010	Y	Hong	David	SPT	10/25/2024		III	N	Tre	N	Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)		10	0	0			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Prostate	NCT05053152	NRG-GU011	Y	Hong	David	BIDD	09/15/2022	02/04/2025	II	N	Tre	N	A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)		3	0	1			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Prostate	NCT05946213	NRG-GU013	Y	Hong	David	SPT	02/02/2024		III	N	Tre	N	The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer		5	1	1			
01/01/2024	12/31/2024	INT	N	Alliance	Lymphoid Leukemia	NCT03150693	ALLIANCE-A041501	Y	Jeyakumar	Deepa	BIDD	08/24/2018		III	N	Tre	N	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL		15	0	10			
01/01/2024	12/31/2024	INT	N	Alliance	Lymphoid Leukemia	NCT03739814	ALLIANCE-A041703	Y	Jeyakumar	Deepa	BIDD	03/04/2022		II	N	Tre	N	Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative Cd22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease		5	1	2			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Lymphoid Leukemia	NCT04530565	ECOG-EA9181	Y	Jeyakumar	Deepa	BIDD	03/31/2021		III	N	Tre	N	A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults		35	2	13			
01/01/2024	12/31/2024	INT	N	ETCTN	Myeloid and Monocytic Leukemia; Other Hematopoietic	NCT05600894	ETCTN-10538	Y	Jeyakumar	Deepa	SPT	09/29/2023		II	N	Tre	N	Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY1 MDS/MPN) a Randomized, Phase II Trial		5	0	0			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Other Digestive Organ	NCT04559139	ECOG-EA2197	Y	Jutric	Zeljka	SPT	09/14/2022		II/III	N	Tre	N	Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial		10	0	0			
01/01/2024	12/31/2024	INT	N	ETCTN	Liver	NCT06050252	ETCTN-10608	Y	Jutric	Zeljka	BIDD	07/16/2024		II	N	Tre	N	A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma		3	2	2			
01/01/2024	12/31/2024	INT	N	Alliance	Prostate	NCT05241860	ALLIANCE-A032101	Y	Kalebasty	Arash Rezazadeh	SPT	11/09/2023	03/29/2024	II	N	Tre	N	A Phase II Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM		5	6	7			
01/01/2024	12/31/2024	INT	N	ETCTN	Urinary Bladder; Kidney	NCT03375307	ETCTN-10144	Y	Kalebasty	Arash Rezazadeh	SPT	01/08/2021		II	N	Tre	N	A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors with DNA-Repair Defects		6	1	3			
01/01/2024	12/31/2024	INT	N	ETCTN	Prostate	NCT05828082	ETCTN-10603	Y	Kalebasty	Arash Rezazadeh	SPT	09/26/2023		II	N	Tre	N	A Phase II Study of M1774 in Refractory SPOP-mutant Prostate Cancer		5	0	0			
01/01/2024	12/31/2024	INT	N	Alliance	Brain and Nervous System	NCT00887146	ALLIANCE-N0577	Y	Kong	Xiao-Tang	BIDD	07/01/2019	05/24/2024	III	N	Tre	N	Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma		4	0	2			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Brain and Nervous System	NCT03180268	NRG-BN003	Y	Kong	Xiao-Tang	BIDD	10/13/2017	09/05/2024	III	N	Tre	N	Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma		6	0	5			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	N	NRG Oncology	Brain and Nervous System	NCT04729959	NRG-BN010	Y	Kong	Xiao-Tang	BIDD	11/14/2023	11/14/2024	II	N	Tre	N	A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy In Recurrent Glioblastoma		6	1	1			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Brain and Nervous System	NCT05095376	NRG-BN011	Y	Kong	Xiao-Tang	SPT	12/06/2022		III	N	Tre	N	A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma		8	4	6			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple	NCT05803382	ETCTN-10579	Y	Lee	Fa Chyi	BIDD	10/27/2023		I	N	Tre	N	Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors		4	2	2			
01/01/2024	12/31/2024	INT	N	Alliance	Multiple Myeloma	NCT06179888	ALLIANCE-A062102	Y	Lee	Lisa Xingguang	BIDD	09/16/2024		II	N	Tre	N	Randomized Phase II Study of Ibrdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma patients		10	0	0			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple Myeloma	NCT06169215	ETCTN-10612	Y	Lee	Lisa Xingguang	SPT	04/25/2024		II	N	Tre	N	A Randomized Phase II Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma		5	2	2			
01/01/2024	12/31/2024	INT	N	SWOG	Multiple Myeloma	NCT04071457	SWOG-S1803	Y	Lee	Lisa Xingguang	BIDD	05/05/2021	01/15/2025	III	N	Tre	N	Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)		25	8	18			
01/01/2024	12/31/2024	INT	N	ETCTN	Prostate	NCT04071236	ETCTN-10301	Y	Mar	Nataliya	BIDD	06/10/2021		I/II	N	Tre	N	A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)		7	5	12			
01/01/2024	12/31/2024	INT	N	SWOG	Urinary Bladder	NCT04579224	SWOG-S1937	Y	Mar	Nataliya	SPT	06/13/2024		III	N	Tre	N	A Phase III Randomized Trial of Eribulin with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy		5	3	3			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Breast	NCT04852887	NRG-BR007	Y	Mehta	Rita	SPT	02/24/2022		III	N	Tre	N	A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer		5	0	1			
01/01/2024	12/31/2024	INT	N	ETCTN	Myeloid and Monocytic Leukemia	NCT05886049	ETCTN-10596	Y	Naqvi	Kiran	BIDD	05/16/2024		I	N	Tre	N	A Phase Ib Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged Disease		5	0	0			
01/01/2024	12/31/2024	INT	N	ETCTN	Myeloid and Monocytic Leukemia	NCT06514261	ETCTN-10630	Y	Naqvi	Kiran	BIDD	12/16/2024		I	N	Tre	N	Phase 1 Trial of Iadademstat in Combination with Venetoclax and Azacitidine in Patients with Treatment Naïve AML		7	1	1			
01/01/2024	12/31/2024	INT	N	Alliance	Breast	NCT04457596	ALLIANCE-A011801	Y	Parajuli	Ritesh	SPT	03/02/2021		III	N	Tre	N	The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib		10	1	4			
01/01/2024	12/31/2024	INT	N	Alliance	Breast	NCT05812807	ALLIANCE-A012103	Y	Parajuli	Ritesh	BIDD	04/23/2024		III	N	Tre	N	Optimice-PCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy		5	0	0			
01/01/2024	12/31/2024	INT	N	Alliance	Breast	NCT05751668	ALLIANCE-A222101	Y	Parajuli	Ritesh	SPT	04/25/2024		II	N	Sup	N	An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy		30	0	0			
01/01/2024	12/31/2024	INT	N	ETCTN	Breast	NCT04090398	ETCTN-10302	Y	Parajuli	Ritesh	BIDD	07/14/2021	05/31/2024	II	N	Tre	N	Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer		10	1	7			
01/01/2024	12/31/2024	INT	N	ETCTN	Breast	NCT05673200	ETCTN-10546	Y	Parajuli	Ritesh	BIDD	06/23/2023		I	N	Tre	N	Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer		5	1	1			
01/01/2024	12/31/2024	INT	N	ETCTN	Breast; Prostate	NCT05807126	ETCTN-10551	Y	Parajuli	Ritesh	BIDD	02/02/2024	04/29/2024	I/II	Y	Tre	N	A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in Patients with BRCA1/2-mutant Tumors		5	0	0			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Breast	NCT05879926	NRG-BR009	Y	Parajuli	Ritesh	SPT	11/15/2024		III	N	Tre	N	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score <= 25 (OFSET)		10	0	0			
01/01/2024	12/31/2024	INT	N	SWOG	Breast; Brain and Nervous System	NCT04647916	SWOG-S2007	Y	Parajuli	Ritesh	BIDD	08/06/2021	03/26/2024	II	N	Tre	N	A Phase II Trial of Sacituzumab govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases		5	0	1			
01/01/2024	12/31/2024	INT	N	SWOG	Breast	NCT06058377	SWOG-S2206	Y	Parajuli	Ritesh	BIDD	03/28/2024		III	N	Tre	N	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.		10	2	2			
01/01/2024	12/31/2024	INT	N	ETCTN	Brain and Nervous System	NCT03604978	ETCTN-10186	Y	Simon	Aaron	BIDD	07/13/2023		I/II	N	Tre	N	A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma		4	1	1			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Brain and Nervous System	NCT05438212	NRG-BN012	Y	Simon	Aaron	BIDD	10/25/2023		III	N	Tre	N	A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases		6	3	4			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Brain and Nervous System	NCT06500455	NRG-BN013	Y	Simon	Aaron	BIDD	12/11/2024		III	N	Tre	N	Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases		5	0	0			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Other Female Genital	NCT05076942	NRG-GY024	Y	Tewari	Krishnansu	BIDD	06/03/2022	11/05/2024	II	N	Tre	N	Gronigen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial		5	0	0			
01/01/2024	12/31/2024	INT	N	ECOG	Melanoma, Skin	NCT04708418	ECOG-EA6194	Y	Tran	Thuy	BIDD	09/20/2023	01/28/2025	II	N	Tre	N	Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study		5	2	3			
01/01/2024	12/31/2024	INT	N	ECOG	Multiple	NCT04031677	ECOG-EA7211	Y	Tran	Thuy	SPT	09/28/2023		III	N	Tre	N	A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)		9	0	0			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	N	NRG Oncology	Ovary	NCT06169124	NRG-GY033	Y	Tseng	Jill	SPT	05/14/2024		II	N	Tre	N	A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-type Ovarian Granulosa Cell Tumor		5	0	0			
01/01/2024	12/31/2024	INT	N	Alliance	Pancreas	NCT04340141	ALLIANCE-A021806	Y	Valerin	Jennifer Brooke	SPT	09/26/2023		III	N	Tre	N	A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer		15	0	0			
01/01/2024	12/31/2024	INT	N	Alliance	Pancreas	NCT06115499	ALLIANCE-A022106	Y	Valerin	Jennifer Brooke	SPT	03/05/2024		II/III	N	Tre	N	Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINIUM)		3	0	0			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Anus	NCT04444921	ECOG-EA2176	Y	Valerin	Jennifer Brooke	BIDD	01/03/2022	09/23/2024	III	N	Tre	N	A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients		5	1	4			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Rectum	NCT04751370	ECOG-EA2201	Y	Valerin	Jennifer Brooke	BIDD	11/22/2021	01/15/2025	II	N	Tre	N	A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma		3	0	0			
01/01/2024	12/31/2024	INT	N	ETCTN	Pancreas	NCT05411094	ETCTN-10464	Y	Valerin	Jennifer Brooke	BIDD	01/23/2024		I	N	Tre	N	A Phase I Study of Olaparib in Combination with Durvalumab (MED14736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer		5	0	0			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple	NCT05687110	ETCTN-10528	Y	Valerin	Jennifer Brooke	BIDD	07/09/2024		I	N	Tre	N	A Phase I Study of the Polymerase Theta Inhibitor Novobiocin in BRCA-Mutant and Other DNA Damage Repair-Deficient Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	N	SWOG	Pancreas	NCT04548752	SWOG-S2001	Y	Valerin	Jennifer Brooke	BIDD	03/02/2022		II	N	Tre	N	Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations		4	0	2			
01/01/2024	12/31/2024	INT	N	SWOG	Pancreas	NCT05040360	SWOG-S2104	Y	Valerin	Jennifer Brooke	SPT	07/29/2022		II	N	Tre	N	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors		2	0	0			
01/01/2024	12/31/2024	INT	N	SWOG	Colon; Rectum	NCT05308446	SWOG-S2107	Y	Valerin	Jennifer Brooke	BIDD	12/15/2022	10/03/2024	II	N	Tre	N	Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer		4	4	4			
01/01/2024	12/31/2024	INT	N	SWOG	Urinary Bladder	NCT03775265	SWOG-S1806	Y	Yaacoub	Ramy	BIDD	01/10/2020	03/01/2024	III	N	Tre	N	Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer		5	0	6			
01/01/2024	12/31/2024	INT	N	SWOG	Melanoma, Skin	NCT03860883	SWOG-S2015	Y	Yamamoto	Maki	SPT	12/13/2022		III	N	Tre	N	S2015: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma		30	8	13			
01/01/2024	12/31/2024	INT	N	Alliance	Rectum	NCT05610163	ALLIANCE-A022104	Y	Zell	Jason	SPT	05/10/2023		II	N	Tre	N	The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy Of Triplet Versus Doublet Chemotherapy To Achieve Clinical Complete Response In Patients With Locally Advanced Rectal Cancer		15	5	6			
01/01/2024	12/31/2024	INT	N	Canadian Cancer Trials Group (CCTG)	Rectum	NCT06205485	CCTG-CO32	Y	Zell	Jason	SPT	04/29/2024		III	N	Tre	N	The NEO-RT Trial: A Phase III Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus Chemoradiotherapy for Early Rectal Cancer		5	2	2			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Anus	NCT04166318	EA2182	Y	Zell	Jason	BIDD	07/02/2020	10/30/2024	II	N	Tre	N	A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)		3	0	1			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Colon	NCT04068103	NRG-GI005	Y	Zell	Jason	BIDD	05/07/2020	02/12/2024	II/III	N	Tre	N	Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)		5	0	2			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Colon	NCT05174169	NRG-GI008	Y	Zell	Jason	CC	09/14/2022		II/III	N	Tre	N	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)		5	0	2			
01/01/2024	12/31/2024	INT	E	Patient-Centered Outcomes Research Institute	Breast	NCT02620852	UCI-16-23	Y	Anton-Culver	Hoda	CC	04/14/2017		N/A	N	Scr	N	Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized versus Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)]		3000	0	2005			
01/01/2024	12/31/2024	INT	E	NCI	Brain and Nervous System	NCT03173950	UCI-20-152	Y	Bota	Daniela	BIDD	03/18/2021	06/17/2024	II	N	Tre	N	Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers		10	0	7			
01/01/2024	12/31/2024	INT	E	NCI	Multiple	NCT03384134	UCI-19-26	Y	Fortier	Michelle	CC	08/01/2019	09/13/2024	III	N	Sup	N	Treating Pain in Children with Cancer: A 21st Century Innovative Approach (Pain Buddy)	206	103	0	0	18	206	206
01/01/2024	12/31/2024	INT	E	NCI	Other Skin	NCT00764920	UCI-11-30	N	Kelly	Kristen	BIDD	11/06/2008		N/A	Y	Dia	N	Skin Imaging with Technologies in Development	750	750	13	632			632
01/01/2024	12/31/2024	INT	I	UCI	Multiple	NCT05497531	UCI-21-124	N	Abi-Jaoudeh	Nadine	BIDD	09/07/2022		N/A	Y	Dia	N	Pilot Trial Comparing Circulating Tumor DNA (ctDNA) From Immediate Draining Vein vs. Standard Peripheral Vein Sample in Patients Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers	17	17	5	14			14
01/01/2024	12/31/2024	INT	I	UCI	Multiple	NCT05283577	UCI-21-33	Y	Chan	Alexandre	BIDD	04/15/2022		N/A	N	Sup	N	Electroacupuncture for the Management of Symptom Clusters in Cancer Patients and Survivors (EAST): A Feasibility Study	58	58	19	47	4	23	70
01/01/2024	12/31/2024	INT	I	UCI	Breast	NCT06580002	UCI-24-05	N	Chan	Alexandre	SPT	12/02/2024		II	Y	Tre	N	Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Breast Cancer Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial	26	26	0	0			0
01/01/2024	12/31/2024	INT	I	UCI	Melanoma, Skin	NCT06771544	UCI-22-49	N	Chow	Warren A	SPT	12/23/2024		II	N	Tre	N	Metronomic Cyclophosphamide with Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma	14	14	0	0			0
01/01/2024	12/31/2024	INT	I	UCI	Multiple	NCT06028828	UCI-21-90	N	Ciurea	Stefan Octavian	BIDD	09/11/2023		II	Y	Tre	N	Risk-ADAPTEd Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)	48	48	12	15			15
01/01/2024	12/31/2024	INT	I	Exelixis, Inc.; UCI	Liver	NCT04472767	UCI-19-49	Y	Dayyani	Farshid	SPT	08/07/2020		II	N	Tre	N	Phase II Study of Cabozantinib Combined with Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma (HCC) Who are not Candidates for Curative Intent Treatment	35	35	4	19	0	0	19
01/01/2024	12/31/2024	INT	I	Memorial Sloan-Kettering Cancer Center	Esophagus	NCT05117931	UCI-23-78	Y	Dayyani	Farshid	BIDD	03/01/2024		II	N	Tre	N	Phase II Study of Amivantamab in EGFR or MET-Amplified Esophagogastric Cancer		3	0	0			
01/01/2024	12/31/2024	INT	I	UCI	Colon; Rectum	NCT04920032	UCI-20-43	N	Dayyani	Farshid	BIDD	08/26/2021		I	N	Tre	N	Proof of Concept Study of ctDNA Guided Change in Treatment for Refractory Minimal Residual Disease in Colon Adenocarcinomas	11	11	3	5			5
01/01/2024	12/31/2024	INT	I	UCI	Multiple		UCI-23-29	N	Eng	Oliver	CC	08/08/2024		II	Y	Sup	N	Electroacupuncture in Symptom Management After CRS/HIPEC: A Pilot Study	15	15	1	1			1



Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	I	Cure Accelerator; UCI	Myeloid and Monocytic Leukemia	NCT05123365	UCI-20-50	N	Fleischman	Angela	SPT	01/03/2022		I/II	N	Tre	N	An Optimal Dose Finding Study of N-Acetylcysteine in Patients with Myeloproliferative Neoplasms	27	27	1	11			11
01/01/2024	12/31/2024	INT	I	University of Washington	Other Skin	NCT03271372	UCI-18-84	Y	Gao	Ling	BIDD	06/10/2019	01/22/2024	III	N	Tre	N	A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of Adjuvant Avelumab (anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases	12	12	0	9			9
01/01/2024	12/31/2024	INT	I	UCI	Soft Tissue	NCT05488366	UCI-21-03	N	Harris	Jeremy	BIDD	08/03/2022		Early Phase I	Y	Tre	N	A Pilot Study of Immunotherapy Combined with Stereotactic Ablative Radiotherapy for Patients with Advanced or Metastatic Sarcoma	6	6	3	6			6
01/01/2024	12/31/2024	INT	I	Memorial Sloan-Kettering Cancer Center	Multiple	NCT04802720	UCI-24-186	Y	Hoyt	Michael A	CC	10/30/2020	04/26/2024	N/A	Y	Sup	N	A Randomized Controlled Trial of Emotion Regulation Therapy for Cancer Caregivers: A Mechanism-Targeted Approach to Addressing Caregiver Distress	999	999	0	0			0
01/01/2024	12/31/2024	INT	I	UCI	Other Male Genital	NCT05836688	UCI-20-59	Y	Hoyt	Michael A	CC	11/01/2023		N/A	N	Sup	N	A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors	200	200	24	24	8	8	32
01/01/2024	12/31/2024	INT	I	UCI	Multiple		UCI-22-193	Y	Hoyt	Michael A	CC	02/12/2024		N/A	N	Sup	N	Goal-Focused Emotion-Regulation Therapy for Young Adult Cancer Survivors: A Biobehavioral Self-Regulation Intervention	15	15	0	0	13	13	13
01/01/2024	12/31/2024	INT	I	UCI	Multiple	NCT06338475	UCI-24-128	Y	Hoyt	Michael A	CC	09/09/2024		N/A	Y	Sup	N	A Biobehavioral Intervention for Latino/Hispanic Young Adults with Cancer	100	100	3	3			3
01/01/2024	12/31/2024	INT	I	Children's Hospital of Orange County	Lymphoid Leukemia	NCT05501899	UCI-21-14	Y	Jeyakumar	Deepa	SPT	11/03/2023		N/A	Y	Sup	N	Use of Levocarnitine for Asparaginase Hepatotoxicity for Acute Lymphoblastic Leukemia Patients	5	5	0	0	0	0	0
01/01/2024	12/31/2024	INT	I	Jazz Pharmaceuticals, Inc.; Pfizer Pharmaceutical Inc.; UCI	Myeloid and Monocytic Leukemia	NCT04231851	UCI-18-105	Y	Jeyakumar	Deepa	SPT	02/19/2020	06/10/2024	II	N	Tre	N	Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients with Acute Myelogenous Leukemia with MDS Related Changes or Therapy-Related Acute Myeloid Leukemia: A University of California Hematologic Malignancies Consortium Protocol	30	19	3	22	2	8	30
01/01/2024	12/31/2024	INT	I	UCI	Other Skin	NCT01771718	UCI-13-13	N	Kelly	Kristen	BIDD	04/11/2012		N/A	Y	Dia	N	Pilot Study on In-Vivo Non-Invasive Skin Imaging Using Multiphoton Microscopy and Multispectral Imaging	250	250	0	202			202
01/01/2024	12/31/2024	INT	I	Eurofins-Viracor	Multiple	NCT06453460	UCI-22-188	N	Kongtim	Piyanuch	BIDD	06/27/2024		II	N	Tre	N	Prospective Evaluation of Efficacy of CMV-specific T Cell Immunity (CMV-TCIP) Directed Letemovir Prophylaxis after Allogeneic Hematopoietic Cell Transplantation	50	50	9	9			9
01/01/2024	12/31/2024	INT	I	UCI	Prostate	NCT06446648	UCI-23-137	N	Lee	David	BIDD	07/12/2024		N/A	Y	Tre	N	Impact of Intraoperative ICG Use During Robotic-Assisted Radical Prostatectomy on Functional Outcomes	400	400	16	16			16
01/01/2024	12/31/2024	INT	I	Gilead	Other Urinary; Urinary Bladder	NCT06682728	UCI-23-59	N	Mar	Nataliya	BIDD	11/15/2024		II	N	Tre	N	Adjuvant Sacituzumab Govitecan Plus Nivolumab in ctDNA Positive Patients with Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence	23	23	1	1	0	0	1
01/01/2024	12/31/2024	INT	I	UCI	Urinary Bladder	NCT06335667	UCI-23-72	N	Mar	Nataliya	CC	03/27/2024		N/A	Y	Dia	N	Outcomes with Multi Parametric MRI (mpMRI) Compared to Diagnostic Transurethral Resection of Bladder Tumor (TURBT) in Patients with Suspected Muscle-Invasive Bladder Cancer - a Pilot Study	30	30	14	14			14
01/01/2024	12/31/2024	INT	I	Vanderbilt University Medical Center	Kidney	NCT05361720	UCI-22-130	Y	Mar	Nataliya	BIDD	02/08/2024		II	N	Tre	N	OPTimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)		9	5	5			
01/01/2024	12/31/2024	INT	I	UCI	Breast	NCT05524584	UCI-19-145	N	Mehta	Rita	SPT	08/31/2022		II	N	Tre	N	Phase II, Open-Labelled, Single-Armed Combination Treatment with Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer	20	20	9	17			17
01/01/2024	12/31/2024	INT	I	UCI	Multiple	NCT06693323	UCI-21-173	N	Nabar	Rupali	BIDD	12/04/2024		II	N	Tre	N	Single-Center Evaluation of the Clinical and Radiological Benefit of AHCC® in Combination with Standard of Care Treatment for HPV-Positive Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)	34	34	0	0			0
01/01/2024	12/31/2024	INT	I	UCI	Lung	NCT06000683	UCI-23-107	N	Sadigh	Gelareh	CC	10/13/2023	10/03/2024	II	Y	Hsr	N	Empowering Patients' Lung Cancer Screening Uptake (Empower LCS)	80	80	69	70			70
01/01/2024	12/31/2024	INT	I	UCI	Lung	NCT06225414	UCI-23-219	N	Sadigh	Gelareh	CC	02/12/2024		N/A	Y	Scr	N	Empowering Hispanic Patient's Lung Cancer Screening Uptake (Empower Latino)	60	60	39	39			39
01/01/2024	12/31/2024	INT	I	On Target Laboratories, LLC.	Stomach; Small Intestine	NCT06511037	UCI-23-184	N	Senthil	Maheswari	BIDD	07/26/2024		I	Y	Tre	N	The Impact of Pafolacianine Injection for Intraoperative Imaging on Outcomes of Gastrointestinal Cancer Peritoneal Carcinomatosis - A Pilot Study	10	10	0	0			0
01/01/2024	12/31/2024	INT	I	UCI	Stomach; Esophagus	NCT04762953	UCI-20-87	N	Senthil	Maheswari	SPT	03/03/2021		II	Y	Tre	N	Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis	40	40	9	27			27
01/01/2024	12/31/2024	INT	I	NIH; Tobacco-Related Disease Research Program; UCI	Lip, Oral Cavity and Pharynx	NCT00540774	UCI-08-52	N	Wilder-Smith	Petra	BIDD	04/23/2003		N/A	N	Dia	N	Optical Sensor for Photodynamic Detection of Oral Pathology	2500	2500	133	1004			1004
01/01/2024	12/31/2024	INT	I	Michelson Diagnostics Ltd.; UCI	Other Skin	NCT04744935	UCI-20-13	N	Zachary	Christopher	BIDD	01/11/2021	11/15/2024	N/A	Y	Tre	N	Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma	30	30	1	29			29
01/01/2024	12/31/2024	INT	D	ABK Biomedical, Inc.	Liver	NCT05953337	UCI-23-75	Y	Abi-Jaoudeh	Nadine	BIDD	03/25/2024		N/A	N	Tre	N	Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)		15	2	2			
01/01/2024	12/31/2024	INT	D	Impact Biotech	Pancreas	NCT05919238	UCI-23-134	Y	Abi-Jaoudeh	Nadine	BIDD	06/21/2024		I	N	Tre	N	A Phase I Trial to Evaluate Safety and Preliminary Efficacy of Endovascularly Applied Padeliporfin Vascular Targeted Photodynamic Therapy for Patients with Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma		8	0	0			
01/01/2024	12/31/2024	INT	D	Instylla, Inc.	Multiple	NCT04523350	UCI-20-84	Y	Abi-Jaoudeh	Nadine	BIDD	08/02/2021	05/01/2024	N/A	N	Tre	N	Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of the Instylla Hydrogel Embolic System (HES) Compared with Standard of Care Transcatheter Arterial Embolization (TAE) / Transcatheter Arterial Chemoembolization (cTACE) for Vascular Occlusion of Hypervascular Tumors; A Pivotal Study (INY-P-20-001)		13	0	8			
01/01/2024	12/31/2024	INT	D	Sirtex Medical Inc.	Liver	NCT04736121	UCI-21-206	Y	Abi-Jaoudeh	Nadine	BIDD	04/06/2023	08/06/2024	N/A	N	Tre	N	A Prospective, Multicenter, Open-Label Single Arm Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres Y-90 Resin Microspheres on Duration of Response (DoR) and Objective Response Rate (ORR) in Unresectable Hepatocellular Carcinoma (HCC) Patients (DOORwaY90 Study)		10	3	5			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Teclison Limited	Liver; Esophagus	NCT03259867	UCI-16-94	Y	Abi-Jaoudeh	Nadine	BIDD	06/30/2017		II	N	Tre	N	Phase IIA Single-Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody		40	7	29			
01/01/2024	12/31/2024	INT	D	Teclison Limited	Liver	NCT03145558	UCI-17-92	Y	Abi-Jaoudeh	Nadine	BIDD	12/04/2017		II	N	Tre	N	TATE versus TACE, an Open-Label Randomized Study Comparing TransArterial Tirapazamine Embolization versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma		15	0	4			
01/01/2024	12/31/2024	INT	D	Teclison Limited	Multiple	NCT04701476	UCI-21-39	N	Abi-Jaoudeh	Nadine	BIDD	08/26/2021		II	N	Tre	N	An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer with a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab		30	3	20			
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Lung	NCT06532032	UCI-22-147-3	Y	Arter	Zhaohui Ann	BIDD	09/18/2024		I/II	N	Tre	N	A Phase I/II Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer		6	0	0			
01/01/2024	12/31/2024	INT	D	Boehringer Ingelheim	Brain and Nervous System	NCT05916313	UCI-23-67	Y	Bota	Daniela	BIDD	12/13/2023		I	N	Tre	N	A Phase Ib Open-Label, Multi-Center, Dose Escalation Trial of BI 764532 Given as Monotherapy Administered by Repeated Intravenous Infusions in Patients with Glioma Expressing DLL3		5	1	1			
01/01/2024	12/31/2024	INT	D	CNS Pharmaceuticals	Brain and Nervous System	NCT04762069	UCI-21-18	N	Bota	Daniela	BIDD	10/27/2021	01/16/2024	II	N	Tre	N	A Multicenter, Open Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy		10	0	8			
01/01/2024	12/31/2024	INT	D	Denovo Biopharma	Brain and Nervous System	NCT03776071	UCI-19-99	Y	Bota	Daniela	SPT	12/11/2020	01/10/2024	III	N	Tre	N	A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1		15	0	11			
01/01/2024	12/31/2024	INT	D	Nerviano	Brain and Nervous System	NCT04910022	UCI-24-27	Y	Bota	Daniela	BIDD	12/03/2024		I/II	N	Tre	N	A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma		5	0	0			
01/01/2024	12/31/2024	INT	D	ONO Pharmaceutical Co., Ltd.	Brain and Nervous System	NCT04947319	UCI-21-77	Y	Bota	Daniela	SPT	04/19/2022	10/17/2024	II	N	Tre	N	An Open-Label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL)		2	0	1			
01/01/2024	12/31/2024	INT	D	VBI Vaccines Inc.	Brain and Nervous System	NCT03382977	UCI-22-58	Y	Bota	Daniela	BIDD	12/02/2022	10/31/2024	I/II	N	Tre	N	A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects		6	3	3			
01/01/2024	12/31/2024	INT	D	Kite Pharma	Non-Hodgkin's Lymphoma	NCT05371093	UCI-22-01	Y	Brem	Elizabeth A	BIDD	03/30/2023	04/22/2024	III	N	Tre	N	A Phase III Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucei Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma		5	0	0			
01/01/2024	12/31/2024	INT	D	Regeneron Pharmaceuticals, Inc	Non-Hodgkin's Lymphoma	NCT06091254	UCI-23-17	Y	Brem	Elizabeth A	BIDD	03/20/2024		III	N	Tre	N	A Phase III, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Investigator's Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)		5	0	0			
01/01/2024	12/31/2024	INT	D	Regeneron Pharmaceuticals, Inc	Non-Hodgkin's Lymphoma	NCT06091865	UCI-23-19	Y	Brem	Elizabeth A	BIDD	03/01/2024		III	N	Tre	N	A Phase III, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN 1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with CHOP (O-CHOP) versus Rituximab in Combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)		5	0	0			
01/01/2024	12/31/2024	INT	D	Viracta Therapeutics, Inc.	Multiple	NCT05011058	UCI-21-04	Y	Brem	Elizabeth A	SPT	10/15/2021	05/01/2024	II	N	Tre	N	An Open-Label, Phase II Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas ("NAVAL-1")		5	1	1			
01/01/2024	12/31/2024	INT	D	Colospan Ltd.	Colon; Rectum	NCT04184973	UCI-20-163	Y	Carmichael	Joseph	CC	04/07/2021		N/A	N	Pre	N	Efficacy and Safety of the CG-100 Intraluminal Bypass Device in Colorectal and Coloanal Anastomoses: Prospective, Open Label, Randomized Trial		10	0	2			
01/01/2024	12/31/2024	INT	D	Bristol-Myers Squibb	Melanoma, Skin	NCT05625399	UCI-22-101	Y	Chow	Warren A	BIDD	04/24/2023	09/26/2024	III	N	Tre	N	A Phase III, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-Dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-Dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma		6	7	10			
01/01/2024	12/31/2024	INT	D	Eisai Inc.	Multiple	NCT05091346	UCI-22-213	Y	Chow	Warren A	BIDD	07/05/2023	03/01/2024	I/II	N	Tre	N	An Open-Label, Multicenter, Phase Ib/II Study of E7386 in Combination with Pembrolizumab in Previously Treated Subjects with Selected Solid Tumors		7	0	0			
01/01/2024	12/31/2024	INT	D	IGM Biosciences, Inc	Multiple	NCT04553692	UCI-21-208	Y	Chow	Warren A	BIDD	11/10/2022	11/04/2024	I	N	Tre	N	An Open-label, Multicenter, Phase Ia/Ib Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed, Refractory, or Newly Diagnosed Cancers		15	5	9			
01/01/2024	12/31/2024	INT	D	Lyvgen BioPharma Holdings Limited	Multiple	NCT04130542	UCI-21-38	Y	Chow	Warren A	BIDD	02/17/2022	01/15/2024	I	N	Tre	N	An Open Label, First in Human (FIH), Phase I Trial of LVGN6051 as Single Agent and in Combination with Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy		5	0	5			
01/01/2024	12/31/2024	INT	D	TopAlliance Biosciences, Inc.	Multiple	NCT04137900	UCI-21-247	Y	Chow	Warren A	BIDD	04/21/2023	01/29/2024	I	N	Tre	N	A First-in-Human, Multicenter, Open-Label, Phase I Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies Including Lymphoma		3	0	1			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Bristol-Myers Squibb	Multiple Myeloma	NCT06045806	UCI-23-70	Y	Ciurea	Stefan Octavian	BIDD	05/23/2024	09/26/2024	III	N	Tre	N	A Randomized, Open-Label, Phase III Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)		6	0	0			
01/01/2024	12/31/2024	INT	D	Cartesian Therapeutics	Multiple Myeloma	NCT06304636	UCI-24-02	Y	Ciurea	Stefan Octavian	BIDD	08/20/2024		I	N	Tre	N	Descartes-15 for Patients with Relapsed/Refractory Multiple Myeloma		5	3	3			
01/01/2024	12/31/2024	INT	D	CytoAgents, Inc.	Non-Hodgkin's Lymphoma	NCT05905328	UCI-23-193	Y	Ciurea	Stefan Octavian	BIDD	07/26/2024		I/II	N	Tre	N	Phase IB/IIA Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients With Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy		5	1	1			
01/01/2024	12/31/2024	INT	D	ImmPACT Bio	Non-Hodgkin's Lymphoma	NCT05826535	UCI-23-114	Y	Ciurea	Stefan Octavian	BIDD	04/26/2024		I/II	N	Tre	N	Phase I/II Multi-Center Study Evaluating the Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma		7	2	2			
01/01/2024	12/31/2024	INT	D	BeiGene, Ltd.	Lymphoid Leukemia	NCT06073821	UCI-23-156	Y	Coombs	Catherine	SPT	03/27/2024		III	N	Tre	N	A Phase III, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia		7	3	3			
01/01/2024	12/31/2024	INT	D	Carna Biosciences, Inc.	Non-Hodgkin's Lymphoma; Lymphoid Leukemia	NCT05602363	UCI-22-134	Y	Coombs	Catherine	BIDD	11/21/2023		I	N	Tre	N	A Phase IB Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma		9	2	2			
01/01/2024	12/31/2024	INT	D	Loxo Oncology, Inc.	Lymphoid Leukemia	NCT04965493	UCI-21-209	Y	Coombs	Catherine	SPT	08/29/2022	06/24/2024	III	N	Tre	N	A Phase III Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma		3	1	2			
01/01/2024	12/31/2024	INT	D	AbbVie	Liver	NCT06109272	UCI-23-104	Y	Dayyani	Farshid	BIDD	03/20/2024		II/III	N	Tre	N	A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment-LIVIGNO-2		7	3	3			
01/01/2024	12/31/2024	INT	D	AbbVie	Liver	NCT05822752	UCI-23-58	Y	Dayyani	Farshid	BIDD	11/14/2023	07/31/2024	II	N	Tre	N	A Phase II, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC-LIVIGNO-1		10	0	0			
01/01/2024	12/31/2024	INT	D	Amgen Inc.	Stomach; Esophagus	NCT05111626	UCI-21-193	Y	Dayyani	Farshid	BIDD	08/12/2022	10/01/2024	I	N	Tre	N	A Phase IB/III Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects with Previously Untreated Advanced Gastric and Gastroesophageal Cancer with FGFR2b Overexpression		12	0	1			
01/01/2024	12/31/2024	INT	D	Amgen Inc.	Multiple	NCT05325866	UCI-22-38	Y	Dayyani	Farshid	BIDD	03/27/2023		I/II	N	Tre	N	A Phase Ib/II, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301)		6	0	1			
01/01/2024	12/31/2024	INT	D	Arcus Biosciences, Inc.	Stomach; Esophagus	NCT05568095	UCI-22-76	Y	Dayyani	Farshid	BIDD	05/15/2023	04/26/2024	III	N	Tre	N	A Randomized, Open-Label, Multicenter Phase III Trial of Domvanalimab, Zimberelilimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma		10	0	1			
01/01/2024	12/31/2024	INT	D	Astellas	Multiple	NCT05365581	UCI-22-51	Y	Dayyani	Farshid	BIDD	03/07/2024		I	N	Tre	N	A Phase I/Ib Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression		20	16	16			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Multiple	NCT04999969	UCI-21-156	Y	Dayyani	Farshid	BIDD	12/16/2022	07/30/2024	II	N	Tre	N	A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumors		10	0	2			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Pancreas; Liver	NCT05775159	UCI-22-211	Y	Dayyani	Farshid	BIDD	10/11/2023		II	N	Tre	N	Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)		8	2	3			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Pancreas; Liver	NCT05771480	UCI-22-212	Y	Dayyani	Farshid	BIDD	12/12/2023		III	N	Tre	N	A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers		8	4	5			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Multiple	NCT06219941	UCI-23-200	Y	Dayyani	Farshid	BIDD	07/24/2024		II	N	Tre	N	A Phase II, Open-Label, Multi-Centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2.(CLARITY-PanTumour01)		10	4	4			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Liver	NCT06109779	UCI-23-99	Y	Dayyani	Farshid	BIDD	09/25/2024		III	N	Tre	N	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment after Resection of Biliary Tract Cancer with Curative Intent		8	0	0			
01/01/2024	12/31/2024	INT	D	Boehringer Ingelheim	Multiple	NCT04752215	UCI-22-221	Y	Dayyani	Farshid	BIDD	08/15/2023	10/02/2024	I	N	Tre	N	A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Bi 765049 and Bi 765049 + Ezabenlimab Administered by Repeated Intravenous Infusions in Patients with Malignant Solid Tumors Expressing B7 H6		12	2	3			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Boehringer Ingelheim	Multiple	NCT06324357	UCI-24-49	Y	Dayyani	Farshid	BIDD	10/22/2024		I	N	Tre	N	Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-Label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination with Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination with Intravenous Trastuzumab Emтанsine (T-DM1) for Treatment of Patients with Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC)		10	0	0			
01/01/2024	12/31/2024	INT	D	Bristol-Myers Squibb	Multiple	NCT03994601	UCI-23-101	Y	Dayyani	Farshid	BIDD	01/23/2024	03/01/2024	I/II	N	Tre	N	A Phase I/II First-in-Human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors		10	0	0			
01/01/2024	12/31/2024	INT	D	Bristol-Myers Squibb	Multiple	NCT05543629	UCI-23-35	Y	Dayyani	Farshid	BIDD	10/30/2023	02/27/2024	I/II	N	Tre	N	A Phase Ib/II Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer		10	1	1			
01/01/2024	12/31/2024	INT	D	Cosmo Technologies, Ltd.	Multiple	NCT03863145	UCI-22-26	Y	Dayyani	Farshid	BIDD	11/17/2022		I	N	Tre	N	Open-Label, Multicenter, Phase I Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 with Dose Expansion Phase, in Subjects with Advanced Solid Tumors		6	3	9			
01/01/2024	12/31/2024	INT	D	Erasca	Multiple	NCT05039177	UCI-21-110	Y	Dayyani	Farshid	BIDD	03/23/2022	03/05/2024	I/II	N	Tre	N	Phase Ib/II Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)		15	0	6			
01/01/2024	12/31/2024	INT	D	Exelixis, Inc.	Colon; Rectum	NCT05425940	UCI-22-131	Y	Dayyani	Farshid	BIDD	09/21/2023	05/21/2024	III	N	Tre	N	A Randomized Open-Label Phase III Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer		10	4	8			
01/01/2024	12/31/2024	INT	D	Frontier Medicine	Multiple	NCT06244771	UCI-24-65	Y	Dayyani	Farshid	BIDD	11/04/2024		I/II	N	Tre	N	An Open-Label, Phase I/II Dose-Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants with KRASG12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	Genentech, Inc.	Liver	NCT06096779	UCI-23-86	Y	Dayyani	Farshid	BIDD	03/22/2024		II	N	Tre	N	A Phase II, Open-label, Multi-Cohort, Multicenter Study in Patients With Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis		10	0	0			
01/01/2024	12/31/2024	INT	D	I-MAB Biopharma	Multiple	NCT04900818	UCI-21-10	N	Dayyani	Farshid	BIDD	12/13/2021		I	N	Tre	N	A Phase I Dose-Escalation and Dose Expansion Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors		10	7	14			
01/01/2024	12/31/2024	INT	D	Nerviano	Liver	NCT05630937	UCI-22-202	Y	Dayyani	Farshid	SPT	10/23/2023	02/06/2024	I/II	N	Tre	N	Phase I/II Study on Safety and Efficacy of NMS-01940153E in Adult Patients with Unresectable Hepatocellular Carcinoma (HCC) Previously Treated with Systemic Therapy		7	0	0			
01/01/2024	12/31/2024	INT	D	Seagen Inc	Multiple	NCT06157892	UCI-23-109	Y	Dayyani	Farshid	BIDD	04/25/2024		I/II	N	Tre	N	A Phase Ib/II Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors		10	2	2			
01/01/2024	12/31/2024	INT	D	Shanghai Miracogen Inc.	Multiple	NCT04843709	UCI-21-146	Y	Dayyani	Farshid	BIDD	04/07/2022		I/II	N	Tre	N	An Open-Label, Multi-Center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors		11	1	5			
01/01/2024	12/31/2024	INT	D	Tachyon Therapeutics, Inc	Multiple	NCT05076552	UCI-22-37	Y	Dayyani	Farshid	BIDD	08/14/2023	07/12/2024	I	N	Tre	N	A Phase Ia/Ib Open-Label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Patients with Advanced or Metastatic Solid Tumors		10	3	6			
01/01/2024	12/31/2024	INT	D	Tvardi Therapeutics, Inc	Liver	NCT05440708	UCI-22-106	Y	Dayyani	Farshid	BIDD	06/23/2023		I/II	N	Tre	N	A Phase IB/II Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma		10	4	7			
01/01/2024	12/31/2024	INT	D	Xiamen LP Pharmaceutical Co., Ltd.	Multiple	NCT05199818	UCI-22-109	Y	Dayyani	Farshid	CC	06/13/2023	04/22/2024	III	N	Pre	N	A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy		30	0	1			
01/01/2024	12/31/2024	INT	D	Ionis Pharmaceuticals	Other Hematopoietic	NCT05143957	UCI-21-204	Y	Fleischman	Angela	SPT	07/07/2022	09/09/2024	II	N	Tre	N	A Phase IIa, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)		5	0	1			
01/01/2024	12/31/2024	INT	D	Genentech, Inc.	Melanoma, Skin	NCT04835805	UCI-20-169	Y	Fruehauf	John P	BIDD	12/17/2021	02/01/2024	I	N	Tre	N	A Phase IB, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination with Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients with NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy		5	0	0			
01/01/2024	12/31/2024	INT	D	AbbVie	Myeloid and Monocytic Leukemia	NCT04086264	UCI-19-138	Y	Jeyakumar	Deepa	BIDD	11/18/2020	07/11/2024	I/II	N	Tre	N	A Phase Ib/II Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia		5	0	2			
01/01/2024	12/31/2024	INT	D	Amgen Inc.	Lymphoid Leukemia	NCT04506086	UCI-20-34	Y	Jeyakumar	Deepa	BIDD	05/04/2021	09/12/2024	IV	N	Tre	N	A Phase IV, Multi-Center Open-Label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects with Minimal Residual Disease (MRD) of B-Precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission		5	0	2			
01/01/2024	12/31/2024	INT	D	Amgen Inc.	Lymphoid Leukemia	NCT04994717	UCI-21-98	Y	Jeyakumar	Deepa	BIDD	08/15/2022	08/02/2024	III	N	Tre	N	Phase III Randomized, Controlled Study of Blinatumomab Alternating with Low-Intensity Chemotherapy Versus Standard of Care for Older Adults with Newly Diagnosed Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia with Safety Run-In		6	1	6			
01/01/2024	12/31/2024	INT	D	Aptose Biosciences Inc.	Myeloid and Monocytic Leukemia	NCT03850574	UCI-22-81	Y	Jeyakumar	Deepa	BIDD	08/31/2023		I/II	N	Tre	N	A Phase I/II, Open-Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)		6	0	0			



Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Astellas Pharma Global Development, Inc.	Myeloid and Monocytic Leukemia	NCT05520567	UCI-21-216	Y	Jeyakumar	Deepa	BIDD	06/28/2023		I/II	N	Tre	N	A Phase I/II, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy		5	1	2			
01/01/2024	12/31/2024	INT	D	Biomea Fusion, Inc.	Multiple	NCT05153330	UCI-22-24	Y	Jeyakumar	Deepa	BIDD	02/28/2023	01/15/2025	I	N	Tre	N	A Phase I First-in-Human Dose-Escalation and Dose-Escalation and Dose-Expansion Study of BMF-219, an Oral, Covalent, Menin Inhibitor, in Adult Patients with Acute Leukemia (AL), Diffuse Large B-Cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)		5	0	1			
01/01/2024	12/31/2024	INT	D	Delta-Fly Pharma, Inc.	Myeloid and Monocytic Leukemia	NCT03926624	UCI-19-93	Y	Jeyakumar	Deepa	BIDD	04/16/2020		III	N	Tre	N	Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage		12	0	11			
01/01/2024	12/31/2024	INT	D	Gilead Sciences, Inc.	Myeloid and Monocytic Leukemia	NCT05079230	UCI-21-180	Y	Jeyakumar	Deepa	BIDD	05/24/2023	02/06/2024	III	N	Tre	N	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy		10	0	0			
01/01/2024	12/31/2024	INT	D	GluBio Therapeutics Inc.	Myeloid and Monocytic Leukemia; Other Hematopoietic	NCT06146257	UCI-23-113	Y	Jeyakumar	Deepa	BIDD	12/29/2023		I	N	Tre	N	A First-in-human (FIH), Phase I, Multicenter, Open- label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes		7	1	1			
01/01/2024	12/31/2024	INT	D	Hutchison MediPharma Limited	Multiple	NCT04764474	UCI-21-144	Y	Jeyakumar	Deepa	BIDD	11/04/2022	05/21/2024	I	N	Tre	N	A Phase I, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignances with Isocitrate Dehydrogenase (IDH) Mutations		5	0	0			
01/01/2024	12/31/2024	INT	D	IRIS	Lymphoid Leukemia	NCT04817761	UCI-22-125	Y	Jeyakumar	Deepa	SPT	08/21/2023		II/III	N	Tre	N	A Multi-Center, Open-Label, Single-Arm Phase II/III Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 to >65 Years with Newly-Diagnosed Philadelphia-Negative ALL		5	0	0			
01/01/2024	12/31/2024	INT	D	Immune-Onc Therapeutics, Inc.	Myeloid and Monocytic Leukemia	NCT04372433	UCI-20-51	Y	Jeyakumar	Deepa	BIDD	12/09/2020	04/30/2024	I	N	Tre	N	A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients		5	0	4			
01/01/2024	12/31/2024	INT	D	PureTech Health, LLC	Myeloid and Monocytic Leukemia; Other Hematopoietic	NCT05829226	UCI-22-151	Y	Jeyakumar	Deepa	BIDD	03/07/2023		I	N	Tre	N	A Phase I, Open-Label, Multi-Center Study of the Safety, Pharmacokinetics (PK), and Anti-Tumor Activity of LYT-200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High-Risk Myelodysplastic Syndrome (MDS)		8	2	5			
01/01/2024	12/31/2024	INT	D	SELLAS Life Sciences Group	Myeloid and Monocytic Leukemia	NCT04229979	UCI-22-183	Y	Jeyakumar	Deepa	BIDD	11/09/2023	03/29/2024	III	N	Tre	N	A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy		5	0	0			
01/01/2024	12/31/2024	INT	D	Arvinas, Inc.	Prostate	NCT03888612	UCI-20-138	Y	Kalebasty	Arash Rezazadeh	BIDD	06/21/2021	03/07/2024	I/II	N	Tre	N	A Phase I/II, Open-Label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients with Metastatic Castration Resistant Prostate Cancer		10	0	7			
01/01/2024	12/31/2024	INT	D	Eikon Therapeutics	Multiple	NCT06253130	UCI-23-162	Y	Kalebasty	Arash Rezazadeh	SPT	04/03/2024		I/II	N	Tre	N	A First-in-human, Phase I/II, Open-label, Multi-center, Dose-Escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy and in Combination in Participants with Advanced Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Urinary Bladder	NCT05562830	UCI-22-128	Y	Kalebasty	Arash Rezazadeh	BIDD	01/23/2023		I/II	N	Tre	N	A Phase I/II Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A		3	0	0			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Urinary Bladder	NCT05845814	UCI-22-129	Y	Kalebasty	Arash Rezazadeh	BIDD	10/06/2023	11/19/2024	I/II	N	Tre	N	A Phase I/II Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B		6	0	0			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Prostate	NCT06136624	UCI-23-118	Y	Kalebasty	Arash Rezazadeh	SPT	06/24/2024		III	N	Tre	N	A Phase III Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated with Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy		6	0	0			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Prostate	NCT06136650	UCI-23-119	Y	Kalebasty	Arash Rezazadeh	SPT	06/20/2024		III	N	Tre	N	A Phase III, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed on or After Prior Treatment with One Next-generation Hormonal Agent (NHA)		9	3	3			
01/01/2024	12/31/2024	INT	D	Navire Pharma Inc.	Multiple	NCT04528836	UCI-20-179	Y	Kalebasty	Arash Rezazadeh	BIDD	07/07/2022	02/21/2024	I	N	Tre	N	A Phase I/IB First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients with Advanced Solid Tumors		10	0	1			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Merck	Lung	NCT06077760	UCI-23-169	Y	Keshava	Hari	BIDD	07/23/2024		III	N	Tre	N	A Phase III, Randomized, Double-blind, Placebo- and Active-Comparator Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer		10	0	0			
01/01/2024	12/31/2024	INT	D	Chimerix, Inc.	Brain and Nervous System	NCT05580562	UCI-22-83	Y	Kong	Xiao-Tang	SPT	06/26/2023		III	N	Tre	N	ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study		5	2	2			
01/01/2024	12/31/2024	INT	D	NovoCure Ltd.	Brain and Nervous System	NCT04471844	UCI-20-65	Y	Kong	Xiao-Tang	BIDD	01/20/2022	01/03/2024	N/A	N	Tre	N	EF-32: Randomized, Open-Label Study of Tumor Treating Fields (Optune®, 200kHz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma		15	0	6			
01/01/2024	12/31/2024	INT	D	NuvOx Pharma	Brain and Nervous System	NCT03862430	UCI-23-198	Y	Kong	Xiao-Tang	BIDD	05/02/2024		II	N	Tre	N	A Phase II Double-blind, Randomized, Prospective, Placebo Controlled Study of Nano2 TM Combined with Radiation and Temozolomide in Patients with Newly-Diagnosed Glioblastoma Multiforme: RESTORE		6	1	1			
01/01/2024	12/31/2024	INT	D	Bexion Pharmaceuticals, Inc.	Colon; Rectum	NCT05322590	UCI-22-07	Y	Lee	Fa Chyi	BIDD	01/24/2023	10/23/2024	I/II	N	Tre	N	A Phase Ib/II Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma		8	4	6			
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Multiple Myeloma	NCT05572515	UCI-22-190	Y	Lee	Lisa Xingguang	BIDD	07/10/2023		III	N	Tre	N	A Phase III Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PvD) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide		6	1	3			
01/01/2024	12/31/2024	INT	D	Regeneron Pharmaceuticals, Inc	Multiple Myeloma	NCT05828511	UCI-23-158	Y	Lee	Lisa Xingguang	BIDD	03/29/2024		I/II	N	Tre	N	Phase I/II Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma		6	1	1			
01/01/2024	12/31/2024	INT	D	Acrivon Therapeutics, Inc.	Multiple	NCT05548296	GOG-3082	Y	Mar	Nataliya	BIDD	09/18/2023	12/03/2024	I/II	N	Tre	N	A Phase Ib/II Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status		10	3	4			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Urinary Bladder	NCT04960709	UCI-21-09	N	Mar	Nataliya	BIDD	12/17/2021	12/31/2024	III	N	Tre	N	A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)		8	6	7			
01/01/2024	12/31/2024	INT	D	F. Hoffmann-La Roche Ltd	Kidney	NCT05805501	UCI-22-53	Y	Mar	Nataliya	BIDD	06/22/2023	09/25/2024	II	N	Tre	N	A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma		10	2	5			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Kidney	NCT05239728	UCI-21-228	Y	Mar	Nataliya	SPT	12/07/2022	04/12/2024	III	N	Tre	N	A Multi-Center, Double-Blind, Randomized Phase III Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (6482-022)		5	0	3			
01/01/2024	12/31/2024	INT	D	Seagen Inc	Urinary Bladder	NCT04879329	UCI-22-39	Y	Mar	Nataliya	BIDD	11/08/2022		II	N	Tre	N	A Phase II Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2		5	4	6			
01/01/2024	12/31/2024	INT	D	DUALITYBIO Inc	Breast	NCT06018337	UCI-23-177	Y	Mehta	Rita	BIDD	08/22/2024		III	N	Tre	N	A Phase III, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)		5	1	1			
01/01/2024	12/31/2024	INT	D	Poseida Therapeutics, Inc.	Multiple	NCT05239143	UCI-23-07	Y	Mehta	Rita	BIDD	04/01/2024		I	N	Tre	N	A Phase I Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Lip, Oral Cavity and Pharynx	NCT06129864	UCI-23-190	Y	Nabar	Rupali	BIDD	06/29/2024		III	N	Tre	N	A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy		5	0	0			
01/01/2024	12/31/2024	INT	D	Flamingo Therapeutics	Lip, Oral Cavity and Pharynx; Larynx	NCT05814666	UCI-23-106	Y	Nabar	Rupali	SPT	12/14/2023		II	N	Tre	N	An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)		4	2	2			
01/01/2024	12/31/2024	INT	D	Takeda	Multiple	NCT04420884	UCI-23-228	Y	Nabar	Rupali	BIDD	11/05/2024		I/II	N	Tre	N	An Open-label, Dose Escalation, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	AnHeart Therapeutics	Lung	NCT04919811	UCI-21-108	Y	Nagasaka	Misako	SPT	05/31/2022		II	N	Tre	N	A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors		5	0	2			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	AstraZeneca	Lung	NCT04686305	UCI-21-187	Y	Nagasaka	Misako	BIDD	04/18/2022		I	N	Tre	N	A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)		5	1	2			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Lung	NCT05048797	UCI-21-234	Y	Nagasaka	Misako	BIDD	10/21/2022		III	N	Tre	N	An Open-label, Randomized, Multicenter, Phase III Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)		10	0	1			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Lung	NCT05687266	UCI-21-242	Y	Nagasaka	Misako	BIDD	12/05/2023	08/29/2024	III	N	Tre	N	A Phase III, Randomised, Open-Label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)		6	0	0			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Lung	NCT05120349	UCI-22-59	Y	Nagasaka	Misako	SPT	12/12/2022	08/23/2024	III	N	Tre	N	Phase III, Double-Blind, Randomized, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Patients with EGFR Mutation-Positive Stage IA2-IA3 Non-Small Cell Lung Cancer, Following Complete Tumour Resection (ADAURA2)		10	1	1			
01/01/2024	12/31/2024	INT	D	BeiGene, Ltd.	Multiple	NCT03744468	UCI-21-62	Y	Nagasaka	Misako	BIDD	07/06/2022	05/22/2024	I/II	N	Tre	N	Phase I/II Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors		5	0	1			
01/01/2024	12/31/2024	INT	D	Bicycle Tx Limited	Multiple	NCT04180371	UCI-21-13	Y	Nagasaka	Misako	BIDD	05/02/2022	12/03/2024	I/II	N	Tre	N	Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression		3	0	2			
01/01/2024	12/31/2024	INT	D	Bioatla	Lung	NCT03504488	UCI-21-161	Y	Nagasaka	Misako	BIDD	11/14/2022	03/07/2024	I/II	N	Tre	N	A Phase I/II Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	Bioatla	Lung	NCT04681131	UCI-21-233	Y	Nagasaka	Misako	SPT	12/07/2022	05/17/2024	II	N	Tre	N	A Phase II Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression On or Are Intolerant to a PD-1/L1, EGFR, or ALK Inhibitor		5	0	1			
01/01/2024	12/31/2024	INT	D	Blueprint Medicines	Lung	NCT04862780	UCI-21-27	N	Nagasaka	Misako	BIDD	12/17/2021	01/08/2024	I/II	N	Tre	N	A Phase I/II Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer		10	0	6			
01/01/2024	12/31/2024	INT	D	Boehringer Ingelheim	Multiple	NCT04886804	UCI-23-66	Y	Nagasaka	Misako	BIDD	02/29/2024		I	N	Tre	N	Beamon LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations		5	2	2			
01/01/2024	12/31/2024	INT	D	CJ Bioscience, Inc.	Lung	NCT05877430	UCI-23-148	Y	Nagasaka	Misako	BIDD	07/30/2024		I/II	N	Tre	N	Phase I/II Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination with Pembrolizumab in Subjects with Selected Types of Advanced or Metastatic Cancer		6	1	1			
01/01/2024	12/31/2024	INT	D	D3 Bio	Multiple	NCT05410145	UCI-22-30	Y	Nagasaka	Misako	BIDD	10/31/2023		I/II	N	Tre	N	A Phase 1/2, Open-label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation		3	0	0			
01/01/2024	12/31/2024	INT	D	J INTS BIO	Lung	NCT05394831	UCI-22-121	Y	Nagasaka	Misako	BIDD	10/02/2023		I/II	N	Tre	N	A Phase I/II, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer		12	1	1			
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Multiple	NCT05498428	UCI-22-217	Y	Nagasaka	Misako	BIDD	10/04/2023		II	N	Tre	N	A Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer		15	3	5			
01/01/2024	12/31/2024	INT	D	Loxo Oncology, Inc.	Multiple	NCT03157128	UCI-18-21	Y	Nagasaka	Misako	BIDD	12/04/2018	02/01/2024	I/II	N	Tre	N	A Phase I/II Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001).		9	0	7			
01/01/2024	12/31/2024	INT	D	Loxo Oncology, Inc.	Multiple	NCT04956640	UCI-21-53	Y	Nagasaka	Misako	BIDD	12/07/2021		I/II	N	Tre	N	A Phase I/2 Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors		8	1	7			
01/01/2024	12/31/2024	INT	D	Merus N.V.	Multiple	NCT02912949	UCI-19-64	Y	Nagasaka	Misako	SPT	09/19/2019		I/II	N	Tre	N	A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors		10	2	8			
01/01/2024	12/31/2024	INT	D	Nuvalent, Inc.	Multiple	NCT05384626	UCI-21-241	Y	Nagasaka	Misako	BIDD	10/04/2022		I/II	N	Tre	N	A Phase I/II Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)		10	9	17			
01/01/2024	12/31/2024	INT	D	Nuvalent, Inc.	Multiple	NCT05118789	UCI-21-47	Y	Nagasaka	Misako	BIDD	11/19/2021		I/II	N	Tre	N	A Phase I/II Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)		16	3	9			
01/01/2024	12/31/2024	INT	D	Summit Therapeutics Sub, Inc	Lung	NCT06396065	UCI-23-95	Y	Nagasaka	Misako	BIDD	11/01/2023	09/10/2024	III	N	Tre	N	A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONI)		5	2	3			
01/01/2024	12/31/2024	INT	D	Turning Point Therapeutics	Multiple	NCT03093116	UCI-16-79	Y	Nagasaka	Misako	BIDD	03/06/2017		I/II	N	Tre	N	A Phase I/II, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)		21	1	17			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Delta-Fly Pharma, Inc.	Myeloid and Monocytic Leukemia	NCT06382168	UCI-24-48	Y	Naqvi	Kiran	BIDD	08/06/2024		I/II	N	Tre	N	Phase I/II Study of DFP-10917 in Combination with Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia		5	2	2			
01/01/2024	12/31/2024	INT	D	Kura Oncology	Myeloid and Monocytic Leukemia	NCT06001788	UCI-23-154	Y	Naqvi	Kiran	BIDD	05/21/2024		I	N	Tre	N	Phase I Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed/Refractory Acute Myeloid Leukemia		5	0	0			
01/01/2024	12/31/2024	INT	D	Kura Oncology	Myeloid and Monocytic Leukemia	NCT05735184	UCI-23-44	Y	Naqvi	Kiran	BIDD	03/04/2024		I	N	Tre	N	Phase I Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia		10	2	2			
01/01/2024	12/31/2024	INT	D	Rigel Pharmaceuticals, Inc.	Myeloid and Monocytic Leukemia	NCT05308264	UCI-21-239	Y	Naqvi	Kiran	BIDD	02/01/2023		I	N	Tre	N	An Open-Label, Phase IB Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndrome (LR MDS) Who are Relapsed/Refractory/Resistant to Prior Therapies		5	1	1			
01/01/2024	12/31/2024	INT	D	Caribou Biosciences, Inc.	Non-Hodgkin's Lymphoma	NCT04637763	UCI-20-126	Y	O'Brien	Susan	BIDD	03/23/2021		I	N	Tre	N	A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER)		5	0	5			
01/01/2024	12/31/2024	INT	D	Mustang	Non-Hodgkin's Lymphoma; Lymphoid Leukemia	NCT05360238	UCI-21-19	Y	O'Brien	Susan	BIDD	07/08/2022	05/16/2024	I/II	N	Tre	N	A Phase I/II, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia ((SHELBY-1)		5	0	1			
01/01/2024	12/31/2024	INT	D	Nurix Therapeutics, Inc.	Non-Hodgkin's Lymphoma; Lymphoid Leukemia	NCT04830137	UCI-20-198	Y	O'Brien	Susan	BIDD	08/09/2021	06/05/2024	I	N	Tre	N	A Phase I, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degradar, in Adults with Relapsed/Refractory B-cell Malignancies		3	0	1			
01/01/2024	12/31/2024	INT	D	Genentech, Inc.	Colon; Rectum	NCT04449874	UCI-20-141	Y	Ou	Sai-Hong	BIDD	10/13/2021	03/07/2024	I	N	Tre	N	A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and In Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors with a KRAS G12c Mutation		20	0	3			
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Lung	NCT04077463	UCI-20-119	Y	Ou	Sai-Hong	BIDD	03/19/2021	07/15/2024	I	N	Tre	N	An Open-Label Phase I/Ib Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations with JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants with Advanced Non-Small Cell Lung Cancer		15	0	11			
01/01/2024	12/31/2024	INT	D	Merus N.V.	Multiple	NCT04868877	UCI-20-195	Y	Ou	Sai-Hong	BIDD	03/31/2021		I/II	N	Tre	N	Phase I/II Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-C-MET Bispecific Antibody, in Patients with Advanced NSCLC and Other Solid Tumors		10	0	12			
01/01/2024	12/31/2024	INT	D	Mirati Therapeutics, Inc.	Multiple	NCT03785249	UCI-18-78	Y	Ou	Sai-Hong	BIDD	01/15/2019		I/II	N	Tre	N	A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation		40	0	24			
01/01/2024	12/31/2024	INT	D	Pfizer Pharmaceutical Inc.	Lung	NCT05144997	UCI-22-145	Y	Ou	Sai-Hong	SPT	03/03/2023	05/16/2024	IV	N	Tre	N	Lorlatinib (PF-06463922) Continuation Protocol: An Open-Label, Single-Arm Continuation Study for Participants with ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Continuing From Pfizer Sponsored Lorlatinib Clinical Studies		4	1	5			
01/01/2024	12/31/2024	INT	D	Regeneron Pharmaceuticals, Inc	Lung	NCT04982224	UCI-21-105	Y	Ou	Sai-Hong	BIDD	09/15/2022	04/11/2024	I/II	N	Tre	N	A Phase I/II Study of REGN5093-M114 (METXMET Antibody-Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer		5	0	0			
01/01/2024	12/31/2024	INT	D	Revolution Medicines	Multiple	NCT05379985	UCI-22-87	Y	Ou	Sai-Hong	BIDD	09/08/2023		I	N	Tre	N	A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS		20	14	17			
01/01/2024	12/31/2024	INT	D	Revolution Medicines	Multiple	NCT05462717	UCI-22-88	Y	Ou	Sai-Hong	BIDD	01/10/2023		I	N	Tre	N	Phase I/IB, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors		25	1	4			
01/01/2024	12/31/2024	INT	D	Revolution Medicines	Multiple	NCT06128551	UCI-23-116	Y	Ou	Sai-Hong	BIDD	11/12/2024		I	N	Tre	N	Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C-Mutated Solid Tumors		10	0	0			
01/01/2024	12/31/2024	INT	D	SystImmune, Inc.	Lung	NCT05983432	UCI-23-178	Y	Ou	Sai-Hong	BIDD	04/04/2024		I	N	Tre	N	A Phase i Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer and other Solid Tumors.		10	2	2			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Breast	NCT05113251	UCI-21-185	Y	Parajuli	Ritesh	BIDD	04/17/2023	03/29/2024	III	N	Tre	N	A Phase III Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)		5	0	4			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Breast	NCT05629585	UCI-22-141	Y	Parajuli	Ritesh	BIDD	06/13/2023	12/31/2024	III	N	Tre	N	A Phase III Open-label, Randomized Study of Datopotamab Deruxtecan (Dato DXd) with or without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple-negative Breast Cancer who have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (D926XC00001; TROPION-Breast03)		5	1	1			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Breast	NCT06112379	UCI-23-124	Y	Parajuli	Ritesh	BIDD	07/25/2024		III	N	Tre	N	A Phase III, Open-Label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer (D926QC00001; TROPION-Breast04)		5	0	0			



Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Celcuity Inc	Breast	NCT05501886	UCI-22-139	Y	Parajuli	Ritesh	SPT	04/28/2023		III	N	Tre	N	A Phase III, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy		5	2	4			
01/01/2024	12/31/2024	INT	D	Eli Lilly	Breast	NCT05514054	UCI-22-111	Y	Parajuli	Ritesh	SPT	12/15/2023		III	N	Tre	N	EMBER-4: A Randomized, Open-Label, Phase III Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence		15	5	5			
01/01/2024	12/31/2024	INT	D	F. Hoffmann-La Roche Ltd	Breast	NCT05646862	UCI-22-222	Y	Parajuli	Ritesh	SPT	09/01/2023	09/05/2024	III	N	Tre	N	A Phase III, Multicenter, Randomized, Open-label Study Evaluating The Efficacy And Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant In Patients with Hormone Receptor-positive, HER2-negative, PIK3CA Mutated, Locally Advanced Or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy		4	0	0			
01/01/2024	12/31/2024	INT	D	Genentech, Inc.	Breast	NCT05306340	UCI-22-114	Y	Parajuli	Ritesh	SPT	06/01/2023	09/17/2024	III	N	Tre	N	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer		5	0	3			
01/01/2024	12/31/2024	INT	D	Gilead Sciences, Inc.	Breast	NCT05382286	UCI-21-212	Y	Parajuli	Ritesh	BIDD	02/28/2023	07/31/2024	III	N	Tre	N	A Randomized, Open-Label, Phase III Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1		3	0	0			
01/01/2024	12/31/2024	INT	D	Mersana Therapeutics, Inc.	Multiple	NCT05377996	UCI-22-09	Y	Parajuli	Ritesh	BIDD	12/28/2022		I	N	Tre	N	A Phase Ib, First-In-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors		5	2	3			
01/01/2024	12/31/2024	INT	D	Orinove, Inc.	Multiple	NCT03950570	UCI-21-82	Y	Parajuli	Ritesh	BIDD	06/07/2022	06/06/2024	I/II	N	Tre	N	A Phase I/II, Open Label, Dose-Escalation Study of Oral ORIN1001 With and Without Chemotherapy in the Treatment of Subjects with Solid Tumors		5	0	1			
01/01/2024	12/31/2024	INT	D	Turnstone Biologics, Corp	Multiple	NCT05576077	UCI-22-156	Y	Parajuli	Ritesh	BIDD	12/20/2023	01/16/2025	I	N	Tre	N	A Phase Ib Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients with Advanced Solid Tumor Malignancies (STARLING)		5	0	0			
01/01/2024	12/31/2024	INT	D	Zymeworks	Multiple	NCT05027139	UCI-21-57	Y	Parajuli	Ritesh	BIDD	12/14/2021	03/27/2024	I/II	N	Tre	N	A Phase Ib/II, Two-Part, Open-Label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination with ALX148 in Advanced HER2-Expressing Cancer		5	0	4			
01/01/2024	12/31/2024	INT	D	Affimed GmbH	Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma	NCT05883449	UCI-23-80	Y	Pinter-Brown	Lauren C	BIDD	02/13/2024		II	N	Tre	N	Phase II, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma		6	0	0			
01/01/2024	12/31/2024	INT	D	F. Hoffmann-La Roche Ltd	Non-Hodgkin's Lymphoma	NCT05364424	UCI-21-225	Y	Pinter-Brown	Lauren C	BIDD	01/27/2023	10/03/2024	I	N	Tre	N	A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients with Relapsed/Refractory Transplant Eligible Diffuse B-Cell Lymphoma		6	3	10			
01/01/2024	12/31/2024	INT	D	Innate Pharma	Non-Hodgkin's Lymphoma	NCT05321147	UCI-21-01	N	Pinter-Brown	Lauren C	BIDD	08/03/2022	01/12/2024	I	N	Tre	N	A Multi-Center Phase IB Trial Evaluating the Safety and Efficacy of Lacutamab in Patients with Relapse Peripheral T-Cell Lymphoma that Express KIR3DL2		5	0	0			
01/01/2024	12/31/2024	INT	D	Kymera Therapeutics	Multiple	NCT05225584	UCI-21-224	Y	Pinter-Brown	Lauren C	BIDD	11/21/2022	06/18/2024	I	N	Tre	N	A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	ONO Pharmaceutical Co., Ltd.	Lymphoid Leukemia	NCT05079282	UCI-21-99	N	Pinter-Brown	Lauren C	BIDD	04/07/2022		I	N	Tre	N	An Open-Label, Multi-Center, Non Randomized Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients with Relapsed or Refractory T-Cell Lymphoma		10	2	3			
01/01/2024	12/31/2024	INT	D	Hoth Therapeutics	Multiple	NCT05639933	UCI-23-153	Y	Smith	Janellen	SPT	06/27/2024		II	N	Sup	N	A Randomized, Placebo-Controlled, Parallel Phase IIa Dose-Ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors		16	0	0			
01/01/2024	12/31/2024	INT	D	Amgen Inc.	Multiple	NCT05317078	UCI-22-77	Y	Tewari	Krishnansu	BIDD	01/03/2023	06/14/2024	I	N	Tre	N	Phase I First-in-Human Study to Explore the Safety, Tolerability and Pharmacokinetics of AMG 794 in Subjects with Claudin 6-Positive Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer or Epithelial Ovarian Cancer and Other Malignant Solid Tumor Indications		5	0	1			
01/01/2024	12/31/2024	INT	D	Ascendis Pharma	Multiple	NCT04799054	UCI-22-42	Y	Tewari	Krishnansu	BIDD	09/22/2023	09/05/2024	I/II	N	Tre	N	Phase I/II, Open-label Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist, Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies		5	0	0			
01/01/2024	12/31/2024	INT	D	Blueprint Medicines	Multiple	NCT05252416	UCI-22-195	Y	Tewari	Krishnansu	BIDD	06/12/2024	10/11/2024	I/II	N	Tre	N	A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	F. Hoffmann-La Roche Ltd	Multiple	NCT05240898	UCI-22-78	Y	Tewari	Krishnansu	BIDD	03/08/2023		I	N	Tre	N	A Phase I Study of RO7623066 Alone and in Combination in Patients with Advanced Solid Tumors		3	0	0			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	GOG Foundation	Multiple	NCT05445778	GOG-3078	Y	Tewari	Krishnansu	BIDD	10/12/2023		III	N	Tre	N	Randomized, Multicenter, Open-label, Phase III Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FrA-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab		5	0	0			
01/01/2024	12/31/2024	INT	D	Genelux Corporation	Multiple	NCT05281471	GOG-3076	Y	Tewari	Krishnansu	BIDD	11/17/2023		III	N	Tre	N	A Randomized Phase III Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime Study)		5	2	2			
01/01/2024	12/31/2024	INT	D	K-Group Beta	Multiple	NCT05128825	GOG-3066	Y	Tewari	Krishnansu	SPT	11/10/2023	06/14/2024	II	N	Tre	N	A Phase II Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer		5	0	0			
01/01/2024	12/31/2024	INT	D	K-Group Beta	Corpus Uteri	NCT04814108	UCI-20-203	Y	Tewari	Krishnansu	SPT	10/26/2021	10/29/2024	II	N	Tre	N	Phase II, Open Label, Single Arm, Efficacy and Safety Study of the WEE1 Inhibitor ZN-c3 as Second Line Oral Therapy in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (USC)		5	0	0			
01/01/2024	12/31/2024	INT	D	Karyopharm Therapeutics, Inc.	Other Female Genital	NCT05611931	GOG-3083	Y	Tewari	Krishnansu	SPT	09/22/2023	11/05/2024	III	N	Tre	N	A Phase III, Randomized, Placebo-controlled, Double-blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With P53 Wild-type, Advanced or Recurrent Endometrial Carcinoma		3	0	0			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Multiple	NCT03486873	UCI-23-186	Y	Tewari	Krishnansu	BIDD	08/16/2024		III	N	Tre	N	A Multicenter, Open-label, Phase III Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab		10	0	0			
01/01/2024	12/31/2024	INT	D	Takeda	Multiple	NCT04381650	UCI-20-110	Y	Tewari	Krishnansu	BIDD	02/03/2022	02/22/2024	I/II	N	Tre	N	A Phase Ib/II Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients with Select Advanced or Metastatic Solid Tumors		5	0	2			
01/01/2024	12/31/2024	INT	D	Replimune	Melanoma, Skin	NCT06264180	UCI-24-112	Y	Tran	Thuy	BIDD	12/23/2024		III	N	Tre	N	A Randomized, Controlled, Multicenter, Phase III Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen		5	0	0			
01/01/2024	12/31/2024	INT	D	Winsantor, Inc	Multiple	NCT05488873	UCI-22-80	N	Tseng	Jill	SPT	05/11/2023	06/20/2024	II	N	Tre	N	A Randomized, Double-Blind, Placebo-Controlled, Phase IIA Study of Topical Pirenzepine or Placebo for the Prevention of Dose Limiting Chemotherapy Induced Peripheral Neuropathy in Oncology Patients Administered Carboplatin and Paclitaxel		15	0	1			
01/01/2024	12/31/2024	INT	D	Astellas Pharma Global Development, Inc.	Urinary Bladder	NCT05014139	UCI-21-41	Y	Uchio	Edward	BIDD	02/01/2022	12/01/2024	I	N	Tre	N	A Study of Intravesical Enfortumab Vedotin for Treatment of Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)		2	0	1			
01/01/2024	12/31/2024	INT	D	Bicycle Tx Limited	Multiple	NCT06225596	UCI-23-103	Y	Uchio	Edward	BIDD	08/13/2024		II/III	N	Tre	N	A Randomized Open-Label Phase II/III Study of BT8009 Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)		5	0	0			
01/01/2024	12/31/2024	INT	D	CG Oncology Inc.	Urinary Bladder	NCT04452591	UCI-20-210	N	Uchio	Edward	BIDD	12/09/2021		III	N	Tre	N	A Phase III of CG0070 in Patients with Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)		3	0	7			
01/01/2024	12/31/2024	INT	D	CG Oncology Inc.	Urinary Bladder	NCT06111235	UCI-23-182	Y	Uchio	Edward	BIDD	07/18/2024		III	N	Tre	N	A Phase III, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)		10	1	1			
01/01/2024	12/31/2024	INT	D	Curium US LLC	Prostate	NCT06235099	UCI-23-222	Y	Uchio	Edward	BIDD	08/21/2024	10/30/2024	III	N	Dia	N	A Phase III, Multi-center, Open-label Study to Test the Diagnostic Performance of Copper Cu64 PSMA I&T PET/CT in Men with Biochemical Recurrence of Prostate Cancer		10	0	0			
01/01/2024	12/31/2024	INT	D	Curium US LLC	Prostate	NCT06235151	UCI-23-223	Y	Uchio	Edward	BIDD	08/21/2024		III	N	Dia	N	A Phase III, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection		10	3	3			
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Urinary Bladder	NCT06211764	UCI-23-202	Y	Uchio	Edward	SPT	06/12/2024		III	N	Tre	N	A Phase III, Randomized, Open-Label, Multi-Center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy		3	1	1			
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Urinary Bladder	NCT06319820	UCI-23-203	Y	Uchio	Edward	SPT	10/01/2024		III	N	Tre	N	A Phase III, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations		5	0	0			
01/01/2024	12/31/2024	INT	D	Merck	Bladder	NCT02625961	UCI-15-77	Y	Uchio	Edward	BIDD	02/10/2016	11/18/2024	II	N	Tre	N	A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy (Keynote 057)		9	0	8			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Bladder	NCT03711032	UCI-18-53	Y	Uchio	Edward	BIDD	06/26/2019	11/19/2024	III	N	Tre	N	A Phase III, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)		30	2	23			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Protara Therapeutics, Inc.	Urinary Bladder	NCT05951179	UCI-23-206	Y	Uchio	Edward	BIDD	07/16/2024		II	N	Tre	N	A Phase 2, Open-Label Study to Evaluate Safety and Anti-Tumor Activity, of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer		12	0	0			
01/01/2024	12/31/2024	INT	D	Steba Biotech	Urinary Bladder	NCT04620239	UCI-21-37	Y	Uchio	Edward	BIDD	12/15/2023		III	N	Tre	N	Multicenter Phase III Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Papeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer (ENLIGHTED Study)		5	1	2			
01/01/2024	12/31/2024	INT	D	enGene Inc.	Urinary Bladder	NCT04752722	UCI-22-69	Y	Uchio	Edward	BIDD	03/22/2024		I/II	N	Tre	N	A Phase I/II Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment		5	0	0			
01/01/2024	12/31/2024	INT	D	Actuate Therapeutics	Pancreas	NCT03678883	UCI-22-12	Y	Valerin	Jennifer Brooke	BIDD	10/16/2023	01/16/2024	I/II	N	Tre	N	Actuate 1801: Phase I/II Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignances or Solid Tumors		5	1	3			
01/01/2024	12/31/2024	INT	D	Bioatla	Multiple	NCT05808634	UCI-23-85	Y	Valerin	Jennifer Brooke	BIDD	09/19/2024		I	N	Tre	N	An Open-Label, Multicenter, Phase I Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, A Bispecific Epithelial Cell Adhesion Molecule (EPCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma		5	0	0			
01/01/2024	12/31/2024	INT	D	Dragonfly Therapeutics, Inc.	Multiple	NCT04143711	UCI-20-67	N	Valerin	Jennifer Brooke	BIDD	01/06/2021		I/II	N	Tre	N	A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications		20	0	18			
01/01/2024	12/31/2024	INT	D	Dragonfly Therapeutics, Inc.	Multiple	NCT04423029	UCI-21-40	Y	Valerin	Jennifer Brooke	BIDD	07/29/2021		I/II	N	Tre	N	A Phase I/II, First-in-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications		6	1	5			
01/01/2024	12/31/2024	INT	D	Dragonfly Therapeutics, Inc.	Multiple	NCT05597839	UCI-22-171	Y	Valerin	Jennifer Brooke	BIDD	08/30/2023		I/II	N	Tre	N	A Phase I/II, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a Monotherapy and in Combination with Nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications		15	1	4			
01/01/2024	12/31/2024	INT	D	Dragonfly Therapeutics, Inc.	Multiple	NCT06108479	UCI-23-197	Y	Valerin	Jennifer Brooke	BIDD	07/12/2024		I	N	Tre	N	A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors		5	1	1			
01/01/2024	12/31/2024	INT	D	Elicio Therapeutics, Inc.	Multiple	NCT05726864	UCI-22-75	Y	Valerin	Jennifer Brooke	BIDD	10/16/2023		I/II	N	Tre	N	First in Human Phase I/II Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and other Solid Tumors		7	5	5			
01/01/2024	12/31/2024	INT	D	Ikena Oncology, Inc.	Multiple	NCT06270082	UCI-24-82	Y	Valerin	Jennifer Brooke	SPT	12/11/2024		I	N	Tre	N	A First-In-Human Study Of IK-595, an Oral Dual MEK/RAF Inhibitor, in Patients with RAS- Or RAF-Altered Advanced Solid Tumors		10	1	1			
01/01/2024	12/31/2024	INT	D	Incyte Corporation	Multiple	NCT05909995	UCI-23-91	Y	Valerin	Jennifer Brooke	BIDD	03/26/2024	05/10/2024	I	N	Tre	N	A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors		15	1	1			
01/01/2024	12/31/2024	INT	D	Terns, Inc.	Other Hematopoietic	NCT06163430	UCI-23-167	Y	Van Etten	Richard	BIDD	02/23/2024		I	N	Tre	N	A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia		5	2	2			
01/01/2024	12/31/2024	INT	D	Amgen Inc.		NCT06333951	UCI-24-78	Y	Villalona-Calero	Miguel	BIDD	12/18/2024		I	N	Tre	N	A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination with Other Therapies in Subjects with Advanced Thoracic Tumors with Homozygous MTAP Deletion		5	0	0			
01/01/2024	12/31/2024	OBS	N	SWOG	Other Male Genital; Ovary	NCT04435756	SWOG-S1823	Y	Daneshvar	Michael	CC	10/22/2020	05/20/2024	N/A	N	Bas	N	A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors		8	1	4			
01/01/2024	12/31/2024	OBS	E	Department of Defense; UCI	Prostate		UCI-18-117	Y	Hoyt	Michael A	CC	06/01/2019		N/A	N	Sup	N	Inflammatory Processes, Emotion Regulation, and Depression in Prostate Cancer Survivors	150	80	19	56	4	37	93
01/01/2024	12/31/2024	OBS	E	Rockefeller University	Melanoma, Skin	NCT02470273	UCI-14-05	Y	Linden	Kenneth	BIDD	06/30/2015	03/19/2024	N/A	N	Dia	N	Multicenter Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)		120	0	106			
01/01/2024	12/31/2024	OBS	I	UCI	Prostate		UCI-17-07	N	Ahlering	Thomas	CC	04/04/2017		N/A	N	Hsr	N	Patient Reported Outcomes via Online Questionnaire (PROVOQ): Post-Radical Prostatectomy Outcome Assessment	1875	1875	182	940			940
01/01/2024	12/31/2024	OBS	I	UCI	Prostate		UCI-98-41	N	Ahlering	Thomas	CC	06/01/1998		N/A	N	Oth	N	Outcomes and Assessment of Prostate Cancer at UCIMC	3380	3380	184	2586			2586
01/01/2024	12/31/2024	OBS	I	UCI	Lip, Oral Cavity and Pharynx; Larynx	NCT05600842	UCI-22-132	N	Chen	Allen Min	BIDD	11/03/2022		N/A	N	Oth	N	De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx	111	111	3	20			20
01/01/2024	12/31/2024	OBS	I	UCI	Other Hematopoietic		UCI-18-127	N	Fleischman	Angela	SPT	02/15/2019		N/A	Y	Bas	N	Assessing Clonal Hematopoiesis in Myeloproliferative Neoplasm Families	350	350	15	188			188
01/01/2024	12/31/2024	OBS	I	UCI	Other Hematopoietic		UCI-23-32	N	Fleischman	Angela	CC	02/09/2023		N/A	Y	Bas	N	Dissecting the Mechanism of Interferon alfa (IFN) Response in Myeloproliferative Neoplasm (MPN)	10	10	5	13			13
01/01/2024	12/31/2024	OBS	I	UCI	Lymphoid Leukemia		UCI-19-27	Y	Fortier	Michelle	CC	12/20/2018	03/02/2023	N/A	N	Sup	N	Influence of Acculturation and Social Support on Health-Related Quality of Life in Survivors of Childhood Cancer	190	190	0	0	0	105	105
01/01/2024	12/31/2024	OBS	I	UCI	Prostate		UCI-24-60	N	Hoyt	Michael A	CC	06/24/2024		N/A	N	Sup	N	Understanding Well-Being in Asian-American Prostate Cancer Survivors	20	20	9	9			9
01/01/2024	12/31/2024	OBS	I	UCI	Myeloid and Monocytic Leukemia	NCT06229860	UCI-23-110	N	Jafari	Mahtab	CC	01/25/2024		N/A	Y	Oth	N	Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia	75	75	38	38			38
01/01/2024	12/31/2024	OBS	I	UCI	Breast		UCI-23-127	N	Kim	Jacqueline	CC	08/01/2023		N/A	Y	Dia	N	Stress & Coping in Asian Americans with Advanced/Metastatic Cancer	400	60	52	58			58

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	OBS	I	Stanford Cancer Center	Other Respiratory and Intrathoracic Organs		UCI-20-206	Y	Kuan	Edward	CC	01/29/2021		N/A	N	Hsr	N	Sinonasal Cancer Study to Evaluate Oncologic Outcomes and Quality of Life		30	2	25			
01/01/2024	12/31/2024	OBS	I	UCI	Multiple		UCI-22-14	Y	Llave	Karen	CC	11/01/2022	07/31/2024	N/A	Y	Sup	N	Transitioning Young Adult Cancer Survivors to Adult Care: Understanding the Role of Cognitive and Emotional Illness Representations of Cancer	150	150	65	65	13	71	136
01/01/2024	12/31/2024	OBS	I	UCI	Multiple		UCI-21-21	Y	Milam	Joel	CC	02/26/2021	11/30/2024	N/A	N	Hsr	N	Project Milestones: Young Adult Cancer Survivorship	2000	2000	248	1848	0	0	1848
01/01/2024	12/31/2024	OBS	I	UCI	Lung	NCT06221800	UCI-22-86	N	Nagasaka	Misako	CC	01/31/2024		N/A	Y	Bas	N	A Pilot Study to Assess the Diversity of Gut Microbiome in Metastatic Non-Small Cell Lung Cancer (NSCLC) in Correlation to Treatment Effects and Adverse Effects	82	82	4	4			4
01/01/2024	12/31/2024	OBS	I	UCSF	Ovary		UCI-21-190	Y	Tseng	Jill	CC	11/03/2023		N/A	Y	Dia	N	Assessing the Predictive Capability of Circulating Tumor DNA (ctDNA) as a Screening Tool for Ovarian Cancer		36	2	2			
01/01/2024	12/31/2024	OBS	I	California Initiative to Advance Precision Medicine (CIAPM); UCI	Prostate	NCT03770351	UCI-17-40	Y	Uchio	Edward	CC	06/19/2017		N/A	N	Hsr	N	Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response	1027	600	0	545	0	427	972
01/01/2024	12/31/2024	OBS	I	UCI	Kidney		UCI-21-131	N	Yazdanpanah	Omid	CC	03/28/2022	10/06/2024	N/A	N	Sup	N	Understanding Patient Preferences in the Treatment of Metastatic Renal Cell Carcinoma	100	100	16	55			55
01/01/2024	12/31/2024	OBS	D	Incyte Corporation	Non-Hodgkin's Lymphoma	NCT04981795	UCI-21-217	Y	Brem	Elizabeth A	CC	02/28/2024		IV	N	Oth	N	realMIND: A multicenter, observational study to characterize the safety and effectiveness of tafasitamab in combination with lenalidomide in US patients with relapsed or refractory diffuse large B-cell lymphoma with a focus on racial and ethnic minority patients		6	0	0			
01/01/2024	12/31/2024	OBS	D	Caribou Biosciences, Inc.	Multiple	NCT05332054	UCI-21-184	Y	O'Brien	Susan	CC	07/25/2022		II	N	Oth	N	An Observational Long-term Follow-up Study of Patients who Received Prior Caribou Cell Therapy		5	2	4			
01/01/2024	12/31/2024	OBS	D	Mustang	Non-Hodgkin's Lymphoma; Lymphoid Leukemia	NCT05645744	UCI-22-182	Y	O'Brien	Susan	CC	05/26/2023	05/30/2024	N/A	N	Oth	N	A Long-term Follow-up Study in Patients Previously Treated with Mustang Bio, Inc. CAR-T Cell Investigational Products		5	0	0			
01/01/2024	12/31/2024	OBS	D	Castle Biosciences Inc	Melanoma, Skin		UCI-19-135	Y	Yamamoto	Maki	CC	03/10/2021		N/A	N	Hsr	N	DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)		50	21	84			



UC Irvine Chao Family Comprehensive Cancer Center

Reporting Period: 01/01/2024 - 12/31/2024

Reporting Prepared: 02/10/2025

Data Table 4 – Clinical Research Protocols (BIDD)

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	ANC/COR	I	UCI	Other Skin		UCI-20-15	N	Gao	Ling	BIDD	01/08/2021	07/11/2024	N/A	N	Bas	N	Mechanisms of Merkel Cell Carcinoma Pathogenesis and Identification of Potential Therapies	50	50	0	0			0
01/01/2024	12/31/2024	ANC/COR	I	UCI	Breast		UCI-17-05	N	Parajuli	Ritesh	BIDD	06/05/2017		N/A	Y	Bas	N	Understanding Intratumoral Heterogeneity Using Single Cell RNA Sequencing	75	75	0	48			48
01/01/2024	12/31/2024	ANC/COR	I	UCI	Breast	NCT99999999	UCI-18-136	N	Parajuli	Ritesh	BIDD	12/01/2021		N/A	N	Bas	N	Blood Collection Protocol for the Analysis of Exosomes in Patients with Breast Cancer	100	100	15	74			74
01/01/2024	12/31/2024	ANC/COR	I	UCI	Multiple		UCI-20-101	N	Senthil	Maheswari	BIDD	04/12/2021	08/15/2024	N/A	N	Bas	N	Prospective Study to Assess the Role of Plasma Exosomal Gene Signature and PD-L1 Expression to Predict Response to Treatment in Solid Organ Malignancies	80	80	0	53			53
01/01/2024	12/31/2024	INT	N	Alliance	Lip, Oral Cavity and Pharynx	NCT05904080	ALLIANCE-A092105	Y	Attarian	Shirin	BIDD	06/06/2024		II	N	Tre	N	Randomized Phase II Study of Nivolumab and Ipilimumab with or without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy		5	0	0			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Lip, Oral Cavity and Pharynx	NCT05063552	ECOG-EA3202	Y	Attarian	Shirin	BIDD	07/11/2024		II/III	N	Tre	N	A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers		5	2	2			
01/01/2024	12/31/2024	INT	N	CHILDREN'S ONCOLOGY GROUP	Non-Hodgkin's Lymphoma	NCT04759586	COG-ANHL1931	Y	Brem	Elizabeth A	BIDD	02/07/2022		III	N	Tre	N	A Randomized Phase III Trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma			1	2			
01/01/2024	12/31/2024	INT	N	SWOG	Non-Hodgkin's Lymphoma	NCT05633615	SWOG-S2114	Y	Brem	Elizabeth A	BIDD	08/16/2023		II	N	Tre	N	A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma		6	0	0			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Melanoma, Skin	NCT02339571	ECOG-EA6141	Y	Chow	Warren A	BIDD	05/18/2021		II/III	N	Tre	N	Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma		7	0	4			
01/01/2024	12/31/2024	INT	N	ETCTN	Liver	NCT04068194	ETCTN-10276	Y	Dayyani	Farshid	BIDD	11/08/2023		I/II	N	Tre	N	A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies		5	2	3			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple	NCT04704661	ETCTN-10358	Y	Dayyani	Farshid	BIDD	05/05/2023		I	N	Tre	N	Phase I/IB Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)		3	2	2			
01/01/2024	12/31/2024	INT	N	ETCTN	Pancreas	NCT04172532	ETCTN-10366	Y	Dayyani	Farshid	BIDD	01/11/2021		I/II	N	Tre	N	A Phase I/II Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma		8	1	5			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple	NCT05372614	ETCTN-10495	Y	Dayyani	Farshid	BIDD	05/24/2023		I	N	Tre	N	Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations		7	1	1			
01/01/2024	12/31/2024	INT	N	ETCTN	Pancreas	NCT05685602	ETCTN-10522	Y	Dayyani	Farshid	BIDD	05/17/2023		I	N	Tre	N	A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma		4	0	3			
01/01/2024	12/31/2024	INT	N	Alliance	Colon; Rectum	NCT05673148	ALLIANCE-A022101	Y	Eng	Oliver	BIDD	09/21/2023		III	N	Tre	N	A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery [ERASUR]		2	0	0			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Other Skin	NCT03712605	EA6174	Y	Gao	Ling	BIDD	04/30/2019	06/06/2024	III	N	Tre	N	STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial		13	0	8			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Lung	NCT04402788	NRG-LU007	Y	Harris	Jeremy	BIDD	05/24/2022		II/III	N	Tre	N	Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial		5	1	2			
01/01/2024	12/31/2024	INT	N	SWOG	Lung	NCT04214262	SWOG-S1914	Y	Harris	Jeremy	BIDD	09/24/2021	09/06/2024	III	N	Tre	N	S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC		5	0	1			
01/01/2024	12/31/2024	INT	N	Canadian Cancer Trials Group (CCTG)	Breast	NCT03488693	CCTG-MA39	Y	Healy	Erin Heather	BIDD	05/19/2022	03/07/2024	III	N	Tre	N	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer		5	0	0			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Breast	NCT05705401	NRG-BR008	Y	Healy	Erin Heather	BIDD	07/24/2023		III	N	Tre	N	A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer" (HERO*)		5	0	0			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Stomach; Esophagus	NCT04248452	ECOG-EA2183	Y	Hong	David	BIDD	02/01/2024		III	N	Tre	N	A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)		7	0	0			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Prostate	NCT05053152	NRG-GU011	Y	Hong	David	BIDD	09/15/2022	02/04/2025	II	N	Tre	N	A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)		3	0	1			
01/01/2024	12/31/2024	INT	N	Alliance	Lymphoid Leukemia	NCT03150693	ALLIANCE-A041501	Y	Jeyakumar	Deepa	BIDD	08/24/2018		III	N	Tre	N	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL		15	0	10			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	N	Alliance	Lymphoid Leukemia	NCT03739814	ALLIANCE-A041703	Y	Jeyakumar	Deepa	BIDD	03/04/2022		II	N	Tre	N	Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative Cd22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease		5	1	2			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Lymphoid Leukemia	NCT04530565	ECOG-EA9181	Y	Jeyakumar	Deepa	BIDD	03/31/2021		III	N	Tre	N	A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults		35	2	13			
01/01/2024	12/31/2024	INT	N	ETCTN	Liver	NCT06050252	ETCTN-10608	Y	Jutric	Zeljka	BIDD	07/16/2024		II	N	Tre	N	A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma		3	2	2			
01/01/2024	12/31/2024	INT	N	Alliance	Brain and Nervous System	NCT00887146	ALLIANCE-N0577	Y	Kong	Xiao-Tang	BIDD	07/01/2019	05/24/2024	III	N	Tre	N	Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma		4	0	2			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Brain and Nervous System	NCT03180268	NRG-BN003	Y	Kong	Xiao-Tang	BIDD	10/13/2017	09/05/2024	III	N	Tre	N	Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma		6	0	5			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Brain and Nervous System	NCT04729959	NRG-BN010	Y	Kong	Xiao-Tang	BIDD	11/14/2023	11/14/2024	II	N	Tre	N	A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy In Recurrent Glioblastoma		6	1	1			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple	NCT05803382	ETCTN-10579	Y	Lee	Fa Chyi	BIDD	10/27/2023		I	N	Tre	N	Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors		4	2	2			
01/01/2024	12/31/2024	INT	N	Alliance	Multiple Myeloma	NCT06179888	ALLIANCE-A062102	Y	Lee	Lisa Xingguang	BIDD	09/16/2024		II	N	Tre	N	Randomized Phase II Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma patients		10	0	0			
01/01/2024	12/31/2024	INT	N	SWOG	Multiple Myeloma	NCT04071457	SWOG-S1803	Y	Lee	Lisa Xingguang	BIDD	05/05/2021	01/15/2025	III	N	Tre	N	Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)		25	8	18			
01/01/2024	12/31/2024	INT	N	ETCTN	Prostate	NCT04071236	ETCTN-10301	Y	Mar	Nataliya	BIDD	06/10/2021		I/II	N	Tre	N	A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)		7	5	12			
01/01/2024	12/31/2024	INT	N	ETCTN	Myeloid and Monocytic Leukemia	NCT05886049	ETCTN-10596	Y	Naqvi	Kiran	BIDD	05/16/2024		I	N	Tre	N	A Phase Ib Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged Disease		5	0	0			
01/01/2024	12/31/2024	INT	N	ETCTN	Myeloid and Monocytic Leukemia	NCT06514261	ETCTN-10630	Y	Naqvi	Kiran	BIDD	12/16/2024		I	N	Tre	N	Phase 1 Trial of Iadademstat in Combination with Venetoclax and Azacitidine in Patients with Treatment Naïve AML		7	1	1			
01/01/2024	12/31/2024	INT	N	Alliance	Breast	NCT05812807	ALLIANCE-A012103	Y	Parajuli	Ritesh	BIDD	04/23/2024		III	N	Tre	N	Optimice-PCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy		5	0	0			
01/01/2024	12/31/2024	INT	N	ETCTN	Breast	NCT04090398	ETCTN-10302	Y	Parajuli	Ritesh	BIDD	07/14/2021	05/31/2024	II	N	Tre	N	Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer		10	1	7			
01/01/2024	12/31/2024	INT	N	ETCTN	Breast	NCT05673200	ETCTN-10546	Y	Parajuli	Ritesh	BIDD	06/23/2023		I	N	Tre	N	Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer		5	1	1			
01/01/2024	12/31/2024	INT	N	ETCTN	Breast; Prostate	NCT05807126	ETCTN-10551	Y	Parajuli	Ritesh	BIDD	02/02/2024	04/29/2024	I/II	Y	Tre	N	A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in Patients with BRCA1/2-mutant Tumors		5	0	0			
01/01/2024	12/31/2024	INT	N	SWOG	Breast; Brain and Nervous System	NCT04647916	SWOG-S2007	Y	Parajuli	Ritesh	BIDD	08/06/2021	03/26/2024	II	N	Tre	N	A Phase II Trial of Sacituzumab govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases		5	0	1			
01/01/2024	12/31/2024	INT	N	SWOG	Breast	NCT06058377	SWOG-S2206	Y	Parajuli	Ritesh	BIDD	03/28/2024		III	N	Tre	N	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.		10	2	2			
01/01/2024	12/31/2024	INT	N	ETCTN	Brain and Nervous System	NCT03604978	ETCTN-10186	Y	Simon	Aaron	BIDD	07/13/2023		I/II	N	Tre	N	A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma		4	1	1			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Brain and Nervous System	NCT05438212	NRG-BN012	Y	Simon	Aaron	BIDD	10/25/2023		III	N	Tre	N	A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases		6	3	4			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Brain and Nervous System	NCT06500455	NRG-BN013	Y	Simon	Aaron	BIDD	12/11/2024		III	N	Tre	N	Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases		5	0	0			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Other Female Genital	NCT05076942	NRG-GY024	Y	Tewari	Krishnansu	BIDD	06/03/2022	11/05/2024	II	N	Tre	N	Gronigen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial		5	0	0			
01/01/2024	12/31/2024	INT	N	ECOG	Melanoma, Skin	NCT04708418	ECOG-EA6194	Y	Tran	Thuy	BIDD	09/20/2023	01/28/2025	II	N	Tre	N	Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study		5	2	3			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Anus	NCT04444921	ECOG-EA2176	Y	Valerin	Jennifer Brooke	BIDD	01/03/2022	09/23/2024	III	N	Tre	N	A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients		5	1	4			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Rectum	NCT04751370	ECOG-EA2201	Y	Valerin	Jennifer Brooke	BIDD	11/22/2021	01/15/2025	II	N	Tre	N	A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma		3	0	0			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	N	ETCTN	Pancreas	NCT05411094	ETCTN-10464	Y	Valerin	Jennifer Brooke	BIDD	01/23/2024		I	N	Tre	N	A Phase I Study of Olaparib in Combination with Durvalumab (MED14736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer		5	0	0			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple	NCT05687110	ETCTN-10528	Y	Valerin	Jennifer Brooke	BIDD	07/09/2024		I	N	Tre	N	A Phase I Study of the Polymerase Theta Inhibitor Novobiocin in BRCA-Mutant and Other DNA Damage Repair-Deficient Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	N	SWOG	Pancreas	NCT04548752	SWOG-S2001	Y	Valerin	Jennifer Brooke	BIDD	03/02/2022		II	N	Tre	N	Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations		4	0	2			
01/01/2024	12/31/2024	INT	N	SWOG	Colon; Rectum	NCT05308446	SWOG-S2107	Y	Valerin	Jennifer Brooke	BIDD	12/15/2022	10/03/2024	II	N	Tre	N	Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer		4	4	4			
01/01/2024	12/31/2024	INT	N	SWOG	Urinary Bladder	NCT03775265	SWOG-S1806	Y	Yaacoub	Ramy	BIDD	01/10/2020	03/01/2024	III	N	Tre	N	Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer		5	0	6			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Anus	NCT04166318	EA2182	Y	Zell	Jason	BIDD	07/02/2020	10/30/2024	II	N	Tre	N	A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)		3	0	1			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Colon	NCT04068103	NRG-GI005	Y	Zell	Jason	BIDD	05/07/2020	02/12/2024	II/III	N	Tre	N	Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)		5	0	2			
01/01/2024	12/31/2024	INT	E	NCI	Brain and Nervous System	NCT03173950	UCI-20-152	Y	Bota	Daniela	BIDD	03/18/2021	06/17/2024	II	N	Tre	N	Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers		10	0	7			
01/01/2024	12/31/2024	INT	E	NCI	Other Skin	NCT00764920	UCI-11-30	N	Kelly	Kristen	BIDD	11/06/2008		N/A	Y	Dia	N	Skin Imaging with Technologies in Development	750	750	13	632			632
01/01/2024	12/31/2024	INT	I	UCI	Multiple	NCT05497531	UCI-21-124	N	Abi-Jaoudeh	Nadine	BIDD	09/07/2022		N/A	Y	Dia	N	Pilot Trial Comparing Circulating Tumor DNA (ctDNA) From Immediate Draining Vein vs. Standard Peripheral Vein Sample in Patients Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers	17	17	5	14			14
01/01/2024	12/31/2024	INT	I	UCI	Multiple	NCT05283577	UCI-21-33	Y	Chan	Alexandre	BIDD	04/15/2022		N/A	N	Sup	N	Electroacupuncture for the Management of Symptom Clusters in Cancer Patients and Survivors (EAST): A Feasibility Study	58	58	19	47	4	23	70
01/01/2024	12/31/2024	INT	I	UCI	Multiple	NCT06028828	UCI-21-90	N	Ciurea	Stefan Octavian	BIDD	09/11/2023		II	Y	Tre	N	Risk-ADAPTEd Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)	48	48	12	15			15
01/01/2024	12/31/2024	INT	I	Memorial Sloan-Kettering Cancer Center	Esophagus	NCT05117931	UCI-23-78	Y	Dayyani	Farshid	BIDD	03/01/2024		II	N	Tre	N	Phase II Study of Amivantamab in EGFR or MET-Amplified Esophagogastric Cancer		3	0	0			
01/01/2024	12/31/2024	INT	I	UCI	Colon; Rectum	NCT04920032	UCI-20-43	N	Dayyani	Farshid	BIDD	08/26/2021		I	N	Tre	N	Proof of Concept Study of ctDNA Guided Change in Treatment for Refractory Minimal Residual Disease in Colon Adenocarcinomas	11	11	3	5			5
01/01/2024	12/31/2024	INT	I	University of Washington	Other Skin	NCT03271372	UCI-18-84	Y	Gao	Ling	BIDD	06/10/2019	01/22/2024	III	N	Tre	N	A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of Adjuvant Avelumab (anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases	12	12	0	9			9
01/01/2024	12/31/2024	INT	I	UCI	Soft Tissue	NCT05488366	UCI-21-03	N	Harris	Jeremy	BIDD	08/03/2022		Early Phase I	Y	Tre	N	A Pilot Study of Immunotherapy Combined with Stereotactic Ablative Radiotherapy for Patients with Advanced or Metastatic Sarcoma	6	6	3	6			6
01/01/2024	12/31/2024	INT	I	UCI	Other Skin	NCT01771718	UCI-13-13	N	Kelly	Kristen	BIDD	04/11/2012		N/A	Y	Dia	N	Pilot Study on In-Vivo Non-Invasive Skin Imaging Using Multiphoton Microscopy and Multispectral Imaging	250	250	0	202			202
01/01/2024	12/31/2024	INT	I	Eurofins-Viracor	Multiple	NCT06453460	UCI-22-188	N	Kongtim	Piyanuch	BIDD	06/27/2024		II	N	Tre	N	Prospective Evaluation of Efficacy of CMV-specific T Cell Immunity (CMV-TCIP) Directed Letemovir Prophylaxis after Allogeneic Hematopoietic Cell Transplantation	50	50	9	9			9
01/01/2024	12/31/2024	INT	I	UCI	Prostate	NCT06446648	UCI-23-137	N	Lee	David	BIDD	07/12/2024		N/A	Y	Tre	N	Impact of Intraoperative ICG Use During Robotic-Assisted Radical Prostatectomy on Functional Outcomes	400	400	16	16			16
01/01/2024	12/31/2024	INT	I	Gilead	Other Urinary; Urinary Bladder	NCT06682728	UCI-23-59	N	Mar	Nataliya	BIDD	11/15/2024		II	N	Tre	N	Adjuvant Sacituzumab Govitecan Plus Nivolumab in ctDNA Positive Patients with Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence	23	23	1	1	0	0	1
01/01/2024	12/31/2024	INT	I	Vanderbilt University Medical Center	Kidney	NCT05361720	UCI-22-130	Y	Mar	Nataliya	BIDD	02/08/2024		II	N	Tre	N	Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)		9	5	5			
01/01/2024	12/31/2024	INT	I	UCI	Multiple	NCT06693323	UCI-21-173	N	Nabar	Rupali	BIDD	12/04/2024		II	N	Tre	N	Single-Center Evaluation of the Clinical and Radiological Benefit of AHCC® in Combination with Standard of Care Treatment for HPV-Positive Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)	34	34	0	0			0
01/01/2024	12/31/2024	INT	I	On Target Laboratories, LLC.	Stomach; Small Intestine	NCT06511037	UCI-23-184	N	Senthil	Maheswari	BIDD	07/26/2024		I	Y	Tre	N	The Impact of Pafolacianine Injection for Intraoperative Imaging on Outcomes of Gastrointestinal Cancer Peritoneal Carcinomatosis - A Pilot Study	10	10	0	0			0
01/01/2024	12/31/2024	INT	I	NIH; Tobacco-Related Disease Research Program; UCI	Lip, Oral Cavity and Pharynx	NCT00540774	UCI-08-52	N	Wilder-Smith	Petra	BIDD	04/23/2003		N/A	N	Dia	N	Optical Sensor for Photodynamic Detection of Oral Pathology	2500	2500	133	1004			1004
01/01/2024	12/31/2024	INT	I	Michelson Diagnostics Ltd.; UCI	Other Skin	NCT04744935	UCI-20-13	N	Zachary	Christopher	BIDD	01/11/2021	11/15/2024	N/A	Y	Tre	N	Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma	30	30	1	29			29
01/01/2024	12/31/2024	INT	D	ABK Biomedical, Inc.	Liver	NCT05953337	UCI-23-75	Y	Abi-Jaoudeh	Nadine	BIDD	03/25/2024		N/A	N	Tre	N	Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)		15	2	2			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Impact Biotech	Pancreas	NCT05919238	UCI-23-134	Y	Abi-Jaoudeh	Nadine	BIDD	06/21/2024		I	N	Tre	N	A Phase I Trial to Evaluate Safety and Preliminary Efficacy of Endovascularly Applied Padeliporfin Vascular Targeted Photodynamic Therapy for Patients with Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma		8	0	0			
01/01/2024	12/31/2024	INT	D	Instylla, Inc.	Multiple	NCT04523350	UCI-20-84	Y	Abi-Jaoudeh	Nadine	BIDD	08/02/2021	05/01/2024	N/A	N	Tre	N	Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of the Instylla Hydrogel Embolic System (HES) Compared with Standard of Care Transcatheter Arterial Embolization (TAE) / Transcatheter Arterial Chemoembolization (cTACE) for Vascular Occlusion of Hypervascular Tumors; A Pivotal Study (INY-P-20-001)		13	0	8			
01/01/2024	12/31/2024	INT	D	Sirtex Medical Inc.	Liver	NCT04736121	UCI-21-206	Y	Abi-Jaoudeh	Nadine	BIDD	04/06/2023	08/06/2024	N/A	N	Tre	N	A Prospective, Multicenter, Open-Label Single Arm Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres Y-90 Resin Microspheres on Duration of Response (DoR) and Objective Response Rate (ORR) in Unresectable Hepatocellular Carcinoma (HCC) Patients (DOORwaY90 Study)		10	3	5			
01/01/2024	12/31/2024	INT	D	Teclison Limited	Liver; Esophagus	NCT03259867	UCI-16-94	Y	Abi-Jaoudeh	Nadine	BIDD	06/30/2017		II	N	Tre	N	Phase IIA Single-Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody		40	7	29			
01/01/2024	12/31/2024	INT	D	Teclison Limited	Liver	NCT03145558	UCI-17-92	Y	Abi-Jaoudeh	Nadine	BIDD	12/04/2017		II	N	Tre	N	TATE versus TACE, an Open-Label Randomized Study Comparing TransArterial Tirapazamine Embolization versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma		15	0	4			
01/01/2024	12/31/2024	INT	D	Teclison Limited	Multiple	NCT04701476	UCI-21-39	N	Abi-Jaoudeh	Nadine	BIDD	08/26/2021		II	N	Tre	N	An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer with a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab		30	3	20			
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Lung	NCT06532032	UCI-22-147-3	Y	Arter	Zhaohui Ann	BIDD	09/18/2024		I/II	N	Tre	N	A Phase I/II Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer		6	0	0			
01/01/2024	12/31/2024	INT	D	Boehringer Ingelheim	Brain and Nervous System	NCT05916313	UCI-23-67	Y	Bota	Daniela	BIDD	12/13/2023		I	N	Tre	N	A Phase Ib Open-Label, Multi-Center, Dose Escalation Trial of BI 764532 Given as Monotherapy Administered by Repeated Intravenous Infusions in Patients with Glioma Expressing DLL3		5	1	1			
01/01/2024	12/31/2024	INT	D	CNS Pharmaceuticals	Brain and Nervous System	NCT04762069	UCI-21-18	N	Bota	Daniela	BIDD	10/27/2021	01/16/2024	II	N	Tre	N	A Multicenter, Open Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy		10	0	8			
01/01/2024	12/31/2024	INT	D	Nerviano	Brain and Nervous System	NCT04910022	UCI-24-27	Y	Bota	Daniela	BIDD	12/03/2024		I/II	N	Tre	N	A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma		5	0	0			
01/01/2024	12/31/2024	INT	D	VBI Vaccines Inc.	Brain and Nervous System	NCT03382977	UCI-22-58	Y	Bota	Daniela	BIDD	12/02/2022	10/31/2024	I/II	N	Tre	N	A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects		6	3	3			
01/01/2024	12/31/2024	INT	D	Kite Pharma	Non-Hodgkin's Lymphoma	NCT05371093	UCI-22-01	Y	Brem	Elizabeth A	BIDD	03/30/2023	04/22/2024	III	N	Tre	N	A Phase III Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucef Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma		5	0	0			
01/01/2024	12/31/2024	INT	D	Regeneron Pharmaceuticals, Inc	Non-Hodgkin's Lymphoma	NCT06091254	UCI-23-17	Y	Brem	Elizabeth A	BIDD	03/20/2024		III	N	Tre	N	A Phase III, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Investigator's Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)		5	0	0			
01/01/2024	12/31/2024	INT	D	Regeneron Pharmaceuticals, Inc	Non-Hodgkin's Lymphoma	NCT06091865	UCI-23-19	Y	Brem	Elizabeth A	BIDD	03/01/2024		III	N	Tre	N	A Phase III, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN 1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with CHOP (O-CHOP) versus Rituximab in Combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)		5	0	0			
01/01/2024	12/31/2024	INT	D	Bristol-Myers Squibb	Melanoma, Skin	NCT05625399	UCI-22-101	Y	Chow	Warren A	BIDD	04/24/2023	09/26/2024	III	N	Tre	N	A Phase III, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-Dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-Dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma		6	7	10			
01/01/2024	12/31/2024	INT	D	Eisai Inc.	Multiple	NCT05091346	UCI-22-213	Y	Chow	Warren A	BIDD	07/05/2023	03/01/2024	I/II	N	Tre	N	An Open-Label, Multicenter, Phase Ib/II Study of E7386 in Combination with Pembrolizumab in Previously Treated Subjects with Selected Solid Tumors		7	0	0			
01/01/2024	12/31/2024	INT	D	IGM Biosciences, Inc	Multiple	NCT04553692	UCI-21-208	Y	Chow	Warren A	BIDD	11/10/2022	11/04/2024	I	N	Tre	N	An Open-label, Multicenter, Phase Ia/Ib Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed, Refractory, or Newly Diagnosed Cancers		15	5	9			
01/01/2024	12/31/2024	INT	D	Lyvgen BioPharma Holdings Limited	Multiple	NCT04130542	UCI-21-38	Y	Chow	Warren A	BIDD	02/17/2022	01/15/2024	I	N	Tre	N	An Open Label, First in Human (FIH), Phase I Trial of LVGN6051 as Single Agent and in Combination with Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy		5	0	5			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	TopAlliance Biosciences, Inc.	Multiple	NCT04137900	UCI-21-247	Y	Chow	Warren A	BIDD	04/21/2023	01/29/2024	I	N	Tre	N	A First-in-Human, Multicenter, Open-Label, Phase I Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies Including Lymphoma		3	0	1			
01/01/2024	12/31/2024	INT	D	Bristol-Myers Squibb	Multiple Myeloma	NCT06045806	UCI-23-70	Y	Ciurea	Stefan Octavian	BIDD	05/23/2024	09/26/2024	III	N	Tre	N	A Randomized, Open-Label, Phase III Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMA-9)		6	0	0			
01/01/2024	12/31/2024	INT	D	Cartesian Therapeutics	Multiple Myeloma	NCT06304636	UCI-24-02	Y	Ciurea	Stefan Octavian	BIDD	08/20/2024		I	N	Tre	N	Descartes-15 for Patients with Relapsed/Refractory Multiple Myeloma		5	3	3			
01/01/2024	12/31/2024	INT	D	CytoAgents, Inc.	Non-Hodgkin's Lymphoma	NCT05905328	UCI-23-193	Y	Ciurea	Stefan Octavian	BIDD	07/26/2024		I/II	N	Tre	N	Phase IB/IIA Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients With Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy		5	1	1			
01/01/2024	12/31/2024	INT	D	ImmPACT Bio	Non-Hodgkin's Lymphoma	NCT05826535	UCI-23-114	Y	Ciurea	Stefan Octavian	BIDD	04/26/2024		I/II	N	Tre	N	Phase I/II Multi-Center Study Evaluating the Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma		7	2	2			
01/01/2024	12/31/2024	INT	D	Carna Biosciences, Inc.	Non-Hodgkin's Lymphoma; Lymphoid Leukemia	NCT05602363	UCI-22-134	Y	Coombs	Catherine	BIDD	11/21/2023		I	N	Tre	N	A Phase IB Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma		9	2	2			
01/01/2024	12/31/2024	INT	D	AbbVie	Liver	NCT06109272	UCI-23-104	Y	Dayyani	Farshid	BIDD	03/20/2024		II/III	N	Tre	N	A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment-LIVIGNO-2		7	3	3			
01/01/2024	12/31/2024	INT	D	AbbVie	Liver	NCT05822752	UCI-23-58	Y	Dayyani	Farshid	BIDD	11/14/2023	07/31/2024	II	N	Tre	N	A Phase II, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC-LIVIGNO-1		10	0	0			
01/01/2024	12/31/2024	INT	D	Amgen Inc.	Stomach; Esophagus	NCT05111626	UCI-21-193	Y	Dayyani	Farshid	BIDD	08/12/2022	10/01/2024	I	N	Tre	N	A Phase IB/III Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects with Previously Untreated Advanced Gastric and Gastroesophageal Cancer with FGFR2b Overexpression		12	0	1			
01/01/2024	12/31/2024	INT	D	Amgen Inc.	Multiple	NCT05325866	UCI-22-38	Y	Dayyani	Farshid	BIDD	03/27/2023		I/II	N	Tre	N	A Phase Ib/II, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301)		6	0	1			
01/01/2024	12/31/2024	INT	D	Arcus Biosciences, Inc.	Stomach; Esophagus	NCT05568095	UCI-22-76	Y	Dayyani	Farshid	BIDD	05/15/2023	04/26/2024	III	N	Tre	N	A Randomized, Open-Label, Multicenter Phase III Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma		10	0	1			
01/01/2024	12/31/2024	INT	D	Astellas	Multiple	NCT05365581	UCI-22-51	Y	Dayyani	Farshid	BIDD	03/07/2024		I	N	Tre	N	A Phase I/Ib Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression		20	16	16			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Multiple	NCT04999969	UCI-21-156	Y	Dayyani	Farshid	BIDD	12/16/2022	07/30/2024	II	N	Tre	N	A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumors		10	0	2			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Pancreas; Liver	NCT05775159	UCI-22-211	Y	Dayyani	Farshid	BIDD	10/11/2023		II	N	Tre	N	Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)		8	2	3			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Pancreas; Liver	NCT05771480	UCI-22-212	Y	Dayyani	Farshid	BIDD	12/12/2023		III	N	Tre	N	A Phase IIlb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers		8	4	5			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Multiple	NCT06219941	UCI-23-200	Y	Dayyani	Farshid	BIDD	07/24/2024		II	N	Tre	N	A Phase II, Open-Label, Multi-Centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2.(CLARITY-PanTumour01)		10	4	4			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Liver	NCT06109779	UCI-23-99	Y	Dayyani	Farshid	BIDD	09/25/2024		III	N	Tre	N	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rlivegostomig in Combination With Chemotherapy as Adjuvant Treatment after Resection of Biliary Tract Cancer with Curative Intent		8	0	0			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Boehringer Ingelheim	Multiple	NCT04752215	UCI-22-221	Y	Dayyani	Farshid	BIDD	08/15/2023	10/02/2024	I	N	Tre	N	A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Bi 765049 and Bi 765049 + Ezabenlimab Administered by Repeated Intravenous Infusions in Patients with Malignant Solid Tumors Expressing B7 H6		12	2	3			
01/01/2024	12/31/2024	INT	D	Boehringer Ingelheim	Multiple	NCT06324357	UCI-24-49	Y	Dayyani	Farshid	BIDD	10/22/2024		I	N	Tre	N	Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-Label, Multicenter Trial of Oral Zongertinib (Bi 1810631) in Combination with Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination with Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients with Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC)		10	0	0			
01/01/2024	12/31/2024	INT	D	Bristol-Myers Squibb	Multiple	NCT03994601	UCI-23-101	Y	Dayyani	Farshid	BIDD	01/23/2024	03/01/2024	I/II	N	Tre	N	A Phase I/II First-in-Human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors		10	0	0			
01/01/2024	12/31/2024	INT	D	Bristol-Myers Squibb	Multiple	NCT05543629	UCI-23-35	Y	Dayyani	Farshid	BIDD	10/30/2023	02/27/2024	I/II	N	Tre	N	A Phase Ib/II Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer		10	1	1			
01/01/2024	12/31/2024	INT	D	Cosmo Technologies, Ltd.	Multiple	NCT03863145	UCI-22-26	Y	Dayyani	Farshid	BIDD	11/17/2022		I	N	Tre	N	Open-Label, Multicenter, Phase I Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 with Dose Expansion Phase, in Subjects with Advanced Solid Tumors		6	3	9			
01/01/2024	12/31/2024	INT	D	Erasca	Multiple	NCT05039177	UCI-21-110	Y	Dayyani	Farshid	BIDD	03/23/2022	03/05/2024	I/II	N	Tre	N	Phase Ib/II Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)		15	0	6			
01/01/2024	12/31/2024	INT	D	Exelixis, Inc.	Colon; Rectum	NCT05425940	UCI-22-131	Y	Dayyani	Farshid	BIDD	09/21/2023	05/21/2024	III	N	Tre	N	A Randomized Open-Label Phase III Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer		10	4	8			
01/01/2024	12/31/2024	INT	D	Frontier Medicine	Multiple	NCT06244771	UCI-24-65	Y	Dayyani	Farshid	BIDD	11/04/2024		I/II	N	Tre	N	An Open-Label, Phase I/II Dose-Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants with KRASG12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	Genentech, Inc.	Liver	NCT06096779	UCI-23-86	Y	Dayyani	Farshid	BIDD	03/22/2024		II	N	Tre	N	A Phase II, Open-label, Multi-Cohort, Multicenter Study in Patients With Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis		10	0	0			
01/01/2024	12/31/2024	INT	D	I-MAB Biopharma	Multiple	NCT04900818	UCI-21-10	N	Dayyani	Farshid	BIDD	12/13/2021		I	N	Tre	N	A Phase I Dose-Escalation and Dose Expansion Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors		10	7	14			
01/01/2024	12/31/2024	INT	D	Seagen Inc	Multiple	NCT06157892	UCI-23-109	Y	Dayyani	Farshid	BIDD	04/25/2024		I/II	N	Tre	N	A Phase Ib/II Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors		10	2	2			
01/01/2024	12/31/2024	INT	D	Shanghai Miracogen Inc.	Multiple	NCT04843709	UCI-21-146	Y	Dayyani	Farshid	BIDD	04/07/2022		I/II	N	Tre	N	An Open-Label, Multi-Center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors		11	1	5			
01/01/2024	12/31/2024	INT	D	Tachyon Therapeutics, Inc	Multiple	NCT05076552	UCI-22-37	Y	Dayyani	Farshid	BIDD	08/14/2023	07/12/2024	I	N	Tre	N	A Phase Ia/Ib Open-Label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Patients with Advanced or Metastatic Solid Tumors		10	3	6			
01/01/2024	12/31/2024	INT	D	Tvardi Therapeutics, Inc	Liver	NCT05440708	UCI-22-106	Y	Dayyani	Farshid	BIDD	06/23/2023		I/II	N	Tre	N	A Phase Ib/II Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma		10	4	7			
01/01/2024	12/31/2024	INT	D	Genentech, Inc.	Melanoma, Skin	NCT04835805	UCI-20-169	Y	Fruehauf	John P	BIDD	12/17/2021	02/01/2024	I	N	Tre	N	A Phase IB, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination with Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients with NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy		5	0	0			
01/01/2024	12/31/2024	INT	D	AbbVie	Myeloid and Monocytic Leukemia	NCT04086264	UCI-19-138	Y	Jeyakumar	Deepa	BIDD	11/18/2020	07/11/2024	I/II	N	Tre	N	A Phase Ib/II Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia		5	0	2			
01/01/2024	12/31/2024	INT	D	Amgen Inc.	Lymphoid Leukemia	NCT04506086	UCI-20-34	Y	Jeyakumar	Deepa	BIDD	05/04/2021	09/12/2024	IV	N	Tre	N	A Phase IV, Multi-Center Open-Label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects with Minimal Residual Disease (MRD) of B-Precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission		5	0	2			
01/01/2024	12/31/2024	INT	D	Amgen Inc.	Lymphoid Leukemia	NCT04994717	UCI-21-98	Y	Jeyakumar	Deepa	BIDD	08/15/2022	08/02/2024	III	N	Tre	N	Phase III Randomized, Controlled Study of Blinatumomab Alternating with Low-Intensity Chemotherapy Versus Standard of Care for Older Adults with Newly Diagnosed Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia with Safety Run-In		6	1	6			
01/01/2024	12/31/2024	INT	D	Aptose Biosciences Inc.	Myeloid and Monocytic Leukemia	NCT03850574	UCI-22-81	Y	Jeyakumar	Deepa	BIDD	08/31/2023		I/II	N	Tre	N	A Phase I/II, Open-Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)		6	0	0			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Astellas Pharma Global Development, Inc.	Myeloid and Monocytic Leukemia	NCT05520567	UCI-21-216	Y	Jeyakumar	Deepa	BIDD	06/28/2023		I/II	N	Tre	N	A Phase I/II, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy		5	1	2			
01/01/2024	12/31/2024	INT	D	Biomea Fusion, Inc.	Multiple	NCT05153330	UCI-22-24	Y	Jeyakumar	Deepa	BIDD	02/28/2023	01/15/2025	I	N	Tre	N	A Phase I First-in-Human Dose-Escalation and Dose-Escalation and Dose-Expansion Study of BMF-219, an Oral, Covalent, Menin Inhibitor, in Adult Patients with Acute Leukemia (AL), Diffuse Large B-Cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)		5	0	1			
01/01/2024	12/31/2024	INT	D	Delta-Fly Pharma, Inc.	Myeloid and Monocytic Leukemia	NCT03926624	UCI-19-93	Y	Jeyakumar	Deepa	BIDD	04/16/2020		III	N	Tre	N	Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage		12	0	11			
01/01/2024	12/31/2024	INT	D	Gilead Sciences, Inc.	Myeloid and Monocytic Leukemia	NCT05079230	UCI-21-180	Y	Jeyakumar	Deepa	BIDD	05/24/2023	02/06/2024	III	N	Tre	N	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy		10	0	0			
01/01/2024	12/31/2024	INT	D	GluBio Therapeutics Inc.	Myeloid and Monocytic Leukemia; Other Hematopoietic	NCT06146257	UCI-23-113	Y	Jeyakumar	Deepa	BIDD	12/29/2023		I	N	Tre	N	A First-in-human (FIH), Phase I, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes		7	1	1			
01/01/2024	12/31/2024	INT	D	Hutchison MediPharma Limited	Multiple	NCT04764474	UCI-21-144	Y	Jeyakumar	Deepa	BIDD	11/04/2022	05/21/2024	I	N	Tre	N	A Phase I, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignances with Isocitrate Dehydrogenase (IDH) Mutations		5	0	0			
01/01/2024	12/31/2024	INT	D	Immune-Onc Therapeutics, Inc.	Myeloid and Monocytic Leukemia	NCT04372433	UCI-20-51	Y	Jeyakumar	Deepa	BIDD	12/09/2020	04/30/2024	I	N	Tre	N	A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients		5	0	4			
01/01/2024	12/31/2024	INT	D	PureTech Health, LLC	Myeloid and Monocytic Leukemia; Other Hematopoietic	NCT05829226	UCI-22-151	Y	Jeyakumar	Deepa	BIDD	03/07/2023		I	N	Tre	N	A Phase I, Open-Label, Multi-Center Study of the Safety, Pharmacokinetics (PK), and Anti-Tumor Activity of LYT-200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High-Risk Myelodysplastic Syndrome (MDS)		8	2	5			
01/01/2024	12/31/2024	INT	D	SELLAS Life Sciences Group	Myeloid and Monocytic Leukemia	NCT04229979	UCI-22-183	Y	Jeyakumar	Deepa	BIDD	11/09/2023	03/29/2024	III	N	Tre	N	A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy		5	0	0			
01/01/2024	12/31/2024	INT	D	Arvinas, Inc.	Prostate	NCT03888612	UCI-20-138	Y	Kalebasty	Arash Rezazadeh	BIDD	06/21/2021	03/07/2024	I/II	N	Tre	N	A Phase I/II, Open-Label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients with Metastatic Castration Resistant Prostate Cancer		10	0	7			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Urinary Bladder	NCT05562830	UCI-22-128	Y	Kalebasty	Arash Rezazadeh	BIDD	01/23/2023		I/II	N	Tre	N	A Phase I/II Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A		3	0	0			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Urinary Bladder	NCT05845814	UCI-22-129	Y	Kalebasty	Arash Rezazadeh	BIDD	10/06/2023	11/19/2024	I/II	N	Tre	N	A Phase I/II Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B		6	0	0			
01/01/2024	12/31/2024	INT	D	Navire Pharma Inc.	Multiple	NCT04528836	UCI-20-179	Y	Kalebasty	Arash Rezazadeh	BIDD	07/07/2022	02/21/2024	I	N	Tre	N	A Phase I/II First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients with Advanced Solid Tumors		10	0	1			
01/01/2024	12/31/2024	INT	D	Merck	Lung	NCT06077760	UCI-23-169	Y	Keshava	Hari	BIDD	07/23/2024		III	N	Tre	N	A Phase III, Randomized, Double-blind, Placebo- and Active-Comparator Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer		10	0	0			
01/01/2024	12/31/2024	INT	D	NovoCure Ltd.	Brain and Nervous System	NCT04471844	UCI-20-65	Y	Kong	Xiao-Tang	BIDD	01/20/2022	01/03/2024	N/A	N	Tre	N	EF-32: Randomized, Open-Label Study of Tumor Treating Fields (Optune®, 200kHz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma		15	0	6			
01/01/2024	12/31/2024	INT	D	NuvOx Pharma	Brain and Nervous System	NCT03862430	UCI-23-198	Y	Kong	Xiao-Tang	BIDD	05/02/2024		II	N	Tre	N	A Phase II Double-blind, Randomized, Prospective, Placebo Controlled Study of Nano2 TM Combined with Radiation and Temozolomide in Patients with Newly-Diagnosed Glioblastoma Multiforme: RESTORE		6	1	1			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Bexion Pharmaceuticals, Inc.	Colon; Rectum	NCT05322590	UCI-22-07	Y	Lee	Fa Chyi	BIDD	01/24/2023	10/23/2024	I/II	N	Tre	N	A Phase Ib/II Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma		8	4	6			
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Multiple Myeloma	NCT05572515	UCI-22-190	Y	Lee	Lisa Xingguang	BIDD	07/10/2023		III	N	Tre	N	A Phase III Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (Pv4) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide		6	1	3			
01/01/2024	12/31/2024	INT	D	Regeneron Pharmaceuticals, Inc	Multiple Myeloma	NCT05828511	UCI-23-158	Y	Lee	Lisa Xingguang	BIDD	03/29/2024		I/II	N	Tre	N	Phase I/II Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma		6	1	1			
01/01/2024	12/31/2024	INT	D	Acrivon Therapeutics, Inc.	Multiple	NCT05548296	GOG-3082	Y	Mar	Nataliya	BIDD	09/18/2023	12/03/2024	I/II	N	Tre	N	A Phase Ib/II Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status		10	3	4			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Urinary Bladder	NCT04960709	UCI-21-09	N	Mar	Nataliya	BIDD	12/17/2021	12/31/2024	III	N	Tre	N	A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)		8	6	7			
01/01/2024	12/31/2024	INT	D	F. Hoffmann-La Roche Ltd	Kidney	NCT05805501	UCI-22-53	Y	Mar	Nataliya	BIDD	06/22/2023	09/25/2024	II	N	Tre	N	A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma		10	2	5			
01/01/2024	12/31/2024	INT	D	Seagen Inc	Urinary Bladder	NCT04879329	UCI-22-39	Y	Mar	Nataliya	BIDD	11/08/2022		II	N	Tre	N	A Phase II Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2		5	4	6			
01/01/2024	12/31/2024	INT	D	DUALITYBIO Inc	Breast	NCT06018337	UCI-23-177	Y	Mehta	Rita	BIDD	08/22/2024		III	N	Tre	N	A Phase III, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)		5	1	1			
01/01/2024	12/31/2024	INT	D	Poseida Therapeutics, Inc.	Multiple	NCT05239143	UCI-23-07	Y	Mehta	Rita	BIDD	04/01/2024		I	N	Tre	N	A Phase I Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Lip, Oral Cavity and Pharynx	NCT06129864	UCI-23-190	Y	Nabar	Rupali	BIDD	06/29/2024		III	N	Tre	N	A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MED15752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy		5	0	0			
01/01/2024	12/31/2024	INT	D	Takeda	Multiple	NCT04420884	UCI-23-228	Y	Nabar	Rupali	BIDD	11/05/2024		I/II	N	Tre	N	An Open-label, Dose Escalation, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Lung	NCT04686305	UCI-21-187	Y	Nagasaka	Misako	BIDD	04/18/2022		I	N	Tre	N	A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)		5	1	2			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Lung	NCT05048797	UCI-21-234	Y	Nagasaka	Misako	BIDD	10/21/2022		III	N	Tre	N	An Open-label, Randomized, Multicenter, Phase III Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)		10	0	1			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Lung	NCT05687266	UCI-21-242	Y	Nagasaka	Misako	BIDD	12/05/2023	08/29/2024	III	N	Tre	N	A Phase III, Randomised, Open-Label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)		6	0	0			
01/01/2024	12/31/2024	INT	D	BeiGene, Ltd.	Multiple	NCT03744468	UCI-21-62	Y	Nagasaka	Misako	BIDD	07/06/2022	05/22/2024	I/II	N	Tre	N	Phase I/II Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors		5	0	1			
01/01/2024	12/31/2024	INT	D	Bicycle Tx Limited	Multiple	NCT04180371	UCI-21-13	Y	Nagasaka	Misako	BIDD	05/02/2022	12/03/2024	I/II	N	Tre	N	Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression		3	0	2			



Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Bioatla	Lung	NCT03504488	UCI-21-161	Y	Nagasaka	Misako	BIDD	11/14/2022	03/07/2024	I/II	N	Tre	N	A Phase I/II Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	Blueprint Medicines	Lung	NCT04862780	UCI-21-27	N	Nagasaka	Misako	BIDD	12/17/2021	01/08/2024	I/II	N	Tre	N	A Phase I/II Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer		10	0	6			
01/01/2024	12/31/2024	INT	D	Boehringer Ingelheim	Multiple	NCT04886804	UCI-23-66	Y	Nagasaka	Misako	BIDD	02/29/2024		I	N	Tre	N	Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (B11810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations		5	2	2			
01/01/2024	12/31/2024	INT	D	CJ Bioscience, Inc.	Lung	NCT05877430	UCI-23-148	Y	Nagasaka	Misako	BIDD	07/30/2024		I/II	N	Tre	N	Phase I/II Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination with Pembrolizumab in Subjects with Selected Types of Advanced or Metastatic Cancer		6	1	1			
01/01/2024	12/31/2024	INT	D	D3 Bio	Multiple	NCT05410145	UCI-22-30	Y	Nagasaka	Misako	BIDD	10/31/2023		I/II	N	Tre	N	A Phase 1/2, Open-label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation		3	0	0			
01/01/2024	12/31/2024	INT	D	J INTS BIO	Lung	NCT05394831	UCI-22-121	Y	Nagasaka	Misako	BIDD	10/02/2023		I/II	N	Tre	N	A Phase I/II, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer		12	1	1			
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Multiple	NCT05498428	UCI-22-217	Y	Nagasaka	Misako	BIDD	10/04/2023		II	N	Tre	N	A Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer		15	3	5			
01/01/2024	12/31/2024	INT	D	Loxo Oncology, Inc.	Multiple	NCT03157128	UCI-18-21	Y	Nagasaka	Misako	BIDD	12/04/2018	02/01/2024	I/II	N	Tre	N	A Phase I/II Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001).		9	0	7			
01/01/2024	12/31/2024	INT	D	Loxo Oncology, Inc.	Multiple	NCT04956640	UCI-21-53	Y	Nagasaka	Misako	BIDD	12/07/2021		I/II	N	Tre	N	A Phase I/2 Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors		8	1	7			
01/01/2024	12/31/2024	INT	D	Nuvalent, Inc.	Multiple	NCT05384626	UCI-21-241	Y	Nagasaka	Misako	BIDD	10/04/2022		I/II	N	Tre	N	A Phase I/II Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)		10	9	17			
01/01/2024	12/31/2024	INT	D	Nuvalent, Inc.	Multiple	NCT05118789	UCI-21-47	Y	Nagasaka	Misako	BIDD	11/19/2021		I/II	N	Tre	N	A Phase I/II Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)		16	3	9			
01/01/2024	12/31/2024	INT	D	Summit Therapeutics Sub, Inc	Lung	NCT06396065	UCI-23-95	Y	Nagasaka	Misako	BIDD	11/01/2023	09/10/2024	III	N	Tre	N	A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)		5	2	3			
01/01/2024	12/31/2024	INT	D	Turning Point Therapeutics	Multiple	NCT03093116	UCI-16-79	Y	Nagasaka	Misako	BIDD	03/06/2017		I/II	N	Tre	N	A Phase I/II, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)		21	1	17			
01/01/2024	12/31/2024	INT	D	Delta-Fly Pharma, Inc.	Myeloid and Monocytic Leukemia	NCT06382168	UCI-24-48	Y	Naqvi	Kiran	BIDD	08/06/2024		I/II	N	Tre	N	Phase I/II Study of DFP-10917 in Combination with Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia		5	2	2			
01/01/2024	12/31/2024	INT	D	Kura Oncology	Myeloid and Monocytic Leukemia	NCT06001788	UCI-23-154	Y	Naqvi	Kiran	BIDD	05/21/2024		I	N	Tre	N	Phase I Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed/Refractory Acute Myeloid Leukemia		5	0	0			
01/01/2024	12/31/2024	INT	D	Kura Oncology	Myeloid and Monocytic Leukemia	NCT05735184	UCI-23-44	Y	Naqvi	Kiran	BIDD	03/04/2024		I	N	Tre	N	Phase I Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia		10	2	2			
01/01/2024	12/31/2024	INT	D	Rigel Pharmaceuticals, Inc.	Myeloid and Monocytic Leukemia	NCT05308264	UCI-21-239	Y	Naqvi	Kiran	BIDD	02/01/2023		I	N	Tre	N	An Open-Label, Phase IB Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndrome (LR MDS) Who are Relapsed/Refractory/Resistant to Prior Therapies		5	1	1			
01/01/2024	12/31/2024	INT	D	Caribou Biosciences, Inc.	Non-Hodgkin's Lymphoma	NCT04637763	UCI-20-126	Y	O'Brien	Susan	BIDD	03/23/2021		I	N	Tre	N	A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER)		5	0	5			
01/01/2024	12/31/2024	INT	D	Mustang	Non-Hodgkin's Lymphoma; Lymphoid Leukemia	NCT05360238	UCI-21-19	Y	O'Brien	Susan	BIDD	07/08/2022	05/16/2024	I/II	N	Tre	N	A Phase I/II, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia ((SHELBY-1)		5	0	1			
01/01/2024	12/31/2024	INT	D	Nurix Therapeutics, Inc.	Non-Hodgkin's Lymphoma; Lymphoid Leukemia	NCT04830137	UCI-20-198	Y	O'Brien	Susan	BIDD	08/09/2021	06/05/2024	I	N	Tre	N	A Phase I, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degradar, in Adults with Relapsed/Refractory B-cell Malignancies		3	0	1			
01/01/2024	12/31/2024	INT	D	Genentech, Inc.	Colon; Rectum	NCT04449874	UCI-20-141	Y	Ou	Sai-Hong	BIDD	10/13/2021	03/07/2024	I	N	Tre	N	A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and In Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors with a KRAS G12c Mutation		20	0	3			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Lung	NCT04077463	UCI-20-119	Y	Ou	Sai-Hong	BIDD	03/19/2021	07/15/2024	I	N	Tre	N	An Open-Label Phase I/Ib Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations with JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants with Advanced Non-Small Cell Lung Cancer		15	0	11			
01/01/2024	12/31/2024	INT	D	Merus N.V.	Multiple	NCT04868877	UCI-20-195	Y	Ou	Sai-Hong	BIDD	03/31/2021		I/II	N	Tre	N	Phase I/II Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-C-MET Bispecific Antibody, in Patients with Advanced NSCLC and Other Solid Tumors		10	0	12			
01/01/2024	12/31/2024	INT	D	Mirati Therapeutics, Inc.	Multiple	NCT03785249	UCI-18-78	Y	Ou	Sai-Hong	BIDD	01/15/2019		I/II	N	Tre	N	A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation		40	0	24			
01/01/2024	12/31/2024	INT	D	Regeneron Pharmaceuticals, Inc	Lung	NCT04982224	UCI-21-105	Y	Ou	Sai-Hong	BIDD	09/15/2022	04/11/2024	I/II	N	Tre	N	A Phase I/II Study of REGN5093-M114 (METXMET Antibody-Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer		5	0	0			
01/01/2024	12/31/2024	INT	D	Revolution Medicines	Multiple	NCT05379985	UCI-22-87	Y	Ou	Sai-Hong	BIDD	09/08/2023		I	N	Tre	N	A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS		20	14	17			
01/01/2024	12/31/2024	INT	D	Revolution Medicines	Multiple	NCT05462717	UCI-22-88	Y	Ou	Sai-Hong	BIDD	01/10/2023		I	N	Tre	N	Phase I/IB, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors		25	1	4			
01/01/2024	12/31/2024	INT	D	Revolution Medicines	Multiple	NCT06128551	UCI-23-116	Y	Ou	Sai-Hong	BIDD	11/12/2024		I	N	Tre	N	Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C-Mutated Solid Tumors		10	0	0			
01/01/2024	12/31/2024	INT	D	SystImmune, Inc.	Lung	NCT05983432	UCI-23-178	Y	Ou	Sai-Hong	BIDD	04/04/2024		I	N	Tre	N	A Phase i Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer and other Solid Tumors.		10	2	2			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Breast	NCT05113251	UCI-21-185	Y	Parajuli	Ritesh	BIDD	04/17/2023	03/29/2024	III	N	Tre	N	A Phase III Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)		5	0	4			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Breast	NCT05629585	UCI-22-141	Y	Parajuli	Ritesh	BIDD	06/13/2023	12/31/2024	III	N	Tre	N	A Phase III Open-label, Randomized Study of Datopotamab Deruxtecan (Dato DXd) with or without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple-negative Breast Cancer who have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (D926XC00001; TROPION-Breast03)		5	1	1			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Breast	NCT06112379	UCI-23-124	Y	Parajuli	Ritesh	BIDD	07/25/2024		III	N	Tre	N	A Phase III, Open-Label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer (D926QC00001; TROPION-Breast04)		5	0	0			
01/01/2024	12/31/2024	INT	D	Gilead Sciences, Inc.	Breast	NCT05382286	UCI-21-212	Y	Parajuli	Ritesh	BIDD	02/28/2023	07/31/2024	III	N	Tre	N	A Randomized, Open-Label, Phase III Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1		3	0	0			
01/01/2024	12/31/2024	INT	D	Mersana Therapeutics, Inc.	Multiple	NCT05377996	UCI-22-09	Y	Parajuli	Ritesh	BIDD	12/28/2022		I	N	Tre	N	A Phase Ib, First-In-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors		5	2	3			
01/01/2024	12/31/2024	INT	D	Orinove, Inc.	Multiple	NCT03950570	UCI-21-82	Y	Parajuli	Ritesh	BIDD	06/07/2022	06/06/2024	I/II	N	Tre	N	A Phase I/II, Open Label, Dose-Escalation Study of Oral ORIN1001 With and Without Chemotherapy in the Treatment of Subjects with Solid Tumors		5	0	1			
01/01/2024	12/31/2024	INT	D	Turnstone Biologics, Corp	Multiple	NCT05576077	UCI-22-156	Y	Parajuli	Ritesh	BIDD	12/20/2023	01/16/2025	I	N	Tre	N	A Phase Ib Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients with Advanced Solid Tumor Malignancies (STARLING)		5	0	0			
01/01/2024	12/31/2024	INT	D	Zymeworks	Multiple	NCT05027139	UCI-21-57	Y	Parajuli	Ritesh	BIDD	12/14/2021	03/27/2024	I/II	N	Tre	N	A Phase Ib/II, Two-Part, Open-Label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination with ALX148 in Advanced HER2-Expressing Cancer		5	0	4			
01/01/2024	12/31/2024	INT	D	Affimed GmbH	Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma	NCT05883449	UCI-23-80	Y	Pinter-Brown	Lauren C	BIDD	02/13/2024		II	N	Tre	N	Phase II, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma		6	0	0			
01/01/2024	12/31/2024	INT	D	F. Hoffmann-La Roche Ltd	Non-Hodgkin's Lymphoma	NCT05364424	UCI-21-225	Y	Pinter-Brown	Lauren C	BIDD	01/27/2023	10/03/2024	I	N	Tre	N	A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients with Relapsed/Refractory Transplant Eligible Diffuse B-Cell Lymphoma		6	3	10			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Innate Pharma	Non-Hodgkin's Lymphoma	NCT05321147	UCI-21-01	N	Pinter-Brown	Lauren C	BIDD	08/03/2022	01/12/2024	I	N	Tre	N	A Multi-Center Phase IB Trial Evaluating the Safety and Efficacy of Lacutamab in Patients with Relapse Peripheral T-Cell Lymphoma that Express KIR3DL2		5	0	0			
01/01/2024	12/31/2024	INT	D	Kymera Therapeutics	Multiple	NCT05225584	UCI-21-224	Y	Pinter-Brown	Lauren C	BIDD	11/21/2022	06/18/2024	I	N	Tre	N	A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	ONO Pharmaceutical Co., Ltd.	Lymphoid Leukemia	NCT05079282	UCI-21-99	N	Pinter-Brown	Lauren C	BIDD	04/07/2022		I	N	Tre	N	An Open-Label, Multi-Center, Non Randomized Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients with Relapsed or Refractory T-Cell Lymphoma		10	2	3			
01/01/2024	12/31/2024	INT	D	Amgen Inc.	Multiple	NCT05317078	UCI-22-77	Y	Tewari	Krishnansu	BIDD	01/03/2023	06/14/2024	I	N	Tre	N	Phase I First-in-Human Study to Explore the Safety, Tolerability and Pharmacokinetics of AMG 794 in Subjects with Claudin 6-Positive Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer or Epithelial Ovarian Cancer and Other Malignant Solid Tumor Indications		5	0	1			
01/01/2024	12/31/2024	INT	D	Ascendis Pharma	Multiple	NCT04799054	UCI-22-42	Y	Tewari	Krishnansu	BIDD	09/22/2023	09/05/2024	I/II	N	Tre	N	Phase I/II, Open-label Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist, Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies		5	0	0			
01/01/2024	12/31/2024	INT	D	Blueprint Medicines	Multiple	NCT05252416	UCI-22-195	Y	Tewari	Krishnansu	BIDD	06/12/2024	10/11/2024	I/II	N	Tre	N	A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors		5	0	0			
01/01/2024	12/31/2024	INT	D	F. Hoffmann-La Roche Ltd	Multiple	NCT05240898	UCI-22-78	Y	Tewari	Krishnansu	BIDD	03/08/2023		I	N	Tre	N	A Phase I Study of RO7623066 Alone and in Combination in Patients with Advanced Solid Tumors		3	0	0			
01/01/2024	12/31/2024	INT	D	GOG Foundation	Multiple	NCT05445778	GOG-3078	Y	Tewari	Krishnansu	BIDD	10/12/2023		III	N	Tre	N	Randomized, Multicenter, Open-label, Phase III Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FrA-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab		5	0	0			
01/01/2024	12/31/2024	INT	D	Genelux Corporation	Multiple	NCT05281471	GOG-3076	Y	Tewari	Krishnansu	BIDD	11/17/2023		III	N	Tre	N	A Randomized Phase III Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime Study)		5	2	2			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Multiple	NCT03486873	UCI-23-186	Y	Tewari	Krishnansu	BIDD	08/16/2024		III	N	Tre	N	A Multicenter, Open-label, Phase III Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab		10	0	0			
01/01/2024	12/31/2024	INT	D	Takeda	Multiple	NCT04381650	UCI-20-110	Y	Tewari	Krishnansu	BIDD	02/03/2022	02/22/2024	I/II	N	Tre	N	A Phase Ib/II Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients with Select Advanced or Metastatic Solid Tumors		5	0	2			
01/01/2024	12/31/2024	INT	D	Replimune	Melanoma, Skin	NCT06264180	UCI-24-112	Y	Tran	Thuy	BIDD	12/23/2024		III	N	Tre	N	A Randomized, Controlled, Multicenter, Phase III Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen		5	0	0			
01/01/2024	12/31/2024	INT	D	Astellas Pharma Global Development, Inc.	Urinary Bladder	NCT05014139	UCI-21-41	Y	Uchio	Edward	BIDD	02/01/2022	12/01/2024	I	N	Tre	N	A Study of Intravesical Enfortumab Vedotin for Treatment of Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)		2	0	1			
01/01/2024	12/31/2024	INT	D	Bicycle Tx Limited	Multiple	NCT06225596	UCI-23-103	Y	Uchio	Edward	BIDD	08/13/2024		II/III	N	Tre	N	A Randomized Open-Label Phase II/III Study of BT8009 Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)		5	0	0			
01/01/2024	12/31/2024	INT	D	CG Oncology Inc.	Urinary Bladder	NCT04452591	UCI-20-210	N	Uchio	Edward	BIDD	12/09/2021		III	N	Tre	N	A Phase III of CG0070 in Patients with Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)		3	0	7			
01/01/2024	12/31/2024	INT	D	CG Oncology Inc.	Urinary Bladder	NCT06111235	UCI-23-182	Y	Uchio	Edward	BIDD	07/18/2024		III	N	Tre	N	A Phase III, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)		10	1	1			
01/01/2024	12/31/2024	INT	D	Curium US LLC	Prostate	NCT06235099	UCI-23-222	Y	Uchio	Edward	BIDD	08/21/2024	10/30/2024	III	N	Dia	N	A Phase III, Multi-center, Open-label Study to Test the Diagnostic Performance of Copper Cu64 PSMA I&T PET/CT in Men with Biochemical Recurrence of Prostate Cancer		10	0	0			
01/01/2024	12/31/2024	INT	D	Curium US LLC	Prostate	NCT06235151	UCI-23-223	Y	Uchio	Edward	BIDD	08/21/2024		III	N	Dia	N	A Phase III, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection		10	3	3			
01/01/2024	12/31/2024	INT	D	Merck	Bladder	NCT02625961	UCI-15-77	Y	Uchio	Edward	BIDD	02/10/2016	11/18/2024	II	N	Tre	N	A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy (Keynote 057)		9	0	8			

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Bladder	NCT03711032	UCI-18-53	Y	Uchio	Edward	BIDD	06/26/2019	11/19/2024	III	N	Tre	N	A Phase III, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)		30	2	23			
01/01/2024	12/31/2024	INT	D	Protara Therapeutics, Inc.	Urinary Bladder	NCT05951179	UCI-23-206	Y	Uchio	Edward	BIDD	07/16/2024		II	N	Tre	N	A Phase 2, Open-Label Study to Evaluate Safety and Anti-Tumor Activity, of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer		12	0	0			
01/01/2024	12/31/2024	INT	D	Steba Biotech	Urinary Bladder	NCT04620239	UCI-21-37	Y	Uchio	Edward	BIDD	12/15/2023		III	N	Tre	N	Multicenter Phase III Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer (ENLIGHTED Study)		5	1	2			
01/01/2024	12/31/2024	INT	D	enGene Inc.	Urinary Bladder	NCT04752722	UCI-22-69	Y	Uchio	Edward	BIDD	03/22/2024		I/II	N	Tre	N	A Phase I/II Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients Who Are BCG Naive or Received Incomplete BCG Treatment		5	0	0			
01/01/2024	12/31/2024	INT	D	Actuate Therapeutics	Pancreas	NCT03678883	UCI-22-12	Y	Valerin	Jennifer Brooke	BIDD	10/16/2023	01/16/2024	I/II	N	Tre	N	Actuate 1801: Phase I/II Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignances or Solid Tumors		5	1	3			
01/01/2024	12/31/2024	INT	D	Bioatla	Multiple	NCT05808634	UCI-23-85	Y	Valerin	Jennifer Brooke	BIDD	09/19/2024		I	N	Tre	N	An Open-Label, Multicenter, Phase I Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, A Bispecific Epithelial Cell Adhesion Molecule (EPCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma		5	0	0			
01/01/2024	12/31/2024	INT	D	Dragonfly Therapeutics, Inc.	Multiple	NCT04143711	UCI-20-67	N	Valerin	Jennifer Brooke	BIDD	01/06/2021		I/II	N	Tre	N	A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications		20	0	18			
01/01/2024	12/31/2024	INT	D	Dragonfly Therapeutics, Inc.	Multiple	NCT04423029	UCI-21-40	Y	Valerin	Jennifer Brooke	BIDD	07/29/2021		I/II	N	Tre	N	A Phase I/II, First-in-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications		6	1	5			
01/01/2024	12/31/2024	INT	D	Dragonfly Therapeutics, Inc.	Multiple	NCT05597839	UCI-22-171	Y	Valerin	Jennifer Brooke	BIDD	08/30/2023		I/II	N	Tre	N	A Phase I/II, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a Monotherapy and in Combination with Nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications		15	1	4			
01/01/2024	12/31/2024	INT	D	Dragonfly Therapeutics, Inc.	Multiple	NCT06108479	UCI-23-197	Y	Valerin	Jennifer Brooke	BIDD	07/12/2024		I	N	Tre	N	A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors		5	1	1			
01/01/2024	12/31/2024	INT	D	Elicio Therapeutics, Inc.	Multiple	NCT05726864	UCI-22-75	Y	Valerin	Jennifer Brooke	BIDD	10/16/2023		I/II	N	Tre	N	First in Human Phase I/II Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and other Solid Tumors		7	5	5			
01/01/2024	12/31/2024	INT	D	Incyte Corporation	Multiple	NCT05909995	UCI-23-91	Y	Valerin	Jennifer Brooke	BIDD	03/26/2024	05/10/2024	I	N	Tre	N	A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors		15	1	1			
01/01/2024	12/31/2024	INT	D	Terns, Inc.	Other Hematopoietic	NCT06163430	UCI-23-167	Y	Van Etten	Richard	BIDD	02/23/2024		I	N	Tre	N	A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia		5	2	2			
01/01/2024	12/31/2024	INT	D	Amgen Inc.		NCT06333951	UCI-24-78	Y	Villalona-Calero	Miguel	BIDD	12/18/2024		I	N	Tre	N	A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination with Other Therapies in Subjects with Advanced Thoracic Tumors with Homozygous MTAP Deletion		5	0	0			
01/01/2024	12/31/2024	OBS	E	Rockefeller University	Melanoma, Skin	NCT02470273	UCI-14-05	Y	Linden	Kenneth	BIDD	06/30/2015	03/19/2024	N/A	N	Dia	N	Multicenter Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)		120	0	106			
01/01/2024	12/31/2024	OBS	I	UCI	Lip, Oral Cavity and Pharynx; Larynx	NCT05600842	UCI-22-132	N	Chen	Allen Min	BIDD	11/03/2022		N/A	N	Oth	N	De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx	111	111	3	20			20

UC Irvine Chao Family Comprehensive Cancer Center

Reporting Period: 01/01/2024 - 12/31/2024

Reporting Prepared: 02/10/2025

Data Table 4 – Clinical Research Protocols (CC)

Reporting Start Date	Reporting End Date	Clinical Research Cat	Study Source	Funding Source	Primary Site	NCT ID	Local Trial ID	Is Multi Inst	Last Name	First Name	Prog Code	Open Date	Close Date	Phase	Is Pilot	Primary Purpose	Prag	Official Title	Entire Study	Your Center Total	Center 12 Mos	Center To Date	Other 12 Mos	Other To Date	Entire Study Accrual To Date
01/01/2024	12/31/2024	ANC/COR	I	Department of Defense; UCI	Other Hematopoietic		UCI-14-03	N	Fleischman	Angela	CC	02/28/2014		N/A	N	Bas	N	Role of Inflammation in the Pathogenesis of Myeloproliferative Neoplasm	225	225	0	121			121
01/01/2024	12/31/2024	ANC/COR	I	UCI	Other Hematopoietic		INDP-14-9995	N	Fleischman	Angela	CC	02/28/2014		N/A	N	Bas	N	Role of Inflammation in the Pathogenesis of Myeloproliferative Neoplasm	225		12	149			149
01/01/2024	12/31/2024	ANC/COR	I	UCI	Non-Hodgkin's Lymphoma; Lymphoid Leukemia		UCI-21-236	N	Fleischman	Angela	CC	05/27/2022		N/A	N	Bas	N	Addressing the Hispanic Cancer Disparity in B Cell Acute Lymphoblastic Leukemia	25	25	4	9			9
01/01/2024	12/31/2024	ANC/COR	I	UCI	Multiple		UCI-20-214	N	Tang	Cathy	CC	07/11/2023		N/A	N	Bas	N	The Interplay of the Skin Microbiome, Solar UV Exposure and Skin Pathologies	50	50	0	0			0
01/01/2024	12/31/2024	INT	N	NRG Oncology	Colon	NCT05174169	NRG-GI008	Y	Zell	Jason	CC	09/14/2022		II/III	N	Tre	N	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)		5	0	2			
01/01/2024	12/31/2024	INT	E	Patient-Centered Outcomes Research Institute	Breast	NCT02620852	UCI-16-23	Y	Anton-Culver	Hoda	CC	04/14/2017		N/A	N	Scr	N	Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized versus Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)]		3000	0	2005			
01/01/2024	12/31/2024	INT	E	NCI	Multiple	NCT03384134	UCI-19-26	Y	Fortier	Michelle	CC	08/01/2019	09/13/2024	III	N	Sup	N	Treating Pain in Children with Cancer: A 21st Century Innovative Approach (Pain Buddy)	206	103	0	0	18	206	206
01/01/2024	12/31/2024	INT	I	UCI	Multiple		UCI-23-29	N	Eng	Oliver	CC	08/08/2024		II	Y	Sup	N	Electroacupuncture in Symptom Management After CRS/HIPEC: A Pilot Study	15	15	1	1			1
01/01/2024	12/31/2024	INT	I	Memorial Sloan-Kettering Cancer Center	Multiple	NCT04802720	UCI-24-186	Y	Hoyt	Michael A	CC	10/30/2020	04/26/2024	N/A	Y	Sup	N	A Randomized Controlled Trial of Emotion Regulation Therapy for Cancer Caregivers: A Mechanism-Targeted Approach to Addressing Caregiver Distress	999	999	0	0			0
01/01/2024	12/31/2024	INT	I	UCI	Other Male Genital	NCT05836688	UCI-20-59	Y	Hoyt	Michael A	CC	11/01/2023		N/A	N	Sup	N	A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors	200	200	24	24	8	8	32
01/01/2024	12/31/2024	INT	I	UCI	Multiple		UCI-22-193	Y	Hoyt	Michael A	CC	02/12/2024		N/A	N	Sup	N	Goal-Focused Emotion-Regulation Therapy for Young Adult Cancer Survivors: A Biobehavioral Self-Regulation Intervention	15	15	0	0	13	13	13
01/01/2024	12/31/2024	INT	I	UCI	Multiple	NCT06338475	UCI-24-128	Y	Hoyt	Michael A	CC	09/09/2024		N/A	Y	Sup	N	A Biobehavioral Intervention for Latino/Hispanic Young Adults with Cancer	100	100	3	3			3
01/01/2024	12/31/2024	INT	I	UCI	Urinary Bladder	NCT06335667	UCI-23-72	N	Mar	Nataliya	CC	03/27/2024		N/A	Y	Dia	N	Outcomes with Multi Parametric MRI (mpMRI) Compared to Diagnostic Transurethral Resection of Bladder Tumor (TURBT) in Patients with Suspected Muscle-Invasive Bladder Cancer - a Pilot Study	30	30	14	14			14
01/01/2024	12/31/2024	INT	I	UCI	Lung	NCT06000683	UCI-23-107	N	Sadigh	Gelareh	CC	10/13/2023	10/03/2024	II	Y	Hsr	N	Empowering Patients' Lung Cancer Screening Uptake (Empower LCS)	80	80	69	70			70
01/01/2024	12/31/2024	INT	I	UCI	Lung	NCT06225414	UCI-23-219	N	Sadigh	Gelareh	CC	02/12/2024		N/A	Y	Scr	N	Empowering Hispanic Patient's Lung Cancer Screening Uptake (Empower Latino)	60	60	39	39			39
01/01/2024	12/31/2024	INT	D	Colospan Ltd.	Colon; Rectum	NCT04184973	UCI-20-163	Y	Carmichael	Joseph	CC	04/07/2021		N/A	N	Pre	N	Efficacy and Safety of the CG-100 Intraluminal Bypass Device in Colorectal and Coloanal Anastomoses: Prospective, Open Label, Randomized Trial		10	0	2			
01/01/2024	12/31/2024	INT	D	Xiamen LP Pharmaceutical Co., Ltd.	Multiple	NCT05199818	UCI-22-109	Y	Dayyani	Farshid	CC	06/13/2023	04/22/2024	III	N	Pre	N	A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy		30	0	1			
01/01/2024	12/31/2024	OBS	N	SWOG	Other Male Genital; Ovary	NCT04435756	SWOG-S1823	Y	Daneshvar	Michael	CC	10/22/2020	05/20/2024	N/A	N	Bas	N	A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors		8	1	4			
01/01/2024	12/31/2024	OBS	E	Department of Defense; UCI	Prostate		UCI-18-117	Y	Hoyt	Michael A	CC	06/01/2019		N/A	N	Sup	N	Inflammatory Processes, Emotion Regulation, and Depression in Prostate Cancer Survivors	150	80	19	56	4	37	93
01/01/2024	12/31/2024	OBS	I	UCI	Prostate		UCI-17-07	N	Ahlering	Thomas	CC	04/04/2017		N/A	N	Hsr	N	Patient Reported Outcomes via Online Questionnaire (PROVOQ): Post-Radical Prostatectomy Outcome Assessment	1875	1875	182	940			940
01/01/2024	12/31/2024	OBS	I	UCI	Prostate		UCI-98-41	N	Ahlering	Thomas	CC	06/01/1998		N/A	N	Oth	N	Outcomes and Assessment of Prostate Cancer at UCIMC	3380	3380	184	2586			2586
01/01/2024	12/31/2024	OBS	I	UCI	Other Hematopoietic		UCI-23-32	N	Fleischman	Angela	CC	02/09/2023		N/A	Y	Bas	N	Dissecting the Mechanism of Interferon alfa (IFN) Response in Myeloproliferative Neoplasm (MPN)	10	10	5	13			13
01/01/2024	12/31/2024	OBS	I	UCI	Lymphoid Leukemia		UCI-19-27	Y	Fortier	Michelle	CC	12/20/2018	03/02/2023	N/A	N	Sup	N	Influence of Acculturation and Social Support on Health-Related Quality of Life in Survivors of Childhood Cancer	190	190	0	0	0	105	105
01/01/2024	12/31/2024	OBS	I	UCI	Prostate		UCI-24-60	N	Hoyt	Michael A	CC	06/24/2024		N/A	N	Sup	N	Understanding Well-Being in Asian-American Prostate Cancer Survivors	20	20	9	9			9
01/01/2024	12/31/2024	OBS	I	UCI	Myeloid and Monocytic Leukemia	NCT06229860	UCI-23-110	N	Jafari	Mahtab	CC	01/25/2024		N/A	Y	Oth	N	Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia	75	75	38	38			38
01/01/2024	12/31/2024	OBS	I	UCI	Breast		UCI-23-127	N	Kim	Jacqueline	CC	08/01/2023		N/A	Y	Dia	N	Stress & Coping in Asian Americans with Advanced/Metastatic Cancer	400	60	52	58			58
01/01/2024	12/31/2024	OBS	I	Stanford Cancer Center	Other Respiratory and Intrathoracic Organs		UCI-20-206	Y	Kuan	Edward	CC	01/29/2021		N/A	N	Hsr	N	Sinonasal Cancer Study to Evaluate Oncologic Outcomes and Quality of Life		30	2	25			
01/01/2024	12/31/2024	OBS	I	UCI	Multiple		UCI-22-14	Y	Llave	Karen	CC	11/01/2022	07/31/2024	N/A	Y	Sup	N	Transitioning Young Adult Cancer Survivors to Adult Care: Understanding the Role of Cognitive and Emotional Illness Representations of Cancer	150	150	65	65	13	71	136
01/01/2024	12/31/2024	OBS	I	UCI	Multiple		UCI-21-21	Y	Milam	Joel	CC	02/26/2021	11/30/2024	N/A	N	Hsr	N	Project Milestones: Young Adult Cancer Survivorship	2000	2000	248	1848	0	0	1848
01/01/2024	12/31/2024	OBS	I	UCI	Lung	NCT06221800	UCI-22-86	N	Nagasaka	Misako	CC	01/31/2024		N/A	Y	Bas	N	A Pilot Study to Assess the Diversity of Gut Microbiome in Metastatic Non-Small Cell Lung Cancer (NSCLC) in Correlation to Treatment Effects and Adverse Effects	82	82	4	4			4

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMultiInst	LastName	FirstName	Prog Code	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	OBS	I	UCSF	Ovary		UCI-21-190	Y	Tseng	Jill	CC	11/03/2023		N/A	Y	Dia	N	Assessing the Predictive Capability of Circulating Tumor DNA (ctDNA) as a Screening Tool for Ovarian Cancer		36	2	2			
01/01/2024	12/31/2024	OBS	I	California Initiative to Advance Precision Medicine (CIAPM); UCI	Prostate	NCT03770351	UCI-17-40	Y	Uchio	Edward	CC	06/19/2017		N/A	N	Hsr	N	Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response	1027	600	0	545	0	427	972
01/01/2024	12/31/2024	OBS	I	UCI	Kidney		UCI-21-131	N	Yazdanpanah	Omid	CC	03/28/2022	10/06/2024	N/A	N	Sup	N	Understanding Patient Preferences in the Treatment of Metastatic Renal Cell Carcinoma	100	100	16	55			55
01/01/2024	12/31/2024	OBS	D	Incyte Corporation	Non-Hodgkin's Lymphoma	NCT04981795	UCI-21-217	Y	Brem	Elizabeth A	CC	02/28/2024		IV	N	Oth	N	realMIND: A multicenter, observational study to characterize the safety and effectiveness of tafasitamab in combination with lenalidomide in US patients with relapsed or refractory diffuse large B-cell lymphoma with a focus on racial and ethnic minority patients		6	0	0			
01/01/2024	12/31/2024	OBS	D	Caribou Biosciences, Inc.	Multiple	NCT05332054	UCI-21-184	Y	O'Brien	Susan	CC	07/25/2022		II	N	Oth	N	An Observational Long-term Follow-up Study of Patients who Received Prior Caribou Cell Therapy		5	2	4			
01/01/2024	12/31/2024	OBS	D	Mustang	Non-Hodgkin's Lymphoma; Lymphoid Leukemia	NCT05645744	UCI-22-182	Y	O'Brien	Susan	CC	05/26/2023	05/30/2024	N/A	N	Oth	N	A Long-term Follow-up Study in Patients Previously Treated with Mustang Bio, Inc. CAR-T Cell Investigational Products		5	0	0			
01/01/2024	12/31/2024	OBS	D	Castle Biosciences Inc	Melanoma, Skin		UCI-19-135	Y	Yamamoto	Maki	CC	03/10/2021		N/A	N	Hsr	N	DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)		50	21	84			

UC Irvine Chao Family Comprehensive Cancer Center

Reporting Period: 01/01/2024 - 12/31/2024

Reporting Prepared: 02/10/2025

Data Table 4 – Clinical Research Protocols (SPT)

Reporting StartDate	Reporting EndDate	Clinical ResearchCat	Study Source	FundingSource	PrimarySite	NCTID	LocalTrialID	IsMulti Inst	LastName	FirstName	ProgCode	OpenDate	CloseDate	Phase	IsPilot	Primary Purpose	Prag	OfficialTitle	EntireStudy	YourCenter Total	Center 12Mos	Center ToDate	Other 12Mos	Other ToDate	EntireStudy AccrualToDate
01/01/2024	12/31/2024	ANC/COR	E	NCI	Multiple	NCT04410302	UCI-20-04	Y	Dayyani	Farshid	SPT	03/16/2020		N/A	N	Bas	N	University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCAcMP) to Reduce Cancer Health Disparities	130	130	4	102			102
01/01/2024	12/31/2024	ANC/COR	I	UCI	Multiple		UCI-23-21	N	Senthil	Maheswari	SPT	11/17/2023	06/13/2024	N/A	Y	Scr	N	Study of Exosomes Gene Expression in Peritoneal Fluid and Plasma in Patients with Gastrointestinal Malignancy	70	70	0	0			0
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Lip, Oral Cavity and Pharynx	NCT02734537	ECOG-EA3132	Y	Attarian	Shirin	SPT	11/01/2024		II	N	Tre	N	Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing		5	0	0			
01/01/2024	12/31/2024	INT	N	ETCTN	Lip, Oral Cavity and Pharynx	NCT05669664	ETCTN-10553	Y	Attarian	Shirin	SPT	06/26/2024		II	N	Tre	N	A Phase II Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer		5	1	1			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Lip, Oral Cavity and Pharynx	NCT05050162	NRG-HN009	Y	Attarian	Shirin	SPT	07/23/2024		II/III	N	Tre	N	Randomized Phase II/III Trial of Radiation with Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation with Weekly Cisplatin at 40 mg/m2 for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)		5	0	0			
01/01/2024	12/31/2024	INT	N	Alliance	Brain and Nervous System	NCT02523014	ALLIANCE-A071401	Y	Bota	Daniela	SPT	01/27/2016		II	N	Tre	N	Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 /CDK Pathway Mutations		3	1	2			
01/01/2024	12/31/2024	INT	N	SWOG	Multiple	NCT04799275	SWOG-S1918	Y	Brem	Elizabeth A	SPT	05/25/2021		II/III	N	Tre	N	A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B-Cell Lymphoma, Grade IIB, Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements	10	10	2	5			5
01/01/2024	12/31/2024	INT	N	Alliance	Multiple	NCT03994796	A071701	Y	Choi	Yoon Jae	SPT	10/16/2019	01/18/2024	II	N	Tre	N	Genomically-Guided Treatment Trial in Brain Metastases		5	0	1			
01/01/2024	12/31/2024	INT	N	Alliance	Brain and Nervous System	NCT03224767	ALLIANCE-A071601	Y	Choi	Yoon Jae	SPT	06/04/2018	05/02/2024	II	N	Tre	N	Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas		5	0	3			
01/01/2024	12/31/2024	INT	N	ETCTN	Bones and Joints; Soft Tissue	NCT05836571	ETCTN-10556	Y	Chow	Warren A	SPT	12/07/2023		II	N	Tre	N	Randomized Phase II Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma		5	1	1			
01/01/2024	12/31/2024	INT	N	SWOG	Multiple	NCT04269902	SWOG-S1925	Y	Coombs	Catherine	SPT	06/10/2021		III	N	Tre	N	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study		10	1	2			
01/01/2024	12/31/2024	INT	N	Alliance	Stomach; Esophagus	NCT05677490	ALLIANCE-A022102	Y	Dayyani	Farshid	SPT	12/13/2023		III	N	Tre	N	A Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-line Treatment of Metastatic HER2-negative Gastroesophageal Adenocarcinoma		14	8	8			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple	NCT05724108	ETCTN-10558	Y	Dayyani	Farshid	SPT	10/29/2024		II	N	Tre	N	A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors		7	0	0			
01/01/2024	12/31/2024	INT	N	ETCTN	Other Skin	NCT05947500	ETCTN-10592	Y	Gao	Ling	SPT	01/29/2024		II	N	Tre	N	A Phase II Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma		6	2	2			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Prostate	NCT04513717	NRG-GU009	Y	Hong	David	SPT	05/11/2022		III	N	Tre	N	Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk And Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (Predict-Rt*)		10	5	8			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Prostate	NCT05050084	NRG-GU010	Y	Hong	David	SPT	10/25/2024		III	N	Tre	N	Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)		10	0	0			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Prostate	NCT05946213	NRG-GU013	Y	Hong	David	SPT	02/02/2024		III	N	Tre	N	The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer		5	1	1			
01/01/2024	12/31/2024	INT	N	ETCTN	Myeloid and Monocytic Leukemia; Other Hematopoietic	NCT05600894	ETCTN-10538	Y	Jeyakumar	Deepa	SPT	09/29/2023		II	N	Tre	N	Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY1 MDS/MPN) a Randomized, Phase II Trial		5	0	0			
01/01/2024	12/31/2024	INT	N	ECOG-ACRIN	Other Digestive Organ	NCT04559139	ECOG-EA2197	Y	Jutric	Zeljka	SPT	09/14/2022		II/III	N	Tre	N	Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial		10	0	0			
01/01/2024	12/31/2024	INT	N	Alliance	Prostate	NCT05241860	ALLIANCE-A032101	Y	Kalebasty	Arash Rezazadeh	SPT	11/09/2023	03/29/2024	II	N	Tre	N	A Phase II Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM		5	6	7			
01/01/2024	12/31/2024	INT	N	ETCTN	Urinary Bladder; Kidney	NCT03375307	ETCTN-10144	Y	Kalebasty	Arash Rezazadeh	SPT	01/08/2021		II	N	Tre	N	A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors with DNA-Repair Defects		6	1	3			
01/01/2024	12/31/2024	INT	N	ETCTN	Prostate	NCT05828082	ETCTN-10603	Y	Kalebasty	Arash Rezazadeh	SPT	09/26/2023		II	N	Tre	N	A Phase II Study of M1774 in Refractory SPOP-mutant Prostate Cancer		5	0	0			
01/01/2024	12/31/2024	INT	N	NRG Oncology	Brain and Nervous System	NCT05095376	NRG-BN011	Y	Kong	Xiao-Tang	SPT	12/06/2022		III	N	Tre	N	A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma		8	4	6			
01/01/2024	12/31/2024	INT	N	ETCTN	Multiple Myeloma	NCT06169215	ETCTN-10612	Y	Lee	Lisa Xingguang	SPT	04/25/2024		II	N	Tre	N	A Randomized Phase II Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma		5	2	2			
01/01/2024	12/31/2024	INT	N	SWOG	Urinary Bladder	NCT04579224	SWOG-S1937	Y	Mar	Nataliya	SPT	06/13/2024		III	N	Tre	N	A Phase III Randomized Trial of Eribulin with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy		5	3	3			

01/01/2024	12/31/2024	INT	N	NRG Oncology	Breast	NCT04852887	NRG-BR007	Y	Mehta	Rita	SPT	02/24/2022		III	N	Tre	N	A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer	5	0	1				
01/01/2024	12/31/2024	INT	N	Alliance	Breast	NCT04457596	ALLIANCE-A011801	Y	Parajuli	Ritesh	SPT	03/02/2021		III	N	Tre	N	The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib	10	1	4				
01/01/2024	12/31/2024	INT	N	Alliance	Breast	NCT05751668	ALLIANCE-A222101	Y	Parajuli	Ritesh	SPT	04/25/2024		II	N	Sup	N	An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy	30	0	0				
01/01/2024	12/31/2024	INT	N	NRG Oncology	Breast	NCT05879926	NRG-BR009	Y	Parajuli	Ritesh	SPT	11/15/2024		III	N	Tre	N	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score <= 25 (OFSET)	10	0	0				
01/01/2024	12/31/2024	INT	N	ECOG	Multiple	NCT04031677	ECOG-EA7211	Y	Tran	Thuy	SPT	09/28/2023		III	N	Tre	N	A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)	9	0	0				
01/01/2024	12/31/2024	INT	N	NRG Oncology	Ovary	NCT06169124	NRG-GY033	Y	Tseng	Jill	SPT	05/14/2024		II	N	Tre	N	A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-type Ovarian Granulosa Cell Tumor	5	0	0				
01/01/2024	12/31/2024	INT	N	Alliance	Pancreas	NCT04340141	ALLIANCE-A021806	Y	Valerin	Jennifer Brooke	SPT	09/26/2023		III	N	Tre	N	A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer	15	0	0				
01/01/2024	12/31/2024	INT	N	Alliance	Pancreas	NCT06115499	ALLIANCE-A022106	Y	Valerin	Jennifer Brooke	SPT	03/05/2024		II/III	N	Tre	N	Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)	3	0	0				
01/01/2024	12/31/2024	INT	N	SWOG	Pancreas	NCT05040360	SWOG-S2104	Y	Valerin	Jennifer Brooke	SPT	07/29/2022		II	N	Tre	N	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors	2	0	0				
01/01/2024	12/31/2024	INT	N	SWOG	Melanoma, Skin	NCT03860883	SWOG-S2015	Y	Yamamoto	Maki	SPT	12/13/2022		III	N	Tre	N	S2015: Melanoma Margins Trial (MeiMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma	30	8	13				
01/01/2024	12/31/2024	INT	N	Alliance	Rectum	NCT05610163	ALLIANCE-A022104	Y	Zell	Jason	SPT	05/10/2023		II	N	Tre	N	The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy Of Triplet Versus Doublet Chemotherapy To Achieve Clinical Complete Response In Patients With Locally Advanced Rectal Cancer	15	5	6				
01/01/2024	12/31/2024	INT	N	Canadian Cancer Trials Group (CCTG)	Rectum	NCT06205485	CCTG-CO32	Y	Zell	Jason	SPT	04/29/2024		III	N	Tre	N	The NEO-RT Trial: A Phase III Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus Chemoradiotherapy for Early Rectal Cancer	5	2	2				
01/01/2024	12/31/2024	INT	I	UCI	Breast	NCT06580002	UCI-24-05	N	Chan	Alexandre	SPT	12/02/2024		II	Y	Tre	N	Repurposing Riluzole for Augmenting Brain-Derived Neurotrophic Factor (BDNF) Levels and Cognitive Function in Breast Cancer Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial	26	26	0	0		0	
01/01/2024	12/31/2024	INT	I	UCI	Melanoma, Skin	NCT06771544	UCI-22-49	N	Chow	Warren A	SPT	12/23/2024		II	N	Tre	N	Metronomic Cyclophosphamide with Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma	14	14	0	0		0	
01/01/2024	12/31/2024	INT	I	Exelixis, Inc.; UCI	Liver	NCT04472767	UCI-19-49	Y	Dayyani	Farshid	SPT	08/07/2020		II	N	Tre	N	Phase II Study of Cabozantinib Combined with Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma (HCC) Who are not Candidates for Curative Intent Treatment	35	35	4	19	0	0	19
01/01/2024	12/31/2024	INT	I	Cure Accelerator; UCI	Myeloid and Monocytic Leukemia	NCT05123365	UCI-20-50	N	Fleischman	Angela	SPT	01/03/2022		I/II	N	Tre	N	An Optimal Dose Finding Study of N-Acetylcysteine in Patients with Myeloproliferative Neoplasms	27	27	1	11			11
01/01/2024	12/31/2024	INT	I	Children's Hospital of Orange County	Lymphoid Leukemia	NCT05501899	UCI-21-14	Y	Jeyakumar	Deepa	SPT	11/03/2023		N/A	Y	Sup	N	Use of Levocarnitine for Asparaginase Hepatotoxicity for Acute Lymphoblastic Leukemia Patients	5	5	0	0	0	0	0
01/01/2024	12/31/2024	INT	I	Jazz Pharmaceuticals, Inc.; Pfizer Pharmaceutical Inc.; UCI	Myeloid and Monocytic Leukemia	NCT04231851	UCI-18-105	Y	Jeyakumar	Deepa	SPT	02/19/2020	06/10/2024	II	N	Tre	N	Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients with Acute Myelogenous Leukemia with MDS Related Changes or Therapy-Related Acute Myeloid Leukemia: A University of California Hematologic Malignancies Consortium Protocol	30	19	3	22	2	8	30
01/01/2024	12/31/2024	INT	I	UCI	Breast	NCT05524584	UCI-19-145	N	Mehta	Rita	SPT	08/31/2022		II	N	Tre	N	Phase II, Open-Labelled, Single-Armed Combination Treatment with Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer	20	20	9	17			17
01/01/2024	12/31/2024	INT	I	UCI	Stomach; Esophagus	NCT04762953	UCI-20-87	N	Senthil	Maheswari	SPT	03/03/2021		II	Y	Tre	N	Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis	40	40	9	27			27
01/01/2024	12/31/2024	INT	D	Denovo Biopharma	Brain and Nervous System	NCT03776071	UCI-19-99	Y	Bota	Daniela	SPT	12/11/2020	01/10/2024	III	N	Tre	N	A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1	15	0	11				
01/01/2024	12/31/2024	INT	D	ONO Pharmaceutical Co., Ltd.	Brain and Nervous System	NCT04947319	UCI-21-77	Y	Bota	Daniela	SPT	04/19/2022	10/17/2024	II	N	Tre	N	An Open-Label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL)	2	0	1				
01/01/2024	12/31/2024	INT	D	Viracta Therapeutics, Inc.	Multiple	NCT05011058	UCI-21-04	Y	Brem	Elizabeth A	SPT	10/15/2021	05/01/2024	II	N	Tre	N	An Open-Label, Phase II Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas ("NAVAL-1")	5	1	1				
01/01/2024	12/31/2024	INT	D	BeiGene, Ltd.	Lymphoid Leukemia	NCT06073821	UCI-23-156	Y	Coombs	Catherine	SPT	03/27/2024		III	N	Tre	N	A Phase III, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia	7	3	3				
01/01/2024	12/31/2024	INT	D	Loxo Oncology, Inc.	Lymphoid Leukemia	NCT04965493	UCI-21-209	Y	Coombs	Catherine	SPT	08/29/2022	06/24/2024	III	N	Tre	N	A Phase III Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	3	1	2				
01/01/2024	12/31/2024	INT	D	Nerviano	Liver	NCT05630937	UCI-22-202	Y	Dayyani	Farshid	SPT	10/23/2023	02/06/2024	I/II	N	Tre	N	Phase I/II Study on Safety and Efficacy of NMS-01940153E in Adult Patients with Unresectable Hepatocellular Carcinoma (HCC) Previously Treated with Systemic Therapy	7	0	0				



01/01/2024	12/31/2024	INT	D	Ionis Pharmaceuticals	Other Hematopoietic	NCT05143957	UCI-21-204	Y	Fleischman	Angela	SPT	07/07/2022	09/09/2024	II	N	Tre	N	A Phase IIa, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)	5	0	1			
01/01/2024	12/31/2024	INT	D	IRIS	Lymphoid Leukemia	NCT04817761	UCI-22-125	Y	Jeyakumar	Deepa	SPT	08/21/2023		II/III	N	Tre	N	A Multi-Center, Open-Label, Single-Arm Phase II/III Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 to >65 Years with Newly-Diagnosed Philadelphia-Negative ALL	5	0	0			
01/01/2024	12/31/2024	INT	D	Eikon Therapeutics	Multiple	NCT06253130	UCI-23-162	Y	Kalebasty	Arash Rezazadeh	SPT	04/03/2024		I/II	N	Tre	N	A First-in-human, Phase I/II, Open-label, Multi-center, Dose-Escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy and in Combination in Participants with Advanced Solid Tumors	5	0	0			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Prostate	NCT06136624	UCI-23-118	Y	Kalebasty	Arash Rezazadeh	SPT	06/24/2024		III	N	Tre	N	A Phase III Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated with Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	6	0	0			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Prostate	NCT06136650	UCI-23-119	Y	Kalebasty	Arash Rezazadeh	SPT	06/20/2024		III	N	Tre	N	A Phase III, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed on or After Prior Treatment with One Next-generation Hormonal Agent (NHA)	9	3	3			
01/01/2024	12/31/2024	INT	D	Chimerix, Inc.	Brain and Nervous System	NCT05580562	UCI-22-83	Y	Kong	Xiao-Tang	SPT	06/26/2023		III	N	Tre	N	ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study	5	2	2			
01/01/2024	12/31/2024	INT	D	Merck Sharp & Dohme Corp.	Kidney	NCT05239728	UCI-21-228	Y	Mar	Nataliya	SPT	12/07/2022	04/12/2024	III	N	Tre	N	A Multi-Center, Double-Blind, Randomized Phase III Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (6482-022)	5	0	3			
01/01/2024	12/31/2024	INT	D	Flamingo Therapeutics	Lip, Oral Cavity and Pharynx; Larynx	NCT05814666	UCI-23-106	Y	Nabar	Rupali	SPT	12/14/2023		II	N	Tre	N	An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	4	2	2			
01/01/2024	12/31/2024	INT	D	AnHeart Therapeutics	Lung	NCT04919811	UCI-21-108	Y	Nagasaka	Misako	SPT	05/31/2022		II	N	Tre	N	A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors	5	0	2			
01/01/2024	12/31/2024	INT	D	AstraZeneca	Lung	NCT05120349	UCI-22-59	Y	Nagasaka	Misako	SPT	12/12/2022	08/23/2024	III	N	Tre	N	Phase III, Double-Blind, Randomized, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Patients with EGFR Mutation-Positive Stage IA2-IA3 Non-Small Cell Lung Cancer, Following Complete Tumour Resection (ADAURA2)	10	1	1			
01/01/2024	12/31/2024	INT	D	Bioatla	Lung	NCT04681131	UCI-21-233	Y	Nagasaka	Misako	SPT	12/07/2022	05/17/2024	II	N	Tre	N	A Phase II Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression On or Are Intolerant to a PD-1/L1, EGFR, or ALK Inhibitor	5	0	1			
01/01/2024	12/31/2024	INT	D	Merus N.V.	Multiple	NCT02912949	UCI-19-64	Y	Nagasaka	Misako	SPT	09/19/2019		I/II	N	Tre	N	A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors	10	2	8			
01/01/2024	12/31/2024	INT	D	Pfizer Pharmaceutical Inc.	Lung	NCT05144997	UCI-22-145	Y	Ou	Sai-Hong	SPT	03/03/2023	05/16/2024	IV	N	Tre	N	Lorlatinib (PF-06463922) Continuation Protocol: An Open-Label, Single-Arm Continuation Study for Participants with ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Continuing From Pfizer Sponsored Lorlatinib Clinical Studies	4	1	5			
01/01/2024	12/31/2024	INT	D	Celcuity Inc	Breast	NCT05501886	UCI-22-139	Y	Parajuli	Ritesh	SPT	04/28/2023		III	N	Tre	N	A Phase III, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy	5	2	4			
01/01/2024	12/31/2024	INT	D	Eli Lilly	Breast	NCT05514054	UCI-22-111	Y	Parajuli	Ritesh	SPT	12/15/2023		III	N	Tre	N	EMBER-4: A Randomized, Open-Label, Phase III Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence	15	5	5			
01/01/2024	12/31/2024	INT	D	F. Hoffmann-La Roche Ltd	Breast	NCT05646862	UCI-22-222	Y	Parajuli	Ritesh	SPT	09/01/2023	09/05/2024	III	N	Tre	N	A Phase III, Multicenter, Randomized, Open-label Study Evaluating The Efficacy And Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant In Patients with Hormone Receptor-positive, HER2-negative, PIK3CA Mutated, Locally Advanced Or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy	4	0	0			
01/01/2024	12/31/2024	INT	D	Genentech, Inc.	Breast	NCT05306340	UCI-22-114	Y	Parajuli	Ritesh	SPT	06/01/2023	09/17/2024	III	N	Tre	N	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer	5	0	3			
01/01/2024	12/31/2024	INT	D	Hoth Therapeutics	Multiple	NCT05639933	UCI-23-153	Y	Smith	Janellen	SPT	06/27/2024		II	N	Sup	N	A Randomized, Placebo-Controlled, Parallel Phase IIa Dose-Ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors	16	0	0			
01/01/2024	12/31/2024	INT	D	K-Group Beta	Multiple	NCT05128825	GOG-3066	Y	Tewari	Krishnansu	SPT	11/10/2023	06/14/2024	II	N	Tre	N	A Phase II Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	5	0	0			

01/01/2024	12/31/2024	INT	D	K-Group Beta	Corpus Uteri	NCT04814108	UCI-20-203	Y	Tewari	Krishnansu	SPT	10/26/2021	10/29/2024	II	N	Tre	N	Phase II, Open Label, Single Arm, Efficacy and Safety Study of the WEE1 Inhibitor ZN-c3 as Second Line Oral Therapy in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (USC)		5	0	0			
01/01/2024	12/31/2024	INT	D	Karyopharm Therapeutics, Inc.	Other Female Genital	NCT05611931	GOG-3083	Y	Tewari	Krishnansu	SPT	09/22/2023	11/05/2024	III	N	Tre	N	A Phase III, Randomized, Placebo-controlled, Double-blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With P53 Wild-type, Advanced or Recurrent Endometrial Carcinoma		3	0	0			
01/01/2024	12/31/2024	INT	D	Winsantor, Inc	Multiple	NCT05488873	UCI-22-80	N	Tseng	Jill	SPT	05/11/2023	06/20/2024	II	N	Tre	N	A Randomized, Double-Blind, Placebo-Controlled, Phase IIA Study of Topical Pirenzepine or Placebo for the Prevention of Dose Limiting Chemotherapy Induced Peripheral Neuropathy in Oncology Patients Administered Carboplatin and Paclitaxel		15	0	1			
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Urinary Bladder	NCT06211764	UCI-23-202	Y	Uchio	Edward	SPT	06/12/2024		III	N	Tre	N	A Phase III, Randomized, Open-Label, Multi-Center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy		3	1	1			
01/01/2024	12/31/2024	INT	D	Janssen Research & Development, LLC	Urinary Bladder	NCT06319820	UCI-23-203	Y	Uchio	Edward	SPT	10/01/2024		III	N	Tre	N	A Phase III, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations		5	0	0			
01/01/2024	12/31/2024	INT	D	Ikena Oncology, Inc.	Multiple	NCT06270082	UCI-24-82	Y	Valerin	Jennifer Brooke	SPT	12/11/2024		I	N	Tre	N	A First-In-Human Study Of IK-595, an Oral Dual MEK/RAF Inhibitor, in Patients with RAS- Or RAF-Altered Advanced Solid Tumors		10	1	1			
01/01/2024	12/31/2024	OBS	I	UCI	Other Hematopoietic		UCI-18-127	N	Fleischman	Angela	SPT	02/15/2019		N/A	Y	Bas	N	Assessing Clonal Hematopoiesis in Myeloproliferative Neoplasm Families	350	350	15	188			188